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Abstract 
Inhibitors of Leishmania major inositol phosphorylceramide synthase: New therapies 
for leishmaniasis 
Christopher Brown 
 
Leishmaniasis is an insect vector-borne Neglected Tropical Disease (NTD) caused by the 
protozoan Leishmania spp. This disease is endemic in 98 countries, claiming 30,000 lives each 
year and putting a further 350 million people at risk. With no vaccine currently available, 
treatment typically requires long, expensive courses of exposure to toxic medicines via 
parenteral administration. Furthermore, resistance to some antileishmanials is an emerging 
threat. There is an urgent need for novel treatments that are inexpensive and free of side 
effects.  
Our group has previously identified and validated the Leishmania major inositol 
phosphorylceramide synthase (LmjIPCS) enzyme as an attractive drug target. This essential 
membrane-bound enzyme has a differential function to the mammalian orthologue 
(sphingomyelin synthase), potentiating the development of safe, selective antileishmanials. 
Using a microtiter plate compatible assay, a set of 1040 pharmacologically active compounds 
were screened for activity against LmjIPCS and L. major parasites. Clemastine, an 
over-the-counter medicine, was found to be effective against L. major promastigotes 
(ED50 = 0.47 µM) and amastigotes (ED50 = 3.06 µM). With well-studied pharmacokinetic and 
mammalian safety profiles, clemastine was chosen as an ideal candidate for further 
development. 
Initial efforts focussed on the synthesis of a series of chimeric analogues, coupling 
2-pyrrolidinyl and 4-chlorobenzhydryl fragments via ether, triazole, amide, ester and olefin 
linkers. Amides presented the most attractive linker group, proving to be robust and amenable 
to parallel synthetic efforts. Despite being well-tolerated by the LmjIPCS enzyme, the 
synthesised amides exhibited low in cellulo activity against L. major promastigotes. 
Two series of amide-linked clemastine analogues were synthesised, exploring 
substitution of the pyrrolidine and benzhydryl moieties. From a synthesised library of 59 
compounds, the indazole N-(1′′-[2′′′-dimethylaminoethyl]indazol-6′′-yl)-2-(4′-chlorophenyl)-2-
phenylacetamide exhibited LmjIPCS inhibition (IC50 = 2.41 µM) comparable to the parent 
molecule, clemastine (IC50 = 2.87 µM). However, this analogue proved to be ineffective against 
L. major promastigotes. In an attempt to restore antiparasitic action, the amide was replaced 
by a flexible ether linker, providing 1-(2′-[dimethylamino]ethyl)-6-([{4′′-
chlorophenyl}{phenyl}methoxy]methyl)indazole. This analogue exhibited inhibition of LmjIPCS 
activity, with an IC50 of 4.72 µM, but only hindered growth of L. major promastigotes above 
5 µM. 
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Chapter 1: Introduction 
1. Introduction 
1.1 Overview 
The work within this thesis is aimed towards the discovery and development of potential 
chemotherapeutic agents for the treatment of the neglected parasitic disease leishmaniasis 
(caused by Leishmania spp.). The specific target of this project is the protozoan inositol 
phosphorylceramide synthase (IPCS), specifically Leishmania major IPCS. This enzyme presents 
an attractive drug target by virtue of the lack of a direct mammalian homologue, offering the 
possibility of drug candidates with low host toxicity. 
 This thesis comprises 9 chapters. Chapters 2 – 7 will discuss the work undertaken and 
the chemical and biological experimental procedures developed in these studies will be 
detailed in Chapters 8 and 9, respectively. The remainder of this first chapter outlines the 
background to the project. 
1.2 The Leishmaniases 
Neglected Tropical Diseases (NTDs) are a group of 17 diseases which are prevalent in poorer 
populations of the world, infecting over 1 billion people.1,2 A large proportion of these diseases 
result from parasitic infection. These diseases have been classified as ‘neglected’ due to their 
predominance in areas of poverty, as well as their relatively low priority on national and 
international health agendas.2 
Infection by obligate kinetoplastid parasites of the genus Leishmania cause a range of 
clinical manifestations collectively termed the leishmaniases. The disease is endemic in over 98 
countries and 3 territories, putting 310 million people at risk, with an estimated 1.3 million 
new cases emerging annually (Figure 1–1).3,4 
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Figure 1–1: Endemicity of cutaneous leishmaniasis and visceral leishmaniasis in 2013. 
Reproduced, with permission of the publisher, from the World Health Organisation (WHO) 
Global Health Observatory map gallery (http://www.who.int/gho/map_gallery/en/) 
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A conservative estimate of 30,000 deaths occur each year due to Leishmania infection.3 A 
more accurate indication of the impact of leishmaniasis is given by disability-adjusted life years 
(DALYs), as they take into account the morbidity of disease. Collectively, the leishmaniases 
inflict a loss of 3.32 million DALYs, accounting for 13% of all NTD-related DALYs lost.5,6 This 
impact is further compounded by the economic burden on already poverty-stricken areas, 
through restricted child development and crippled adult worker productivity.5,7  
1.2.1 Life cycle of Leishmania spp. 
The human infective variants of leishmaniasis are caused by about 21 of 30 species that infect 
mammals. These include the L. donovani complex with 3 species (L. donovani, L. infantum, and 
L. chagasi); the L. mexicana complex with 3 main species (L. mexicana, L. amazonensis, and 
L. venezuelensis); L. tropica; L. major; L. aethiopica; and the subgenus Viannia with 4 main 
species (L. (V.) braziliensis, L. (V.) guyanensis, L. (V.) panamensis, and L. (V.) peruviana).8  
These parasites reside in the midgut of the Phlebotomus and Lutzomyia sandfly vectors 
(Figure 1–2). In their log-phase procyclic promastigote form, they proliferate until they reach 
stationary phase. The parasites then transform into infective metacyclic promastigotes (a 
process called metacyclogenesis), which are transmitted to humans as the sandfly takes a 
blood meal. In the bloodstream they are phagocytised by macrophages, where they transform 
into their non-motile amastigote form, residing within the acidic phagolysosome. These 
amastigotes multiply and infect other tissues, giving rise to the clinical manifestations of 
Leishmania infection. The cycle is propagated when a sandfly ingests amastigote-infected 
blood. 
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Figure 1–2: Life cycle of Leishmania spp. Image provided by the Center for Disease Control 
and Prevention - Division of Parasitic Diseases (CDC-DPDx).  
1.2.2 Symptoms of leishmaniasis 
Three main disease states are possible, depending on the infective species. Cutaneous 
leishmaniasis (CL), most commonly caused by L. major, presents as ulcerations that may heal 
spontaneously. In more extreme cases, as with recidivans and diffuse cutaneous leishmaniasis, 
these lesions are chronic and difficult to treat.2  
Mucocutaneous leishmaniasis (MCL), caused mostly by Leishmania species of the 
Viannia subgenus, is the most disfiguring form involving the destruction of soft tissue in the 
nose, mouth and throat. Whilst they are non-fatal, CL and MCL can be extremely debilitating 
and stigmatise those afflicted.2  
By contrast, visceral leishmaniasis (VL), caused mainly by L. donovani, manifests as 
fever, hepatosplenomegaly and pancytopenia. It is the most severe form of Leishmaniasis; if 
left untreated it is always fatal. Even if effective treatment is given, the patient may then suffer 
from a cutaneous form known as post-kala azar dermal leishmaniasis.2  
 | 5 | 
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1.2.3 Current therapies  
There is currently no approved vaccine against Leishmania infection,5 so control of the disease 
relies on a limited number of drug treatments (Figure 1–3). 
 
Figure 1–3: Current therapies for leishmaniasis 
Key information on the individual therapies is provided in Table 1–1. Although a detailed 
description of the merits and challenges of current antileishmanial treatment is beyond the 
scope of this thesis, there exist a number of comprehensive reviews for further reading.9–11 
Generally, the available drugs for leishmaniasis suffer from a number of inadequacies. 
The majority of treatments require slow, often painful injections of active ingredients which 
carry significant toxicity issues. Although efforts have been made to mitigate specific issues, 
such as the advent of liposomal formulations of amphotericin B and the development of 
miltefosine (the only orally available antileishmanial), it remains that no single therapy for 
leishmaniasis exists that does not have a significant drawback. 
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Table 1–1: Current therapies for leishmaniasis 
Drug Route Mode of action (MOA) Toxicity Advantages Disadvantages 
Sb
V 
1, 2 IV, IM Sb
III
: trypanothione reductase;
12
 
Zn-finger proteins;
13
 increasing 
DNA fragmentation;
14
 increasing 
intracellular Ca
II 
concentration.
15
 
Sb
V
: stimulating macrophage 
microbicidal mechanisms.
16
 
Cardiotoxicity; pancreatitis; 
hepatotoxicity; 
nephrotoxicity.
17
 
Readily available; 
low cost (~$60).
9
  
Long, painful treatment; toxicity; resistance 
in India.
18
 
Amphotericin B 3  IV Complexes ergosterol to disrupt 
membranes.
19
 
 
Severe nephrotoxicity.
20
  High efficacy 
(>97%); low cost 
(~$20) 
Slow injection; high toxicity; thermal 
instability; resistance appearing in clinical 
isolates.
21
  
Amphotericin B 3 
(liposomal) 
IV  Low nephrotoxicity Well tolerated; 
reduced toxicity 
Very high cost ($280–3000); slow injection; 
thermal instability 
Miltefosine 4 PO Fatty acid and sterol metabolism;
22
 
cytochrome-c oxidase inhibition;
23
 
immunomodulatory inhibition of 
PI3k/Akt.
24
 
Mild gastrointestinal effects; 
teratogenicity; nephrotoxicity.
25
 
Only oral drug 
available 
Susceptibility differs across Leishmania 
species;
26
 long half-life (resistance risk);
27
 
teratogenic; relatively high cost ($65–150).
9
 
Pentamidine 5 IM Polyamine biosynthesis and 
uptake,
28
 DNA binding.
29
 
Death; diabetes mellitus; 
cardiotoxicity; nephrotoxicity.
30
 
 High toxicity; low efficacy;
11
 resistance.
31
  
 
Paromomycin 6 IM (VL), 
topical (CL) 
Inhibition of polyphenylalanine 
synthesis.
32
 
Mild hepatotoxicity; 
ototoxicity.
33
 
Low cost ($15).
9
 Painful injections;
33
 resistance in laboratory 
isolates;
34
 variation in efficacy.
35,36
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It is clear that there is an urgent need for antileishmanial treatments that are efficacious, orally 
available, cheap and do not suffer from significant toxicity or a high potential for resistance. 
The lack of such drugs results in part from underinvestment in drug discovery by the 
pharmaceutical industry. Between 2000 and 2011, only 3.8% of all registered drugs listed 
neglected or tropical diseases as the principal indication.37  
The past two decades have seen an increase in efforts toward controlling the global 
burden of neglected diseases. Product Development Partnerships (PDPs) such as Drugs for 
Neglected Diseases initiative (DNDi), PATH and the Sabin Vaccine Institute PDP were 
established between 1999 and 2011. These partnerships aim to co-ordinate the efforts of 
academia, the pharmaceutical industry, the public sector and philanthropic organisations 
towards drug development.38 Furthermore, in 2012, leading pharmaceutical companies, 
charities and NGOs announced their commitment to achieve goals set out by the WHO to 
control or eliminate ten NTDs by 2020.39  
1.2.4 Drugs in clinical trials 
Until novel therapies for leishmaniasis are brought to market, combination therapies have 
been investigated as a means of increasing efficacy and tolerance, as well as reducing 
treatment duration, cost and resistance potential.17,40 Combination therapies based on 
liposomal amphotericin B 3, miltefosine 4, paromomycin 6 and pentavalent antimonials 1 and 
2 are being developed and implemented throughout Africa, Asia and South America.41–43 
 Assessing different formulations of available drugs has been used as another method 
of addressing their drawbacks. The liposomal formulation of amphotericin B 3 successfully 
curtailed serious toxicity concerns and other reformulations have been investigated.44,45 
Clinical trials revealed a reduction in creatinine levels (indicative of lower nephrotoxicity), 
chills, rigors and nausea, when compared to conventional amphotericin B desoxycholate.46 
Recently, a pilot study in Iran focussed on the application of liposomal formulations of 
meglumine antimoniate 1 and paromomycin 6.47 
 Some new therapies are currently going through clinical trials, either as monotherapies 
or in combination with existing antileishmanials (Table 1–2 and Figure 1–4). 
  
C
h
ap
te
r 1
: In
tro
d
u
ctio
n
 
| 8
 | 
Table 1–2: Prospective new therapies for leishmaniasis in clinical trials 
Drug Description MOA Trials 
Sitamaquine 7 Oral VL treatment No defined mode of action.
48
 Phase II trials have been carried out in Africa.
49
 A recent phase II study in India 
displayed cure rates comparable to amphotericin B 3.
50
 
Fexinidazole 8 Oral VL treatment Putative activation by 
nitroreductases.
51
 
Recently terminated phase II trial in Sudan due to lack of efficacy.
52
 
Combination therapy with miltefosine 4 currently being evaluated.
53
 
Pentoxifylline 9 Oral CL treatment  Possible host immunomodulation.
54
  Combination treatment with Sb
V
 1 and 2 against MCL encouraging,
55
 but 
lacking against CL.
56
 Further Phase II/III trials taking place,
57
 including 
combination therapy with miltefosine 4.
58
 
Gentamicin 10 
(WR 279396) 
Topical combination therapy 
with Paromomycin 6 
Not leishmanicidal, but postulated to 
aid host immunity.
59
 
A series of Phase II trials studying New and Old World CL have been 
completed.
60,61
 Phase III trials are in progress.
62,63
 
Imiquimod 11 Topical combination therapy Boosts macrophage production of 
cytokines and NO.
64
 
Combination therapy with Sb
V
 1 and 2 not definitive.
65,66
 A study with oral 
miltefosine were conducted in Bolivia, but no results have been published.
67
 
Allopurinol 12 Oral treatment Putative inhibitor of protein 
synthesis;
68
 Purine salvage inhibitor.
69
 
Not effective as a monotherapy.
70
 Combination treatment with Sb
V
 1 and 2 
against CL has potential,
71
 and trials continue.
72
 
Azithromycin 13 Oral treatment Unknown in Leishmania.
73
 Clinical trials against CL infection proved ineffective.
74,75
 
Fluconazole 14 Oral treatment  Ergosterol biosynthesis inhibitor.
76
 Successful phase II trials of monotherapeutic fluconazole 14 have been carried 
out against CL,
77,78
 highlighting minor side effects (cheilitis and nausea). Phase 
III trials are underway.
79
 
Terbinafine 15 Oral or topical treatment Ergosterol biosynthesis inhibitor.
80
 Oral treatment and topical treatment in combination with Sb
V
 1 and 2 
promising.
81,82
 Phase I trials underway in Iran.
83,84
 
 | 9 | 
Chapter 1: Introduction 
 
Figure 1–4: Prospective new therapies for leishmaniasis 
Overall, the majority of current clinical trials are focussed on reformulating or combining 
existing antileishmanial treatments, or combination therapy with prospective new drugs. Of 
the new treatments being trialled, few have a clearly defined mode of action in Leishmania. As 
such, the potential for resistance through modification of protein targets, drug transport, and 
drug efflux remains a concern.70 Access to a diverse arsenal of drugs with different 
mechanisms of action and no cross-resistance will help avoid this problem. Despite the efforts 
described above, there remains a dearth of studies into novel therapies for leishmaniasis, and 
no new chemical entities (NCEs) are being trialled.37 
1.2.5 Drug discovery efforts 
With the advent of PDPs and commitment of the pharmaceutical industry to tackling NTDs, 
there are a number of potential new therapies for leishmaniasis on the horizon. A detailed 
analysis of the NTD drug discovery process is provided by a number of recent reviews.10,40,85–87 
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The following section will summarise the most promising candidates, and the paradigms used 
to discover them. 
1.2.5.1 Phenotypic screening 
The resources available to medicinal chemists tackling neglected diseases are limited when 
compared to conventional drug discovery. As such, researchers have had to work around a lack 
of funding, tools, validated targets and suitable assays.38 One way of doing this is through high-
throughput screening (HTS) of existing compound libraries (owned by private or public sector 
organisations) in whole cell assays against target organisms in a phenotypic assay (the desired 
phenotype being reduced cell viability).29 
Phenotypic screening campaigns have been used to discover NCEs with antiparasitic 
activity but unknown MOA (Figure 1–5). As part of a collaboration between Anacor 
Pharmaceuticals and DNDi, oxaborole SCYX-6759/AN-4169 16 was found to have micromolar 
activity against intracellular L. donovani amastigotes.88 Discovered in their Human African 
Trypanosomiasis drug discovery program, the compound also displayed a good 
pharmacokinetic profile in rats and primates.89 Further work identified a compound named 
DNDi-2035804 (structure unavailable), which despite showing good clearance of L. donovani in 
an animal model, failed toxicity screening.90 Similarly, aminopyrazoles, such as compound 17, 
were discovered in a Pfizer compound library screen,38 with reductions in parasitaemia of up to 
>99% being found in a hamster VL model. Studies continue with an aim to identify a lead 
compound in 2016.91  
 
Figure 1–5: Example hit compounds from phenotypic screening 
Nitroaromatic compounds have gained much attention for their potential as antiparasitics.92 
Nitroimidazole DNDi-VL-2001 18 was identified from a library of anti-tubercular compounds as 
having potent leishmanicidal activity (ED50 = 0.03 µM), in a screen against luciferase-expressing 
L. donovani (Figure 1–6).93 Specifically, the R-enantiomer, DNDi-VL-2098 (R)-18, displayed 
efficacy against L. braziliensis and L. major at sub-micromolar levels. DNDi-VL-2098 (R)-18 
exhibited high parasite clearance in vivo,93 and a favourable pharmacokinetic profile, with high 
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permeability, good oral bioavailability (37% – 100%) and a half-life of up to 6 h.94 However, 
recently discovered testicular toxicity in some animal models halted its progression to clinical 
trials.95 DNDi is currently investigating two nitroimidazooxazines DNDi-0690 and DNDi-8219 
(structures unavailable) as successors for oral treatment.96 
 
Figure 1–6: Nitroimidazole antileishmanial compounds 
Further pharmacophores discovered through whole cell phenotypic screening include 
azoles,97–99 chalcones,100,101 quinazolines,102,103 and quinolines.104,105 
Phenotypic screening campaigns have been preferred for NTD research due to their 
pragmatic nature. Hits from these screens are guaranteed to have drug-like properties under 
physiological conditions, potentially expediting pharmacokinetic optimisation.106 Furthermore, 
hits may act on several targets within the parasite, potentially reducing resistance risk. 
Nevertheless, there are some limitations to this strategy. Promastigote assays are still heavily 
relied upon for HTS campaigns due to their ease of operation. However, it has been estimated 
that only 4% of hits against promastigotes have an effect on intracellular amastigotes, 
highlighting their significant differences in biochemistry.107 Reflecting this, suitable 
intramacrophage assays are increasing in number, in an attempt to reduce the risk of false 
results.108–110 Advances in genomics and proteomics have improved target identification 
capability,111–113 but this may not be straightforward, especially when more than one molecular 
interaction is involved.114 This in turn may hamper optimisation of hit compounds.115 
1.2.5.2 Target-based strategies 
Despite the popularity of phenotypic screening approaches, target based strategies are 
important for the discovery of leishmanicidal compounds. Identifying protozoan enzymes 
which have no (or a substantially different) human ortholog can aid the development of 
selective drugs with low host toxicity.116 Further understanding of targets can be gained, 
assisted by advances in the ‘omics’.112,113 For example, studies across species, and at different 
life-cycle stages, can help identify broad-spectrum antileishmanials.116 Some of the approaches 
employed in the rational design of potential drugs are discussed below. 
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 N-Myristoyl transferase (NMT) enzymes, which catalyse protein modification with 
myristic acid, have been discovered as an attractive target for antitrypanosomal agents.117 
Recently, Hutton et al. published work on the development of a potent and selective inhibitor 
of L. donovani NMT.117 Hits from a high-throughput screen against LdNMT were identified, 
before X-ray crystallography and in silico approaches guided the synthesis of a novel inhibitor 
19 with Ki = 1.6 nM and a selectivity index (SI) of 17 against the human NMT1 (Figure 1–7). 
Unfortunately, cytotoxic activity against L. donovani extracellular amastigotes was not 
sufficient for further development (ED50 = 10 – 30 µM), this was attributed to poor cellular 
uptake. A separate study into Plasmodium falciparum NMT inhibitors revealed compound 20 
as a potent LdNMT inhibitor (Ki = 0.01 µM) (Figure 1–7).118 Once again however, this 
compound did not exhibit the desired leishmanicidal activity, displaying an ED50 of >50 µM 
against axenic L. donovani amastigotes.  
 
Figure 1–7: Leishmania N-myristoyl transferase inhibitors 
The trypanothione redox system, unique to kinetoplastids, has been the centre of much 
activity. Research by Fairlamb et al. highlighted trypanothione reductase (TR) as an essential 
enzyme in Leishmania.119,120 A number of compound classes which inhibit TR have been 
identified through in vitro and in silico work (Figure 1–8).121,122 However, issues of low 
selectivity and poor translation to antileishmanial activity have hindered further progress.121 
The wide, relatively featureless active site of TR and its similarity to the human homologue, 
glutathione reductase, are possible reasons for the observed poor selectivity.85,123 Other 
potential targets in the trypanothione pathway are the essential enzymes trypanothione 
synthetase and tryparedoxin peroxidase.85 
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Figure 1–8: Inhibitors of Leishmania trypanothione reductase 
Other putative antileishmanial drug targets have been reviewed recently;10,85,116 notable 
examples include kinases,124–126 sterol biosynthesis,127,128 folate biosynthesis;129,130 
topoisomerases,131–133 and proteases.134,135 
 In spite of these efforts, it remains that target based approaches are generally less 
successful than phenotypic screening methods.136 One key criticism is the disparity between 
potency against enzyme and target organism.115 This may be due to instability within the acidic 
parasitophorous vacuole,137 ineffective penetration of the parasite’s unique cell surface,138 or 
susceptibility to removal via metabolism or efflux.115,137 With the comparative lack of resources 
available for NTD drug discovery, it remains a large endeavour to develop a rationally designed 
drug molecule with a specific mode of action. 
1.2.5.3 ‘Piggy-back’ approaches 
Another strategy, known as ‘piggy back’ drug discovery, makes use of phenotypic and 
target-based approaches to exploit compounds which have known biological function in other 
organisms.87 Provided the target parasite has an orthologous enzyme, these compounds may 
provide a good starting point for hit to lead studies.  
 Histone deacetylase (HDAC) enzymes are popular targets in oncological drug 
discovery; two inhibitors are currently approved for T-cell lymphoma treatment in the US, and 
other potential anti-cancer drugs are in clinical studies.139 A recent study was conducted in 
which known inhibitors of human lysine deacetylase (KDAC) enzymes were tested against a 
range of parasitic pathogens.140 Hydroxamate 21 was found to have sub-micromolar activity 
against axenic L. donovani amastigotes (Figure 1–9). Future aims are centred on identifying 
Leishmania KDACs and in silico homology modelling with human enzymes to inform the 
development of selective inhibitors. In a separate investigation into HDAC inhibitor analogues, 
triazole 22 was found to have modest activity against L. donovani promastigotes 
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(EC50 = 15.8 µM) (Figure 1–9).
141 These studies highlight deacetylase enzymes as potential 
therapeutic targets for Leishmania infection.  
 
Figure 1–9: Deacetylase enzyme inhibitors discovered via a ‘piggy back’ approach 
Recently, a high-throughput screen of the GlaxoSmithKline diversity set of 1.8 million 
compounds was conducted against L. donovani at 5 µM.142 The potential modes of action for 
hits were found by comparing known human protein targets with the parasite genome; from 
this, kinases were revealed as the most common target, alongside proteases, cytochromes and 
phosphodiesterases. Over the past few years, vast amounts of data from such phenotypic 
screens have been made publically accessible.143 In addition, some compound sets are freely 
available for use, circumventing a previous road block to academic researchers.144 
1.2.5.4 Drug repurposing, repositioning and rescue 
Discovering and developing a NCE drug is estimated to cost ~$US800 million and take up to 20 
years.87 The investigation of already licenced medicines has become a popular method of 
shortening the drug discovery process for neglected diseases. A drug may be repurposed 
(applied to a new disease), repositioned (used as a template for further development against a 
new indication), or rescued (applied to a new disease after being abandoned from its original 
use). These terms are generally used interchangeably. The main advantage of this technique is 
that candidates have passed through several stages of clinical trials and hence have well 
understood pharmacokinetic and safety profiles.145,146 
 This is not a new concept in antileishmanial drug development, most of the currently 
used medicines were initially utilised against other diseases. Amphotericin B 3 is a repurposed 
antifungal treatment,147 paromomycin 6 a broad spectrum antibiotic,148 and miltefosine 4 a 
failed antineoplastic agent.149 Furthermore, many of the therapeutics undergoing clinical trials 
(Table 1–2 above) are currently licenced for other indications. A recent screen of 
agrochemicals against L. donovani and the suggestion that veterinary medicines are an 
untapped resource highlight the fact that research is extending beyond repurposing human 
therapeutics.87,150  
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1.3 Inositol phosphorylceramide synthase (IPCS) 
1.3.1 Sphingolipids 
Sphingolipids (SLs) are a class of amphipathic lipids which form a major component of 
eukaryotic membranes, particularly the plasma membrane.151 Additionally, they are key 
signalling components, implicit within a range of biological processes including cell growth, 
membrane trafficking and apoptosis.152–154 SLs are characterised by an amino alcohol backbone 
unit, termed a sphingoid base, with varying head group functionalities and N-acyl substitution 
(Figure 1–10). Sphingoid bases differ vastly across nature, with variations in unsaturation, 
hydroxylation and alkyl chain tail being observed.155 Because of this, there exists significant 
diversity in the structures of the principal sphingolipid species of mammals, fungi and plants, 
and the kinetoplastids. 
 
Figure 1–10: Variation in sphingoid bases and sphingolipids 
1.3.2 De novo synthesis 
The biochemical synthesis of SLs in eukaryotes begins with the rate-limiting condensation of 
˪-serine 23 and palmitoyl CoA 24 to form 3-ketodihydrosphingosine 25, a reaction catalysed by 
serine palmitoyltransferase (SPT) (Scheme 1–1).156 Following reduction to dihydrosphingosine 
26 by 3-ketodihydrosphingosine reductase and NADPH, divergence in the metabolic pathway is 
encountered.156,157  
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Scheme 1–1: Conserved sphingolipid biosynthetic pathway 
In mammals, dihydrosphingosine 26 is subjected to N-acylation followed by unsaturation to 
afford ceramide 27, whereas in fungi and higher plants, a hydroxylation step with successive N-
acylation forms phytoceramide 28 (Scheme 1–2).156 Subsequently, these simple sphingolipids 
are transported from the endoplasmic reticulum to the Golgi apparatus, where they may 
undergo further biosynthetic transformations. In mammalian cells, attachment of a choline 
head group to ceramide 27 via a phosphate ester linkage gives the principal sphingolipid 
sphingomyelin (SM) 29, a process catalysed by sphingomyelin synthase (SMS).156 In contrast, 
fungi and higher plants use inositol phosphorylceramide synthase (IPCS) to append a 
phosphoinositol head group onto phytoceramide 28, furnishing inositol phosphorylceramide 
(IPC) 30B.156 Kinetoplastids, such as Leishmania, also form their principal sphingolipid 30A via 
IPC synthase.158,159 Interestingly, despite having separate functions, the human SM and 
protozoan IPC synthases both utilise ceramide 27 as a common substrate.  
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Scheme 1–2: Divergent sphingolipid biosynthetic pathways. IPC refers to the general class of 
complex sphingolipids containing the inositol sugar group. For clarity, the kinetoplastid and 
plant/fungal IPCs discussed in this chapter are labelled 30A and 30B respectively. 
1.3.3 Sphingolipid metabolism and function in Leishmania 
While sphingolipid biosynthesis in Leishmania has not been studied in its entirety, the majority 
of efforts have focussed on characterising the first step of de novo synthesis, catalysed by SPT, 
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and IPC synthesis. The discoveries made will be discussed below, including an evaluation of the 
SL biosynthetic pathway as a therapeutic target. 
1.3.3.1 Serine palmitoyl transferase (SPT) 
Studies by the Denny and Beverley groups found that SPT in L. major promastigotes is fully 
functional during log-phase growth of the procyclic form, but is gradually downregulated 
during metacyclogenesis, when the parasite differentiates to its metacyclic form.160–162    
Furthermore, SPT knock-out (spt2−) mutant L. major promatigotes, generated by ablation of 
the SPT2 subunit gene, were found to be viable in the procyclic stage, but unable to conduct 
metacyclogenesis.160,161 This observation suggests that de novo SL synthesis is necessary for 
differentiation in promastigotes.160 Indeed, SL-free spt2− L. major promastigotes exhibited poor 
infectivity against macrophages and mice, reflecting an inability to form infective metacyclic 
parasites.160,161 Interestingly, SPT was found to be inactive in L. major amastigotes, and 
intracellular spt2− amastigotes were able to maintain their virulence in vitro and in mice. This 
implies that de novo SL synthesis is important for initial infection by metacyclic promastigotes, 
but is not essential for pathogenesis within macrophages.160,162 By contrast, preliminary 
metabolomics and proteomics work on L. mexicana showed that LmxSPT is not downregulated 
in amastigotes, although the implications of this have yet to be revealed.163,164 
Myriocin 31 (a potent SPT inhibitor) and fumonisin B1 32 (an inhibitor of 
dihydroceramide synthase) do not inhibit proliferation of L. major promastigotes or 
intracellular amastigotes (Figure 1–11).162 Similarly, promastigotes and amastigotes of 
L. mexicana prove resistant to myriocin 31,163 although fumonisin B1 32 inhibits replication of 
intramacrophage L. donovani.165 Recently, myriocin 31 was found to inhibit sphingolipid 
synthesis in L. braziliensis promastigotes, disrupting growth and cytokinesis.166 This differential 
activity of SL biosynthesis inhibitors across Old and New World Leishmania species is indicative 
of complex interactions which require further analysis.  
 
Figure 1–11: Inhibitors of early sphingolipid biosynthesis 
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1.3.3.2 Inositol phosphorylceramide synthase (IPCS) 
Inositol phosphorylceramide 30A (IPC) is the principal complex sphingolipid of Leishmania, 
accounting for 5 – 10% of total cellular lipids,158 comprising a key component of detergent 
resistant membranes (DRMs), or lipid rafts, in Leishmania promastigotes.167–169 Both wild type 
(WT) and spt2− L. major amastigotes, in which de novo SL synthesis is absent, were discovered 
to have an active IPCS enzyme, using salvaged host SL metabolites to produce IPC 30A at levels 
comparable to those observed in WT promastigotes.162 It is worth noting that phagocytised 
L. donovani upregulate the production of host ceramide 27, which may act as a feedstock for 
IPC 30A synthesis.170 The fact that L. major amastigotes maintain high levels of IPC 30A may 
indicate that this complex SL is required for survival within host macrophages. Indeed, 
remodelled host sphingolipids were implicated in the maintenance of acidocalcisomes in 
L. major promastigotes and amastigotes.162 Acidocalcisomes are organelles which have been 
found to be important for stress responses and growth in the related protozoa Trypanosoma 
cruzi and Trypanosoma brucei.171,172 Thus, targeting the synthesis of IPC 30A in Leishmania may 
have therapeutic potential. 
Aureobasidin A (AbA) 33, a potent fungal IPCS inhibitor,173 has been tested against 
promastigotes of L. amazonensis, L. braziliensis and L. major, exhibiting ED50 values of 4.1 µM, 
13.7 µM and 12.6 µM respectively (Figure 1–12).168,174 However, the action of AbA 33 against 
Leishmania does not seem to be caused by IPCS inhibition. Denny found AbA 33 to be effective 
against mutant spt2− L. major promastigotes, where de novo SL synthesis is absent, rendering 
IPCS activity redundant.159 A further experiment against Leishmania major IPCS, expressed in a 
mutant yeast system, found that AbA 33 has no effect until 100 µM, confirming that AbA 33 
acts against Leishmania through a different, unknown mechanism.159 This data highlights a 
significant difference between the IPC synthases of Leishmania and yeast.  
 
Figure 1–12: Aureobasidin A 33, a potent fungal IPCS inhibitor 
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1.3.3.3 Sphingolipid degradation 
Studies by Zhang on SL degradation revealed the presence of a homolog of human 
sphingomyelinase (SMase) in L. major.175 This inositol phosphosphingolipid phospholipase 
C-like (ISCL) protein was found to have dual SMase and IPCase activity, presumably for the 
breakdown of both host salvaged SM 29 and endogenous IPC 30A. ISCL-null promastigote 
mutants (iscl−) proliferated in a normal manner in vitro, but failed to proliferate or cause 
pathology in immunocompetent or even immunodeficient mice.176 Iscl− L. major promastigotes 
were also found to be vulnerable in acidic medium (pH 5), explaining their inability to survive 
within the acidic phagolysosomes of murine macrophages.176 Further work showed that the 
breakdown of IPC 30A conferred acid resistance to promastigotes during initial infection, but 
SM 29 degradation was responsible for enabling virulence and proliferation of amastigotes in 
mice.177  
ISCL in L. amazonensis promastigotes was found to have an expression profile and 
biochemical properties similar to its ortholog in L. major.178 Mutants lacking LaISCL 
accumulated IPC 30A, and could still undergo transformation to axenic amastigotes, but, as 
expected, had lower survival levels in acidic (pH 5.3) media. Unlike L. major iscl− parasites, 
however, L. amazonensis mutants were fully infective against BALB/c mice.178  
Zhang et al. investigated another enzyme involved in SL degradation, sphingosine-1-
phosphate lyase (SPL).179 A study of spl− mutant L. major promastigotes exhibited phenotypes 
similar to those observed in SL free spt2− parasites. Ethanolamine was found to reverse the 
viability and differentiation defects of these mutants; it was put forward that an important role 
of SL synthesis and degradation in Leishmania is the production of ethanolamine phosphate, a 
metabolite essential for metacyclogenesis.179 However, in myriocin 31 treated L. braziliensis, 
defects in growth and cytokinesis were not rescued by ethanolamine, but rather the addition 
of 3-ketodihydrosphingosine 25.166 Furthermore, ISCL activity does not seem to be related to 
ethanolamine production,175 which may relate to the observation that L. major amastigotes 
either do not require ethanolamine, or scavenge it from host macrophages.179 Thus, while SL 
metabolism may be important for ethanolamine production in L. major promastigotes, it does 
not seem to fill this role for amastigotes or other Leishmania species. 
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1.3.3.4 Leishmania SL synthesis as a therapeutic target 
Although the full role of sphingolipid synthesis in Leishmania has yet to be realised, it remains 
that metabolites along the biosynthetic pathway must maintain a fine balance. For example, 
preliminary work on a sphingosine kinase (SK) in L. major revealed that ska− knock out 
mutants, lacking the sphingosine kinase A enzyme, had compromised viability due to toxic 
accumulation of sphingoid bases and susceptibility to the host immune system.180 Ceramide 27 
is well known for its function in apoptosis (programmed cell death).181–184 Reports detailing the 
modulation of ceramide 27 activity by sphingosine-1-phosphate and diacylglycerol (DAG) 
species highlight the delicate balance of cell growth and death.185,186 More specifically, DAG 
produced by sphingomyelin synthase activity is important for the proliferation of mammalian 
cells.187–189 Thus, interfering with intracellular levels of ceramide 27 and DAG, respective 
substrate and by-product of IPCS, in Leishmania can potentially trigger apoptosis, whilst 
starving the parasite of mitogenic DAG. The Leishmania IPCS therefore represents an attractive 
drug target.159,190 Furthermore, the differential function of human SMS opens up an 
opportunity to develop specific inhibitors of Leishmania IPCS which will have low host 
toxicity.159  
1.3.4 Leishmania major IPCS 
1.3.4.1 Precedent of fungal IPCS as a drug target 
In pathogenic fungi, IPCS, encoded by the AUR1 gene, has been investigated as a viable 
therapeutic target, due to the lack of a mammalian equivalent.191,192 The enzyme, located 
within the Golgi apparatus,193 was found to be essential for survival, as mutants of 
Saccharomyces cerevisiae lacking IPCS accumulated ceramide, leading to cell death.192 
Furthermore, mutagenesis of the catalytic triad (two histidines and one aspartate) inactivated 
the enzyme and prohibited cell growth.193 Of particular note is the discovery that IPCS is 
required for virulence and growth of Cryptococcus neoformans, a pathogenic yeast which, like 
Leishmania, resides inside host phagolysosomes.194 A number of IPCS inhibitors have been 
described that demonstrate potent antifungal activity.173,195,196 
1.3.4.2 Discovery of LmjIPCS  
Denny et al. identified the single copy gene encoding the functional AUR1 orthologue from 
L. major (LmjIPCS, LmjF35.4990) through bioinformatics and functional genetic methods.159 
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Phylogenetic analysis defined LmjIPCS as belonging to a class of kinetoplastid SL synthases 
distinct from fungal and mammalian orthologues.  
Leishmania major IPCS is a membrane bound protein, localised within the Golgi 
apparatus, comprised of 338 amino acids with a mass of approximately 38 kDa (Figure 1–13). 
The enzyme contains a putative catalytic triad of conserved histidine and aspartate residues, as 
defined in the orthologous yeast IPCS and animal SMS enzymes.197,198 As LmjIPCS is an integral 
membrane protein, traditional structure elucidation methods, such as protein crystallography, 
remain a significant challenge. Thus, the true structure of LmjIPCS remains unknown. However, 
a hypothetical topology model was proposed by Sutterwala et al., based on alignment of 
kinetoplastid SLS sequences with a model for human SMS2 (Figure 1–13).198,199 Interestingly, 
despite possessing functional similarity to fungal IPC synthases, LmjIPCS shares greater 
similarity with mammalian SMS enzymes, perhaps due to the requirement for ceramide 27 as a 
substrate.159,199 
 
Figure 1–13: Top: LmjIPCS protein sequence, with highlighted catalytic triad; Bottom: Bangs’  
theoretical topology of kinetoplastid SLS with highlighted catalytic triad. Reprinted with 
permission.199 
1  MTSHVTAHDV  GGNEDIGTDH  VPWYKQPLPL  CTQVMRFILL  LLLTVMFLGV   
51 AILVANARMP  DPEKVRPLPD  LLLESIPKVA  LLENGTNVII  FLLNATTVVV   
101 GFKVFLLERH  MNGLPRVTFL   VGVPKIGSFL  NRMAFGVLDS  GRRPFPLKNV   
151 FPIMAIRFLT  SYAVVMVFRA  FVIMGTSYPA  TDNHCQNPQV IEHPVLNVIL   
201 TLVTLGSGAI  HCGDLMFSGH  TMILSLAFIL  AWDYSPFLHP  WAVRVWVSVL   
251 LPISYYCILA  SRSHYTDDIL  VAMYVMIATY  KVIDHAETGA  PWQMQLLIRW  
301  MPWPGANTIE  KWTADEVVVV  VQTPAEDSTD  ASAALPEH 
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1.3.4.3 Genetic validation of LmjIPCS 
Methods for genetic manipulation of Leishmania suffer from a number of limitations. 
Leishmania is an asexual diploid, hindering forward and reverse genetic methods and requiring 
two rounds of gene targeting to generate null mutants.200,201 Further complications arise from 
the tendency of Leishmania towards ‘mosaic aneuploidy’,202,203 meaning additional copies of 
essential genes may still be found, even after two rounds of targeting.204 
Utilisation of RNA interference (RNAi), a popular method of supressing gene 
expression, is not viable for Old World species, such as L. major and L. donovani, as they lack a 
functional RNAi pathway.111,200 Interestingly, however, New World L. braziliensis possesses a 
full complement of RNAi pathway genes;205,206 the source of this incongruity between 
Leishmania species remains unclear.207 
Denny et al. sought to create ipcs− mutant L. major through homologous 
recombination. This did not prove to be possible with WT promastigotes, presumably due to 
an accumulation of toxic metabolites (data unpublished). Attention then turned towards 
targeting LmjIPCS in spt2− L. major, where the lack of de novo SL synthesis would ensure no 
lethal build-up of biosynthetic intermediates. Removal of the first LmjIPCS chromosomal gene 
was facile, but upon attempting removal of the second gene copy it became apparent that the 
parasite avoided loss of the enzyme by translocation of the coding region (data unpublished). 
This phenomenon has previously been observed for other essential genes.208 Thus, a 
Leishmania major mutant lacking a functional IPC synthase remains elusive. Nevertheless, the 
sphingolipid deficient spt2− L. major mutant may serve as a proxy to test the selectivity of 
potential IPCS inhibitors, as the LmjIPCS enzyme is redundant in these parasites. 
1.3.4.4 Characterisation of LmjIPCS 
Mina characterised the Leishmania major IPC synthase enzyme, through development of a cell-
free microtiter plate compatible assay, adapted from a method used for the study of the 
orthologous Candida albicans AUR1p enzyme (Scheme 1–3).209,210 Firstly, a mutant S. cerevisiae 
yeast strain (YPH499–HIS–GAL–AUR1 pRS246–LmjIPCS), under which ScAUR1 production is 
repressed in the presence of glucose,159 was used for the isolation of microsomal membranes 
enriched in LmjIPCS.209 This microsomal material was used to measure the conversion of 
fluorescent NBD-C6-ceramide 34 to NBD-C6-IPC 35, with the respective substrate and product 
being separated by anion exchange chromatography prior to fluorescence spectroscopy. 
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Scheme 1–3: LmjIPCS biochemical assay (see Section 9.4 for further information) 
Using this method, the kinetic parameters of LmjIPCS were examined, showing the enzyme 
function to occur via a bi-bi (ping-pong) model with double displacement kinetics (Scheme 1–
4).209 Furthermore, ceramide 27 was found to have a higher affinity for the enzyme than 
phosphatidylinositol (PI) 36; which, when taken into account with the observation that PI 36 is 
relatively abundant, suggests that ceramide 27 is the rate-limiting substrate in this 
reaction.158,209  
 
Scheme 1–4: Catalytic cycle of LmjIPCS 
Further work by Mina centred on probing the ceramide binding domain of LmjIPCS through 
synthesis of a number of ceramide analogues.190 Utilising the 96-well plate compatible assay 
introduced above (Scheme 1–3), coupled with mass spectrometry analysis, a number of 
structure-activity relationships (SARs) were uncovered (Figure 1–14). Additionally, ceramide 
analogue 38 demonstrated cytotoxicity against L. major promastigotes, including modest 
selectivity over the SL free spt2− mutant, serving as chemical validation of LmjIPCS as a viable 
target.190 
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Figure 1–14: SAR of ceramide analogues and free amine derivative 38 
Similarities between this work and reported activity of sphingosine analogues against a lipid 
phosphate phosphatase (LPP),211 combined with the observation of conserved catalytic 
residues between LPP and SLS enzymes,159,198 point towards a common mechanism of action. 
Sigal et al. proposed a general mechanism for phosphoryl transferase enzymes, which include 
LPPs and SLSs, which was adapted by Mina et al. to propose a putative mechanism of action 
for LmjIPCS (Figure 1–15).190,212 Of particular note is the conserved Arg262 residue, which is 
assumed to be protonated to provide electrostatic stabilisation of the negatively charged 
transition state. It was postulated that the ammonium salt of sphingosine analogue 38 may 
interfere with this interaction, giving rise to the observed IPCS inhibition.190 
 
Figure 1–15: Left: Sigal’s proposed general mechanism of lipid phosphatases;212 Right: Sigal’s 
model applied to the putative mechanism of LmjIPCS 
1.4 Previous work within the group 
Utilising the assay described above (Scheme 1–3),209 a 1040 member set of pharmacologically 
active compounds* was screened at 20 µM against the LmjIPCS enzyme (data unpublished) 
(Figure 1–16). Fifty-seven compounds were found to exhibit >70% inhibition of the IPC 
                                                          
*
 National Institute of Neurological Disorders and Stroke (NINDS) library, supplied by Medical Research 
Council Technology (MRCT) Ltd. 
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synthase; analysis of Z-factor values confirmed that all data obtained was of excellent 
quality.213  
 
 
Figure 1–16: Top: Primary biochemical screen of NINDS set against LmjIPCS; Bottom: 
Calculation of Z-factor values as a measure of data quality. 
A second round of screening was conducted, in which these 57 inhibitors were tested for 
cytotoxicity against L. major promastigotes at 10 µM (data unpublished) (Figure 1–17). Using a 
resazurin-based cell-viability assay,214 the majority of compounds were found to inhibit 
promastigote growth after 24 hours. In order to assess the difference between cytostatic and 
cytotoxic agents, the assay was repeated with a post-dosage incubation of 72 hours. As 
expected, the activity of most compounds diminished, leaving known cytotoxic agents (red 
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bars), the control amphotericin B 3 (lane 59) and a number of new inhibitors (green bars). 
Following removal of the known cytotoxic compounds, included in the library as controls, 16 
new inhibitors were identified as potential lead structures. These represented the starting 
point for the work described in the following chapter. 
 
 
Figure 1–17: Cytotoxicity of compounds from NINDS library against L. major promastigotes. 
Top: 24 hrs post dosage and Bottom: 72 hrs post dosage with compounds. (Lane 1: no 
inhibitor; Lane 59: amphotericin B control; Lanes 2, 4, 26, 38, 39, 53 and 56 (red bars) are 
known non-selective cytotoxic compounds; Lane 22 is the known antileishmanial 
pentamidine 5). 
1.5 Project objectives 
In light of the preliminary data obtained from the NINDS library screen, the first objective was 
to continue analyses of the 16 chosen inhibitors. Confirmation of hit compound activity would 
be carried out, prior to a challenge against the clinically relevant amastigote form of 
Leishmania major.  
0%
20%
40%
60%
80%
100%
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59
%
 P
ar
as
it
e
 c
yt
o
to
xi
ci
ty
 
Compound number 
L. major promastigote assay 10 µM - 24 hours incubation 
0%
20%
40%
60%
80%
100%
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59
%
 P
ar
as
it
e
 c
yt
o
to
xi
ci
ty
 
Compound number 
L. major promastigote assay 10 µM - 72 hours incubation 
 | 28 | 
Chapter 1: Introduction 
Subsequent work would then focus on chemical elaboration of the most promising 
hit(s) from the NINDS set, with a view to generating SAR data to probe the Leishmania major 
IPCS enzyme. This data would inform the synthesis of a second generation of LmjIPCS 
inhibitors with leishmanicidal action. 
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2. NINDS Library Screen 
The results within this chapter comprise work carried out by the Denny group. Other than the 
exceptions detailed in Table 2–1 and Figure 2–2, all work is the author’s own. The experiments 
in Section 2.2 were undertaken by the author at the London School of Hygiene and Tropical 
Medicine, with guidance kindly provided by Dr Yardley and Professor Croft. 
2.1 Confirmation of hit compound activity 
The screening data, and structures, of the 16 compounds identified via the efforts discussed in 
Section 1.4 are displayed below (Table 2–1 and Figure 2–1). 
Table 2–1: Preliminary screening data from the chosen NINDS library hits, carried out by 
J.G.M. Mina with compounds supplied by Medical Research Council Technology Ltd 
Compound LmjIPCS inhibition (20 µM) L. major inhibition 72 h (10 µM) 
Amlodipine 39 80% 62% 
Chlorpromazine 40 88% 76% 
Clemastine 41 83% 61% 
Clomiphene 42 76% 65% 
Doxepin 43 74% 44% 
Fendiline 44 71% 74% 
Flunarizine 45 74% 56% 
Pararosaniline 46 78% 75% 
Pentamidine 5 86% 6% 
Pimozide 47 77% 56% 
Prochlorperazine 48 83% 11% 
(±)-Propranolol 49 73% 84% 
Sertraline 50 78% 48% 
Sulfamethizole 51 77% 68% 
Suloctidil 52 81% 74% 
Trifluoperazine 53 86% 67% 
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Figure 2–1: NINDS library hit compounds selected for further study 
The antileishmanial activity of the structurally similar tricyclic compounds prochlorperazine 48 
(11%), chlorpromazine 40 (76%) and trifluoperazine 53 (67%), at 10 µM, were found to differ 
significantly (Table 2–1). It was postulated that the observed difference either reflected a 
genuine structure-activity relationship (SAR) finding, or was a discrepancy caused by the 
plausible presence of degradation products in the supplied DMSO solutions. Indeed, this 
phenomenon has been previously reported with prolonged storage of DMSO solutions.215 
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Furthermore, this latter hypothesis was corroborated by the fact that the supplied 
pentamidine 5, a known antileishmanial drug, exhibited uncharacteristically low parasiticidal 
activity (6% after 72 h incubation). 
In order to confirm the activity observed with the chosen hit compounds, pure 
material from commercial sources was used in a dose-response study against Leishmania 
major IPCS and promastigote parasites (Figure 2–2). IC50 values could not be determined for 
pararosaniline 46 and sulfamethizole 51, which also exhibited poor antileishmanial activity 
(ED50 = 9.78 µM and 39.6 µM respectively). Interestingly, whilst IPCS inhibition was confirmed 
for doxepin 43 and pimozide 47, these compounds displayed ED50 values significantly higher 
than 10 µM against L. major promastigotes (30.0 µM and 22.9 µM respectively). These 
observations disagree with the inhibition values observed in the initial NINDS library screen 
(c.f. Table 2–1), plausibly due to the presence of degraded material. 
The tricyclic compounds chlorpromazine 40, prochlorperazine 48 and trifluoperazine 
53 all displayed similar inhibitory effects against L. major IPCS (Figure 2–2). Furthermore, no 
significant difference was found between the antileishmanial activity of prochlorperazine 48 
(ED50 = 12.9 µM, 95% CI: 11.3 – 14.7 µM) and that of chlorpromazine 40 (ED50 = 9.80 µM, 95% 
CI: 6.94 – 13.9 µM), indicating that the disparate values in Table 2–1 may be due to error or 
compound degradation. It is worth noting, however, that the leishmanicidal activity of 
trifluoperazine 53 (ED50 = 7.17 µM, 95% CI: 6.28 – 8.19 µM) was found to be nearly double that 
of prochlorperazine 48. This highlights an interesting structure-activity relationship for these 
tricyclic inhibitors: meta-trifluoromethylation is preferred over meta-chlorination for 
antileishmanial activity. 
Pentamidine 5 was confirmed as an inhibitor of LmjIPCS, displaying an IC50 value of 
3.10 µM (95% CI: 2.20 – 4.35 µM). Moreover, the comparatively lower ED50 value (2.05 µM, 
95% CI: 1.34 – 3.00 µM), obtained against L. major promastigotes, reflects the additional 
known modes of action of pentamidine 5 (see Table 1–1). 
Comparatively, the compounds clomiphene 42, fendiline 44, (±)-propranolol 49 and 
sertraline 50 were all found to display moderate biochemical and antileishmanial activity. In 
addition, for the individual compounds, there do not seem to be any notable disparities 
between the data in Table 2–1 and Figure 2–2. For these reasons, the compounds were not 
studied further. 
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Figure 2–2: Comparison of IC50 vs. LmjIPCS and ED50 vs. L. major promastigotes. Error bars portray 95% confidence interval. IC50 data was gathered by the 
author. ED50 data was gathered by J.G.M. Mina. 
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Four compounds exhibited antileishmanial activity exceeding that of pentamidine 5 (Figure 2–
2). Amlodipine 39 (ED50 = 1.91 µM, 95% CI: 1.70 – 2.16 µM), clemastine 41 
(ED50 = 0.47 µM, 95% CI: 0.37 – 0.59 µM), flunarizine 45 (ED50 = 1.73 µM, 95% CI: 1.28 – 
2.33 µM) and suloctidil 52 (ED50 = 1.33 µM, 95% CI: 1.07 – 1.66 µM) were all selected for 
further investigation. Interestingly, these compounds were found to have higher potency 
against promastigotes than the LmjIPCS enzyme. This phenomenon may be attributed to 
multiple factors, for example: activity against more than one enzyme (pleiotropism); increased 
concentration around the Golgi apparatus where LmjIPCS is predicted to be localised;159 or 
conversion of compounds to metabolites with enhanced cytotoxicity. 
 Overall, the majority of the 16 NINDS compounds that were retested were confirmed 
to have micromolar activity against the LmjIPCS enzyme and L. major promastigote parasites. It 
is interesting to note that many of these compounds have structural similarity, in that they 
contain both an aryl-rich portion and an amine moiety, connected via an aliphatic linker. It was 
acknowledged that no significant SAR data could be drawn from the above results and hence 
further investigation would be required. 
2.2 Activity against intramacrophage L. major amastigotes 
The most effective leishmanicidal compounds, amlodipine 39, clemastine 41, flunarizine 45 
and suloctidil 52, were tested against murine peritoneal macrophages infected with 
Leishmania major amastigotes. Whilst flunarizine 45 only displayed activity at concentrations 
greater than 30 µM (data not shown), amlodipine 39 (ED50 = 3.65 µM, 95% CI: 3.42 – 3.89 µM), 
clemastine 41 (ED50 = 3.06 µM, 95% CI: 2.57 – 3.66 µM) and suloctidil 52 (ED50 = 4.28 µM, 95% 
CI: 3.64 – 5.04 µM) exhibited micromolar inhibition of parasite growth (Figure 2–3). 
Macrophage cytotoxicity was observed for concentrations of amlodipine 39 and suloctidil 52 
over 10 µM, and clemastine 41 over 20 µM, hindering a more accurate assessment of activity. 
This cytotoxicity was confirmed against uninfected macrophages (Figure 2–3). 
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Figure 2–3: Activity against intramacrophage L. major and cytotoxicity of clemastine 41. 
Error bars portray 95% confidence interval. 
Nevertheless, the in vivo safety profile of clemastine 41 is well documented,216,217 with oral 
LD50 values of 730 mg.kg
−1 (mouse) and 3550 mg.kg−1 (rat).216 Furthermore, clemastine 41 
displays low toxicity against human liver HepG2 cells (ED50 > 50 µM),
218 and low 
cardiotoxicity.219 Due to its reported safety, and the observed potency against L. major 
promastigotes and clinically relevant amastigotes, clemastine 41 was advanced as the lead hit 
from the NINDS library screen. 
2.3 Clemastine activity against spt− L. major mutant  
To establish whether the antileishmanial action of clemastine 41 occurred via its activity as an 
inhibitor of LmjIPCS, experiments were conducted with the sphingolipid-free spt2− Leishmania 
major mutant.160 Whilst these parasites contain a functional IPC synthase, the lack of de novo 
synthesised ceramide renders IPCS activity redundant. The dose-dependent growth inhibition 
of spt2− L. major was assessed, revealing an ED50 of 8.65 µM (95% CI: 7.08 – 10.56 µM) and a 
selectivity index of ~20, compared to wild type promastigotes (Figure 2–4). By contrast, 
amphotericin B 3 maintained sub-micromolar activity against the mutant promastigotes 
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(ED50 = 0.15 µM, 95% CI: 0.08 – 0.27 µM against spt2
−; ED50 = 0.11 µM, 95% CI: 0.10 – 0.13 µM 
against WT), highlighting its separate mode of action (see Table 1–1). 
  
Figure 2–4: Activity of clemastine 41 against SL-deficient L. major promastigotes. Error bars 
portray 95% confidence interval. 
The ability of clemastine 41 to inhibit IPCS in cellulo was measured in an experiment where 
spt2− L. major were incubated with clemastine 41 for 18 h prior to the addition of ceramide 
labelled with a BODIPY fluorophore (Figure 2–5). The use of this cell line ensured that IPCS 
activity relied solely on the addition of exogenous ceramide. Following cell lysis, fluorescent 
ceramide and IPC were separated via high performance thin layer chromatography (HPTLC) 
and quantified through fluorescence spectroscopy. Cells were incubated in media lacking 
foetal bovine serum (FBS) to ensure only fluorescent ceramide was metabolised by the active 
IPC synthase. 
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Figure 2–5: Clemastine 41 reduces BODIPY-IPC production in spt− L. major. Mean values and 
range are shown. Values are normalised to IPC synthesis in the absence of clemastine 41.  
A decrease in IPC synthesis was seen with increasing concentrations of clemastine 41, 
consistent with LmjIPCS inhibition. However, the data are not sufficient to calculate an 
accurate IC50 value (25.77 µM, 95% CI: 8.89 – 74.72 µM). Nevertheless, it is worth noting that 
spt2− L. major promastigotes have a vastly different glycolipid composition compared to WT 
parasites,160 manifesting as a thicker glycan surface coat and the accumulation of vesicles and 
glycosylated material around the Golgi.160,162 This may significantly perturb the ability of 
clemastine 41 to enter cells and efficiently inhibit LmjIPCS. 
 Overall, clemastine 41 was discovered to have significantly lower activity against spt2− 
L. major, where IPCS is redundant, compared to wild-type promastigotes. Furthermore, the 
ability to inhibit IPC synthesis in a cellular context supports the hypothesis that this inhibition is 
responsible for the leishmanicidal effect of clemastine 41, chemically validating LmjIPCS as a 
viable target. 
2.4 Conclusions 
A primary screen of the NINDS compound library revealed a number of compounds with 
activity against L. major IPC synthase and promastigote parasites. The majority of these hits 
were confirmed using commercially sourced material, revealing four promising candidates: 
amlodipine 39, clemastine 41, flunarizine 45 and suloctidil 52. Subsequent experiments against 
intramacrophage L. major amastigotes highlighted clemastine 41 as the most effective 
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compound. An investigation utilising sphingolipid-free (spt2−) parasites confirmed the action of 
clemastine 41 as an inhibitor of LmjIPCS in cellulo. Further to this, clemastine 41 exhibited 
selectivity for wild type L. major promastigotes over sphingolipid-free mutant parasites, in 
which the IPC synthase enzyme is redundant. These findings support the hypothesis that 
clemastine 41 impedes Leishmania major growth via inhibition of IPCS. 
 Further work is in progress, towards gauging the effectiveness of clemastine 41 against 
other Leishmania species and progression to an in vivo cutaneous leishmaniasis model. This 
data will measure the potential of clemastine 41 as a therapy for Leishmania infection.
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3. Clemastine Analogue Synthesis 
This chapter focusses on an exploration of strategies with a view to synthesising a small library 
of analogues based on clemastine 41. The synthesis and in vitro testing of nor-clemastine 
analogues (lacking one or two methyl groups), to assess the tractability of future synthetic 
efforts, will first be discussed. Then, a study into a number of connection strategies for library 
synthesis will be presented. 
3.1 Review of the NINDS library set  
Clemastine 41 was highlighted as the most promising LmjIPCS inhibitor from the NINDS library 
screening campaign. In order to understand the interaction of clemastine 41 with the IPC 
synthase enzyme, a structure-activity study was necessary. As the Leishmania IPCS is a 
membrane-bound protein, hindering protein crystallography and spectroscopy efforts, SAR 
data would be gained through the screening of synthetic clemastine analogues. 
A further analysis of the 1040 compounds within the NINDS set was conducted in 
order to draw any primary SAR data that could be built upon. A large number of LmjIPCS 
inhibitors were found to be chemically similar to clemastine 41 (i.e. possess an aryl-rich moiety 
connected, through a flexible linker, to a nitrogen containing residue). However, these 
compounds displayed a lack of variation within the aryl and amino moieties. Furthermore, 
sporadic results of some compounds hampered attempts to correlate structure and activity, 
perhaps reflecting a presence of degraded material. Facing a dearth of concrete SAR data, it 
was decided to take an incremental approach to developing clemastine analogues. Only one 
half of the molecule would be altered at a time, giving rise to two separate series (Figure 3–1). 
 
Figure 3–1: Strategy for clemastine analogue synthesis 
A suitable linker would be required to allow for rapid access to a varied array of potential 
inhibitors. It was deemed appropriate to vary the linker initially as this represented the least 
functionalised part of clemastine 41 and hence it was hypothesised that changes to this moiety 
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would have the lowest effect on biochemical and antileishmanial activity. Using this strategy, a 
pharmacophore may be elucidated in a straightforward manner, without reliance on structural 
biology elements that are unavailable for the lipid-bound IPCS. 
3.2 Synthesis of nor-clemastine analogues 
Before an exploration of possible connection strategies could be made, research into the 
synthetic tractability of clemastine analogues was required. The necessity of optically pure 
material was a primary interest, followed by the requirement for a quaternary benzhydryl 
carbon. This latter concern was highlighted by studies within the group that demonstrated 
tertiary alcohol 54 was unstable towards formation of phenyl styrene 55 (Scheme 3–1). 
Additionally, the necessity of N-methylated pyrrolidine for IPCS inhibition was also probed. If 
activity against LmjIPCS was unaffected by the presence of 1H-pyrrolidine, then future 
synthetic routes could utilise a protected nitrogen strategy, improving tractability. 
 
Scheme 3–1: Instability of alcohol 54 
Reported syntheses of clemastine 41 focussed on ether formation, via displacement of 
chloride 56 with deprotonated benzhydrylamine 54, as the convergent step (Scheme 3–2).220–
222 Access to chloride 56 was achieved by activation of the precursor homoprolinol 57 using 
thionyl chloride. This synthetic route was employed for the construction of the desired 
nor-clemastine analogues. 
 
Scheme 3–2: Literature precedent for the synthesis of clemastine 41 
3.2.1 Routes to homoprolinol 
Initial efforts began with the attempted synthesis of homoprolinol 57. A first route was 
explored involving straightforward homologation of proline (S)-58 via nitrile (S)-61 (Scheme 3–
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3 and Scheme 3–4). The carbamate protected proline (S)-58 was subjected to reduction by 
borane, furnishing prolinol (S)-59 in good yield. The prepared alcohol (S)-59 was found to have 
an optical rotation of [α]21D = −29.5°(c = 1.00 g/100 mL, CHCl3), comparable to the reported 
literature value of [α]25D = 
 −39.8° (c = 1.20 g/100 mL, CHCl3).
223 However, the enantiopurity of 
prolinol (S)-59 was not experimentally verified via chromatography using a chiral column. 
Activation of the hydroxyl group by tosyl chloride provided the unstable tosylate (S)-60 which 
was immediately displaced by a cyanide anion to access the desired nitrile (S)-61 in modest 
yield (47%, 4 steps).224 Synthesis of nitrile (S)-61 was confirmed by the presence of a 
characteristic IR stretch at 2242 cm−1. The chirality of nitrile (S)-61 was inferred from the 
precursor alcohol (S)-59, although enantiopurity was not determined through methods 
involving optical rotation, chiral HPLC or NMR measurements.  
 
Scheme 3–3: Synthesis of nitrile (S)-61 from ˪-proline 
Next, a protocol reported by Vaughn et al. effected mild hydrolysis of nitrile (S)-61 to furnish 
homoproline (S)-62,225 corroborated by replacement of the characteristic nitrile stretch, in the 
IR spectrum, with that for the C=O bond at 1719 cm−1 (Scheme 3–4). Subsequent reduction 
using BH3 afforded homoprolinol (S)-63, which displayed an optical rotation value of 
[α]28D = −28.3° (c = 1.00 g/100 mL, CHCl3). The obtained value was found to vary from the 
literature value ([α]25D (c = 1.43 g/100 mL, CHCl3) −10.7°),
223 which may be indicative of 
contamination or complex concentration-dependent dimer interactions.226 A further 
investigation into the enantiopurity or the dependence of concentration of alcohol (S)-63 on 
optical rotation was not performed. 
 
Scheme 3–4: Synthesis of (S)-homoprolinol (S)-63 
With an overall yield of 33% over 6 steps, encumbered particularly by the cyanide 
displacement step, a shorter, higher yielding route was desired. Attention turned towards a 
 | 41 | 
Chapter 3: Clemastine Analogue Synthesis 
route utilising Wittig homologation with subsequent hydroboration (Scheme 3–5 and Scheme 
3–6). 
 
Scheme 3–5: Synthesis of olefin 65 
A brief investigation into the oxidation of prolinol (S)-59 revealed Parikh-Doering oxidation, 
with SO3•pyridine, to be more amenable to gram-scale reactions than the Jones variant with 
pyridinium chlorochromate.227,228 Prolinal (S)-64 was isolated in good yield, with the presence 
of the aldehydic proton verified by 1H NMR (δH ~ 9.50 ppm). Successive Wittig reaction with 
Ph3MePBr proved to be lower yielding, proceeding with racemisation of the stereocentre, 
confirmed by optical rotation measurements of the olefin product 65.229 1H NMR analysis of 
the product revealed loss of the aldehydic proton, and appearance of olefinic signals at 
δH = 6.00 – 5.00 ppm corresponding to the isolation of alkene 65.  
Prolinal (S)-64 was found to be unstable towards degradation over time, hindering 
further characterisation through measurement of its optical rotation. However, it was inferred 
that racemisation did not occur during the oxidation of prolinol (S)-59 as the resultant 
aldehyde (S)-64 was carried forth in other syntheses, with observed retention of 
stereochemistry (see Scheme 3–21, page 52). With olefin 65 in hand, it was then subjected to 
standard hydroboration using BH3, followed by oxidation with hydrogen peroxide (Scheme 3–
6).223 
 
Scheme 3–6: Hydroboration of olefin 65 with BH3 
Surprisingly, the regioselectivity of this reaction proved to be poor, resulting in the production 
of isomers 63 and 66, which could not be separated by flash chromatography on silica. 
However, secondary alcohol 66 was isolated successfully when the mixture was exposed to 
tosylation conditions (vide supra), which only converted homoprolinol 63 (Scheme 3–7). 
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Scheme 3–7: Tosylation of alcohol mixture 63 and 66 
The poor regioselectivity in the hydroboration step was postulated to occur due to 
co-ordination of the carbamoyl group of alkene 65 to borane, resulting in a lowering of the 
energy of transition state 65a (Scheme 3–8). Addressing this issue by using a more hindered 
dialkylborane reagent, such as Cy2BH, was assumed to negate this reactivity due to steric 
clashes preventing coordination. 
 
Scheme 3–8: Hypothesis for poor the regioselectivity of BH3 hydroboration of alkene 65 
A modified hydroboration protocol was then carried out, with initial formation of 
dicyclohexylborane and successive exposure to alkene 65 (Scheme 3–9).230 Subsequent 
oxidation furnished the desired alcohol 63 exclusively. 
 
Scheme 3–9: Anti-Markovnikov addition of Cy2BH to alkene 65 with following oxidation 
Ultimately, although this procedure was successful, the overall yield was poor (14%, 5 steps). 
This, combined with the loss of enantiopurity rendered this synthetic sequence as unsuitable 
for further study. 
 A synthesis involving homologation via Arndt-Eistert chemistry, as previously 
demonstrated by Clayden’s group, was utilised in which N-Z-proline (S)-68 was initially 
converted to the diazoketone (S)-69, before Wolff rearrangement furnished the homologated 
ester (S)-70 (Scheme 3–10).222 This rearrangement appeared to operate with retention of 
stereochemistry, as indicated by optical rotation measurements, with ester (S)-70 exhibiting a 
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[α]D
28 value of  −30.2° (c = 1.00 g/100 mL, CHCl3) (lit.:
231 [α]25D
 (c = 1.33 g/100 mL, CHCl3) 
−36.6°). However, this finding was not corroborated experimentally by chiral HPLC or NMR 
methods, so the enantiomeric excess of compounds (S)-68, (S)-69 and (S)-70 could not be 
calculated. 
Successful rearrangement to form diazoketone (S)-70 was confirmed through COSY 2D 
NMR experiment (shown below), which revealed mutual coupling between the 1H chemical 
shifts at δH = 4.23 ppm (pyrrolidinyl CH) and δH = 3.01 – 2.34 ppm (α-carbonyl CH2). 
 
Scheme 3–10: Arndt-Eistert reaction of N-Z-proline (S)-68 
Global reduction of the β-amino acid ester (S)-70 gave the desired (S)-N-methyl homoprolinol 
(S)-57 in excellent yield, with loss of the carbonyl groups verified by 13C NMR (Scheme 3–11). 
This route was then repeated with the unnatural (R)-proline (R)-68 to rapidly access the 
desired homoprolinol (R)-57. This route proved to be the most efficient, providing yields of 
62% and 43% across 4 steps for respective alcohols (S)-57 and (R)-57.  
 
Scheme 3–11: Reduction of ester (S)-70 and homologation sequence with the (R)-enantiomer 
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3.2.2 Etherification attempts 
In the reported synthesis of (S,S)-clemastine (S,S)-41, Fournier et al. activated homoprolinol 
(S)-57 to chloride (S)-56, prior to displacement with deprotonated benzhydrol (S)-54 (Scheme 
3–12).222 However, anchimeric assistance by the amine N gave rise to azepane 71 as a by-
product. 
 
Scheme 3–12: Synthesis of (S,S)-clemastine (S,S)-41 by Fournier et al.222 
It was hypothesised that activation of the Boc-protected homoprolinol 63 may circumvent this 
undesired reactivity by modulating nucleophilicity of the nitrogen atom. A test reaction was 
performed to assess whether tosylation was a viable activation strategy for displacement by 
benzhydrol 73 (Scheme 3–13). Facile reaction of benzaldehyde 72 and phenyl Grignard reagent 
furnished the benzhydrol 73, which was reacted with tosylated hexanol 74. Ether 75 was 
obtained in agreeable yield after chromatography on silica, confirmed by lack of an IR-active 
O–H stretch. 
 
Scheme 3–13: Test displacement reaction with deprotonated benzhydrol 73 
 | 45 | 
Chapter 3: Clemastine Analogue Synthesis 
Next, a repeated tosylation attempt with N-Boc homoprolinol 63 resulted in a poor yield of 
tosylate 67, with no starting material recovered via column chromatography (Scheme 3–14, 
c.f. Scheme 3–7). Furthermore, attempts to repeat this reaction proved capricious, pointing to 
an inherent instability of the activated alcohol 67. This was confirmed as the compound 
degraded before full characterisation could be made. A final attempt to prepare the putative 
tosylate 67 immediately before use also proved to be fruitless and this route was abandoned. 
 
Scheme 3–14: Tosylation of homoprolinol 63 and attempted displacement reaction 
The reason for the instability of tosylate 67 is unknown, but may occur via neighbouring group 
participation of the carbamate group (Scheme 3–15). Nevertheless, it was decided not to 
attempt alternative methods of activation, based on the observation by Clayden’s group that 
the stable iodide analogue 76 was unreactive.222 
 
Scheme 3–15: Postulated instability of tosylate 67 
It has been previously shown that benzhydrols can undergo acid-catalysed ether 
formation.232,233 With this in mind, it was envisaged that N-Boc homoprolinol 63 would 
undergo simultaneous etherification and deprotection to afford the desired nor-clemastine 
analogue 77 (Scheme 3–16). Gratifyingly, heating alcohols 63 and 73 under reflux with 1.1 eq. 
of p-toluenesulfonic acid in the presence of 4 Å molecular sieves (4 Å MS) furnished ether 77, 
as a mixture of the four diastereomers (2R,1′′R), (2R, 1′′S), (2S,1′′R) and (2S,1′′S), in reasonable 
yield. Preferential C-O bond formation over C-N bond formation was confirmed by the HMBC 
correlation depicted below. 
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Scheme 3–16: Condensation of alcohols 63 and 73 
This methodology was subsequently applied to methylated alcohols (S)-57 and (R)-57 to 
provide the respective clemastine analogues 78A and 78B, as mixtures of diastereomers 
(Scheme 3–17). Due to the postulated reaction pathway, the formation of these 
diastereomeric mixtures was viewed as unavoidable. Separation of the respective 
diastereomers of compounds 78A and 78B via chromatography was found to be unfeasible, as 
no separation was observed by both TLC and HPLC. 
 
Scheme 3–17: Synthesis of clemastine analogues 78A and 78B 
It must also be noted that the enantiomeric excess of homoprolinol compounds (S)-57 and 
(R)-57 was not measured, and their chirality was inferred from the optical rotation 
measurements of the respective ester precursors (S)-70 and (R)-70. The implications of this are 
that there may be trace amounts of the undesired diastereomers (2R,1′′R) and (2R,1′′S), in 
mixture 78A, and (2S,1′′R) and (2S,1′′S), in mixture 78B. 
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3.2.3 In vitro activity of nor-clemastine analogues 
With analogues 77, 78A and 78B in hand, attention then turned towards measuring their 
activity against Leishmania major IPC synthase and promastigotes. A preliminary dose-
response investigation into inhibition of LmjIPCS revealed all analogues to have micromolar 
activity (Figure 3–2).  
 
 
 
 
 
 
 
 
 
Figure 3–2: Biochemical activity of analogues 78A, 78B and 77. Error bars portray 95% 
confidence interval. 
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Compared to clemastine 41 (IC50 = 2.87 µM, 95% CI: 2.25 – 3.66 µM), analogues 78A and 78B 
(lacking one methyl group) exhibited respective IC50 values of 4.45 µM (95% CI: 4.01 – 
4.94 µM) and 4.13 µM (95% CI: 3.72 – 4.59 µM). The relative lower activity of these 
compounds may be explained by the absence of a benzhydryl methyl group, pointing to 
potential interactions between the LmjIPCS enzyme and the hydrophobic region of the 
molecule. From the similar IC50 values calculated for the diastereomeric mixtures 78A and 78B, 
it is not possible to assert whether pyrrolidine stereochemistry has an effect on compound 
potency. To assess this, it would be necessary to isolate and screen the four separate 
diastereomers within these mixtures. Specifically, testing the (2R,1′′R) diastereomer of 
compound mixture 78B, the closest analogue to (R,R)-clemastine 41, would allow for a direct 
comparison, giving a definitive answer as to the effect, if any, of benzhydryl C-methylation on 
activity. 
The potency of analogue 77 (lacking two methyl groups) was found to be even lower 
(IC50 = 6.26 µM, 95% CI: 5.60 – 7.00 µM), suggesting that presence of the tertiary amine group 
is important for IPCS inhibition. The drop in potency may be due to lowered amine basicity and 
nucleophilicity. 
 The effect of methylation on antileishmanial activity was then probed (Figure 3–3). 
Interestingly, the mixture 78B exhibited sub-micromolar activity (ED50 = 0.78 µM, 95% CI: 0.63 
– 0.96 µM), whereas the complementary analogue 78A was ~2-fold less effective 
(ED50 = 1.69 µM, 95% CI: 1.23 – 2.32 µM). This indicates that one, or both, of the (2R,1′′S) and 
(2R,1′′R) diastereomers within mixture 78B has a higher antileishmanial effect than the 
(2S,1′′R) and (2S,1′′S) isomers of mixture 78A. However, this would need to be experimentally 
verified through the testing and analysis of all four separated isomers, which may in turn 
uncover important links between LmjIPCS inhibition and antiparasitic activity. It is pertinent to 
note that the observed difference in potency may be due to improved cell penetration and 
transport to LmjIPCS, or lower susceptibility to removal via metabolism or efflux. Additionally, 
the potential for interaction with other target enzymes cannot be ruled out as a potential 
contributing factor. 
Desmethyl analogue 77 was found to have significantly lower activity against 
Leishmania major (ED50 = 4.10 µM, 95% CI: 3.35 – 5.01 µM), in agreement with the observed 
impact on IPCS inhibition. As with clemastine 41, analogues 78A, 78B and 77 all exhibited 
increased potency against L. major promastigotes over the IPC synthase (c.f. Figure 2–2). As 
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discussed in Chapter 2, this may be due to pleiotropic effects, increased relative concentration 
around the Golgi apparatus, or metabolism to compounds with increased potency. 
 
 
 
 
 
 
 
 
 
Figure 3–3: Leishmanicidal activity of analogues 78A, 78B and 77. Error bars portray 95% 
confidence interval. 
In conclusion, a brief investigation into the synthetic tractability of clemastine 41 analogues 
revealed that a lack of methylation on the pyrrolidinyl nitrogen, or benzhydryl carbon, did not 
ablate inhibition of IPCS or parasite growth. More specifically, the presence of N-methylated 
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pyrrolidine appears to result in moderately improved activity against the LmjIPCS enzyme and 
Leishmania major parasites. Furthermore, it seems that the stereochemistry of the 2-position 
of the pyrollidine group has an impact on potency against L. major promastigotes, although 
(R,R) stereochemistry, such as that of clemastine 41, is not vital for activity. However, this 
observation, and any potential link to IPCS inhibition, requires further exploration through 
testing of the separate diastereomers comprising the mixtures 78A and 78B. 
3.3 Possible routes for library synthesis 
As described earlier (Figure 3–1), accessing a diverse library of clemastine analogues required a 
straightforward connection strategy. The condensation methodology utilised for the syntheses 
of nor-clemastine analogues 78A, 78B and 77 may be useful in this context, but was restricted 
by the requirement for benzhydryl alcohols as substrates. This was confirmed by the reaction 
below in which 1-phenyl ethanol 79 and benzyl alcohol 80 failed to react with amino alcohol 81 
(Scheme 3–18). 
 
Scheme 3–18: Alcohols 79, 80 and 81 do not react under acid-catalysed etherification 
conditions 
Therefore, a number of different strategies were explored with a view to increasing the 
substrate scope for analogue synthesis. Three commonly used tactics were employed in 
parallel, namely Cu(I)-catalysed 1,2,3-triazole synthesis, amide and ester bond formation, and 
alkene metathesis. The simultaneous in vitro testing of analogues synthesised using these 
methods would allow for a direct comparison to be made, highlighting the best strategy for 
further synthetic efforts. 
3.3.1 Triazole analogue synthesis 
1,2,3-Triazoles are popular in medicinal chemistry due to their biocompatibility and stability 
under physiological conditions.234 Furthermore, their creation via ‘click chemistry’ is ideal due 
to the high efficiency and functional group tolerance that characterise this transformation. 
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Thus, an exploration into the synthesis of clemastine analogues containing a 1,2,3-triazole 
linker was carried out.  
It was apparent that two different routes could be followed to furnish a triazole-linked 
clemastine analogue (Scheme 3–19). It was viewed that the pyrrolidine fragment 82 could be 
accessed from the previously prepared prolinal 64, potentially expediting the synthesis of 
triazole 83. Therefore, route A was preferentially chosen for the synthesis of a triazole-linked 
analogue of clemastine.  
 
Scheme 3–19: Synthetic routes to triazole-linked clemastine analogues 
Synthesis of the azide fragment proved facile, with the conversion of benzhydrol 73 to azide 84 
occurring in high yield on reaction with TMSN3 and BF3●OEt2 (Scheme 3–20).
235 The successful 
introduction of the azide functionality was confirmed by the observation of a characteristic 
stretch at 2095 cm−1 in the IR spectrum. 
 
Scheme 3–20: Conversion of alcohol 73 to azide 84  
Accessing the corresponding alkyne fragment (S)-86 from prolinal (S)-64 was also 
straightforward, through utilisation of Corey-Fuchs methodology (Scheme 3–21).228 
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Scheme 3–21: Corey-Fuchs reaction, providing alkyne (S)-86  
Dibromoalkene (S)-85 was synthesised in modest yield, confirmed by mass spectrum revealing 
a characteristic dibromo isotope pattern (m/z = 354 [M(79Br2)H
+], 356 [M(79Br81Br)H+], 
358 [M(81Br2)H
+]), which was then converted to alkyne (S)-86. Analysis of the 1H NMR spectrum 
revealed disappearance of the olefinic proton (δH = 6.38 – 6.25 ppm) and appearance of a 
signal at δH = 2.21 – 2.15 ppm, consistent with the presence of a terminal alkyne. The 
measured optical rotations of compounds (S)-85, [α]21D = +8.5° (c = 1.00 g/100 mL, CHCl3) 
(lit.:228 [α]26D = +24.0° (c = 0.89 g/100 mL, DCM)), and (S)-86, [α]
27
D = −49.5° (c = 1.00 g/100 mL, 
CHCl3) (lit.:
236 [α]25D = −66.3° (c = 1.35 g/100 mL, CHCl3)), indicated an excess of the desired 
S-enantiomer. However, further verification was not obtained through chiral HPLC or NMR 
methods, meaning the exact enantiomeric excess could not be calculated. As discussed earlier 
in this chapter, this carries the implication that a potentially unknown, albeit likely to be small, 
quantity of the opposite R-enantiomer may be present in subsequent synthetic steps. 
With alkyne (S)-86 and azide 84 in hand, their connection via Cu(I)-catalysed Huisgen 
cycloaddition was investigated.237 Initially, the reaction of these fragments at RT was explored, 
resulting in very little conversion of the starting materials 84 and (S)-86, as observed by TLC 
(Table 3–1 entry 1). Slight elevation of the temperature to 40 °C similarly had no effect. It has 
been reported by Bouillon et al. that microwave assisted cycloaddition occurs rapidly.238 
Following this procedure, alkyne (S)-86 and azide 84 were combined in a 1.1 : 1 ratio 
respectively and heated at 60 °C for 20 min, yielding cycloadduct 87A in 70% yield (Table 3–1, 
entry 2). Optimisation of these conditions was briefly explored, with 79% of the diastereomeric 
mixture 87A being isolated following a longer reaction time of 30 min (Table 3–1, entry 3). 
Reaction of (S)-86 and 84 in a 1 : 1 ratio resulted in a lower yield, even with extension of the 
heating time to 40 min (Table 3–1, entry 4). 
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Table 3–1: Cu(I) catalysed 1,2,3-triazole formation 
Entry 
Ratio 
(S)-86 : 84 
Eq. Cu(I) 
Eq. Na 
ascorbate 
Δ / μW Solvent Time 
Yield 
87A 
1 1 : 1 0.02 0.1 Δ, 40 °C tBuOH/H2O 2 days – 
2 1.1 : 1 0.4 2 μW, 60°C MeOH/H2O 20 min 70 % 
3 1.1 : 1 0.4 2 μW, 60°C MeOH/H2O 30 min 79 % 
4 1 : 1 0.4 2 μW, 60°C MeOH/H2O 40 min 65 % 
 
It was hypothesised that the success of the microwave reaction over the thermal reaction 
(Table 3–1, entries 1 & 4), may be due to the relatively low equivalents of CuSO4 and Na 
ascorbate employed in the former reaction. This, however, remains to be experimentally 
verified.  
The absence of the characteristic IR azide stretch at 2095 cm−1 was noted in the 
purified product 87A, as well as the significantly higher chemical shift of the benzhydryl proton 
(δH = 7.71 ppm), observed in the 
1H NMR spectrum. Triazole 87A was also found to be 
rotameric, with variable temperature NMR experiments demonstrating coalescence of peaks 
at 90 °C in DMSO-d6 (Figure 3–4).  
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Figure 3–4: VT 1H NMR experiment with triazole 87A (tert-butyl peaks shown) 
With a viable synthetic route in hand, attention then turned towards its application to (R)-N-
Boc prolinol (R)-59 (Scheme 3–22). Alkyne (R)-86 was subsequently prepared in 40% yield over 
3 steps, with successive click reaction of fragments 84 and (R)-86 furnishing triazole 87B, as a 
mixture of diastereomers, in almost quantitative yield. 
 
Scheme 3–22: Synthetic route to cycloadduct 87B 
A number of strategies were employed in the attempted synthesis of N-methyl triazole 83 
(Scheme 3–23 and Scheme 3–24). A primary effort involved acid mediated Boc deprotection of 
triazole 87A, followed by treatment of the deprotected amine 88 with aq. formaldehyde and 
NaBH(OAc)3, according to precedent by Abdel-Magid et al. (Scheme 3–23).
239 Unfortunately a 
complex mixture resulted, from which only 34% of unprotected amine 88 could be recovered.  
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Scheme 3–23: Failed reductive amination attempt 
Reduction of Boc-protected analogue 87A was also investigated in parallel (Scheme 3–24). An 
initial attempt utilising LiAlH4 in THF at reflux resulted in degradation of the starting material 
87A to an intractable mixture, as judged by TLC and 1H NMR of the crude material.240 A second 
trial reaction at ambient temperature, using Et2O as solvent, resulted in clean conversion of 
starting material observed by TLC.241 Following purification by chromatography on silica, the 
desired N-methyl analogue 83A was obtained in 34% yield. Analysis of the 1H NMR spectrum of 
this compound revealed absence of the tert-butyl shift of analogue 87A, and appearance of a 
new singlet peak at δH = 2.26 ppm. Additionally, full resolution of peaks was observed in the 
1H 
NMR spectrum of triazole 83A, contrasting with the observation of rotamers with analogue 
87A (c.f. Figure 3–4). 
 
Scheme 3–24: Hydride reduction of N-Boc triazole 87A 
Following this, LiAlH4 reduction of analogue 87B furnished the corresponding N-methyl triazole 
83B in acceptable yield (Scheme 3–25). 
 
Scheme 3–25: Hydride reduction of N-Boc triazole 87B 
In summary, triazole-linked analogues 83A and 83B were accessed after successful 
microwave-mediated Cu(I)-catalysed formal cycloaddition. This connection step proved to be 
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fast and high yielding and so could be used effectively for the synthesis of an array of 
clemastine analogues. 
3.3.2 Amide and ester analogue synthesis 
Acylation reactions, notably peptide bond formation, are a key tool within the medicinal 
chemist’s repertoire.242,243 Hence, routes to ester and amide linked clemastine analogues were 
explored. A brief analysis revealed that six fragments were required (Figure 3–5). For ease of 
purification it was decided to keep the pyrrolidinyl nitrogen protected throughout the 
synthetic route. Furthermore, to improve tractability of synthesis, N-methylation would not be 
pursued as a final step.  
 
Figure 3–5: Precursors required for synthesis of acyl-linked clemastine analogues 
Alcohols (S)-59 and 73 were synthesised as previously described (Scheme 3–3 and Scheme 3–
13), with the other fragments 62, 89 and 91 purchased from commercial sources. However, 
acid 90 was not available and needed to be prepared. Initial approaches explored the 
homologation of benzhydrol 73 (Scheme 3–26), however, the nitrile 92 could not be isolated. 
 
Scheme 3–26: Failed homologation attempt of benzhydrol 73 
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Next, a precedent was followed in which a benzhydryl cation was formed from alcohol 73 in 
strong acid, prior to trapping by carbon monoxide formed in situ (Scheme 3–27).244 Whilst the 
presence of a carbonyl group was verified by an IR-active stretch at 1707 cm−1, the desired acid 
90 could only be isolated in low yield. 
 
Scheme 3–27: Synthesis of acid 90 
In an effort to access acid 90 in more acceptable yield, a protocol utilising Lewis-acid mediated 
Friedel-Crafts arylation of mandelic acid 93 was employed (Scheme 3–28).245 Following 
re-crystallisation of the crude product from acetone and petrol, the acid 90 was provided in 
modest but acceptable yield (40%). 
 
Scheme 3–28: Friedel-Crafts arylation of mandelic acid 93 
With all the required fragments in hand, attention turned toward the synthesis of amide and 
ester linked clemastine analogues (Scheme 3–29 and Scheme 3–30). Using carbodiimide as an 
activating reagent, amides 94 and 95 were synthesised in reasonable yield (Scheme 3–29).246 
Successful peptide bond formation was confirmed by the presence of distinctive IR-active 
vibrations at circa 1650 cm−1 and 1540 cm−1. 
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Scheme 3–29: Synthesis of amide analogues 94 and 95 
Ester bond formation was effected with the addition of EDCI and 1.1 eq. DMAP, furnishing 
analogues 96 and 97 in good yield (Scheme 3–30). The 1H and 13C NMR spectra of these esters 
were complicated by the presence of both diastereoisomers and rotamers. However, effective 
acylation was verified by 3JCH correlations (HMBC) as depicted in Scheme 3–30. 
 
Scheme 3–30: Synthesis of ester analogues 96 and 97 
Acid mediated carbamate deprotection of amide 94 occurred cleanly, providing TFA salt 98 in 
good yield (Scheme 3–31). In contrast, amine 99, derived from the amide 95, was isolated in 
28% yield after re-crystallisation of the crude material from EtOAc and ether. The reasons 
behind this disparity in yield remain unclear. Analysis of 13C NMR spectra revealed 
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disappearance of the carbamate acyl carbon resonance at δC = 155 ppm, supporting effective 
deprotection. 
 
Scheme 3–31: Acid mediated Boc cleavage of amides 94 and 95 
Esters 96 and 97 were subjected to the same deprotection conditions (Scheme 3–32). 
Analogue 100 could not be cleanly isolated as either a TFA or p-TSA salt, and so the free amine 
was purified via preparative TLC. Unfortunately, the acidic conditions led to complete 
degradation of the protected ester 96, presumably due to the propensity for benzhydryl cation 
formation. 
 
Scheme 3–32: Attempted carbamate deprotection of esters 96 and 97 
To conclude, N-Boc clemastine analogues 94, 95, 96 and 97 were readily accessed via 
carbodiimide-mediated N- and O-acylation. However, subsequent deprotection attempts 
resulted in the decomposition of ester 96, revealing the esterification route to have lower 
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functional group tolerance. Therefore, amide bond formation represented a more tractable 
synthetic strategy. 
3.3.3 Olefin analogue synthesis 
Olefin metathesis is another popular linking strategy, characterised by high efficiency and 
functional group tolerance.247,248 A brief investigation into the tractability of this method was 
performed. Two routes to an alkene linked clemastine analogue were considered (Scheme 3–
33). The route to analogue 101 was viewed as the most expedient, as vinyl pyrrolidine 102 was 
easily accessible (see Scheme 3–5 above). 
 
Scheme 3–33: Potential routes to olefin analogues 101 and 103 
With this in mind, Cbz-protected proline (S)-68 was chosen as a precursor (Scheme 3–34), as 
the carbamate could be subjected to reduction using LiAlH4 to give an N-methylated product 
(see Scheme 3–11). Additionally, exposure to hydrogenation conditions would effect 
simultaneous deprotection and saturation of the alkene moiety, introducing flexibility. 
Aldehyde 105 was prepared from proline (S)-68 in modest yield (32% over 2 steps), with the 
presence of the characteristic aldehydic proton observed by 1H NMR (δH = 9.60 – 
9.50 ppm).249,250 Wittig olefination of prolinal 105 furnished the desired alkene 106, as 
evidenced by resonances at δH = 5.82 – 5.71 ppm and 5.19 – 5.08 ppm in the 
1H NMR 
spectrum.229 
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Scheme 3–34: Synthetic route to alkene 106 from (S)-N-Z-proline (S)-68 
The complementary fragment 107 was accessed by activation of alcohol 73 with mesyl 
chloride, prior to displacement by allyl magnesium bromide (Scheme 3–35). Analysis of a 2D 
NMR COSY experiment confirmed mutual coupling between the signals at δH = 3.99 ppm and 
2.84 – 2.74 ppm, corresponding to the hydrogens at the benzylic and allylic positions 
respectively.  
 
Scheme 3–35: Conversion of benzhydrol 73 to olefin 107 
Application of cross metathesis conditions, using the Grubbs’ generation II catalyst, led to the 
generation of a number of products, as revealed by TLC and LCMS analysis of the crude 
material (Scheme 3–36).251 In particular, the pyrrolidine dimer 108 (m/z = 435 [MH+]), the 
desired compound 109 (m/z = 446 [M(35Cl)H+], 448 [M(37Cl)H+]) and unreacted alkene 106 
(m/z = 232 [MH+]) were observed. This poor selectivity is a general feature in the metathesis 
reactions of terminal olefin species.252 
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Scheme 3–36: Application of alkene metathesis conditions to alkenes 106 and 107 
Unfortunately, this mixture proved to be impossible to separate by silica column 
chromatography and consequently was taken forward and subjected to reduction using 10% 
Pd on carbon under H2 atmosphere, in an attempt to deconvolute the combination of products 
(Scheme 3–37). This produced an intractable mixture, confirming the unsuitability of this 
synthetic route for the synthesis of clemastine analogues. 
 
Scheme 3–37: Attempted reduction of metathesis products 
Overall, a study into a number of different linking strategies revealed 1,2,3-triazole synthesis 
and amide bond formation as the most promising candidates for the synthesis of a library of 
potential LmjIPCS inhibitors based on clemastine 41. Ester formation was ruled out due to the 
sensitivity of analogue 96 to degradation in acidic conditions (Scheme 3–32). Additionally, 
olefin metathesis did not prove to be a viable route, due to poor product selectivity (Scheme 
3–36). The analogues that were successfully prepared, namely triazoles 83A and 83B, and 
amides 98 and 99, were then screened against the L. major IPC synthase enzyme and 
promastigote parasites. 
3.3.4 In vitro assessment of different linker groups 
A primary screen of the analogues synthesised was performed at 20 µM against the L. major 
IPC synthase (Figure 3–6). From the results, it was evident that all N-Boc protected analogues 
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exhibited poor activity. Furthermore, ester 100 was found to be inactive at 20 µM, ruling out 
esterification as a viable connection strategy. 
 
Figure 3–6: Inhibition of LmjIPCS at 20 µM by triazole, amide and ester analogues. Error bars 
portray standard deviation. 
The free amine triazole and amide analogues 83A, 83B, 98 and 99 all exhibited reasonable 
inhibition, and their dose-response relationships were investigated (Figure 3–7 and Figure 3–
8). Interestingly, the introduction of rigidity revealed the (R,S) and (R,R) diastereomers of 
triazole mixture 83B (IC50 = 8.49 µM, 95% CI: 7.67 – 9.39 µM) to be 2-fold more potent against 
LmjIPCS than the (S,R) and (S,S) diastereomers of mixture 83A (IC50 = 14.52 µM, 95% CI: 12.39 – 
17.02 µM). This observation mirrors the trend of antileishmanial activity observed with 
nor-clemastine analogues 78A and 78B (c.f. Figure 3–3). However, in both cases it is unclear 
whether the observed difference in activity is a general feature of the (2R)-pyrrolidine unit, or 
is the caused by one particular diastereomer. Therefore, it is not possible to state whether 
there exists a correlation between activity against LmjIPCS and L. major promastigotes, 
particularly, as the nor-clemastine diastereomeric mixtures 78A and 78B demonstrated 
equivalent potency against LmjIPCS (c.f. Figure 3–2). Further investigation is required, through 
the isolation and testing of all diastereomers, before any definitive links may be drawn. 
Next, screening against L. major promastigotes revealed diastereomeric triazole 
mixtures 83A and 83B to have low leishmanicidal activity, with parasite growth inhibition only 
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being observed at 100 µM (Figure 3–7). This poor translation of biochemical to antiparasitic 
activity may be due to decreased cell penetration or solubility imparted by the rigid triazole 
group.253 
 
 
 
 
 
Figure 3–7: Inhibition of LmjIPCS and L. major promastigote growth by triazoles 83A and 83B. 
Error bars portray 95% confidence interval. 
Amides 98 and 99 were then tested against the L. major IPCS enzyme, revealing respective IC50 
values of 6.95 µM (95% CI: 6.15 – 7.85 µM) and 6.90 µM (95% CI: 6.10 – 7.80 µM) (Figure 3–8). 
The reduction in rigidity, compared to triazoles 83A and 83B, may be the cause of the 
observed increase in relative activity. Furthermore, the equivalence of dose-response curves 
shows that the position of the amide bond is unimportant, indicating that it may not 
contribute towards any hydrogen bonding interactions with the enzyme. A subsequent enquiry 
into the activity of amides 98 and 99 against L. major promastigotes revealed a lack of 
 | 65 | 
Chapter 3: Clemastine Analogue Synthesis 
cytotoxic effect until 100 µM (Figure 3–8). As with the triazole analogues 83A and 83B, the low 
observed leishmanicidal activity may be caused by poor cell penetration. In addition, the 
amide bonds of analogues 98 and 99 may be susceptible to metabolism via cleavage by 
parasite peptidase enzymes.  
 
 
 
 
 
Figure 3–8: Inhibition of LmjIPCS and L. major promastigote growth by amides 98 and 99. 
Error bars portray 95% confidence interval. 
3.3.5 Conclusions 
A number of desmethyl clemastine compounds, 77, 78A and 78B, were synthesised in order to 
assess the synthetic tractability of clemastine 41 analogues. Biochemical and cellular screening 
highlighted that N-methylation of the pyrrolidine group improves activity against L. major IPC 
synthase and promastigote parasites. However, as analogues 78A and 78B are diastereomeric 
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mixtures, it is not possible to say whether pyrrolidine stereochemistry or the lack of 
benzhydryl C-methylation, or both, are responsible for the observed decrease in activity of 
these compounds, relative to clemastine 41. Interestingly, the higher potency of mixture 78B 
over 78A against L. major promastigotes hints at the possible impact of stereochemistry of the 
pyrrolidine group on leishmanicidal activity. Further testing of the individual diastereomers 
would be necessary to validate this hypothesis, however. Nevertheless, it was confirmed that a 
variation in methylation did not result in the complete loss of inhibitory activity. 
A following investigation into viable routes for the synthesis of clemastine analogues 
revealed triazole and amide formation as suitable for the development of IPCS inhibitors. The 
synthesised analogues were found to be effective against LmjIPCS, but displayed unsuitable 
activity against L. major promastigotes. Of particular interest was the observed higher 
biochemical activity of triazole analogue mixture 83B, compared to the complementary (S,S) 
and (S,R) diastereomers in mixture 83A. The implications of this for antileishmanial activity 
remain uncertain, however. 
These findings come with the caveat that the enantiomeric excesses of the chemical 
precursors for mixtures 78A, 78B, 83A and 83B were not measured. As such, the possibility 
that undesired diastereomers are present in an unknown, albeit likely small, quantity cannot 
be ruled out. Therefore, the above observations can only be corroborated through isolation 
and subsequent screening of all possible diastereomers. This is beyond the initial scope of the 
project, which was to identify suitable connection strategies for the synthesis of clemastine 41 
analogues. Because of the observed higher affinity of amide analogues 98 and 99 (compared to 
triazole analogues 83A and 83B) for LmjIPCS and the breadth of potential substrates, peptide 
bond formation was chosen for the synthesis of a library of small molecule inhibitors based on 
clemastine 41. 
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4. Synthesis of a Small Library of Clemastine Analogues 
As discussed in Section 3.1, there was a paucity of SAR data from the primary screen of the 
NINDS compound set. In addition, inhibitors exhibited narrow chemical diversity. Therefore, a 
study into the synthesis of a small library of clemastine analogues had two aims: 
 Probe the fundamental requirements for activity of clemastine 41 against LmjIPCS 
 Explore a more varied chemical landscape for potential inhibitors 
Amide bond formation was discovered to be the most promising connection strategy for 
analogue synthesis (see Section 3.3.4). In addition, IPCS inhibition was not affected by the 
position of the peptide bond. In collaboration with MRCT Ltd., the project sponsor, an 
investigation was launched into the synthesis and testing of two series of amide-linked 
analogues (Figure 4–1). Series 1 would focus on variation of the pyrrolidine moiety of 
clemastine, whilst the second series would probe the structure-activity relationships of the 
benzhydryl unit.  
 
Figure 4–1: Proposed clemastine amide analogue series 
4.1 Testing tractability of synthesis 
Before embarking on the synthesis of a library of clemastine analogues, preliminary work was 
required to develop a protocol that would tolerate a wide range of different substrates. First, 
the procedure employed in the synthesis of amide analogues 94 and 95 was applied to a 
hindered primary amine 112 and piperazine 113 (Table 4–1, entries 1 & 3).246  
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Table 4–1: Synthesis of amides 110 and 111 
Entry Reaction Conditions Yield 
1 A EDCI●HCl (1.1 eq.), NMM (1.1 eq.), DCM 0% 
2 A EDCI●HCl (1.1 eq.), HOBt (1.1 eq.), NMM (1.1 eq.), DCM 110, 67% 
3 B EDCI●HCl (1.1 eq.), NMM (1.1 eq.), DCM 0% 
4 B EDCI●HCl (1.1 eq.), HOBt (1.1 eq.), NMM (1.1 eq.), DCM 111, 37% 
 
Both reactions were found to be unsuccessful, with LCMS analysis of the crude mixtures 
revealing the presence of a species with m/z = 402, consistent with the formation of urea 
compounds 114 and 115 (Scheme 4–1). The prevalence of this species highlighted that 
rearrangement of the activated ester 116 to the undesired ureas 114 and 115 was competing 
with amide formation. To circumvent this issue, a modified procedure was carried out using 
stoichiometric hydroxybenzotriazole (Table 4–1, entries 2 & 4). LCMS analysis of the reaction 
mixtures showed disappearance of the postulated urea (m/z = 402), allowing the desired 
amides 110 and 111 to be isolated. Successful coupling reactions were confirmed by the 
presence of the amide carbonyl stretches at around 1640 cm−1 in the IR spectra. This protocol 
was taken forward and applied to the synthesis of a small library of amide analogues. 
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Scheme 4–1: Formation of putative urea by-products 114 and 115 
4.2 Synthesis of amide library 
Peptide coupling reactions were conducted in parallel, in groups of 10 – 20, according to the 
EDCI and HOBt mediated conditions described above. Briefly, the reaction mixtures were 
stirred at RT in DCM, until HPLC monitoring of two separate reactions indicated either reagent 
consumption or lack of progression. The reactions were then quenched with water and passed 
through hydrophobic phase separators, prior to concentration under a flow of air with heating 
at 40 °C. If a Boc-deprotection step was required, then the concentrated residues were 
dissolved in DCM and reacted with TFA at room temperature for 1 hour. After a second 
concentration step, purification of the crude mixtures was then attempted via either normal or 
reversed-phase flash chromatography, or preparative HPLC. 
From a total of 82 reactions, 61 compounds were isolated, highlighting an overall 
success rate of 74% with an average yield of 37% (see Chapter 8). The majority of failed 
reactions involved arylamine species which were not commercially sourced and as such may 
have contained impurities and degradation products. Other compounds proved difficult to 
purify by both normal and reversed phase flash chromatography and were therefore deemed 
impractical to pursue. 
4.3 In vitro testing of compounds 
Primarily, the synthesised analogues were screened, in triplicate, against the L. major IPC 
synthase enzyme at a concentration of 20 µM (Figure 4–2) (see Appendix A). The majority of 
compounds tested were found to have low activity (<20% inhibition). 
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Figure 4–2: Assay of amide library against LmjIPCS at 20 µM. Compound numbers are 
arbitrarily assigned, relative to their order of testing. 63 Compounds were screened overall, 
with numbers 62 and 63 (green) representing the parent amides 98 and 99, included as 
controls. The red dotted line represents the inhibition % value over which compounds were 
selected for further investigation. Error bars portray standard deviation. 
Fifteen compounds that exhibited moderate to high activity (>40% inhibition) against the 
protozoan enzyme were investigated further through the measurement of their dose-response 
relationships (Figure 4–3). Compared to clemastine 41 (green bar, IC50 = 2.87 µM, 95% CI: 2.25 
– 3.66 µM), the majority of compounds displayed low efficacy (IC50 >10 µM). 
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Figure 4–3: IC50 measurement of most active amide analogues. Compound numbers 
correspond to those in Figure 4–2. The final lane (green) represents clemastine 41, included 
as a control. Error bars portray 95% confidence interval. 
However, amine 117 (Figure 4–3, compound 24), indazoles 118 and 119 (Figure 4–3, 
compounds 36 and 37), and pyrimidine 120 (Figure 4–3, compound 39) exhibited comparable 
activity to clemastine 41 (Figure 4–4). Notably, indazole 118 proved to be as active as 
clemastine 41 against LmjIPCS.  
 
Figure 4–4: The most active IPCS inhibitors from the amide library 
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Indazole 118 was then tested for parasite toxicity against L. major promastigotes, but was only 
effective above 33 µM (Figure 4–5). As with amide clemastine analogues 98 and 99, it was 
postulated that presence of the amide functionality was responsible for the poor translation to 
antileishmanial activity. In order to test this hypothesis, an analogue of indazole 118 bearing a 
flexible linker, similar to that of clemastine 41, would need to be synthesised and screened 
against both the L. major IPCS and promastigote parasites (see Chapter 5). 
  
Figure 4–5: Comparison of antileishmanial activity of clemastine 41 and indazole 118. Error 
bars portray 95% confidence interval. 
To conclude, the synthesised library of 61 amide-linked clemastine analogues were assayed 
against LmjIPCS at 20 µM, revealing the majority (39 compounds, 66%) as poor inhibitors 
(<20% activity). Fifteen compounds, which inhibited enzyme activity by >40%, were taken 
forward for dose-response studies against the enzyme, revealing amine 117, indazoles 118 and 
119, and pyrimidine 120 as the only compounds exhibiting IC50 values below 10 µM. 
Specifically, indazole 118 was found to be as potent as the parent compound, clemastine 41, 
although this analogue proved to have poor cytotoxic effect on L. major promastigotes.  
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4.4 Structure-Activity Relationship analysis 
A number of structure-activity relationships were drawn from the data introduced above, 
shedding some light on the activity profile of clemastine 41. 
4.4.1 Amine substituted series 
A series of aromatic N-heterocycles were screened, including imidazoles, oxazoles, pyrazoles, 
pyridines, pyrimidines and benzo-fused moieties (Figure 4–6). Low activity was observed at 
20 µM with the majority of compounds tested, with the exception of the indazoles 118 and 
119, pyrimidine 120, imidazole 121 and benzothiazole 122. Whilst indazoles 118 and 119, and 
pyrimidine 120 proved to be effective inhibitors of LmjIPCS (see Figure 4–4), imidazole 121 and 
benzothiazole 122 displayed significantly higher IC50 values (23.89 µM and 36.21 µM 
respectively). 
 
Figure 4–6: Example aromatic N-heterocyclic analogues tested 
The indazoles 118 and 119, and pyrimidine 120 all feature a terminal aliphatic amine moiety, 
whereas imidazole 121 and benzothiazole 122 do not. This may be important for activity, 
although further experiments would be required to make a direct comparison. Indeed, the 
higher activity of 1-substituted indazole 118 over 2-substituted indazole 119 indicates that the 
placement of the dimethylamino group has an effect on potency (Figure 4–4). 
A study into aliphatic substituted analogues provided further insight (Figure 4–7, 
Figure 4–8 and Figure 4–9). Azetidine analogues 127 and 128 proved effective in the primary 
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20 µM screen, but displayed lower potency compared to the parent amides 98 and 99. 
Similarly, pyrrolidine 129 exhibited a relatively high IC50 value (20.49 µM). This observation 
may be explained by the position of the nitrogen atom. For example, the amine moiety of 
analogues 127, 128 and 129 is located 4 bonds away from the amide bond, whilst 3 bonds 
separate the pyrrolidine nitrogen of parent analogues 98 and 99. A more detailed study into 
pyrrolidine containing analogues of varying chain length is required to verify this hypothesis.  
 
Figure 4–7: Pyrrolidine and azetidine analogues 
Morpholine and piperazine analogues, such as compounds 130 and 131, fared poorly against 
the IPCS enzyme (Figure 4–8). It is worth noting, however, that the pyrimidine analogue 120 
(89.6% inhibition at 20 µM), which contains an N-methylpiperazine unit, exhibits higher activity 
than the aliphatic analogue 131 (16.3% inhibition at 20 µM). The higher affinity of analogue 
120 may be due to the pyrimidine unit, or the increased distance between the benzhydryl and 
piperazine moieties. 
 
Figure 4–8: Morpholine and piperazine analogues 
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An important conclusion was drawn from cyclopentyl and tetrahydrofuranyl analogues 132 
and 133 (Figure 4–9). Their lack of activity at 20 µM, compared to pyrrolidine analogues 98 and 
99 (c.f. Figure 4–7), highlighted the necessity of nitrogen-containing functionality. The poor 
activity of tetrahydrofuran 133 also indicated that H-bond acceptor capability may not be 
important for inhibition. Furthermore, a comparison between pyrrolidine 129 and lactam 134 
reveal that IPCS inhibition relies on basic amino moieties. Drawing a parallel to the ceramide 
analogue work by Mina,190 the presence of a protonated nitrogen species may interfere with 
the active site, bringing about inhibition of IPC synthesis (see Section 1.3.4.4). 
 
Figure 4–9: Example aliphatic analogues tested 
4.4.2 Benzhydryl substituted series 
A number of analogues with bis-aryl functionality were explored (Figure 4–10). Compared to 
the parent amide 98 (82.7% inhibition at 20 µM), increasing rotational freedom via insertion of 
a methylene linker resulted in a dramatic drop in IPC synthase inhibition at 20 µM (compound 
135, 44% inhibition), whilst an attempt to restrict rotation, in the case of amine 136, 
maintained activity (89% inhibition). However, dose-response measurements revealed both 
amides 135 and 136 to be comparatively weak inhibitors.   
 
Figure 4–10: Example bis-aryl analogues  
A brief exploration into aryl substituents saw electron deficient amine 137 exhibit poor 
inhibition at 20 µM. A complementary analogue bearing a para-methoxy substituent could not 
be purified and hence was not tested. In addition, there remains the caveat to these findings 
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that the compounds 135, 136 and 137 were tested as diastereomeric mixtures, which may 
account for an as yet unknown effect on potency against the LmjIPCS enzyme.  
 Replacement of one of the aryl groups revealed a preference for long-chain fatty 
residues (Figure 4–11). Testing of analogues 138 and 139 against LmjIPCS at 20 µM revealed a 
complete loss in activity upon replacement with a hydrogen or methyl unit. By contrast, amide 
140 was found to be very potent at 20 µM, though determination of an IC50 value revealed 
lower efficacy, compared to parent amides 98 and 99 (c.f. Figure 4–7). Furthermore, it was 
found that n-pentyl substitution was preferred over cyclopentyl (analogue 141, 
IC50 = 28.31 µM), with cyclohexyl substituted amide 142 exhibiting even lower activity (24.7% 
inhibition at 20 µM). 
 
Figure 4–11: Mono-aryl amide analogues 
Of the other analogues tested, a notable comparison of cyclopentyl and tetrahydrofuranyl 
analogues 141 and 143 revealed a potential low tolerance to the presence of heteroatoms 
(Figure 4–12). Additionally, bis-trifluromethyl benzyl amide 144 displayed a significant increase 
in potency over the related benzyl compound 139. Incorporation of the trifluoromethyl group 
into other analogues of clemastine 41 may furnish an increase in activity against LmjIPCS.  
The discovery of higher activity with analogues bearing both aliphatic and aryl 
substituents points towards potential hydrophobic and π-stacking interactions. Alternatively, 
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the observed potency may reflect a higher concentration of these compounds near the 
lipid-bound LmjIPCS.  
 
Figure 4–12: Other substituted benzyl amides 
4.5 Conclusions 
A library of 61 clemastine analogues was synthesised utilising a straightforward peptide 
coupling strategy. Subsequent screening of these analogues revealed indazole 118 to be as 
effective as clemastine 41 against LmjIPCS. However, this analogue exhibited low activity 
against Leishmania major promastigotes, possibly due to the presence of amide bond 
functionality. 
A number of important SAR discoveries were made from the biochemical screening 
data gathered. These findings are summarised below, alongside the features learned from 
Chapter 3 (Figure 4–13).  
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Figure 4–13: Key SAR observations 
One of the more notable discoveries in this investigation was the requirement of basic amino 
functionality for IPCS inhibition. Additionally, studies on the benzhydryl portion of the 
molecule revealed a preference for large hydrophobic substituents.  
The SAR data gained have highlighted some key areas for further investigation. A study 
of analogues bearing a range of aryl-substituents will provide in-depth information on the 
interactions of the benzhydryl unit with the IPC synthase enzyme, shedding light on potential 
π-stacking and hydrophobic interactions. In addition, altering the linker chain length, as well as 
the position of the nitrogen on the pyrrolidine ring, may reveal different activity profiles. This 
in turn could point towards specific interactions with the LmjIPCS enzyme. More 
fundamentally, as reflected in Chapter 3, an in-depth investigation into the effects of 
pyrrolidinyl and benzhydryl stereochemistry on potency against both L. major IPCS and 
promastigote parasites may consolidate some of the patterns discovered in this work. 
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5. Efforts Towards the Development of a Second Generation 
Inhibitor 
As described in Section 4.3, indazolyl amide 118 was discovered to have activity against 
LmjIPCS at concentrations comparable to clemastine 41, but exhibited poor antileishmanial 
action. This observation mirrored the low cytotoxic activity displayed by clemastine amide 
analogues 98 and 99 (see Section 3.3.4). Therefore, it was decided to synthesise an 
ether-linked analogue of indazole 118, to test whether presence of the amide bond was 
responsible for this differential action. 
5.1 Synthetic strategy 
As with the synthesis of nor-clemastine analogues 77, 78A and 78B (see Section 3.2.2), it 
was postulated that alcohols 73 and 145 could be connected via acid catalysed ether 
formation to access indazole analogue 146 (Scheme 5–1). With benzhydrol 73 readily 
available, attention turned towards the synthesis of fragment 145. 
 
Scheme 5–1: Retrosynthetic analysis of indazole 145 
5.2 Synthesis of indazolyl methanol 145 
Indazole-6-carboxylic acid 147 was converted to the methyl ester 148 via acid catalysed 
esterification, as confirmed by the appearance of the molecular ion in the LCMS spectrum 
(m/z = 177 [MH+]) (Scheme 5–2).254 Initial attempts to alkylate the indazole utilising NaH 
and 2-chloro-N,N-dimethylethylamine (as a free base) resulted in no conversion of ester 
148, as judged by TLC analysis.255   
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Scheme 5–2: Esterification and attempted N-alkylation of indazole-6-carboxylic acid 147 
Alternative conditions, using potassium carbonate as base, resulted in the full consumption 
of ester 148, but provided 4 compounds as observed by TLC and LCMS analysis of the crude 
reaction mixture (m/z = 203 and 248) (Scheme 5–3). Straightforward separation on SiO2 
column afforded N-alkylation products 149 and 150, as well as N-vinyl indazoles 151 and 
152. Characterisation of the separate isomers was confirmed through analysis of 2D NMR 
HMBC correlations (shown below). Specifically, the desired product 149 revealed mutual 
coupling between the quaternary carbon at δC = 139.2 ppm and the methylene unit at 
δH = 4.52 ppm. 
 
Scheme 5–3: Alkylation of ester 148 under K2CO3 conditions 
The mechanism by which elimination products 151 and 152 were formed was not 
investigated, but may have involved anchimeric assistance, as exemplified by the putative 
intermediate 149a (Scheme 5–4). An optimisation of this alkylation step was not pursued, 
as the difficulty of achieving exclusive 1-N or 2-N alkylation with indazoles is well 
documented.255–257  
 | 81 | 
Chapter 5: Efforts Towards the Development of a Second Generation Inhibitor 
 
Scheme 5–4: Possible elimination mechanism for the formation of olefin 151 
Hydride reduction of the ester moiety of indazole 149 resulted in clean conversion to 
alcohol 145, as evidenced by the disappearance of the IR-active carbonyl stretch and 
appearance of a broad O–H vibration at 3348 cm−1. Indazole 145 proved to be unstable to 
chromatography on silica and so was used without purification. 
 
Scheme 5–5: Ester reduction of indazole 149  
5.3 Ether formation 
Initial attempts to couple benzhydrol 73 and indazole 145 followed the acid catalysis 
protocol employed for the synthesis of nor-clemastine analogues 77, 78A and 78B (see 
Section 3.2.2) (Scheme 5–6). However, an intractable mixture resulted, probably reflecting 
the instability of the indazole alcohol 145. 
 
Scheme 5–6: Failed ether formation attempt with alcohols 73 and 145 
An alternative strategy for the preparation of the desired analogue 146, through 
Williamson-type ether synthesis, was then investigated, beginning with an exploration of 
the synthesis of alkylating agents 153 and 154 (Scheme 5–7). 
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Scheme 5–7: Displacement strategy for the synthesis of indazole 146 
Initial attempts examined the reaction of indazole 145 with mesyl chloride (Scheme 5–8). 
Although consumption of the starting material was observed on TLC analysis of the 
reaction mixture, upon workup of the reaction, a complex mixture resulted from which the 
desired mesylate 155 could not be obtained. It is speculated that this may be due to 
participation of the indazole nitrogen, activating the putative mesylate 155 towards further 
reaction. As it was previously demonstrated that benzhydrol 73 could be activated using 
mesyl chloride (see Scheme 3–35), the conversion of alcohol 73 to a suitable electrophile 
was then explored. 
 
 Scheme 5–8: Attempted activation of alcohols 73 and 145  
The reaction of benzhydrol 73 with methanesulfonyl chloride proceeded cleanly, as judged 
by TLC analysis (Scheme 5–8). After washing the resulting crude product with NaHCO3(aq.), 
GCMS analysis revealed the presence of chloride 156, displaying a characteristic Cl2 isotopic 
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pattern (m/z = 236 [100%, M(35Cl)(35Cl)], 238 [83, M(35Cl)(37Cl)], 240 [8, M(37Cl)(37Cl)]). This 
was in agreement with the crude 1H NMR spectrum, where no methyl group was observed, 
presumably due to removal of methanesulfonic acid (δH ~2.80 ppm). Unfortunately, an 
attempt to purify chloride 156 via SiO2 column resulted in the complete loss of material. 
With the knowledge that aryl chloride 156 could be accessed, an attempted 
two-step reaction was conducted with activation of benzhydrol 73 prior to displacement by 
the alkoxide of indazole 145 (Scheme 5–9). The desired ether 146 was isolated in 14% yield 
after chromatography on silica, confirmed by a 2D NMR HMBC experiment, which revealed 
coupling between the depicted methine (δH = 5.45 ppm, δC = 82.1 ppm) and methylene 
(δH = 4.68 ppm, δC = 71.0 ppm) units. 
 
Scheme 5–9: Synthesis of indazolyl ether 146 
5.4 In vitro activity of ether analogue 146 
With the desired ether 146 in hand, a dose-response assay against the L. major IPC 
synthase enzyme was conducted (Figure 5–1). Surprisingly, the synthesised analogue 146 
was found to have a lower IC50 value (4.72 µM, 95% CI: 3.90 – 5.72 µM), compared to the 
parent indazole amide 118 (c.f. Figure 4–4, 2.41 µM, 95% CI: 1.84 – 3.16 µM). The reason 
for this discrepancy is unclear, but may be due to the loss of H-bond donor/acceptor 
capability of the amide, or a loss of conformational rigidity. 
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Figure 5–1: Dose-response relationship of indazole 146 against LmjIPCS. Error bars 
portray 95% confidence interval 
Subsequently, cell-viability assays against L. major promastigotes were undertaken. Whilst 
ether 146 saw a modest improvement in activity when compared to the parent amide 118 
(Figure 5–2), the activity was considerably lower (ED50 >5 µM) than that observed for 
clemastine 41 (ED50 = 0.47 µM). 
 
Figure 5–2: Compared activity of indazoles 118 and 146 against L. major promastigotes. 
Error bars portray 95% confidence interval. 
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The reasons for the poor leishmanicidal activity of indazole 146 remain unknown, but may 
be due to poor cell permeability, metabolism by the parasite, or an inability to reach the 
target IPCS. However, the increase in antileishmanial activity upon removal of the amide 
bond is consistent with the observation that the diastereomeric mixture 77 exhibits 
micromolar leishmanicidal action, unlike amide analogues 98 and 99, which also contain a 
mixture of 4 diastereomers (c.f. Figure 3–3 and Figure 3–8).  
5.5 Conclusions 
Based on the most active LmjIPCS inhibitor from the library of amide-linked compounds, 
indazole 118 (see Figure 4–4), the ether-linked analogue 146 was prepared, in order to 
assess the effect of the amide bond on leishmanicidal activity. Although the synthesised 
ether 146 was found to be a slightly less effective inhibitor of LmjIPCS, it displayed higher 
potency against L. major promastigotes. Nevertheless, ether 146 proved to be much less 
effective than clemastine 41 against the flagellate parasites. This verifies that removal of 
the amide functionality allows for an increase in antileishmanial activity, but is not the only 
factor affecting compound efficacy. 
As observed with other target-based screening projects, biochemical activity does 
not necessarily translate to efficacy in cellulo (see Section 1.2.5.2).115 However, the work 
presented in this thesis has established an iterative method of analogue synthesis and in 
vitro screening, to allow for the straightforward elucidation of SAR data. This in turn will 
inform the generation of more active chemical tools to further probe the Leishmania major 
IPC synthase enzyme. 
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6. Additional Work 
This chapter covers additional work that was conducted to support the main investigation 
discussed throughout Chapters 2 – 5. Section 6.1 discusses the construction of a mutant yeast 
strain that was required to effectively produce microsomal material enriched in the LmjIPCS 
enzyme. This work was conducted collaboratively within the Denny group, and due credit is 
given where appropriate. 
 Section 6.2 introduces efforts made towards developing a photoaffinity probe that 
may potentially shed light on the interactions of clemastine 41 analogues with the LmjIPCS 
enzyme. All work conducted in this section is the author’s own. 
6.1 Construction of a LmjIPCS complemented mutant yeast strain 
The yeast system initially used to probe the activity of LmjIPCS (YPH499–HIS–GAL–AUR1 
pRS246–LmjIPCS, see Section 1.3.4.4) produces LmjIPCS, but not the fungal S. cerevisiae IPCS 
(AUR1), in the presence of glucose.159,209 However, concerns over the potential for leaky 
expression of ScAUR1 were raised by Sevova et al.258 To address this concern, work within the 
Denny group focussed on the generation of a yeast knock-out mutant which lacked the AUR1 
gene. As S. cerevisiae requires a functional IPCS to survive,192 transformation with the 
exogenous LmjIPCS gene would rescue the mutant yeast. 
To this end, an auxotrophic ΔAUR1 S. cerevisiae strain was utilised (α ade− lys− leu− 
AUR1Δ::TRP1 pRS316–ScAUR1), in which the genomic AUR1 was replaced by a TRP1 gene, 
encoding de novo tryptophan biosynthesis.259 The mutant yeast was rescued by inclusion of a 
pRS316 plasmid containing the essential AUR1 enzyme. This plasmid also contains a URA3 
gene, which encodes the orotidine 5′-phosphate decarboxylase enzyme, required for uracil 
production.260 Presence of the URA3 gene confers a sensitivity to 5-fluoroorotic acid 157 
(5-FOA), which is converted to toxic 5-fluorouracil 158 by orotidine 5′-phosphate 
decarboxylase (Scheme 6–1). The use of 5-FOA 157 is a well-established strategy for the 
counter-selection of genes in yeast.261 
 | 87 | 
Chapter 6: Additional Work 
 
Scheme 6–1: Biosynthesis of 5-fluorouracil 158, catalysed by orotidine 5′-phosphate 
decarboxylase 
The Leishmania major IPCS and ScAUR1 coding sequences were cloned into separate pESC–LEU 
expression vectors, bringing the expression of these open reading frames under the control of 
a GAL1 promoter, meaning the respective IPC synthases are expressed in the presence of 
galactose but suppressed by glucose (Figure 6–1). The resulting pESC–LEU–LmjIPCS and pESC–
LEU–ScAUR1 plasmids were subsequently used to transform the ΔAUR1 yeast strain, which 
was then subjected to 5-FOA 157 selection conditions. 
 
 
Figure 6–1: The pESC–LEU vector. Multiple cloning sites (MCSs) are under GAL promotion, 
meaning gene expression is activated by galactose and repressed by glucose. The presence 
of the LEU2 marker allows for growth of transformed yeast in media lacking leucine. 
These selection conditions successfully cured the transgenic yeast of the pRS316–ScAUR1 
plasmid, which was confirmed in a complementation assay (Figure 6–2). The transformed 
ΔAUR1 pESC–LEU–LmjIPCS and ΔAUR1 pESC–LEU–ScAUR1 yeast strains were found to grow on 
galactose containing medium (SGR−W−L), under which IPCS expression is activated. 
Furthermore, the lack of growth on glucose containing medium (SD−W−L), where expression 
from the pESC–LEU plasmid is suppressed, proves the absence of the pRS316–ScAUR1 plasmid. 
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Lastly, no yeast growth was observed on medium containing galactose but lacking uracil 
(SGR−W−L−URA), indicating the absence of the URA3 gene, and hence pRS316–ScAUR1. This 
experiment confirms the construction of a mutant yeast strain complemented with the 
LmjIPCS enzyme as its only functional sphingolipid synthase. 
 
Figure 6–2: Complementation assay of ΔAUR1 pESC–LEU–LmjIPCS and ΔAUR1 pESC–LEU–
ScAUR1 S. cerevisiae strains. Assay conducted by J.L. Norcliffe (data unpublished). Minimal 
media are lacking either tryptophan (−W), leucine (−L) or uracil (−URA), and with either 
glucose (SD) or galactose/raffinose (SGR) as carbon sources. 
Following this, the function of the IPC synthases within these yeast strains was confirmed via 
an ex cellulo experiment (Figure 6–3). Microsomal membranes were harvested from the 
mutant yeast and used to catalyse the reaction of fluorescent NBD-C6-ceramide and 
phosphatidylinositol (PI). The resulting mixture of ceramide and NBD-C6-IPC 35 was separated 
by HPTLC and visualised through fluorescence spectroscopy. IPCS activity was confirmed for 
both sets of microsomal material due to the presence of NBD-C6-IPC 35. Furthermore, upon 
the addition of aureobasidin A (AbA) 33, a potent yeast AUR1 inhibitor, at 5 µM, ablation of 
activity was observed for ScIPCS but not LmjIPCS. This agrees with previously reported 
findings,159 confirming the successful complementation of ΔAUR1 S. cerevisiae with the 
Leishmania major IPC synthase. 
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Figure 6–3: Microsomal membranes from ΔAUR1 pESC–LEU–LmjIPCS and ΔAUR1 pESC–LEU–
ScAUR1 S. cerevisiae exhibit IPCS activity. Furthermore, AbA 33 inhibits ScIPCS but not 
LmjIPCS at 5 µM. Experiment conducted by the author. 
6.2 Preliminary efforts towards developing photoaffinity probes 
6.2.1 Background information 
While it is clear that clemastine 41 is an effective inhibitor of the Leishmania major IPCS, the 
mechanism by which this activity is achieved is unknown. Therefore, the precise action of 
clemastine-like inhibitors requires experimental verification. As X-ray crystallographic methods 
are not easily applicable to the membrane bound IPC synthase, other approaches must be 
employed. The use of photoaffinity probes, coupled with mass spectrometry (and MS/MS) 
analyses, have been reported in the literature for the identification and characterisation of 
protein targets.262,263 In this, a protein and photoactive probe are incubated until sufficient 
binding is achieved. On irradiation, a highly reactive species, such as a nitrene or carbene, is 
generated which inserts into the protein to provide a cross-linked species (Scheme 6–2). 
NBD-C6-ceramide 
 
NBD-C6-IPC 
LmjIPCS    ScIPCS 
Aureobasidin A (5 µM) − + − + 
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Subsequent proteolytic cleavage (e.g. using trypsin) yields fragments which can then be 
analysed using mass spectrometry. Comparing the output with that obtained from 
non-labelled protein enables the sites of probe-binding to be elucidated. Confirmation can be 
obtained by modifying these residues via site-directed mutagenesis to create engineered 
proteins which are resistant to the probe molecule.264  
 
Scheme 6–2: Characterisation of a protein using a photolabelling-mass spectrometry 
experiment 
A suitable probe molecule must fulfil certain criteria, such as chemical stability under 
enzymatic conditions, short irradiation period (to minimise potential damage to the protein 
target), a suitable wavelength for irradiation and a low propensity for non-specific labelling 
(i.e. irradiated species have a life span which enables efficient crosslinking).263,265 Importantly, a 
synthesised probe must have comparable activity to the inhibitor it is based on. In addition, a 
photoaffinity probe may also bear other features such as fluorescent moieties, biotin residues 
or radioisotopic labels, to allow for facile identification and separation of labelled peptides.262 
This method could potentially be used with membrane-bound proteins, such as LmjIPCS, 
where a crosslinked probe may be used as a purification tag, to remove the enzyme from other 
membrane components prior to analysis. 
 The most commonly used photoreactive groups are benzophenones 159, aryl azides 
160 and diazirines 161 (Scheme 6–3).265 Using clemastine 41 as a scaffold, it was viewed that 
introducing one of these functionalities onto an aryl ring would be relatively straightforward. A 
preliminary synthetic attempt focussed on the construction of aryl azide clemastine analogue 
162, as it was assumed that the azide precursor 163 could be rapidly accessed. 
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Scheme 6–3: Example photoreactive groups 
6.2.2 Synthesis of azide analogue 162 
Following precedent by Andersen et al., it was viewed that the azide benzhydrol 163 could be 
accessed from the corresponding aryl bromide 164 (Scheme 6–4).266 4-Bromobenzaldehyde 
165 was reacted with freshly prepared phenyl Grignard reagent, furnishing the desired 
bromide precursor 164 in excellent yield, as evidenced by the presence of an IR-active O–H 
vibration at 3352 cm−1. 
 
Scheme 6–4: Synthesis of para-bromo benzhydrol 164 
Next, aryl bromide 164 was reacted with sodium azide in the presence of a copper catalyst 
under microwave heating (Scheme 6–5).266 Infrared spectroscopic analysis of the resultant 
crude material revealed a characteristic azide vibration at 2120 cm−1. Without purification, the 
crude azide 163 was coupled with homoprolinol (S)-57 to afford the desired ether 162, as 
confirmed by a 2D NMR HMBC experiment, which revealed coupling, between the benzylic 
(δH = 5.30 ppm) and methylene (δH = 3.53 – 3.43 ppm) positions.  
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Scheme 6–5: Synthesis of azide clemastine analogue 162 
6.2.1 In vitro testing of azide analogue 162 
The azide analogue 162 was tested against the L. major IPCS enzyme in a dose-response study 
(Figure 6–4). Azide 162 exhibited micromolar activity against the enzyme (IC50 = 3.66 µM, 95% 
CI: 3.24 – 4.14 µM), at concentrations comparable to the clemastine analogue 78A 
(IC50 = 4.45 µM, 95% CI: 4.01 – 4.94 µM). 
 
 
Figure 6–4: Biochemical activity of azide 162 against LmjIPCS. Nor-clemastine 78A is shown 
for comparison. Error bars portray 95% confidence interval. 
Next, an assay against L. major promastigotes revealed the azide analogue 162 to have lower 
antileishmanial activity (ED50 = 2.85 µM, 95% CI: 2.28 – 3.56 µM) than nor-clemastine 78A by a 
factor of ~2 (ED50 = 1.69 µM, 95% CI: 1.23 – 2.32 µM) (Figure 6–5). The contribution of the 
azide moiety to this modest decrease in activity remains unclear. 
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Figure 6–5: Comparison of antileishmanial activity of azide 162 and clemastine analogue 
78A. Error bars portray 95% confidence interval. 
6.2.2 UV absorption measurement of azide 162 
Once the inhibitory effect of azide 162 on L. major IPCS activity and promastigote growth was 
confirmed, the UV absorption profile of the potential photoaffinity probe was measured 
(Figure 6–6). Upon analysis of the obtained data, it was apparent that the absorption band of 
interest (235 – 275 nm) was similar to the ‘near-UV’ region (240 – 300 nm) generally observed 
in the UV spectra of proteins.267,268 This is a common drawback of aryl azide probes,269 but may 
be circumvented by modifying substituents on the aromatic ring, thereby altering the 
photochemical properties of the probe.270 Measurement of the UV absorbance of LmjIPCS 
would allow for a direct comparison, however the presence of other membrane components 
would interfere, requiring the deconvolution of any obtained spectra. Furthermore, removal of 
the membrane lipids would risk unfolding the enzyme, which would furnish an unreliable UV 
absorption spectrum.268 
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Figure 6–6: UV absorption profile of azide 162 (blue line) at 25 µM in 50 mM phosphate 
buffer with 600 µM CHAPS. The green line represents blank buffer. 
6.2.3 Conclusions  
In conclusion, azide 162 was synthesised and found to maintain activity against the L. major 
IPCS enzyme and promastigote parasites, when compared to nor-clemastine 78A. However, an 
assessment of its potential as a photoaffinity probe revealed the lack of a suitable irradiation 
wavelength which would not be liable to interference from biological material.  
Future work should focus on the synthesis of substituted aryl azides, which may 
influence UV absorption (Figure 6–7).270 Additionally, an exploration of other clemastine 
derivatives featuring the benzophenone and diazirine photoreactive groups may reveal a 
promising alternative compound series. Identification of a viable crosslinking moiety may then 
inform the syntheses of analogues bearing additional functionality, such as purification tags or 
fluorescent groups. 
 
Figure 6–7: Other potential clemastine-based photoaffinity probes 
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7. Conclusions and Further Work 
7.1 Conclusions 
This thesis comprises efforts made towards the discovery and development of novel small 
molecule inhibitors of the Leishmania major inositol phosphoryl ceramide synthase (LmjIPCS) 
enzyme, with a view to elucidating information about the enzyme whilst uncovering potential 
new therapies for leishmaniasis. 
 A screening campaign using the 1040 member NINDS compound library revealed 
clemastine 41 to be an effective inhibitor of LmjIPCS. Importantly, clemastine 41 also displayed 
antileishmanial activity against the pathologically relevant amastigote form of Leishmania 
major, through its tentative role as an inhibitor of IPC production. 
 In order to probe the possible interactions between clemastine 41 and LmjIPCS, a 
range of analogues were prepared, the majority through a facile peptide coupling strategy. The 
synthesised analogue compounds were screened against the enzyme, revealing the following 
structure-activity relationships (SARs) (Figure 7–1). 
 
Figure 7–1: A summary of SAR observations 
Of the 61 amide-containing analogues screened, indazole 118 was found to be the most 
effective against LmjIPCS, displaying similar potency to clemastine 41 (Figure 7–2). However, 
indazole 118 was found to be ineffective against L. major promastigote parasites, a drawback 
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which was not rectified through replacement of the amide moiety with ether functionality 
(indazole 146). 
 
Figure 7–2: Analogues of clemastine 41 bearing an indazole moiety 
Another investigation into the possible interactions between clemastine 41 and LmjIPCS 
focused on the development of a photoaffinity probe. Azide 162 was prepared in a 
straightforward manner, and exhibited biochemical and antileishmanial activity similar to that 
of clemastine 41. However it’s measured UV spectrum revealed no suitable target wavelength 
for activation of the putative probe 162 in the presence of enzymatic material. 
 
Figure 7–3: Azide analogue 162 
7.2 Further work 
Although an effective antileishmanial compound based on the clemastine 41 scaffold was not 
found, there remain a number of avenues of exploration for this compound class. Further 
efforts may focus on investigating the aryl substituents of the benzhydryl moiety, the position 
of the nitrogen on the pyrrolidine ring, and the effect of linker chain length on activity. 
 More fundamentally, an in-depth study on the impact of benzhydryl and pyrrolidinyl 
stereochemistry on LmjIPCS inhibition may point towards important enzyme-inhibitor 
interactions. This would require separate synthesis, where necessary, and screening of the 
four possible diastereomers of clemastine 41: (R,R), (R,S), (S,R) and (S,S). 
 Structural studies of the LmjIPCS enzyme represent another significant area for further 
investigation. As described in Chapter 6, a continuation of efforts around the generation of 
photoaffinity probes may focus on the synthesis of analogues bearing substituted aryl azides, 
benzophenone or diazirine derivatives (Figure 7–4). Once a suitable labelling tool is found, 
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further work should focus on the development of a robust protocol for isolation of the LmjIPCS 
enzyme, such that enzyme-probe adducts may be suitably analysed. This may be done through 
the addition of purification tags to either the probe molecule or the LmjIPCS enzyme itself. 
 
Figure 7–4: Potential clemastine-based photoaffinity probes 
Computational studies may also be undertaken to support the above described SAR and 
photolabelling studies. For example, Neuwald reported an observed relationship in the 
structures and catalytic mechanisms of membrane phosphatases (e.g. LPPs) and 
haloperoxidase enzymes, for which resolved crystal structures are known.271 As the 
conservation of catalytic residues among LPP enzymes and sphingolipid synthases has also 
been demonstrated,212 it may be possible to build a putative 3D model of the catalytic site of 
LmjIPCS, based on known haloperoxidases. An in silico model could shed light on the 
interaction, if any, of clemastine analogues with the catalytic site, adding a rational design 
element to further analogue synthesis. 
 Lastly, the initial screen of the NINDS set revealed chemical scaffolds other than 
clemastine 41, which may be used as a starting point for other SAR studies. Examples include 
amlodipine 39, flunarizine 45 and suloctidil 52. However, these compounds provide limited 
scope in that their activity against intramacrophage L. major amastigotes could not be 
accurately assessed. Therefore, SAR studies based on these compounds may not yield effective 
antileishmanials. 
 In the long term, the approaches discussed throughout this thesis may be applied to 
an investigation of the IPCS enzymes of other Leishmania species, such that vital information 
may be gained concerning the biosynthesis of sphingolipids within these complex organisms. 
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8. Chemical Experimental Details 
8.1 General experimental details 
SOLVENTS AND REAGENTS: Solvents and commercially available reagents were dried and 
purified as required, using standard procedures. DCM, DMF, DMSO, ether (diethyl ether), 
hexanes, MeCN, MeOH and THF were obtained dry from Inert Techonolgy Inc. SPS (solvent 
purification systems) and stored under argon. N,N′-Dimethylethylenediamine (DMEDA) and 
triethylamine were distilled from, and stored over, KOH. Petrol refers to the fraction of 
petroleum ether boiling in the range 40 – 60 °C. All reactions were performed in round 
bottomed flasks, with stirring, under an atmosphere of argon unless otherwise stated. 
Butyllithium refers to n-butyllithium. 
CHROMATOGRAPHY: Thin layer chromatography (TLC) was carried out using Merck aluminium 
or glass backed precoated plates (silica gel 60 Å F254). Compounds were visualised under UV 
radiation (λmax = 254 nm and 365 nm) and then stained, using the appropriate reagent, and 
heated. Retention factors (Rf) are reported along with the solvent system used in parenthesis. 
Purification via flash column chromatography was conducted manually on silica gel (40 – 
60 µm, 60 Å) or automatically using a CombiFlash® system with normal-phase and C-18 
reversed-phase silica gel columns (purchased from Teledyne Isco Inc.).  
NUCLEAR MAGNETIC RESONANCE: 1H and 13C NMR spectra were recorded on Varian VNMRS 
700 (1H at 700 MHz, 13C at 176 MHz), Varian VNMRS 600 (1H at 600 MHz, 13C at 151 MHz), 
Inova 500 (1H at 500 MHz) and Bruker Avance-400 (1H at 400 MHz, 13C at 101 MHz) 
instruments at room temperature, unless otherwise stated. 1H-coupled 19F NMR spectra were 
recorded on Bruker Avance-400 and Varian Mercury-400 instruments at a frequency of 
376 MHz. Chemical shifts (δH or δC) are reported in parts per million (ppm) of tetramethylsilane 
using residual solvent as an internal standard. Coupling constants (J) are quoted to the nearest 
0.5 Hertz (Hz). The multiplicity is indicated by singlet (s), doublet (d), triplet (t), quartet (q), 
quintet (quin), heptet (hept), multiplet (m), broad (br) or a combination thereof. Al and Ar 
refer to the respective alkyl and aryl resonances which could not be accurately assigned. In the 
case of rotameric compounds, proton and carbon resonances of the major and minor rotamers 
are assigned as A and B respectively, with their relative integration values reported. 
Diastereomeric resonances are labelled arbitrarily as 1 and 2, where elucidation of the 
separate isomers is possible. 
 | 99 | 
Chapter 8: Chemical Experimental Details 
INFRARED SPECTROSCOPY: Infrared (IR) spectra were recorded using a Perkin-Elmer Paragon 
1000 FT-IR with Diamond ATR module. Absorption maxima (νmax) are reported in wavenumbers 
(cm−1) and are described as strong (s), medium (m), weak (w) or broad (br) or a combination 
thereof.  
MASS SPECTROMETRY: Low resolution mass spectra (LRMS) were recorded via electron 
ionisation (EI), using Thermo Trace and Shimadzu gas chromatography (GC) instruments, or 
electrospray ionisation (ESI), using a Waters TQD spectrometer equipped with an Acquity 
UPLC. High resolution mass spectra (HRMS) were obtained using Waters LCT Premier XE or 
QTOF Premier instruments (ESI). Mass to charge ratios (m/z) are reported in Daltons with the 
corresponding fragment ion, where known. 
OPTICAL ROTATION: Measurements were performed on a JASCO P-1020 polarimeter, and are 
stated alongside temperature, solvent and concentration, in mgmL-1 with corresponding 
literature values. 
MELTING POINTS: Melting points were determined using Fisher Scientific™ IA9000 series 
melting point apparatus and are uncorrected. Decomp. refers to material that decomposed 
upon heating. 
MICROWAVE MEDIATED REACTIONS: Reactions under microwave irradiation conditions were 
performed using monomodal EmrysTM Optimizer from Personal Chemistry, in sealed 
microwave process vials. The time reported reflects the time that the reaction mixture was 
kept at designated temperature (fixed hold time) by varying irradiation power.  
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8.2 Experimental procedures  
General procedure A: Amide bond formation  
 
Procedure:246 To a mixture of amine (1 eq.), N-methylmorpholine (NMM) (1.1 eq.) and 
EDCI•HCl (1.1 eq.) in DCM (3 mL.mmol−1) at 0 °C was added acid (1 eq.) and HOBt (1.1 eq.) in 
DCM (3 mL.mmol−1). DMF was added as required to aid solvation. After being stirred at RT 
overnight, the reaction mixture was quenched with H2O (4 mL.mmol
−1) and passed through a 
phase separator. The resultant solution was concentrated under reduced vacuum and purified 
via reversed-phase flash column chromatography. 
 
General procedure B: Condensation of two alcohols 
 
Procedure:233 A flask fitted with a water condenser was charged with primary alcohol (1 eq.), 
benzhydryl alcohol (1.1 eq.), p-toluenesulfonic acid monohydrate (1.1 eq.), toluene 
(4 mL.mmol−1) and 4 Å molecular sieves (100 mg.mmol−1). The reaction mixture was heated to 
reflux for 2 h before being cooled and quenched by the addition of 1 M NaOH(aq.) 
(4 mL.mmol−1). The mixture was extracted with EtOAc and the organic extracts washed with 
brine, dried over MgSO4 and concentrated in vacuo. Purification of the resultant crude 
material was performed on SiO2 column. 
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General procedure C: Preparation of benzhydryl alcohols 
 
Procedure:272 To a 2-necked round bottomed flask equipped with a reflux condenser and a 
pressure equalising addition funnel was added Mg turnings (1.6 eq.), THF (0.1 mL.mmol−1) and 
a small portion of bromobenzene (0.16 eq.). The reaction was initiated by addition of a crystal 
of I2 and gentle warming until reflux temperature was reached. This reflux was maintained by 
slow addition of bromobenzene (1.5 eq.) in THF (0.5 mL.mmol−1). After addition was complete, 
the reaction mixture was heated to reflux for 1 h. The freshly prepared Grignard reagent was 
then cooled in an ice bath before benzaldehyde (1 eq.) in THF (1 mL.mmol−1) was added 
dropwise. The reaction mixture was warmed to RT and reacted for 4 h, after which the solution 
was poured onto ice-cold saturated NH4Cl(aq.). THF was removed under reduced pressure and 
the residue extracted with EtOAc. The combined organic extracts were washed with brine and 
dried over MgSO4 prior to concentration in vacuo. The crude material was purified by silica 
column chromatography. 
 
General procedure D: Fieser’s method for the workup of LiAlH4 reactions 
Procedure:273 A reaction containing X g of lithium aluminum hydride was first cooled to 0 °C 
and diluted with ether. Then, cold H2O (X mL) was slowly added, followed by 3 M NaOH(aq.) 
(X mL) and H2O (3X mL). The quenched mixture was warmed to RT and stirred for 15 min, after 
which MgSO4 was added and the mixture stirred for an additional 5 min. The combined lithium 
and magnesium salts were then removed by filtration, before removal of volatiles under 
reduced pressure afforded the crude product. 
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8.3 Compound characterisation  
(2S)-2-(2′-Hydroxyethyl)-1-methylpyrrolidine222 (S)-57 
 
Procedure:222 To a 0 °C solution of methyl ester (S)-70 (671 mg, 2.42 mmol) in THF (12 mL) was 
slowly added LiAlH4 (2.4 M solution in THF, 3.00 mL, 7.26 mmol), before being allowed to 
warm to RT. After 3 h the mixture was cooled once more in an ice bath and quenched 
according to Fieser’s method (general procedure D).273 The combined organic filtrates were 
concentrated in vacuo and purified by SiO2 column (0% → 10% MeOH in CHCl3 with 1% NEt3) to 
afford the title compound (309 mg, 99%) as a thick clear colourless oil. 
No optical rotation measurement was obtained. Rf 0.18 (50% EtOAc in hexanes); νmax (ATR) 
3288 (br), 2941 (m), 2840 (m), 2792 (m), 1455 (m), 1210 (w), 1056 (s), 1016 (m) cm−1; 
δH (600 MHz, CDCl3) 5.18 – 5.04 (1H, s, OH), 3.92 (1H, td, J = 10.5, 3.5 Hz, 2′-HH′), 3.66 – 3.59 
(1H, m, 2′-HH′), 3.06 – 3.00 (1H, m, 5-HH′), 2.57 – 2.50 (1H, m, 2-H), 2.33 (3H, s, NCH3), 2.18 – 
2.10 (1H, m, 5-HH′), 1.96 – 1.82 (2H, m, 3-HH′, 1′-HH′), 1.82 – 1.66 (3H, m, 3-HH′, 4-H2), 1.53 – 
1.46 (1H, m, 1′-HH′); δC (151 MHz, CDCl3) 65.2 (C-2), 60.3 (C-2′), 57.0 (C-5), 40.9 (NCH3), 31.8 (C-
1′), 28.5 (C-3), 23.1 (C-4); m/z (LCMS, ESI+) 130 (MH+). 
(2R)-2-(2′-Hydroxyethyl)-1-methylpyrrolidine274 (R)-57  
 
Procedure:222 Methyl ester (R)-70 (405 mg, 1.46 mmol) was reduced according to the 
conditions for the synthesis of alcohol (S)-57 to afford the title compound (122 mg, 65%) as a 
thick clear colourless oil. 
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No optical rotation measurement was obtained. Rf 0.18 (50% EtOAc in hexanes); νmax (ATR) 
3318 (br), 2945 (m), 2876 (m), 2848 (m), 2786 (m), 1455 (m), 1058 (m), 1018 (m) cm−1; δH (600 
MHz, CDCl3) 3.98 (1H, ddd, J = 11.0, 10.5, 3.0 Hz, 2′-HH′), 3.69 – 3.65 (1H, m, 2′-HH′), 3.04 (1H, 
ddd, J = 9.5, 7.0, 2.0 Hz, 5-HH′), 2.59 – 2.54 (1H, m, 2-H), 2.35 (3H, s, NCH3), 2.15 (1H, td, 
J = 9.5, 7.0 Hz, 5-HH′), 1.97 (1H, ddt, J = 15.0, 10.5, 4.5 Hz, 1′-HH′), 1.92 – 1.85 (1H, m, 3-HH′), 
1.82 – 1.71 (3H, m, 3-HH′, 4-H2), 1.48 (1H, dtd, J = 15.0, 3.5, 3.0 Hz, 1′-HH′); δC (151 MHz, CDCl3) 
65.3 (C-2), 60.4 (C-2′), 57.1 (C-5), 41.0 (NCH3), 31.5 (C-1′), 28.4 (C-3), 23.3 (C-4); m/z (LCMS, 
ESI+) 130 (MH+). 
(2S)-(N-tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid275 (S)-58 
 
Procedure:275 To a stirring biphasic mixture of saturated NaHCO3(aq.) (50 mL) and THF (17 mL) 
was added L-proline (4.00 g, 34.74 mmol). Once the proline was fully dissolved, the mixture 
was cooled in an ice bath before Boc2O (97%, 9.05 mL, 38.22 mmol) was added dropwise. The 
reaction mixture was warmed to RT and stirred for 16 h. Following this, THF was removed 
under reduced pressure and the remaining mixture cooled to 0 °C before being acidified to 
pH = 2 using 1M HCl(aq.) solution. This was extracted with EtOAc (3 × 100 mL), the combined 
organic extracts being washed with brine (70 mL) and dried over MgSO4, before being 
concentrated under reduced pressure and dried under high vacuum to afford the title 
compound (7.39 g, 99%) as a white solid.  
Melting point data were not obtained. [α]20D
 (c = 1.00 g/100 mL, CHCl3) −90.6° (lit.:
275 [α]20D
 
(c = 1.38 g/100 mL, CHCl3) −80.0°); νmax (ATR) 3070 (br), 2971 (m), 2876 (w), 1736 (m), 1689 (s), 
1655 (s), 1391 (s), 1365 (m), 1241 (m), 1162 (s), 1128 (s) cm−1; δH (600 MHz, CDCl3, mixture of 
rotamers) 4.31 – 4.27 (0.6H, m, 2-H rotamer A), 4.20 – 4.16 (0.4H, m, 2-H rotamer B), 3.52 – 
3.46 (0.4H, m, 5-HH′ rotamer B), 3.42 – 3.36 (1H, m, 5-HH′), 3.32 – 3.26 (0.6H, m, 5-HH′ 
rotamer A), 2.28 – 2.17 (1.2H, m, 3-HH′ rotamer A, 4-HH′ rotamer A), 2.04 – 1.96 (0.8H, m, 
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3-HH′ rotamer B, 4-HH′ rotamer B), 1.92 – 1.79 (2H, m, 3-HH′, 4-HH′), 1.42 (5.4H, s, C(CH3)3 
rotamer A), 1.36 (3.6H, s, C(CH3)3 rotamer B); δC (151 MHz, CDCl3, mixture of rotamers) 178.7 
(CO2H rotamer B), 174.7 (CO2H rotamer A), 156.6 (C=O rotamer A), 153.8 (C=O rotamer B), 81.5 
(C(CH3)3 rotamer A), 80.3 (C(CH3)3 rotamer B), 59.2 (C-2 rotamer A), 58.9 (C-2 rotamer B), 47.0 
(C-5 rotamer A), 46.3 (C-5 rotamer B), 30.8 (C-3 rotamer B), 28.4 (C(CH3)3), 28.3 (C-3 rotamer 
A), 24.5 (C-4 rotamer A), 23.6 (C-4 rotamer B); m/z (LCMS, ESI−) 214 (M − H). 
(2S)-(N-tert-Butoxycarbonyl)-2-(hydroxymethyl)pyrrolidine276 (S)-59 
 
Procedure :276 A round bottomed flask equipped with a reflux condenser was charged with 
N-Boc-L-proline (S)-58 (3.42 g, 15.88 mmol) and THF (80 mL). The mixture was cooled in an ice 
bath before dropwise addition of a solution of BH3•SMe2 (1.70 mL, 17.93 mmol) in THF (9 mL). 
The reaction mixture was heated to reflux for 1 h, after which complete conversion of starting 
material was observed by TLC. After cooling to 0 °C, the reaction was quenched with the 
addition of cold H2O (5 mL) and THF was removed from the crude mixture in vacuo. The 
residual material was diluted with H2O (100 mL) and extracted with DCM (3 × 30 mL). The 
combined organic extracts were washed with brine (60 mL) and dried over MgSO4 before being 
concentrated under reduced pressure to furnish the title compound (3.14 g, 98%) as a clear 
viscous oil. 
Rf 0.55 (4:1:1, petrol : EtOAc : EtOH); [α]
21
D
 (c = 1.00 g/100 mL, CHCl3) −29.5° (lit.:
223 [α]25D
 
(c = 1.20 g/100 mL, CHCl3) −39.8°); νmax (ATR) 3403 (br), 2976 (m), 2928 (w), 2881 (m), 1663 (s), 
1391 (s), 1365 (m), 1244 (w), 1162 (s), 1106 (m) cm−1; δH (700 MHz, CDCl3) 4.73 (1H, d, 
J = 6.0 Hz, OH), 3.96  – 3.89 (1H, m, 2-H), 3.63 – 3.58 (1H, m, 1′-HH′), 3.58 – 3.53 (1H, m, 
1′-HH′), 3.46 – 3.38 (1H, m, 5-HH′), 3.31 – 3.25 (1H, m, 5-HH′), 2.02 – 1.93 (1H, m, 3-HH′), 1.86 
– 1.78 (1H, m, 4-HH′), 1.77 – 1.71 (1H, m, 4-HH′), 1.55 – 1.48 (1H, m, 3-HH′), 1.44 (9H, s, 
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C(CH3)3); δC (176 MHz, CDCl3) 157.1 (C=O), 80.2 (C(CH3)3), 67.6 (C-1′), 60.1 (C-2), 47.5 (C-5), 28.7 
(C-3), 28.4 (C(CH3)3), 24.0 (C-4); m/z (LCMS, ESI
+) 202 (MH+), 224 (MNa+). 
(2S)-(N-tert-Butoxycarbonyl)-2-(cyanomethyl)pyrrolidine277 (S)-61 
 
Procedure:224 To a 0 °C solution of alcohol (S)-59 (819 mg, 4.07 mmol) in DCM (8 mL) was 
added NEt3 (1.26 mL, 8.95 mmol) then p-toluenesulfonyl chloride (98%, 1.16 g, 6.10 mmol). 
The reaction mixture was warmed to RT and stirred for 15 h, after which time TLC analysis 
showed consumption of starting material. The reaction mixture was diluted with H2O (10 mL) 
and extracted with DCM (3 × 10 mL). The combined organic extracts were washed with 
saturated NH4Cl(aq.) (20 mL), brine (20 mL) and saturated NaHCO3(aq.) (20 mL) before being dried 
over MgSO4 and concentrated in vacuo. The crude material was briefly purified by column 
chromatography (5% → 20% EtOAc in petrol) to give tosylate (S)-60 (1.28 g, 88%) as an 
unstable thick clear oil which could not be characterised and was taken immediately forward 
to the next step. 
To a solution of tosylate (S)-60 (710 mg, 2.00 mmol) in dry DMSO (2 mL) was added NaCN 
(277 mg, 5.65 mmol) and the reaction mixture stirred at 90 °C for 4 h. After cooling to RT, the 
mixture was diluted with H2O (20 mL) and the aqueous layer extracted with ether (4 × 15 mL). 
The combined organic extracts were then washed with brine (20 mL), dried over MgSO4 and 
concentrated in vacuo before being passed through a SiO2 plug (30% EtOAc in hexanes) to 
afford the title compound (233 mg, 55%) as a pale orange oil. 
No optical rotation measurement was obtained. Rf 0.27 (30% EtOAc in hexanes); νmax (ATR) 
2971 (w), 2885 (w), 2242 (w), 1685 (s), 1387 (s), 1158 (m), 1115 (w) cm−1; δH (700 MHz, CDCl3, 
mixture of rotamers) 4.02 – 3.96 (1H, m, 2-H), 3.48 – 3.43 (0.4H, m, 5-HH′ rotamer B), 3.43 – 
3.35 (1.6H, m, 5-H2 rotamer A, 5-HH′ rotamer B), 2.86 – 2.79 (0.6H, m, 1′-HH′ rotamer A), 2.73 
– 2.64 (1H, m, 1′-HH′ rotamer A, 1′-HH′ rotamer B), 2.58 – 2.52 (0.4H, m, 1′-HH′ rotamer B), 
2.19 – 2.11 (1H, m, 3-HH′), 2.04 – 1.93 (1H, m, 4-HH′), 1.93 – 1.88 (1H, m, 3-HH′), 1.88 – 1.81 
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(1H, m, 4-HH′), 1.49 – 1.46 (3.6H, s, C(CH3)3 rotamer B), 1.46 – 1.44 (5.4H, s, C(CH3)3 rotamer 
A); δC (176 MHz, CDCl3, mixture of rotamers) 154.5 (C=O rotamer A), 153.9 (C=O rotamer B), 
118.0 (CN rotamer A), 117.7 (CN rotamer B), 80.4 (C(CH3)3 rotamer B), 80.0 (C(CH3)3 rotamer 
A), 53.7 (C-2), 47.1 (C-5 rotamer A), 46.7 (C-5 rotamer B), 30.4 (C-3), 28.4 (C(CH3)3), 23.7 (C-4 
rotamer A), 23.1 (C-4 rotamer B), 22.8 (C-1′ rotamer B), 22.3 (C-1′ rotamer A); m/z (LCMS, ESI+) 
211 (MH+), 233 (MNa+). 
(2S)-(N-tert-Butoxycarbonyl)-2-(ethyl-2′-carboxylic acid)pyrrolidine278 (S)-62  
 
Procedure:225 To a round bottomed flask equipped with a reflux condenser was added nitrile 
(S)-61 (250 mg, 1.19 mmol), H2O (3.6 mL) and THF (2 mL). To this biphasic mixture was added 
Na2O2 (185 mg, 2.38 mmol) slowly and the reaction heated to 70 °C until TLC analysis revealed 
consumption of starting material. The reaction was heated for a further 2 h before being 
cooled to 0 °C and acidified to pH = 2 with 1 M HCl(aq.). THF was removed under reduced 
pressure and the resultant liquid extracted with EtOAc (3 × 10 mL). The combined organic 
extracts were washed with brine (15 mL) and dried over MgSO4 before being concentrated in 
vacuo to furnish the title compound (205 mg, 75%) as a light yellow solid. 
No optical rotation measurement was obtained. Melting point data were not obtained. νmax 
(ATR) 2976 (w), 2928 (w), 2876 (w), 1719 (m), 1689 (s), 1391 (s), 1162 (s) cm−1; δH (700 MHz, 
CDCl3, mixture of rotamers) 4.18  – 4.06 (1H, m, 2-H), 3.40 – 3.27 (2H, m, 5-H2), 3.00 – 
2.89 (0.5H, m, 1′-HH′ rotamer A), 2.89 – 2.79 (0.5H, m, 1′-HH′ rotamer B), 2.39 – 2.29 (1H, m, 
1′-HH′ rotamer A, 1′-HH′ rotamer B), 2.07 (1H, dq, J = 12.5, 8.0 Hz, 3-HH′), 1.89 – 1.79 (2H, m, 
4-H2), 1.79 – 1.71 (1H, m, 3-HH′), 1.44 (9H, s, C(CH3)3); δC (176 MHz, CDCl3, mixture of 
rotamers) 176.8 (C-2′ rotamer A), 176.1 (C-2′ rotamer B), 154.8 (C=O rotamer A), 154.3 (C=O 
rotamer B), 78.9 (C(CH3)3), 53.9 (C-2), 46.6 (C-5 rotamer A), 46.2 (C-5 rotamer B), 39.3 (C-1′), 
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31.3 (C-3 rotamer A), 31.2 (C-3 rotamer B), 28.4 (C(CH3)3), 23.5 (C-4 rotamer A), 22.8 (C-4 
rotamer B); m/z (LCMS, ESI−) 228 (M − H+). 
(2S)-(N-tert-Butoxycarbonyl)-2-(2′-hydroxyethyl)pyrrolidine278 (S)-63 
 
Procedure A:276 : A round bottomed flask equipped with a reflux condenser was charged with 
homoproline (S)-62 (184 mg, 0.8 mmol) and THF (4 mL). The mixture was cooled in an ice bath 
before dropwise addition of a solution of BH3·SMe2 (85 µL, 0.90 mmol) in THF (0.5 mL). The 
reaction mixture was heated to reflux for 1 h, after which complete conversion of starting 
material was observed by TLC. After cooling to 0 °C, the reaction was quenched with the 
addition of cold H2O (1 mL) and THF was removed from the crude mixture under reduced 
pressure. The residual material was diluted with H2O (5 mL) and extracted with DCM 
(3 × 10 mL). The combined organic extracts were washed with brine (20 mL) and dried over 
MgSO4 before being concentrated in vacuo to furnish the enantiomerically pure title 
compound (162 mg, 94%) as a clear, colourless viscous oil. 
Procedure B:223 To a 0 °C solution of alkene 65 (178 mg, 0.90 mmol) in THF (2.3 mL) was added 
BH3·SMe2 (0.26 mL, 2.71 mmol) and the reaction mixture stirred at RT for 3 h. The reaction was 
cooled in an ice bath then quenched by the addition of 3 M NaOH(aq.) (0.73 mL) and 27.5% v/v 
H2O2(aq.) (0.16 mL), with stirring at RT for a further hour. THF was then removed under reduced 
pressure and the residue diluted with H2O (3 mL) and extracted with EtOAc (3 × 5 mL). The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo to provide an 
inseparable mixture of the racemic title compound (104 mg, 53%) and by-product alcohol 66 
(41 mg, 21%) as a clear, colourless thick oil. The ratio of the two products was judged by 1H 
NMR spectrum of the crude material. 
Procedure C:230 A modified Method B was conducted in which cyclohexene (1.05 mL, 
10.41 mmol) was added dropwise to a solution of BH3·SMe2 (0.49 mL, 5.21 mmol) in THF 
(3.6 mL) in an ice bath. The reaction mixture was stirred at RT for 45 min before being cooled 
to 0 °C prior to slow addition of a solution of alkene 65 (685 mg, 3.47 mmol) in THF (4 mL). The 
reaction was quenched and extracted according to Method B to furnish the racemic title 
compound exclusively (293 mg, 39%) as a clear, colourless viscous oil. 
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Rf 0.20 (30% EtOAc in petrol); [α]
28
D
 (c = 1.00 g/100 mL, CHCl3) −28.3° (lit.:
223 [α]25D
 
(c = 1.43 g/100 mL, CHCl3) −10.7°); νmax (ATR) 3429 (br), 2971 (m), 2924 (m), 2871 (m), 1668 (s), 
1395 (s), 1365 (w), 1249 (w), 1167 (s), 1102 (w) cm−1; δH (700 MHz, CDCl3) 4.40 – 4.35 (1H, m, 
OH), 4.17  – 4.12 (1H, m, 2-H), 3.62 – 3.57 (1H, m, 2′-HH′), 3.57 – 3.51 (1H, m, 2′-HH′), 3.34 – 
3.27 (2H, m, 5-H2), 2.00 – 1.94 (1H, m, 3-HH′), 1.90 – 1.84 (2H, m, 4-H2), 1.71 – 1.65 (1H, m, 1′-
HH′), 1.62 – 1.57 (1H, m, 3-HH′), 1.45 (9H, s, C(CH3)3), 1.47 – 1.40 (1H, m, 1′-HH′); δC (176 MHz, 
CDCl3) 156.5 (C=O), 79.8 (C(CH3)3), 59.1 (C-2′), 53.5 (C-2), 46.4 (C-5), 38.4 (C-1′), 31.2 (C-3), 28.4 
(C(CH3)3), 23.5 (C-4); m/z (LCMS, ESI
+) 216 (MH+), 238 (MNa+). 
(2S)-(N-tert-Butoxycarbonyl)-2-formylpyrrolidine249 (S)-64 
 
Procedure A:228 To a water bath cooled solution of prolinol (S)-59 (371 mg, 1.84 mmol) in DCM 
(9 mL) was added pyridinium chlorochromate (600 mg, 2.78 mmol), 4 Å molecular sieves 
(1.30 g) and acetic acid (0.16 mL, 2.80 mmol). The reaction mixture was stirred at RT for 2 h 
followed by addition of celite® (920 mg) and ether (18 mL). The suspension was then filtered 
over a celite® plug and concentrated under reduced pressure. The residue was passed through 
a plug of SiO2 using ether (20 mL) as an eluent. Following removal of solvent under reduced 
pressure, the crude title compound was obtained (271 mg, 74%) as a yellow oil that was used 
in the next step without further purification. 
Procedure B:227 To a solution of prolinol (S)-59 (1.70 g, 8.44 mmol) in DMSO (20 mL) was added 
NEt3 (3.90 mL, 27.87 mmol), immediately followed by SO3•pyridine (8.46 g, 53.17 mmol) in 
DMSO (20 mL). The resulting yellow-orange reaction mixture was stirred at RT until TLC 
analysis revealed complete conversion of starting material. The reaction was quenched with 
saturated NH4Cl(aq.) (20 mL) and extracted with ether (6 × 20 mL). The combined organic 
extracts were washed with saturated NH4Cl(aq.) (30 mL), brine (30 mL) then saturated 
NaHCO3(aq.) (30 mL), before being dried over MgSO4 and concentrated in vacuo to provide the 
crude title compound (1.44 g, 86%) as a pale yellow oil that was used without purification. 
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No optical rotation measurement was obtained. Rf 0.17 (19:1:1, petrol : EtOAc : EtOH); νmax 
(ATR) 2971 (m), 2928 (m), 2881 (w), 1784 (w), 1732 (m), 1693 (s), 1391 (s), 1365 (m), 1309 (w), 
1249 (w), 1158 (s), 1115 (m) cm−1; δH (700 MHz, CDCl3, mixture of rotamers) 9.55 (0.4H, br s, 
CHO rotamer B), 9.45 (0.6H, br s, CHO rotamer A), 4.21 – 4.18 (0.4H, m, 2-H rotamer B), 4.06 – 
4.01 (0.6H, m, 2-H rotamer A), 3.57 – 3.53 (0.6H, m, 5-HH′ rotamer A), 3.50 – 3.41 (1.4H, m, 5-
HH′ rotamer A, 5-H2 rotamer B), 2.14 – 2.10 (0.6H, m, 3-HH′ rotamer A), 2.00 – 1.92 (1.4H, m, 
3-HH′ rotamer A, 3-H2 rotamer B), 1.89 – 1.85 (2H, m, 4-H2), 1.47 (3.6H, s, C(CH3)3 rotamer B), 
1.42 (5.4H, s, C(CH3)3 rotamer A); δC (176 MHz, CDCl3) 200.6 (CHO rotamer B), 200.4 (CHO 
rotamer A), 153.9 (C=O), 80.6 (C(CH3)3 rotamer A), 80.2 (C(CH3)3 rotamer B), 65.0 (C-2 rotamer 
A), 64.8 (C-2 rotamer B), 46.8 (C-5 rotamer B), 46.7 (C-5 rotamer A), 28.5 (C-3 rotamer A), 28.3 
(C-3 rotamer B), 28.4 (C(CH3)3 rotamer B), 28.2 (C(CH3)3 rotamer A), 23.9 (C-4); m/z (LCMS, ESI
+) 
200 (MH+). 
(N-tert-Butoxycarbonyl)-2-vinylpyrrolidine223 65 
 
Procedure:229 Methyltriphenylphosphonium bromide (98%, 4.77 g, 13.07 mmol) was dissolved 
in THF (26 mL) and cooled to −10 °C. Butyllithium (1.6 M in hexanes, 8.17 mL, 13.07 mmol) was 
added slowly. The resultant dark orange solution was stirred at RT for 30 min then re-cooled 
before the addition of aldehyde (S)-64 (1.56 g, 7.83 mmol) in THF (8 mL) gave a dark red 
solution that was reacted at RT for 4 h. The reaction was quenched by addition of saturated 
NH4Cl(aq.) (15 mL) before removal of volatiles under reduced pressure. The crude residue was 
diluted with H2O (20 mL) and extracted with ether (3 × 20 mL). The combined organic extracts 
were washed with brine (20 mL) and saturated NaHCO3(aq.) (20 mL) before being dried over 
MgSO4 and concentrated in vacuo. Purification by column chromatography (5% → 20% ether in 
petrol) yielded the title compound (685 mg, 44%) as a clear colourless oil. 
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Rf 0.20 (20% EtOAc in petrol); νmax (ATR) 2972 (w), 2933 (w), 2877 (w), 1689 (s), 1477 (w), 
1453 (w), 1389 (s), 1365 (m), 1253 (w), 1166 (s), 1113 (m) cm−1; δH (600 MHz, CDCl3, mixture of 
rotamers) 5.81 – 5.64 (1H, m, 1′-H), 5.12 – 4.96 (2H, m, 2′-H2), 4.38 – 4.27 (0.4H, m, 2-H 
rotamer B), 4.27 – 4.16 (0.6H, m, 2-H rotamer A), 3.43 – 3.28 (2H, m, 5-H2), 2.07 – 1.92 (1H, m, 
3-HH′), 1.87 – 1.74 (2H, m, 4-H2), 1.72 – 1.65 (1H, m, 3-HH′), 1.48 – 1.37 (9H, s, C(CH3)3); 
δC (151 MHz, CDCl3, mixture of rotamers) 154.7 (C=O), 138.9 (C-1′ rotamer A), 138.6 (C-1′ 
rotamer B), 113.6 (C-2′), 79.1 (C(CH3)3), 59.2 (C-2 rotamer A), 58.9 (C-2 rotamer B), 46.5 (C-5 
rotamer B), 46.1 (C-5 rotamer A), 32.0 (C-3 rotamer A), 31.4 (C-3 rotamer B), 28.5 (C(CH3)3), 
23.4 (C-4 rotamer B)), 22.7 (C-4 rotamer A)); m/z (LCMS, ESI+) 142 (M − C(CH3)3 + 2H
+), 183 (M –
 CH3 + H
+). 
(N-tert-Butoxycarbonyl)-2-(1′-hydroxyethyl)pyrrolidine279 66 
 
Procedure B for the synthesis of alcohol 63 also formed the title compound (41 mg, 21% by 1H 
NMR analysis) as a by-product. 
Rf 0.23 (30% EtOAc in petrol); νmax (ATR) 3439 (br), 2972 (m), 2929 (w), 2880 (w), 1667 (s), 
1454 (w), 1400 (s), 1366 (m), 1253 (w), 1167 (s), 1111 (m) cm−1; δH (700 MHz, CDCl3) 3.99 – 
3.93 (1H, m, 2-H), 3.93 – 3.86 (1H, m, 1′-H), 3.55 – 3.48 (1H, m, 5-HH′), 3.23 (1H, dt, J = 10.5, 
7.5 Hz, 5-HH′), 2.05 – 1.97 (1H, m, 3-HH′), 1.87 – 1.79 (1H, m, 4-HH′), 1.72 (1H, dquin, J = 12.5, 
7.5 Hz, 4-HH′), 1.66 – 1.58 (1H, m, 3-HH′), 1.45 (9H, s, C(CH3)3), 1.09 – 1.03 (3H, m, 2′-H3); 
δC (176 MHz, CDCl3) 156.7 (C=O), 80.0 (C(CH3)3), 69.9 (C-1′), 63.5 (C-2), 48.2 (C-5), 28.4 
(C(CH3)3), 28.1 (C-3), 24.1 (C-4), 17.4 (C-2′); m/z (LCMS, ESI
+) 238 (MNa+). 
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(2S)-2-(1′-Oxo-2′-diazoethyl)pyrrolidine-1-carboxylic acid benzyl ester222 (S)-69  
 
Procedure:222 To a solution of (S)-N-Z-proline (S)-68 (95%, 1.22 g, 4.65 mmol) in DCM (15 mL) 
at 0 °C was added oxalyl chloride (98%, 0.54 mL, 6.28 mmol) dropwise, followed by DMF (10 
drops). The mixture was stirred at RT for 2 h prior to concentration under reduced pressure 
and the addition of THF (20 mL) and MeCN (20 mL). After cooling the solution in an ice bath, 
NEt3 (1.30 mL, 9.30 mmol) and TMSCHN2 (2 M solution in hexanes, 5.11 mL, 10.23 mmol) were 
added and the reaction mixture stirred for 5 h at 0 °C. The completed reaction was then 
quenched with AcOH (2 mL), diluted with H2O (40 mL) and concentrated in vacuo before 
addition of EtOAc (30 mL) and washing with saturated NaHCO3(aq.) (3 × 20 mL). The organic 
phase was washed with brine (20 mL) and dried over MgSO4 before evaporation of solvent 
under reduced pressure and column chromatography (0% → 40% EtOAc in hexanes) to furnish 
the title compound (967 mg, 76%) as a yellow oil. 
Rf 0.20 (50% EtOAc in hexanes); [α]
28
D
 (c = 1.00 g/100 mL, CHCl3) −135.8° (lit.:
231 [α]25D
 
(c = 1.10 g/100 mL, CHCl3) −131.8°); νmax (ATR) 3068 (w), 3031 (w), 2953 (w), 2879 (w), 2101 (s), 
1694 (s), 1639 (s), 1409 (s), 1351 (s), 1113 (m) cm−1; δH (600 MHz, CDCl3, mixture of rotamers) 
7.40 – 7.27 (5H, m, ArH), 5.48 (0.5H, s, CHN2), 5.25 (0.5H, s, CHN2), 5.21 – 5.04 (2H, m, PhCH2), 
4.37 –4.31 (0.5H, m, 2-H), 4.31 – 4.25 (0.5H, m, 2-H), 3.59 – 3.52 (1.5H, m, 5-H2, 5-HH′), 3.53 – 
3.45 (0.5H, m, 5-HH′), 2.22 – 2.15 (0.5H, m, 3-HH′), 2.13 – 2.01 (1.5H, m, 3-H2, 3-HH′), 1.99 – 
1.84 (2H, m, 4-H2); δC (151 MHz, CDCl3, mixture of rotamers) 195.4 (C-1′), 194.5 (C-1′), 155.4 
(NCO2), 154.7 (NCO2), 136.6 (ArC), 136.5 (ArC), 128.6(3) (ArC), 128.5(8) (ArC), 128.2(4) (ArC), 
128.2(3) (ArC), 128.1(7) (ArC), 128.1 (ArC), 67.4 (PhCH2), 64.2 (C-2), 64.1 (C-2), 53.5 (CHN2), 
52.8 (CHN2), 47.5 (C-5), 47.1 (C-5), 31.4 (C-3), 29.8 (C-3), 24.5 (C-4), 23.7 (C-4); m/z (LCMS, ESI
+) 
296 (MNa+). 
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(2R)-2-(1′-Oxo-2′-diazoethyl)pyrrolidine-1-carboxylic acid benzyl ester280 (R)-69  
 
Procedure:222 (R)-N-Z-proline (R)-68 (2.08 g, 8.18 mmol) was reacted using the same conditions 
for the synthesis of diazoketone (S)-69, furnishing the title compound (1.60 g, 72%) as a yellow 
oil. 
Rf 0.20 (50% EtOAc in hexanes); [α]
28
D
 (c = 1.00 g/100 mL, CHCl3) +118.6° (lit.:
231 [α]25D
 
(c = 1.10 g/100 mL, CHCl3) −131.8° for (S) enantiomer); νmax (ATR) 3066 (w), 3022 (w), 2951 (w), 
2880 (w), 2101 (s), 1695 (s), 1641 (s), 1408 (s), 1351 (s), 1113 (m) cm−1; δH (400 MHz, CDCl3, 
mixture of rotamers) 7.40 – 7.27 (5H, m, ArH), 5.48 (0.5H, s, CHN2), 5.25 (0.5H, s, CHN2), 5.21 – 
5.04 (2H, m, PhCH2), 4.37 – 4.31 (0.5H, m, 2-H), 4.31 – 4.25 (0.5H, m, 2-H), 3.59 – 3.52 (1.5H, 
m, 5-H2, 5-HH′), 3.53 – 3.45 (0.5H, m, 5-HH′), 2.22 – 2.15 (0.5H, m, 3-HH′), 2.13 – 2.01 (1.5H, m, 
3-H2, 3-HH′), 1.99 – 1.84 (2H, m, 4-H2); δC (101 MHz, CDCl3, mixture of rotamers) 195.4 (C-1′), 
194.5 (C-1′), 155.4 (NCO2), 154.7 (NCO2), 136.6 (ArC), 136.5 (ArC), 128.6(0) (ArC), 128.5(7) 
(ArC), 128.2 (ArC), 128.1 (ArC), 128.0 (ArC), 67.4 (PhCH2), 64.2 (C-2), 64.1 (C-2), 53.5 (CHN2), 
52.8 (CHN2), 47.5 (C-5), 47.1 (C-5), 31.4 (C-3), 29.8 (C-3), 24.5 (C-4), 23.7 (C-4); m/z (LCMS, ESI
+) 
296 (MNa+); Accurate mass: Found MNa+, 296.1012: C14H15N3O3Na requires M, 296.1006. 
(2S)-2-(Methoxycarbonylmethyl)pyrrolidine-1-carboxylic acid benzyl ester222 (S)-70 
 
Procedure:222 Diazoketone (S)-69 (544 mg, 1.99 mmol) was dissolved in dry MeOH (6.4 mL) 
then treated dropwise with a solution of silver benzoate (46 mg, 0.20 mmol) in NEt3 (0.83 mL, 
5.97 mmol). The exothermic reaction mixture was stirred at RT for 3 h before being cooled in 
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an ice bath and quenched with aq. sodium metabisulfite (20%, 6.2 mL). The resulting silver 
salts were removed by filtration and washed with EtOAc (3 × 15 mL), then the organic filtrate 
washed with brine (30 mL) and dried over MgSO4. Removal of solvent under reduced pressure 
and purification by SiO2 column (0% → 50% EtOAc in hexanes) afforded the title compound 
(452 mg, 82%) as a clear colourless oil. 
Rf 0.46 (50% EtOAc in hexanes); [α]
28
D
 (c = 1.00 g/100 mL, CHCl3) −30.2° (lit.:
231 [α]25D
 
(c = 1.33 g/100 mL, CHCl3) −36.6°); νmax (ATR) 2950 (w), 2879 (w), 1733 (m), 1693 (s), 1407 (m), 
1356 (m), 1154 (m), 1095 (m) cm−1; δH (600 MHz, CDCl3, mixture of rotamers) 7.37 – 7.32 (4H, 
m, ArH), 7.31 – 7.27 (1H, m, ArH),  5.17 – 5.08 (2H, m, PhCH2), 4.23 (1H, ddt, J = 9.5, 7.5, 3.5 Hz, 
2-H), 3.64 (3H, s, CO2CH3), 3.48 – 3.38 (2H, m, 5-H2), 3.01 – 2.91 (0.6H, m, 1′-HH′ rotamer A), 
2.88 – 2.76 (0.4H, m, 1′-HH′ rotamer B), 2.34 (1H, apparent dd, J = 15.0, 9.5 Hz, 1′-HH′ rotamer 
A, 1′-HH′ rotamer B), 2.07 (1H, dq, J = 12.5, 8.0 Hz, 3-HH′), 1.91 – 1.81 (2H, m, 4-H2), 1.79 – 1.73 
(1H, m, 3-HH′); δC (151 MHz, CDCl3, mixture of rotamers) 171.9 (CO2CH3), 154.7(NCO2), 136.9 
(ArC), 128.5 (ArC), 128.0 (ArC), 127.9 (ArC), 66.7 (PhCH2), 54.6 (C-2), 54.1 (C-2), 51.6 (CO2CH3), 
46.8 (C-5), 46.5 (C-5), 39.2 (C-1′), 38.2 (C-1′), 31.4 (C-3), 30.7 (C-3), 23.6 (C-4), 22.8 (C-4); 
m/z (LCMS, ESI+) 278 (MH+), 300 (MNa+). 
(2R)-2-(Methoxycarbonylmethyl)pyrrolidine-1-carboxylic acid benzyl ester280 (R)-70  
 
Procedure:222 The conditions for the rearrangement of diazoketone (S)-69 were applied to 
diazoketone (R)-69 (630 mg, 2.31 mmol) furnishing the title compound (587 mg, 92%) as a 
clear colourless oil. 
Rf 0.46 (50% EtOAc in hexanes); [α]
27
D
 (c = 1.00 g/100 mL, CHCl3) +27.2° (lit.:
231 [α]25D
 
(c = 1.33 g/100 mL, CHCl3) −36.6° for (S)-isomer); νmax (ATR) 2949 (w), 2875 (w), 1733 (m), 1693 
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(s), 1407 (s), 1356 (m), 1156 (m), 1095 (m) cm−1; δH (400 MHz, CDCl3, mixture of rotamers) 
7.38 – 7.26 (5H, m, ArH), 5.17 – 5.08 (2H, m, PhCH2), 4.27 – 4.19 (1H, m, 2-H), 3.64 (3H, s, 
CO2CH3), 3.48 – 3.38 (2H, m, 5-H2), 2.97 (0.6H, apparent br d, J = 14.5 Hz, 1′-HH′ rotamer A), 
2.79 (0.4H, apparent br d, J = 14.5 Hz, 1′-HH′ rotamer B), 2.34 (1H, dd, J = 15.0, 9.5 Hz, 1′-HH′ 
rotamer A, 1′-HH′ rotamer B), 2.07 (1H, dq, J = 12.5, 8.0 Hz, 3-HH′), 1.91 – 1.81 (2H, m, 4-H2), 
1.79 – 1.73 (1H, m, 3-HH′); δC (101 MHz, CDCl3, mixture of rotamers) 171.9 (CO2CH3), 154.7 
(NCO2), 136.9 (ArC), 128.5 (ArC), 128.0 (ArC), 127.9 (ArC), 66.7 (PhCH2), 54.6 (C-2), 54.1 (C-2), 
51.6 (CO2CH3), 46.8 (C-5), 46.5 (C-5), 39.2 (C-1′), 38.2 (C-1′), 31.4 (C-3), 30.7 (C-3), 23.6 (C-4), 
22.8 (C-4); m/z (LCMS, ESI+) 278 (MH+), 300 (MNa+); Accurate mass: Found MH+, 278.1393: 
C15H20NO4 requires M, 278.1387. 
4-Chlorophenyl(phenyl)methanol281 73 
 
Procedure: 4-Chlorobenzaldehyde 72 (98%, 2.00 g, 13.94 mmol) was reacted according to 
general procedure C, furnishing the title compound (2.72 g, 89%) as a white solid after 
chromatography on silica (10% → 60% ether in petrol).  
Rf 0.37 (25% ether in petrol); M.p. 59 – 60 °C (lit.:
282 59 – 61 °C); νmax (ATR) 3308 (br), 3062 (w), 
3027 (w), 2885 (w), 1594 (w), 1486 (s), 1447 (m), 1408 (m), 1175 (m), 1085 (s), 1011 (s) cm−1; 
δH (700 MHz, CDCl3) 7.35 – 7.33 (4H, m, ArH), 7.31 – 7.30 (3H, m, ArH), 7.30 – 7.27 (2H, m, 
ArH), 5.80 (1H, s, Ar2CH(OH)), 2.25 (1H, s, OH); δC (176 MHz, CDCl3) 143.4 (C-1′), 142.2 (C-1), 
133.3 (C-4), 128.6 (ArC), 128.5 (ArC), 127.9 (ArC), 127.8 (ArC), 126.5 (ArC), 75.6 (Ar2CH(OH)); 
m/z (LCMS, ESI+) 201 (M(35Cl) − OH–), 203 (M(37Cl) − OH–). 
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p-Toluenesulfonic acid hexyl ester283 74 
 
Procedure: The tosylation procedure employed in the synthesis of nitrile (S)-61 was applied to 
hexan-1-ol (0.50 mL, 3.98 mmol). The crude material was not purified but instead treated with 
NH4OH(aq.) (28% NH3, 5 mL) with stirring for 30 min. The mixture was then separated and the 
organic layer washed with 1 M HCl(aq.) (2 × 5 mL) and brine (10 mL), dried over MgSO4 and 
concentrated under reduced pressure to afford the title compound (1.02 g, quantitative) as a 
pale yellow oil. 
Rf 0.36 (25% ether in petrol); νmax (ATR) 2955 (w), 2930 (w), 2860 (w), 1598 (w), 1467 (w), 
1359 (m), 1175 (s), 1097 (w) cm−1; δH (700 MHz, CDCl3) 7.78 (2H, d, J = 8.0 Hz, 2′-H2), 7.33 (2H, 
d, J = 8.0 Hz, 3′-H2), 4.01 (2H, t, J = 7.0 Hz, 1-H), 2.44 (3H, s, 5′-H3), 1.62 (2H, tt, J = 7.5, 7.0 Hz, 
2-H2), 1.28 (2H, quin, J = 7.5 Hz, 3-H2), 1.23 (2H, tq, J = 7.5, 7.0 Hz, 5-H2), 1.19 (2H, quin, 
J = 7.5 Hz, 4-H2), 0.84 (3H, t, J = 7.0 Hz, 6-H3); δC (176 MHz, CDCl3) 144.6 (C-1′), 133.3 (C-4′), 
129.7 (C-3′), 127.9 (C-2′), 70.7 (C-1), 31.1 (C-4), 28.8 (C-2), 25.0 (C-3), 22.4 (C-5), 21.6 (C-5′), 
13.9 (C-6); m/z (GCMS, EI) 91 (M − C6H13SO3
•), 173 (M − C6H13
•). 
4-Chlorophenyl(phenyl)(hexyloxy)methane 75 
 
Procedure: A round bottomed flask fitted with a reflux condenser was charged with NaH (60%, 
94 mg, 2.34 mmol) and toluene (4 mL). To this was added alcohol 73 (256 mg, 1.17 mmol) and 
the solution heated to reflux for 3 h. The reacton mixture was allowed to cool to RT and 
tosylate 74 (200 mg, 0.78 mmol) in toluene (1.3 mL) was added. The resultant mixture was 
heated to reflux for 20 h after which the reaction was cooled in an ice bath and quenched with 
H2O (2 mL). The biphasic mixture was extracted with EtOAc (3 × 5 mL) and the combined 
 | 116 | 
Chapter 8: Chemical Experimental Details 
organic extracts washed with brine (10 mL), dried over MgSO4 and concentrated in vacuo. The 
resulting residue was then purified by chromatography on SiO2 (0% → 20% ether in petrol) to 
furnish the title compound (193 mg, 55%) as a clear oil. 
Rf 0.73 (25% ether in petrol); νmax (ATR) 2953 (m), 2928 (m), 2856 (m), 1597 (w), 1489 (m), 
1453 (w), 1089 (s), 1014 (m) cm−1; δH (700 MHz, CDCl3) 7.32 – 7.24 (9H, m, ArH), 5.28 (1H, s, 
Ar2CHO), 3.42 (2H, apparent tt, J = 6.5, 3.0 Hz, 1′′-H2), 1.62 (2H, tt, J = 7.5, 6.5 Hz, 2′′-H2), 
1.36 (2H, quin, J = 7.5 Hz, 3′′-H2), 1.32 – 1.23 (4H, m, 4′′-H2, 5′′-H2), 0.87 (3H, t, J = 6.5 Hz, 6′-H3); 
δC (176 MHz, CDCl3) 142.1 (C-1′), 141.3 (C-1), 133.0 (C-4), 128.5 (ArC), 128.4 (ArC), 128.2 (ArC), 
127.5 (ArC), 126.9 (ArC), 82.9 (Ar2CHO), 69.3 (C-1′′), 31.6 (C-4′′), 29.8 (C-2′′), 25.9 (C-3′′), 
22.6 (C-5′′), 14.0 (C-6′′); m/z (GCMS, EI) 201 (M(35Cl) − C6H13O
•), 203 (M(37Cl) − C6H13O
•). 
2-(2′-[{4′′′Chlorophenyl}{phenyl}methoxy]ethyl)pyrrolidine 77 
A mixture of (2R,1′′R), (2R,1′′S), (2S,1′′R) and (2S,1′′S) diastereomers 
 
Procedure: General procedure B was used in the reaction of alcohol 73 (99 mg, 0.45 mmol) and 
racemic homoprolinol 63 (100 mg, 0.45 mmol). Silica flash column chromatography (0% → 5% 
MeOH in CHCl3 with 1% NEt3), furnished the title compound (94 mg, 66%) as a clear light brown 
oil. 
Rf 0.35 (10% MeOH and 1% NH4OH(aq.) in CHCl3); νmax (ATR) 3368 (br), 2938 (m), 2866 (m), 1489 
(m), 1452 (w), 1400 (w), 1181 (w), 1087 (s), 1012 (m) cm−1; δH (700 MHz, CDCl3 mixture of 
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diastereomers) 7.33 – 7.27 (4H, m, ArH), 7.27 – 7.23 (5H, m, ArH), 5.30 (1H, s, 1′′-H), 4.30 – 
4.10 (1H, m, NH), 3.55 – 3.49 (2H, m, 2′-H2), 3.31 – 3.25 (1H, m, 2-H), 3.06 (1H, dddd, J = 10.5, 
9.0, 8.0, 6.0 Hz, 5-HH′), 2.93 (1H, dtd, J = 10.5, 8.5, 6.5 Hz, 5-HH′), 1.96 – 1.87 (2H, m, 3-HH′, 
1′-HH′), 1.86 – 1.78 (2H, m, 4-HH′, 1′-HH′), 1.78 – 1.71 (1H, m, 4-HH′), 1.41 – 1.34 (1H, m, 
3-HH′); δC (176 MHz, CDCl3, mixture of diastereomers) 142.0 (ArC), 141.9 (ArC), 141.1(1) (ArC), 
141.0(5) (ArC), 133.3 (ArC), 133.2 (ArC), 128.7 (ArC), 128.6(3) (ArC), 128.6(1) (ArC), 128.3(8) 
(ArC), 128.3(7) (ArC), 127.7(9) (ArC), 127.7(7) (ArC), 127.0(3) (ArC), 127.0(0) (ArC), 83.2(2) 
(C-1′′), 83.2(0) (C-1′′), 67.3 (C-2′), 67.2 (C-2′), 57.1(7) (C-2), 57.1(5) (C-2), 46.1(3) (C-5), 46.1(2) 
(C-5), 35.4 (C-1′), 35.3 (C-1′), 31.6(0) (C-3), 31.5(7) (C-3), 25.0 (C-4), 24.9 (C-4); m/z (LCMS, ESI+) 
316 (M(35Cl)H+), 318 (M(37Cl)H+); Accurate mass: Found MH+, 316.1467: C19H23NO
35Cl requires 
M, 316.1468. 
2-(2′-[{4′′′-Chlorophenyl}{phenyl}methoxy]ethyl)-1-methylpyrrollidine 78A 
A mixture of (2S,1′′R) and (2S,1′′S) diastereomers 
 
Procedure: General procedure B was used in the reaction of alcohol 73 (109 mg, 0.50 mmol) 
and homoprolinol (S)-57 (65 mg, 0.50 mmol). Silica flash column chromatography (0% → 10% 
MeOH in CHCl3 with 1% NEt3), furnished the title compound (56 mg, 34%) as a thick, clear 
colourless oil. 
Rf 0.36 (10% MeOH and 1% NEt3 in CHCl3); νmax (ATR) 2946 (m), 2940 (w), 2771 (m), 1488 (m), 
1452 (m), 1086 (s), 1013 (m) cm−1; δH (400 MHz, CDCl3, mixture of diastereomers) 7.28 –
 7.16 (9H, m, ArH), 5.22 (1H, s, 1′′-H), 3.48 – 3.35 (2H, m, 2′-H2), 3.07 – 3.00 (1H, m, 5-HH′), 2.27 
(3H, s, NCH3), 2.22 – 1.97 (3H, m, 2-H, 5-HH′, 1′-HH′), 1.91 – 1.79 (1H, m, 3-HH′), 1.77 – 1.67 
(1H, m, 4-HH′), 1.66 – 1.58 (1H, m, 4-HH′), 1.57 – 1.47 (1H, m, 1′-HH′), 1.46 – 1.36 (1H, m, 
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3-HH′); δC (101 MHz, CDCl3, mixture of diastereomers) 142.0(9) (ArC), 142.0(5) (ArC), 141.2(2) 
(ArC), 141.1(9) (ArC), 133.2(4) (ArC), 133.2(1) (ArC), 128.6(4) (ArC), 128.6(3) (ArC), 128.6(0) 
(ArC), 128.4 (ArC), 128.3 (ArC), 127.8 (ArC), 127.7 (ArC), 127.0(3) (ArC), 126.9(7) (ArC), 83.2(4) 
(C-1′′), 83.2(2) (C-1′′), 67.2 (C-2′), 67.1 (C-2′), 64.2 (C-2), 57.2 (C-5), 40.5 (NCH3), 33.9 (C-1′), 31.0 
(C-3), 30.9 (C-3), 22.0 (C-4); m/z (LCMS, ESI+) 330 (M(35Cl)H+), 332 (M(37Cl)H+); Accurate mass: 
Found MH+, 330.1617: C20H25NO
35Cl requires M, 330.1625. 
2-(2′-[{4′′′-Chlorophenyl}{phenyl}methoxy]ethyl)-1-methylpyrrollidine 78B 
A mixture of (2R,1′′R) and (2R,1′′S) diastereomers 
 
Procedure: General procedure B was used in the reaction of alcohol 73 (109 mg, 0.50 mmol) 
and homoprolinol (R)-57 (65 mg, 0.50 mmol). Silica flash column chromatography (0% → 10% 
MeOH in CHCl3 with 1% NEt3), furnished the title compound (94 mg, 57%) as a thick, clear 
colourless oil. 
Rf 0.36 (10% MeOH and 1% NEt3 in CHCl3); νmax (ATR) 3026 (w), 2938 (m), 2840 (w), 2774 (m), 
1488 (m), 1452 (m), 1087 (s), 1013 (m) cm−1; δH (700 MHz, CDCl3, mixture of diastereomers) 
7.33 – 7.22 (9H, m, ArH), 5.28 (1H, s, Ar2CHO), 3.52 – 3.42 (2H, m, 2′-H2), 3.07 – 3.03 (1H, m, 5-
HH′), 2.30 (3H, s, NCH3), 2.18 – 2.04 (3H, m, 2-H, 5-HH′, 1′-HH′), 1.92 – 1.86 (1H, m, 3-HH′), 1.77 
– 1.70 (1H, m, 4-HH′), 1.68 – 1.62 (1H, m, 4-HH′), 1.57 – 1.50 (1H, m, 1′-HH′), 1.48 – 1.41 (1H, 
m, 3-HH′); δC (176 MHz, CDCl3, mixture of diastereomers) 142.2 (ArC), 142.1 (ArC), 141.2(8) 
(ArC), 141.2(5) (ArC), 133.2(2) (ArC), 133.1(9) (ArC), 128.6(4) (ArC), 128.6(3) (ArC), 128.6(0) 
(ArC), 128.4 (ArC), 128.3 (ArC), 127.8 (ArC), 127.7 (ArC), 127.0(3) (ArC), 126.9(8) (ArC), 83.2(3) 
(Ar2CHO), 83.2(1) (Ar2CHO), 67.2(9) (C-2′), 67.2(6) (C-2′), 63.9(4) (C-2), 63.9(3) (C-2), 57.3 (C-5), 
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40.6 (NCH3), 34.2 (C-1′), 31.1 (C-3), 31.0 (C-3), 22.1 (C-4); m/z (LCMS, ESI
+) 330 (M(35Cl)H+), 332 
(M(37Cl)H+); Accurate mass: Found MH+, 330.1619: C20H25NO
35Cl requires M, 330.1625. 
(N-Methyl)-2-(1′-[{4′′′-chlorophenyl}{phenyl}methyl]-1′,2′,3′-triazol-4′-yl)pyrrolidine 83A 
A mixture of (2S,1′′R) and (2S,1′′S) diastereomers 
 
Procedure:241 To a suspension of LiAlH4 (95%, 45 mg, 1.12 mmol) in ether (4.5 mL), cooled in an 
ice bath, was added triazole (S)-87 (123 mg, 0.28 mmol). The reaction mixture was allowed to 
warm to RT and stirred for 2 h, after which the solution was re-cooled to 0 °C quenched 
according to Fieser’s method (general procedure D).273 The residue was purified by column 
chromatography (0% → 5% EtOH in petrol with 5% EtOAc and 10% NEt3) to furnish the title 
compound (34 mg, 34%) as a white solid.  
Rf 0.22 (5% EtOH, 5% EtOAc and 10% NEt3 in petrol); M.p. 100 – 103 °C; νmax (ATR) 2971 (m), 
2933 (m), 2876 (m), 2784 (m), 1491 (m), 1438 (m) cm−1; δH (700 MHz, CDCl3, mixture of 
diastereomers) 7.37 – 7.30 (6H, m, ArH), 7.10 – 7.07 (3H, m, ArH, 1′′-H isomer 1), 7.04 –
 7.00 (2H, m, ArH, 1′′-H isomer 2), 3.44 (1H, t, J = 8.0 Hz, 2-H), 3.15 (1H, apparent t, J = 8.5 Hz, 
5-HH′), 2.32 – 2.24 (2H, m, 5-HH′, 3-HH′), 2.26 (3H, s, NCH3), 1.94 – 1.86 (1H, m, 4-HH′), 1.86 –
 1.77 (2H, m, 3-HH′, 4-HH′); δC (176 MHz, CDCl3, mixture of diastereomers) 150.4 (C-4′ isomer 
1), 150.1 (C-4′ isomer 2), 138.3 (ArC), 137.7 (ArC), 136.9 (ArC), 134.5 (ArC), 129.4 (ArC), 129.3 
(ArC), 129.1 (ArC), 129.0 (ArC), 128.9 (ArC), 128.7 (ArC), 128.5 (ArC), 128.4 (ArC), 128.1 (ArC), 
128.0 (ArC), 120.6 (C-5′ isomer 1), 120.5 (C-5′ isomer 2), 68.1 (C-1′′ isomer 1), 67.4 (C-1′′ isomer 
2), 62.8 (C-2 isomer 1), 62.7 (C-2 isomer 2), 56.8 (C-5), 40.6 (C-6), 33.2 (C-3), 22.3 (C-4); 
m/z (LCMS, ESI+) 353 (M(35Cl)H+), 355 (M(37Cl)H+); Accurate mass: Found MH+, 353.1530: 
C20H22N4
35Cl requires M, 353.1533. 
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(N-Methyl)-2-(1′-[{4′′′-chlorophenyl}{phenyl}methyl]-1′,2′,3′-triazol-4′-yl)pyrrolidine 83B 
A mixture of (2R,1′′R) and (2R,1′′S) diastereomers 
 
Procedure:241 To a suspension of LiAlH4 (95%, 82 mg, 2.05 mmol) in ether (5 mL), cooled in an 
ice bath, was added triazole (R)-87 (143 mg, 0.33 mmol). The reaction mixture was allowed to 
warm to RT and stirred for 2 h, after which the solution was re-cooled to 0 °C and quenched 
according to Fieser’s method (general procedure D).273 The residue was purified by column 
chromatography (0% → 5% EtOH in petrol with 5% EtOAc and 10% NEt3) to furnish the title 
compound (17 mg, 15%) as a yellow oil. 
Rf 0.22 (5% EtOH, 5% EtOAc and 10% NEt3 in petrol); νmax (ATR) 2950 (m), 2840 (m), 2773 (m), 
1491 (s), 1451 (m), 1210 (m), 1090 (s), 1041 (s) cm−1; δH (400 MHz, CDCl3, mixture of 
diastereomers) 7.38 – 7.29 (6H, m, ArH), 7.12 – 7.00 (5H, m, ArH, 1′′-H), 3.46 (1H, t, J = 8.0 Hz, 
2-H), 3.16 (1H, ddd, J = 10.0, 8.5, 2.5 Hz, 5-HH′), 2.36 – 2.22 (5H, m, 3-HH′, 5-HH′, NCH3), 1.96 –
 1.77 (3H, m, 3-HH′, 4-H2); δC (101 MHz, CDCl3, mixture of diastereomers) 150.4 (C-4′), 
138.4 (ArC), 137.9 (ArC), 137.0 (ArC), 134.6 (ArC), 129.6 (ArC), 129.5 (ArC), 129.2(3) (ArC), 
129.1(8) (ArC), 129.0 (ArC), 128.9(0) (ArC), 128.8(7) (ArC), 128.6(2) (ArC), 128.6(0) (ArC), 128.3 
(ArC), 128.2 (ArC), 120.8 (C-5′), 67.6 (C-1′′), 62.9 (C-2), 57.0 (C-5), 40.7 (NCH3), 33.3 (C-3), 
22.5 (C-4); m/z (LCMS, ESI+) 353 (M(35Cl)H+), 355 (M(37Cl)H+); Accurate mass: Found MH+, 
353.1527: C20H22N4
35Cl requires M, 353.1533. 
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4-Chlorophenyl(phenyl)azidomethane284 84 
 
Procedure:235 To a 0 °C solution of TMSN3 (94%, 2.82 mL, 20.04 mmol), TsOH•H2O (98%, 1.30 g, 
6.68 mmol) and BF3•Et2O (1.68 mL, 13.36 mmol) in toluene (17 mL) was slowly added a solution 
of alcohol 73 (1.46 g, 6.68 mmol) in toluene (17 mL). The reaction mixture was stirred at 0 °C 
for 30 min, after which TLC analysis revealed consumption of the starting material. The 
mixture was quenched with the addition of saturated NaHCO3(aq.) (15 mL) and extracted with 
EtOAc (3 × 20 mL). The combined organic extracts were washed with saturated NaHCO3(aq.) 
(30 mL) and brine (30 mL), then concentrated in vacuo before purification by chromatography 
on SiO2 (10% → 20% ether in petrol) to afford the title compound (1.47 g, 90%) as a pale 
yellow oil. 
Rf 0.61 (25% ether in petrol); νmax (ATR) 3083 (w), 3058 (w), 3023 (w), 2095 (s), 1594 (w), 
1486 (m), 1447 (m), 1244 (m), 1089 (m), 1011 (m) cm−1; δH (700 MHz, CDCl3) 7.39 – 7.35 (2H, 
m, 3′-H2), 7.34 – 7.31 (3H, m, 3-H2, 4′-H), 7.28 (2H, d, J = 7.5 Hz, 2′-H2), 7.25 (2H, d, J = 8.5 Hz, 
2-H2), 5.68 (1H, s, Ar2CH(N3)); δC (176 MHz, CDCl3) 139.1 (C-1′), 138.2 (C-1), 133.9 (C-4), 
128.9 (C-3′), 128.8 (C-3), 128.7 (C-2), 128.3 (C-4′), 127.4 (C-2′), 67.8 (Ar2CH(N3)); m/z (LCMS, 
ESI+) 216 (M(35Cl) − N2 + H
+), 218 (M(37Cl) − N2 + H
+). 
(2S)-(N-tert-Butoxycarbonyl)-2-(2′,2′-dibromoethenyl)pyrrolidine228 (S)-85 
 
Procedure:228 A solution of aldehyde (S)-64 (1.44 g, 7.23 mmol) in DCM (14 mL) was added 
dropwise to a 0 °C solution of PPh3 (7.58 g, 28.91 mmol) and CBr4 (4.79 g, 14.45 mmol) in DCM 
(120 mL). The resulting solution was stirred at RT for 30 min before being poured into cooled 
saturated NaHCO3(aq.) (100 mL) and separated. The aqueous phase was washed with DCM 
(20 mL) and the combined organic extracts dried over MgSO4 and concentrated under reduced 
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pressure. The crude residue was purified by column chromatography (40:1:1 → 10:1:1, petrol : 
EtOAc : EtOH) to afford the title compound (1.52 g, 59%) as an off-white solid.  
Rf 0.45 (19:1:1, petrol : EtOAc : EtOH); M.p. 62 – 64 °C (lit.:
228 58 – 59 °C); [α]21D
 
(c = 1.00 g/100 mL, CHCl3) +8.5° (lit.:
228 [α]26D
 (c = 0.89 g/100 mL, DCM) +24.0°); νmax (ATR) 
2976 (m), 2933 (w), 2872 (w), 1689 (s), 1607 (w), 1391 (s), 1365 (m), 1244 (m), 1162 (s), 
1102 (m) cm−1; δH (600 MHz, CDCl3, mixture of rotamers) 6.38 – 6.25 (1H, m, 1′-H), 4.43 – 4.34 
(0.3H, m, 2-H rotamer B), 4.33 – 4.25 (0.7H, m, 2-H rotamer A), 3.44 – 3.35 (0.7H, m, 5-HH′ 
rotamer A), 3.32 (1.3H, apparent dt, J = 10.5, 7.0 Hz, 5-HH′ rotamer A, 5-H2 rotamer B), 2.14 – 
2.06 (1H, m, 3-HH′), 1.82 – 1.75 (2H, m, 4-H2), 1.70 – 1.63 (1H, m, 3-HH′), 1.40 (9H, s, C(CH3)3); 
δC (151 MHz, CDCl3) 154.3 (C=O), 140.4 (C-1′), 88.2 (C-2′), 79.8 (C(CH3)3), 59.5 (C-2), 46.4 (C-5), 
31.8 (C-3), 28.5 (C(CH3)3), 23.6 (C-4); m/z (LCMS, ESI
+) 354 (M(79Br2)H
+), 356 (M(79Br81Br)H+), 
358 (M(81Br2)H
+). 
(2R)-(N-tert-Butoxycarbonyl)-2-(2′,2′-dibromoethenyl)pyrrolidine228 (R)-85  
 
Procedure:228 N-Boc-ᴅ-prolinol (R)-59 (98%, 1.97 g, 9.59 mmol) was subjected to 
Parikh-Doering oxidation (see Procedure B for the synthesis of (S)-64), furnishing the crude 
aldehyde (R)-64 (1.47 g, 77%) as a pale yellow oil which was used without further purification. 
A solution of (R)-N-Boc-prolinal (R)-64 (618 mg, 3.10 mmol) in DCM (3 mL) was added 
dropwise to a 0 °C solution of PPh3 (3.25 g, 12.41 mmol) and CBr4 (2.10 g, 6.20 mmol) in DCM 
(48 mL). The resulting solution was stirred at RT for 30 min before being poured into cooled 
saturated  NaHCO3(aq.) (50 mL) and separated. The aqueous phase was washed with DCM 
(20 mL) and the combined organic extracts dried over MgSO4 and concentrated under reduced 
pressure. The crude residue was purified by column chromatography (0% → 30% EtOAc in 
hexanes) to afford the title compound (738 mg, 67%) as an off-white solid. 
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Rf 0.45 (0.5% EtOAc and 0.5% EtOH in petrol); [α]
28
D
 (c = 1.00 g/100 mL, CHCl3) −32.6° (lit.:
228 
[α]26D
 (c = 1.15 g/100 mL, CH2Cl2) −24.0°); νmax (ATR) 2973 (m), 2875 (w), 1693 (s), 1390 (s), 
1241 (w), 1163 (m), 1107 (m) cm−1; δH (700 MHz, CDCl3, mixture of rotamers) 6.44 – 6.30 (1H, 
m, 1′-H), 4.50 – 4.28 (1H, m, 2-H), 3.51 – 3.42 (0.7H, m, 5-H2 rotamer B), 3.42 – 3.35 (1.3H, m, 
5-H2 rotamer A), 2.17 (1H, dq, J = 14.0, 7.0 Hz, 3-HH′), 1.89 – 1.80 (2H, m, 4-H2), 1.76 – 
1.70 (1H, m, 3-HH′), 1.47 (9H, s, C(CH3)3); δC (176 MHz, CDCl3) 154.5 (C=O), 140.6 (C-1′), 88.5 
(C-2′), 79.9 (C(CH3)3), 59.7 (C-2), 46.6 (C-5), 32.0 (C-3), 28.7 (C(CH3)3), 23.8 (C-4); m/z (LCMS, 
ESI+) 354 (M(79Br2)H
+), 356 (M(79Br81Br)H+), 358 (M(81Br2)H
+). 
(2S)-(N-tert-Butoxycarbonyl)-2-ethynylpyrrolidine228 (S)-86 
 
Procedure:228 To a solution of dibromoethenyl compound (S)-85 (1.33 g, 3.75 mmol) in THF 
(33 mL), cooled to −78 °C, was added butyllithium (1.6 M in hexanes, 24.70 mL, 7.49 mmol). 
The reaction mixture was stirred at −78 °C for 1 h, when consumption of starting material was 
observed by TLC, then quenched by the addition of saturated NH4Cl(aq.) (30 mL). The mixture 
was allowed to warm to RT, after which THF was removed under reduced pressure before 
extraction with ether (3 × 20 mL). The combined organic extracts were washed with brine 
(30 mL), dried over MgSO4 and concentrated in vacuo prior to purification by SiO2 column 
(10% → 30% EtOAc in petrol) to furnish the title compound (549 mg, 75%) as a yellow oil.  
Rf 0.31 (19:1:1, petrol : EtOAc : EtOH); [α]
27
D
 (c = 1.00 g/100 mL, CHCl3) −49.5° (lit.:
236 [α]25D
 
(c = 1.35 g/100 mL, CHCl3) −66.3°); νmax (ATR) 3304 (w), 3239 (w), 2971 (m), 2872 (w), 1689 (s), 
1392 (s), 1365 (m), 1244 (m), 1158 (s), 1115 (m) cm−1; δH (700 MHz, CDCl3, mixture of rotamers-
) 4.50 – 4.42 (0.4H, m, 2-H rotamer B), 4.40 – 4.33 (0.6H, m, 2-H rotamer A), 3.46 – 3.38 (1H, 
m, 5-HH′), 3.31 – 3.23 (1H, m, 5-HH′), 2.21 – 2.15 (1H, m, 2′-H), 2.08 – 2.00 (2H, m, 3-HH′, 
4-HH′), 2.00 – 1.96 (1H, m, 3-HH′), 1.89 – 1.83 (1H, m, 4-HH′), 1.44 (9H, s, C(CH3)3); 
δC (176 MHz, CDCl3, mixture of rotamers) 154.0 (C=O), 84.4 (C-1′ rotamer A), 84.1 (C-1′ rotamer 
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B), 79.7 (C(CH3)3), 69.8 (C-2′ rotamer B), 69.4 (C-2′ rotamer A), 48.0 (C-2 rotamer A), 47.7 (C-2 
rotamer B), 45.9 (C-5 rotamer B), 45.4 (C-5 rotamer A), 33.6 (C-3 rotamer A), 32.9 (C-3 rotamer 
B), 28.4 (C(CH3)3), 24.4 (C-4 rotamer B), 23.5 (C-4 rotamer A); m/z (LCMS, ESI
+) 218 (MNa+). 
(2R)-(N-tert-Butoxycarbonyl)-2-ethynylpyrrolidine285 (R)-86 
 
Procedure:228 To a solution of dibromoethenyl compound (R)-85 (710 mg, 2.00 mmol) in THF 
(18 mL), cooled to −78 °C, was added butyllithium (1.6 M in hexanes, 2.5 mL, 4.00 mmol). The 
reaction mixture was stirred at −78 °C for 1 h, when consumption of starting material was 
observed by TLC, then quenched by the addition of saturated NH4Cl(aq.) (20 mL). The mixture 
was allowed to warm to RT, after which THF was removed under reduced pressure before 
extraction with ether (3 × 10 mL). The combined organic extracts were washed with brine 
(20 mL), dried over MgSO4 and concentrated in vacuo prior to purification by SiO2 column (10% 
→ 20% EtOAc in petrol) to furnish the title compound (300 mg, 77%) as a yellow oil.  
Rf 0.31 (0.5% EtOAc and 0.5% EtOH in petrol); [α]
29
D
 (c = 1.00 g/100 mL, CHCl3) +65.3° (lit.:
285 
[α]26D
 (c = 0.94 g/100 mL, MeOH) +113.0°); νmax (ATR) 3293 (w), 3244 (w) 2975 (m), 2875 (w), 
1690 (s), 1390 (s), 1366 (m), 1252 (m), 1162 (s), 1121 (m), 1091 (w) cm−1; δH (700 MHz, CDCl3, 
mixture of rotamers) 4.55 – 4.47 (0.4H, m, 2-H rotamer B), 4.46 – 4.37 (0.6H, m, 2-H rotamer 
A), 3.51 – 3.40 (1H, m, 5-HH′), 3.35 – 3.25 (1H, m, 5-HH′), 2.25 – 2.17 (1H, m, 2′-H), 2.12 – 
1.98 (3H, m, 3-H2, 4-HH′), 1.94 – 1.86 (1H, m, 4-HH′), 1.47 (9H, s, C(CH3)3); δC (176 MHz, CDCl3, 
mixture of rotamers) 154.2 (C=O), 84.6 (C-1′ rotamer B), 84.3 (C-1′ rotamer A), 79.9 (C(CH3)3), 
70.0 (C-2′ rotamer B), 69.6 (C-2′ rotamer A), 48.2 (C-2 rotamer B), 47.9 (C-2 rotamer A), 46.1 
(C-5 rotamer B), 45.6 (C-5 rotamer A), 33.8 (C-3 rotamer B), 33.1 (C-3 rotamer A), 
28.6 (C(CH3)3), 24.6 (C-4 rotamer B), 23.8 (C-4 rotamer A); m/z (LCMS, ESI
+) 196 (MH+). 
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(N-tert-Butoxycarbonyl)-2-(1′-[{4′′′-chlorophenyl}{phenyl}methyl]-1′,2′,3′-triazol-4′-
yl)pyrrolidine 87A 
A mixture of (2S,1′′R) and (2S,1′′S) diastereomers 
 
Procedure:238 A microwave vial was charged with azide 84 (139 mg, 0.57 mmol), alkyne (S)-86 
(98 mg, 0.50 mmol), CuSO4•5H2O(aq.) (1 M, 0.20 mL, 0.20 mmol), freshly prepared Na 
ascorbate(aq.) (1 M, 1.00 mL, 1.00 mmol), H2O (1 mL) and MeOH (1 mL). The vial was sealed and 
reacted at 60 °C for 40 min, with a 30 s pre-mixing time. The mixture was then cooled, diluted 
with H2O (5 mL) and extracted with DCM (3 × 10 mL) and the combined organic extracts 
washed with brine (10 mL), dried over MgSO4 and concentrated under reduced pressure. The 
crude residue was then purified by column chromatography (50% → 70% ether in petrol) to 
provide the title compound (153 mg, 70%) as a white solid. 
Rf 0.10 (50% ether in petrol); M.p. 56 – 58 °C; νmax (ATR) 2976 (w), 2928 (w), 2881 (w), 
2017 (w), 1676 (s), 1490 (m), 1452 (w), 1391 (s), 1248 (w), 1162 (m), 1110 (w) cm−1; 
δH (500 MHz, (CD3)2SO, 90 °C, mixture of diastereomers) 7.71 (1H, apparent d, J = 1.0 Hz, 1′′-H), 
7.42 (2H, d, J = 8.5 Hz, ArH), 7.40 – 7.34 (3H, m, ArH), 7.24 – 7.18 (5H, m, ArH), 4.88 (1H, dd, 
J = 8.0, 3.0 Hz, 2-H), 3.42 – 3.32 (2H, m, 5-H2), 2.25 – 2.16 (1H, m, 3-HH′), 2.10 – 2.01 (1H, m, 3-
HH′), 2.00 – 1.91 (1H, m, 4-HH′), 1.89 – 1.81 (1H, m, 4-HH′), 1.23 (9H, s, C(CH3)3); δC (176 MHz, 
CDCl3, mixture of rotamers and diastereomers) 154.2 (C=O), 150.7 (ArC), 149.1 (ArC), 
137.8 (ArC), 136.9 (ArC), 134.6 (ArC), 129.3 (ArC), 129.0 (ArC), 127.9 (ArC), 122.6 (ArC), 
120.9 (ArC), 79.5 (C(CH3)3 rotamer A), 79.3 (C(CH3)3 rotamer B), 67.3 (C-1′′) 53.6 (C-2 rotamer 
A), 52.7 (C-2 rotamer B), 46.6 (C-5 rotamer B), 46.4 (C-5 rotamer A), 32.8 (C-3), 28.3 (C(CH3)3), 
24.6 (C-4 rotamer B), 23.4 (C-4 rotamer A); m/z (LCMS, ESI+) 439 (M(35Cl)H+), 441 (M(37Cl)H+); 
Accurate mass: Found MH+, 439.1898: C24H28N4O2
35Cl requires M, 439.1901. 
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(N-tert-Butoxycarbonyl)-2-(1′-[{4′′′-chlorophenyl}{phenyl}methyl]-1′,2′,3′-triazol-4′-
yl)pyrrolidine 87B 
A mixture of (2R,1′′R) and (2R,1′′S) diastereomers 
 
Procedure:238 A microwave vial was charged with azide 84 (307 mg, 1.26 mmol), alkyne (R)-86 
(200 mg, 1.02 mmol), CuSO4·5H2O(aq.) (1 M, 0.41 mL, 0.41 mmol), freshly prepared Na 
ascorbate(aq.) (1 M, 2.05 mL, 2.05 mmol), water (1.25 mL) and MeOH (1.25 mL). The vial was 
sealed and reacted at 60 °C for 30 min, with a 30 s pre-mixing time. The mixture was then 
cooled, diluted with water (5 mL) and extracted with DCM (3 × 15 mL) and the combined 
organic extracts washed with brine (25 mL), dried over MgSO4 and concentrated under 
reduced pressure. The crude residue was then purified by column chromatography (50% → 
70% ether in petrol) to provide the title compound (432 mg, 96%) as a thick yellow oil. 
Rf 0.10 (50% ether in petrol); νmax (ATR) 2978 (w), 2875 (w), 1682 (s), 1491 (m), 1453 (w), 
1391 (s), 1364 (m), 1241 (w), 1159 (m), 1109 (w) cm−1; δH (400 MHz, CDCl3, mixture of rotamers 
and diastereomers) 7.42 – 7.26 (5H, m, ArH), 7.17 – 6.96 (6H, m, ArH, 1′′-H), 4.99 – 4.89 (1H, 
m, 2-H), 3.50 – 3.30 (2H, m, 5-H2), 2.48 – 2.38 (0.4H, m, 3-HH′ rotamer B), 2.30 – 2.08 (2H, m, 
3-H2 rotamer A, 3-HH′ rotamer B, 4-HH′ rotamer B), 2.01 – 1.80 (1.6H, m, 4-H2 rotamer A, 4-HH′ 
rotamer B), 1.37 (3.6H, s, C(CH3)3 rotamer B), 1.20 (5.4H, s, C(CH3)3 rotamer A); δC (101 MHz, 
CDCl3, mixture of rotamers and diastereomers) 154.2 (C=O), 150.7 (ArC), 149.1 (ArC), 137.8 
(ArC), 137.0 (ArC), 134.5 (ArC), 129.3 (ArC), 129.1 (ArC), 128.0 (ArC), 122.7 (ArC), 121.0 (ArC), 
79.4 (C(CH3)3 rotamer B), 77.4 (C(CH3)3 rotamer A), 67.3 (C-1′′), 53.6 (C-2 rotamer B), 52.8 (C-2 
rotamer A), 46.4 (C-5), 32.8 (C-3 rotamer B), 30.7 (C-3 rotamer A), 28.3 (C(CH3)3), 24.6 (C-4 
rotamer B), 23.5 (C-4 rotamer A); m/z (LCMS, ESI+) 439 (M(35Cl)H+), 441 (M(37Cl)H+); Accurate 
mass: Found MH+, 439.1899: C24H28N4O2
35Cl requires M, 439.1895. 
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(4′-Chlorophenyl)phenylacetic acid286 90  
 
Procedure A:244 To alcohol 73 (821 mg, 3.75 mmol) at 0 °C was added concentrated H2SO4 (33 
mL) and formic acid (1.5 mL). The reaction mixture was allowed to reach RT with no stirring, 
and after 1 h TLC analysis showed consumption of the starting material. Once cooled in an ice 
bath, H2O (30 mL) was added and the solution extracted with DCM (3 × 20 mL). The combined 
organic extracts were washed with 3 M NaOH(aq.) (3 × 20 mL), the aqueous extracts then being 
acidified and extracted with DCM (3 × 20 mL). Concentration of the organic washings under 
reduced pressure afforded the title compound (302 mg, 33%) as an off-white solid. 
Procedure B:245 SnCl4 (1.89 mL, 16.00 mmol) was added slowly to a solution of mandelic acid 
93 (1.54 g, 10.00 mmol) in chlorobenzene (6 mL). The reaction mixture was heated to reflux for 
5.5 h before being cooled in an ice bath and quenched by the slow addition of saturated 
NH4Cl(aq.) (20 mL) and H2O (10 mL). Extraction of the biphasic mixture with DCM (3 × 15 mL) 
followed by removal of volatiles under reduced pressure provided the crude product which 
was then recrystallised from acetone and petrol to provide the title compound (985 mg, 40%) 
as an off-white solid.  
Rf 0.52 (10% MeOH in DCM); M.p. 109 – 111 °C (lit.:
287 116 °C); νmax (ATR) 3028 (br), 1707 (s), 
1491 (m), 1403 (w), 1277 (w), 1215 (w), 1092 (w), 1015 (w) cm−1; δH (700 MHz, CDCl3) 7.37 – 
7.26 (9H, m, ArH), 5.02 (1H, s, 2-H); δC (176 MHz, CDCl3) 178.2 (C=O), 137.6 (ArC), 136.5 (ArC), 
133.7 (C-4′), 130.2 (ArC), 128.9(6) (ArC), 128.9(5), (ArC), 128.7 (ArC), 127.9 (ArC), 56.4 (C-2); 
m/z (LCMS, ESI−) 201 (M(35Cl) − CO2), 203 (M(
37Cl) − CO2). 
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N-([4′′′-Chlorophenyl]phenylmethyl)-2-(1′-[tert-butoxycarbonyl]pyrrolidin-2′-yl)acetamide 94 
A mixture of (2′R,1′′R), (2′R,1′′S), (2′S,1′′R) and (2′S,1′′S) diastereomers 
 
Procedure: Homoproline 62 (57 mg, 0.25 mmol) and 4-chlorobenzhydryl amine HCl salt 89 
(98%, 73 mg, 0.28 mmol) were reacted according to general procedure A. SiO2 column 
chromatography (0% → 40% EtOAc in hexanes) yielded the title compound (72 mg, 67%) as a 
clear colourless gum. 
Rf 0.32 (40% EtOAc in hexanes); νmax (ATR) 3272 (br), 2970 (w), 2922 (w), 2872 (w), 1689 (s), 
1642 (s), 1537 (m), 1490 (m), 1394 (s), 1366 (m), 1169 (m), 1124 (m) cm−1; δH (700 MHz, CDCl3, 
mixture of rotamers and diastereomers) 7.33 – 7.30 (2H, m, ArH), 7.29 – 7.25 (3H, m, ArH), 
7.23 – 7.16 (4H, m, ArH), 6.20 (1H, d, J = 7.5 Hz, 1′′-H), 4.08 (1H, tt, J = 7.5, 4.0 Hz, 2′-H), 3.35 
(1H, apparent ddt, J = 15.0, 11.0, 7.5 Hz, 5′-HH′), 3.27 (1H, apparent dtd, J = 11.0, 7.5, 5.0 Hz, 
5′-HH′), 2.73 (1H, apparent ddd, J = 14.0, 9.5, 4.0 Hz, 2-HH′), 2.56 – 2.41 (1H, m, 2-HH′), 2.03 – 
1.97 (1H, m, 3′-HH′), 1.97 – 1.90 (1H, m, 3′-HH′), 1.88 – 1.82 (1H, m, 4′-HH′), 1.82 – 1.76 (1H, m, 
4′-HH′), 1.43 – 1.41 (9H, m, C(CH3)3); δC (176 MHz, CDCl3, mixture of rotamers and 
diastereomers) 170.3 (C-1), 155.2 (C(O)NO), 141.3 (ArC), 141.2 (ArC), 140.5 (ArC), 140.3 (ArC), 
133.3 (ArC), 133.2 (ArC), 128.9(0) (ArC), 128.8(7) (ArC), 128.8(4) (ArC), 128.8(2) (ArC), 127.8 
(ArC), 127.7 (ArC), 127.5(8) (ArC), 127.5(6) (ArC), 80.0(1) (C(CH3)3), 79.9(8) (C(CH3)3), 56.5(7) 
(C-1′′), 56.5(5) (C-1′′), 55.3 (C-2′), 55.2 (C-2′), 46.9 (C-5′), 46.8 (C-5′), 41.8(2) (C-2), 41.7(6) (C-2), 
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31.3(7) (C-3′), 31.3(5) (C-3′),  28.6 (C(CH3)3), 23.6 (C-4′); m/z (LCMS, ESI
+) 429 (M(35Cl)H+), 431 
(M(37Cl)H+); Accurate mass: Found MH+, 429.1939: C24H30N2O3
35Cl requires M, 429.1945. 
N-([1′′-{tert-Butoxycarbonyl}pyrrolidin-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 
95 
A mixture of (2′′R,2R), (2′′R,2S), (2′′S,2R) and (2′′S,2S) diastereomers 
 
Procedure: Amine 91 (100 mg, 0.53 mmol) and acid 90 (131 mg, 0.53 mmol) were reacted 
according to general procedure A. SiO2 column chromatography (0% → 50% EtOAc in hexanes) 
yielded the title compound (132 mg, 58%) as a viscous clear colourless oil. 
Rf 0.31 (40% EtOAc in hexanes); νmax (ATR) 3298 (br), 3058 (w), 2968 (w), 2938 (w), 2876 (w), 
1653 (br, s), 1538 (m), 1486 (m), 1388 (s), 1365 (m), 1165 (s), 1104 (m) cm−1; δH (700 MHz, 
CDCl3, mixture of rotamers and diastereomers) 7.37 – 7.18 (9H, m, ArH), 4.82 – 4.80 (1H, m, 
2-H), 3.98 – 3.88 (1H, m, 2′′-H), 3.48 – 3.40 (1H, m, NH(CHH′)), 3.35 (1H, dt, J = 11.0, 7.5 Hz, 
5′′-HH′), 3.29 – 3.16 (2H, m, 5′′-HH′, NH(CHH′)), 2.00 – 1.91 (1H, m, 3′′-HH′), 1.88 – 1.74 (2H, m, 
4′′-H2), 1.64 (1H, apparent ddd, J = 16.5, 7.0, 4.0 Hz, 3′′-HH′), 1.44 – 1.37 (9H, m, C(CH3)3); 
δC (176 MHz, CDCl3, mixture of rotamers and diastereomers) 171.8(4) (C-1), 171.8(2) (C-1), 
156.5 (C(O)NO), 139.4 (ArC), 139.3 (ArC), 138.3(4) (ArC), 138.2(7) (ArC), 133.1 (ArC), 133.0 
(ArC), 130.3(9) (ArC), 130.3(8) (ArC), 128.9 (ArC), 128.8(0) (ArC), 128.7(7) (ArC), 128.7(6) (ArC), 
127.4 (ArC), 80.1(7) (C(CH3)3), 80.1(5) (C(CH3)3), 58.5 (C-2), 56.5 (C-2′′), 47.3 (C-5′′), 46.4 
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(NH(CHH′)), 29.8(0) (C-3′′), 29.7(7) (C-3′′),  28.5(2) (C(CH3)3), 28.5(0) (C(CH3)3), 23.9 (C-4′′); 
m/z (LCMS, ESI+) 429 (M(35Cl)H+), 431 (M(37Cl)H+); Accurate mass: Found MH+, 429.1937: 
C24H30N2O3
35Cl requires M, 429.1945. 
([4′′′-Chlorophenyl]phenylmethyl)-2-(1′-[tert-butoxycarbonyl]pyrrolidin-2′-yl)acetate 96 
A mixture of (2′R,1′′R), (2′R,1′′S), (2′S,1′′R) and (2′S,1′′S) diastereomers 
 
Procedure:246 Homoproline 62 (57 mg, 0.25 mmol) was dissolved in DCM (1.7 mL) and cooled 
to 0 °C prior to the addition of alcohol 73 (35 mg, 0.25 mmol), 4-dimethylaminopyridine (35 
mg, 0.28 mmol), N-methylmorpholine (31 μL, 0.28 mmol) and EDCI•HCl (54 mg, 0.28 mmol). 
The reaction mixture was stirred at RT for 24 h before being cooled in an ice bath, quenched 
with ice cold 1 M HCl(aq.) (0.75 mL) and stirred for 5 min. The biphasic mixture was diluted with 
H2O (10 mL), extracted with DCM (3 × 5 mL) and the collected organic extracts were washed 
with saturated NaHCO3(aq.) (2 × 5 mL), dried over MgSO4 and concentrated in vacuo. Silica gel 
chromatography (0% → 40% EtOAc in hexanes) of the crude material furnished the title 
compound (58 mg, 54%) as a clear colourless oil. 
Rf 0.47 (30% EtOAc in hexanes); νmax (ATR) 2978 (w), 2930 (w), 2876 (w), 1737 (w), 1690 (s), 
1490 (w), 1395 (s), 1252 (w), 1109 (m), 1090 (w) cm−1; δH (700 MHz, CDCl3, mixture of rotamers 
and diastereomers) 7.35 – 7.25 (9H, m, ArH), 6.84 (1H, s, 1′′-H), 4.19 – 4.11 (1H, m, 2′-H), 3.13 
– 3.25 (2H, m, 5′-H2), 3.13 – 2.88 (1H, m, 2-HH′), 2.43 (1H, dd, J = 15.0, 10.0 Hz, 2-HH′), 2.00 
(1H, dq, J = 13.0, 8.0 Hz, 3′-HH′), 1.82 – 1.75 (2H, m, 4′-H2), 1.72 – 1.66 (1H, m, 3′-HH′), 1.49 – 
1.44 (9H, m, C(CH3)3); δC (176 MHz, CDCl3, mixture of rotamers and diastereomers) 170.5 (C-1), 
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154.4 (C(O)NO), 143.6 (ArC), 142.4 (ArC), 139.8 (ArC), 138.9 (ArC), 133.9 (ArC), 133.4 (ArC), 
128.8(3) (ArC), 128.7(8) (ArC), 128.7(3) (ArC), 128.6(6) (ArC), 128.6 (ArC), 128.3 (ArC), 128.0(2) 
(ArC), 127.9(8) (ArC), 127.2 (ArC), 127.1 (ArC), 126.7 (ArC), 79.7 (C(CH3)3), 76.3 (Ar2CH), 75.8 
(C-1′′), 54.2 (C-2′), 46.6 (C-5′), 39.7 (C-2), 38.8 (C-2), 31.0 (C-3′), 28.7 (C(CH3)3), 23.6 (C-4′); 
m/z (LCMS, ESI+) 452 (M(35Cl)Na+), 454 (M(37Cl)Na+); Accurate mass: Found MNa+, 452.1606: 
C24H28NO4
35Cl23Na requires M, 452.1605. 
([1′′-{tert-Butoxycarbonyl}pyrrolidin-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetic acid 97 
A mixture of (2′′S,2R) and (2′′S,2S) diastereomers 
 
Procedure:246 Prolinol (S)-59 (101 mg, 0.50 mmol) and acid 90 (123 mg, 0.50 mmol) were 
subjected to the esterification conditions utilised in the synthesis of ester 96 to give the title 
compound (152 mg, 71%) as a clear oil. 
Rf 0.45 (30% EtOAc in hexanes); νmax (ATR) 2973 (w), 2876 (w), 1735 (m), 1690 (s), 1450 (m), 
1389 (s), 1134 (m), 1090 (m), 1014 (m) cm−1; δH (700 MHz, CDCl3, mixture of rotamers and 
diastereomers) 7.38 – 7.14 (9H, m, ArH), 4.98 (1H, s, 2-H), 4.31 – 4.13 (2H, m, OCH2), 4.06 – 
3.96 (0.5H, m, 2′′-H isomer 1), 3.94 – 3.84 (0.5H, m, 2′′-H isomer 2), 3.37 – 3.08 (2H, m, 5′′-H2), 
1.89 – 1.79 (1H, m, 3′′-HH′), 1.72 – 1.59 (3H, m, 3′′-HH′, 4′′-H2), 1.44 (9H, s, C(CH3)3); 
δC (176 MHz, CDCl3, mixture of rotamers and diastereomers) 171.9(C-1), 154.5 (C(O)NO), 154.3 
(C(O)NO), 138.3 (ArC), 138.1 (ArC), 137.3 (ArC), 137.1 (ArC), 133.3 (ArC), 133.2 (ArC), 130.1 
(ArC), 128.8 (ArC), 128.5 (ArC), 127.6 (ArC), 79.8 (C(CH3)3), 79.5 (C(CH3)3), 65.7 (OCH2), 65.3 
(OCH2), 56.5(9) (C-2), 56.5(8) (C-2), 55.6 (C-2′′), 55.5 (C-2′′), 46.8 (C-5′′), 46.6 (C-5′′), 29.0 (C-3′′), 
28.5 (C(CH3)3), 28.0 (C-3′′), 23.8 (C-4′′), 23.0 (C-4′′); m/z (LCMS, ESI
+) 430 (M(35Cl)H+), 432 
(M(37Cl)H+); Accurate mass: Found MH+, 430.1774: C24H29NO4
35Cl requires M, 430.1785. 
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N-([4′′′-Chlorophenyl]phenylmethyl)-2-(pyrrolidin-2′-yl)acetamide TFA salt 98 
A mixture of (2′R,1′′R), (2′R,1′′S), (2′S,1′′R) and (2′S,1′′S) diastereomers 
 
Procedure: Amide 94 (56 mg, 0.13 mmol) was dissolved in a mixture of DCM (0.9 mL) and TFA 
(0.1 mL) and stirred for 3 h, after which all volatiles were removed under high vacuum to 
provide the title compound (58 mg, 77%) as an off-white solid.  
M.p. 189 – 191 °C; νmax (ATR) 3262 (br), 3031 (w), 2951 (w), 2360 (w), 1653 (br, s), 1542 (m), 
1491 (m), 1197 (s), 1137 (s) cm−1; δH (600 MHz, CDCl3, mixture of diastereomers) 9.17 – 9.06 
(1H, m, 1′-NH2
+), 8.92 – 8.82 (1H, m, 1′-NH2
+), 7.52 (0.5H, d, J = 7.0 Hz, 1-NH isomer 1), 7.47 
(0.5H, d, J = 7.0 Hz, 1-NH isomer 2), 7.34 – 7.24 (5H, m, ArH), 7.20 – 7.12 (4H, m, ArH),  6.03 – 
5.97 (1H, m, 1′′-H), 3.79 – 3.71 (1H, m, 2′-H), 3.21 – 3.13 (1H, m, 5′-HH′), 3.13 – 3.05 (1H, m, 5′-
HH′), 3.01 – 2.94 (1H, m, 2-HH′), 2.77 – 2.69 (1H, m, 2-HH′), 2.12 – 2.04 (1H, m, 3′-HH′), 2.02 – 
1.94 (1H, m, 4′-HH′), 1.91 – 1.82 (1H, m, 4′-HH′),  1.70 – 1.62 (1H, m, 3′-HH′); δC (151 MHz, 
CDCl3, mixture of diastereomers) 170.0(4) (C-1), 170.0(2) (C-1), 161.3 (q, J = 38.5 Hz, TFA C=O), 
140.3(2) (ArC), 140.3(1) (ArC), 139.4 (ArC), 133.8 (ArC), 133.6 (ArC), 129.1 (ArC), 129.0(3) (ArC), 
129.0(0) (ArC), 128.9 (ArC), 128.7 (ArC), 128.2 (ArC), 128.0 (ArC), 127.5 (ArC), 127.2 (ArC), 57.6 
(C-1′′), 57.5 (C-1′′), 57.2 (C-2′), 57.1 (C-2′), 45.5 (C-5′), 36.3(6) (C-2), 36.3(5) (C-2),  30.0 (C-3′), 
29.9 (C-3′), 23.7(7) (C-4′), 23.7(5) (C-4′); δF (376 MHz, CDCl3) −76.19 (CF3CO2H); m/z (LCMS, ESI
+) 
329 (M(35Cl)H+), 331 (M(37Cl)H+); Accurate mass: Found MH+, 329.1422: C19H22N2O
35Cl requires 
M, 329.1421. 
 | 133 | 
Chapter 8: Chemical Experimental Details 
N-([Pyrrolidin-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide TFA salt 99 
A mixture of (2′′R,2R), (2′′R,2S), (2′′S,2R) and (2′′S,2S) diastereomers 
 
Procedure: The protected amide 95 was subjected to the same conditions used for the 
synthesis of amide 98, with the crude material being recrystallised from EtOAc and ether to 
give the title compound (38 mg, 28%) as a white solid.  
M.p. 149 – 151 °C; νmax (ATR) 3252 (br), 3066 (w), 1665 (s), 1646 (s), 1563 (m), 1191 (m), 1156 
(m) 1133 (s) cm−1; δH (600 MHz, CDCl3, mixture of diastereomers) 10.13 – 9.95 (1H, m, 
1′′-NH2
+), 8.85 – 8.65 (1H, m, 1′′-NH2
+), 8.06 (0.5H, t, J = 6.0 Hz, 1-NH isomer 1), 7.98 (0.5H, t, 
J = 6.0 Hz, 1-NH isomer 2), 7.40 – 7.10 (9H, m, ArH), 4.92 (1H, s, 2-H), 3.76 – 3.63 (1H, m, 2′′-H), 
3.62 – 3.50 (1H, m, NH(CHH′)), 3.45 – 3.29 (1H, m, NH(CHH′)), 3.13 – 2.94 (2H, m, 5′′-H2), 2.02 – 
1.93 (1H, m, 3′′-HH′), 1.92 – 1.80 (2H, m, 4′′-H2), 1.65 – 1.52 (1H, m, 3′′-HH′); δC (151 MHz, 
CDCl3, mixture of diastereomers) 174.4 (9) (C-1), 174.4(8) (C-1), 162.3 (q, J = 37.5 Hz, TFA C=O), 
138.8 (ArC), 138.6 (ArC), 137.7 (ArC), 137.5 (ArC), 133.4(3) (ArC), 133.3(9) (ArC), 130.3(4) (ArC), 
130.2(7) (ArC), 129.0 (ArC), 128.9 (ArC), 128.8 (ArC), 128.7 (ArC), 127.7(0) (ArC), 127.6(6) (ArC), 
60.7(1) (C-2′′), 60.6(9) (C-2′′), 57.4(3) (C-2), 57.3(8) (C-2), 45.4 (C-5′′), 45.3 (C-5′′), 40.8 
(NH(CHH′)), 27.6 (C-3′′), 24.0 (C-4′′); δF (376 MHz, CDCl3) −75.88 (CF3CO2H); m/z (LCMS, ESI
+) 
329 (M(35Cl)H+), 331 (M(37Cl)H+); Accurate mass: Found MH+, 329.1426: C19H22N2O
35Cl requires 
M, 329.1421. 
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([Pyrrolidin-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetic acid 100 
A mixture of (2′′S,2R) and (2′′S,2S) diastereomers 
 
Procedure: Ester 97 was deprotected using the same procedure for the synthesis of salt 98, 
with the resulting crude material being neutralised with 3 M NaOH(aq.) (2 mL) and extracted 
with EtOAc (3 × 5 mL). The collected organic extracts were dried over MgSO4 and concentrated 
in vacuo before being purified by preparative TLC (5% MeOH and 1% NH4OH(aq.) in DCM) to 
yield the title compound (17 mg, 15%) as a clear colourless oil. 
Rf 0.83 (10% MeOH and 1% NH4OH(aq.) in CHCl3); νmax (ATR) 3364 (br), 2959 (m), 2877 (m), 1620 
(s), 1489 (m), 1421 (s), 1263 (w), 1174 (w), 1087 (m), 1048 (m), 1015 (m) cm−1; δH (700 MHz, 
CDCl3, mixture of diastereomers) 7.37 – 7.15 (9H, m, ArH), 5.08 – 5.05 (1H, m, 2-H), 4.31 – 4.27 
(1H, m, 2′′-H), 3.68 (1H, apparent ddd, J = 11.5, 5.0, 2.5 Hz, O(CHH′)), 3.64 – 3.57 (1.5H, m, 
5′′-HH′ isomer 1, O(CHH′)), 3.54 (0.5H, dt, J = 10.0, 7.0 Hz, 5′′-HH′ isomer 2), 3.44 (0.5H, dt, 
J = 10.0, 7.0 Hz, 5′′-HH′ isomer 2),  3.35 (0.5H, dt, J = 10.5, 7.0 Hz, 5′′-HH′ isomer 1), 2.03 (1H, 
apparent ddt, J = 20.0, 14.5, 7.5 Hz, 3′′-HH′), 1.92 – 1.84 (1H, m, 4′′-HH′), 1.84 – 1.72 (1H, m, 
4′′-HH′), 1.61 – 1.55 (1H, m, 3′′-HH′); δC (176 MHz, CDCl3, mixture of diastereomers) 172.8(9) 
(C-1), 172.8(8) (C-1), 138.6 (ArC), 138.3 (ArC), 137.8 (ArC), 137.6 (ArC), 133.3(1) (ArC), 133.2(7) 
(ArC), 130.6 (ArC), 130.5 (ArC), 129.1 (ArC), 129.0 (ArC), 128.9 (ArC), 128.8 (ArC), 127.6(1) (ArC), 
127.5(7) (ArC), 67.6 (O(CHH′)), 65.5 (O(CHH′)), 62.0(1) (C-2′′), 61.9(8) (C-2′′), 56.2(2) (C-2), 
56.2(0) (C-2), 48.3(7) (C-5′′), 48.3(5) (C-5′′), 28.5 (C-3′′), 28.4 (C-3′′), 24.6 (C-4′′), 24.5 (C-4′′); 
m/z (LCMS, ESI+) 330 (M(35Cl)H+), 332 (M(37Cl)H+); Accurate mass: Found MH+, 330.1273: 
C19H21NO2
35Cl requires M, 330.1261. 
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(2S)-(N-Carboxybenzyl)-2-(hydroxymethyl)pyrrolidine288 (S)-104 
 
Procedure:249 A round bottomed flask equipped with a reflux condenser was charged with 
(S)-N-Z-proline (S)-68 (1.65 g, 6.62 mmol) and THF (33 mL). The mixture was cooled in an ice 
bath before dropwise addition of a solution of BH3•SMe2 (0.69 mL, 7.28 mmol) in THF (3 mL). 
The reaction mixture was heated to reflux for 2 h, after which complete conversion of starting 
material was observed by TLC. After cooling to 0 °C, the reaction was quenched with the 
addition of cold water (5 mL) and THF was removed from the crude mixture under reduced 
pressure. The residual material was diluted with water (30 mL) and extracted with DCM 
(3 × 20 mL). The combined organic extracts were washed with brine (30 mL) and dried over 
MgSO4 before being concentrated under reduced pressure. Column chromatography (10% → 
50% EtOAc in hexanes) furnished the title compound (1.17 g, 75%) as a viscous clear colourless 
oil. 
Rf 0.21 (50% EtOAc in hexanes); [α]
28
D
 (c = 1.00 g/100 mL, CHCl3) −40.43° (lit.:
289 [α]20D
 
(c = 1.00 g/100 mL, CHCl3) −40.2°); νmax (ATR) 3391 (br), 2950 (w), 2876 (w), 1670 (s), 1414 (s), 
1356 (s), 1191 (m), 1103 (s), 1048 (m) cm−1; δH (700 MHz, CDCl3) 7.38 – 7.34 (4H, m, ArH), 
7.34 – 7.30 (1H, m, ArH),  5.17 – 5.11 (2H, m, PhCH2), 4.05 – 3.91 (1H, m, 2-H), 3.70 – 3.66 (1H, 
m, 1′-HH′), 3.63 (1H, dd, J = 11.5, 7.5 Hz, 1′-HH′), 3.55 (1H, dt, J = 11.5, 7.0 Hz, 5-HH′), 3.39 (1H, 
dt, J = 10.5, 7.0 Hz, 5-HH′), 2.06 – 1.98 (1H, m, 3-HH′), 1.92 – 1.83 (1H, m, 4-HH′), 1.83 – 1.76 
(1H, m, 4-HH′), 1.60 (1H, dq, J = 13.5, 7.0 Hz, 3-HH′); δC (176 MHz, CDCl3) 157.3 (NCO2), 136.6 
(ArC), 128.6 (ArC), 128.2 (ArC), 128.0 (ArC), 67.4 (PhCH2), 67.2 (C-1′), 60.9 (C-2), 47.5 (C-5), 28.8 
(C-3), 24.2 (C-4); m/z (LCMS, ESI+) 236 (MH+), 258 (MNa+). 
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(N-Carboxybenzyl)-2-formylpyrrolidine290 105  
 
Procedure:250 To a flask fitted with a condenser was added alcohol (S)-104 (1.25 g, 5.31 mmol), 
Cu(MeCN)4PF6 (101 mg, 0.27 mmol), 2,2´-bipyridine (42 mg, 0.27 mmol), TEMPO (43 mg, 
0.27 mmol), N-methylimidazole (43 μL, 0.53 mmol) and MeCN (25 mL). The reaction mixture 
was stirred, open to air, at 70 °C for 18 h after which TLC analysis showed consumption of the 
starting material. A 1:1 mixture of hexanes and ether (20 mL) was added and the solids 
removed by filtration through a celite® plug before being washed with a small amount of 1:1 
hexanes : ether. The collected filtrates were concentrated in vacuo before purification by SiO2 
column (0% → 30% EtOAc in hexanes) provided the title compound (520 mg, 42%) as a clear 
oil. 
Rf 0.35 (25% EtOAc in hexanes); νmax (ATR) 2946 (w), 2882 (w), 1786 (w), 1696 (s, br), 1406 (s), 
1352 (m), 1294 (m), 1110 (m), 1039 (m) cm−1; δH (700 MHz, CDCl3, mixture of rotamers) 9.60 – 
9.58 (0.5H, br m, 1′-H rotamer A), 9.49 (0.5H, d, J = 2.0 Hz, 1′-H rotamer B), 7.39 – 7.28 (5H, m, 
ArH), 5.20 – 5.10 (2H, m, PhCH2), 4.31 – 4.28 (0.5H, m, 2-H rotamer A), 4.22 – 4.18 (0.5H, m, 
2-H rotamer B), 3.63 – 3.49 (2H, m, 5-H2), 2.13 (0.5H, dq, J = 13.5, 8.0 Hz, 3-HH′ rotamer A),  
2.10 – 2.04 (0.5H, m, 3-HH′ rotamer B), 2.04 – 1.99 (1H, m, 3-HH′ rotamer A, 3-HH′ rotamer B), 
1.95 – 1.81 (2H, m, 4-H2); δC (176 MHz, CDCl3, mixture of rotamers) 200.1 (C-1′), 155.5 (NCO2), 
154.6 (NCO2), 136.6 (ArC), 136.4 (ArC), 128.6 (ArC), 128.2 (ArC), 128.1 (ArC), 67.4(2) (PhCH2), 
67.3(7) (PhCH2), 65.4 (C-2 rotamer A), 65.0 (C-2 rotamer B), 47.4 (C-5), 46.8 (C-5), 28.0 (C-3 
rotamer A), 26.7 (C-3 rotamer B), 24.6 (C-4), 23.9 (C-4); m/z (LCMS, ESI+) 234 (MH+), 256 
(MNa+). 
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(N-Carboxybenzyl)-2-vinylpyrrolidine291 106  
 
Procedure:229 Methyltriphenylphosphonium bromide (1.04 g, 2.85 mmol) was dissolved in THF 
(6 mL) and cooled to −10 °C. Butyllithium (1.6 M in hexanes, 1.78 mL, 2.85 mmol) was added 
slowly. The resultant dark orange solution was stirred at RT for 30 min then re-cooled prior to 
addition of aldehyde 105 (398 mg, 1.71 mmol) in THF (2 mL). The resultant dark red solution 
was reacted at RT for 2.5 h then quenched by addition of saturated NH4Cl(aq.) (10 mL) before 
removal of volatiles under reduced pressure. The crude residue was diluted with H2O (20 mL) 
and extracted with ether (3 × 15 mL). The combined organic extracts were washed with brine 
(20 mL) and saturated NaHCO3(aq.) (20 mL) before being dried over MgSO4 and concentrated in 
vacuo. Purification by column chromatography (0% → 25% EtOAc in hexanes) yielded the title 
compound (214 mg, 54%) as a thin clear colourless oil. 
Rf 0.34 (25% EtOAc in hexanes); νmax (ATR) 2974 (w), 2928 (w), 2884 (w), 1698 (s), 1409 (s), 
1352 (m), 1094 (m) cm−1; δH (700 MHz, CDCl3, mixture of rotamers) 7.40 – 7.28 (5H, m, ArH), 
5.82 – 5.71 (1H, m, 1′-H), 5.19 – 5.08 (3H, m, PhCH2, 2′-HH′), 5.08 – 4.99 (1H, m, 2′-HH′), 4.45 – 
4.36 (1H, m, 2-H), 3.52 – 3.41 (2H, m, 5-H2), 2.06 – 1.97 (1H, m, 3-HH′), 1.92 – 1.81 (2H, m, 
4-H2), 1.77 – 1.71 (1H, m, 3-HH′); δC (176 MHz, CDCl3, mixture of rotamers) 155.0 (NCO2), 138.7 
(C-1′), 138.2 (C-1′), 137.2 (ArC), 128.6 (ArC), 128.5 (ArC), 128.0 (ArC), 127.9 (ArC), 114.5 (C-2′), 
114.2 (C-2′), 66.8 (PhCH2), 59.6 (C-2), 59.2 (C-2), 46.9 (C-5), 46.5 (C-5), 32.2 (C-3), 31.4 (C-3), 
23.6 (C-4), 22.7 (C-4); m/z (LCMS, ESI+) 232 (MH+). 
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4-(4′-Chlorophenyl)-4-phenylbut-1-ene292 107  
 
Procedure: A flask was charged with alcohol 73 (262 mg, 1.20 mmol), DCM (2.4 mL) and NEt3 
(0.17 mL, 1.20 mmol) before methanesulfonyl chloride (93 μL, 1.20 mmol) was added dropwise 
at RT. The solution was stirred until TLC analysis showed consumption of alcohol 73, after 
which the reaction mixture was cooled to −10 °C and toluene (6 mL) was added followed by 
the slow addition of allyl grignard reagent (1 M in ether, 3.60 mL, 3.60 mmol) and the reaction 
allowed to warm slowly to RT overnight. The reaction was cooled in an ice bath, quenched 
with saturated NH4Cl(aq.) (10 mL) and extracted with DCM (3 × 10 mL). The combined organic 
extracts were dried over MgSO4 and concentrated in vacuo before being purified by column 
chromatography (0% → 8% ether in hexanes) to provide the title compound (214 mg, 74%) as 
a clear colourless oil.  
Rf 0.71 (10% ether in hexanes); νmax (ATR) 3070 (w), 3028 (w), 2924 (w), 2844 (w), 1640 (w), 
1599 (w), 1489 (s), 1449 (w), 1407 (w), 1262 (w), 1091 (s), 1013 (s) cm−1; δH (600 MHz, CDCl3) 
7.30 – 7.27 (2H, m, 3′′-H2), 7.26 – 7.23 (2H, m, 3′-H2), 7.22 – 7.15 (5H, m, 2′-H2, 2′′-H2, 4′′-H), 
5.70 (1H, ddt, J = 17.0, 10.0, 7.0 Hz, 2-H), 5.03 (1H, ddt, J = 17.0, 2.0, 1.5 Hz, 1-Hcis), 4.96 (1H, 
ddt, J = 10.0, 2.0, 1.0 Hz, 1-Htrans), 3.99 (1H, t, J = 8.0 Hz, 4-H), 2.84 – 2.74 (2H, m, 3-H2); 
δC (151 MHz, CDCl3) 144.1 (C-1′′), 143.1 (C-1′), 136.5 (C-2), 132.1 (C-4′), 129.5 (C-2′), 128.7 (C-3′, 
C-3′′), 128.0 (ArC), 126.5 (ArC), 116.8 (C-1), 50.7 (C-4), 40.0 (C-3). 
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N-(Diphenylmethyl)-2-(4′-chlorophenyl)-2-phenylacetamide 110 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and benzhydrylamine 112 (36 µL, 0.20 mmol) were 
reacted according to general procedure A. Following reversed-phase column chromatography 
(5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (55 mg, 67%) was isolated 
as an off-white solid. 
M.p. 196 – 199 °C; νmax (ATR) 3270 (br), 3070 (w), 3021 (w), 1647 (s), 1490 (m), 1481 (m), 1368 
(w), 1222 (w) cm−1; δH (600 MHz, CDCl3) 7.35 – 7.26 (11H, m, 3′-H2, 3
Ph′-(H2)2, 4
Ph′-(H)2, 3
Ph-H2, 
4Ph-H), 7.22 (2H, d, J = 7.5 Hz, 2Ph-H2), 7.18 (2H, d, J = 8.0 Hz, 2′-H2), 7.11 (4H, d, J = 8.0 Hz, 
2Ph′-(H2)2), 6.29 (1H, d, J = 8.0 Hz, NHCHPh2), 6.17 (1H, d, J = 8.0 Hz, NHCHPh2), 4.93 (1H, s, 2-H); 
δC (151 MHz, CDCl3) 170.6 (C=O), 141.3(3) (C-1
Ph′), 141.3(0) (C-1Ph′), 139.0 (C-1Ph), 137.9 (C-1′), 
133.4 (C-4′), 130.4 (C-2′), 129.1 (ArC), 129.0 (ArC), 128.9 (ArC), 128.8 (ArC), 127.8 (ArC), 127.7 
(ArC), 127.4 (C-2Ph′), 58.5 (C-2), 57.3 (NHCHPh2); m/z (LCMS, ESI
+) 412 (M(35Cl)H+), 414 
(M(37Cl)H+); Accurate mass: Found MH+, 412.1473: C27H23NO
35Cl requires M, 412.1468. 
1-(4′′-[{1′′′-Methylimidazol-2′′′-yl}methyl]piperazin-1′′-yl)-2-(4′-chlorophenyl)-2-phenylethan-
1-one 111 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 4-[{1′-methylimidazol-2′-yl}methyl]piperazine 113 
(36 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
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column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(30 mg, 37%) was isolated as an orange-brown oil. 
νmax (ATR) 3061 (w), 3026 (w), 2942 (w), 2817 (w), 1640 (s), 1434 (m), 1366 (m), 1267 (m), 1199 
(s), 1126 (s), 1032 (m) cm−1; δH (600 MHz, CDCl3) 7.34 – 7.30 (2H, m, 3
Ph-H2), 7.28 – 7.24 (3H, m, 
3′-H2, 4
Ph-H), 7.21 – 7.17 (2H, m, 2Ph-H2), 7.14 – 7.10 (3H, m, 2′-H2, 4′′′-H), 6.94 (1H, d, J = 1.0 Hz, 
5′′′-H), 5.13 (1H, s, 2-H), 3.81 – 3.70 (3H, m, 2′′-HH′, NCH2), 3.77 (3H, s, NCH3), 3.68 – 3.60 (1H, 
m, 2′′-HH′), 3.43 – 3.34 (2H, m, 2′′-H2), 2.55 – 2.45 (2H, m, 3′′-H2(HH′)), 2.33 – 2.27 (1H, m, 
3′′-H2(HH′)), 2.23 – 2.16 (1H, m, 3′′-H2(HH′)); δC (151 MHz, CDCl3) 170.0 (C=O), 143.7 (C-2′′′), 
138.7 (C-1Ph), 138.1 (C-1′), 133.1 (C-4′), 130.6 (C-2′), 129.0 (C-3Ph), 128.8(2) (ArC), 128.7(8) (ArC), 
127.5 (ArC), 123.7 (C-4′′′), 122.4 (C-5′′′), 54.4 (C-2), 52.9 (C-3′′), 52.6 (NCH2), 52.5 (C-3′′), 45.8 
(C-2′′), 42.1 (C-2′′), 33.9 (NCH3); m/z (LCMS, ESI
+) 409 (M(35Cl)H+), 411 (M(37Cl)H+); Accurate 
mass: Found MH+, 409.1799: C23H26N4O
35Cl requires M, 409.1795. 
N-(8′′-Azabicyclo[3.2.1]octan-3′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 117 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 8-boc-8-azabicyclo[3.2.1]octanylamine (45 mg, 
0.20 mmol) were reacted according to general procedure A. Following TFA-mediated 
deprotection and reversed-phase column chromatography (5% → 95% MeCN in H2O with 0.5% 
formic acid), the title compound (12 mg, 17%) was isolated as a white solid. 
M.p. 189 – 191 °C (decomp.); νmax (ATR) 3278 (br), 3066 (w), 2958 (w), 2876 (w), 1644 (s), 1550 
(m), 1490 (s), 1408 (w), 1312 (w), 1226 (w), 1162 (w), 1090 (m), 1015 (m) cm−1; δH (600 MHz, 
CDCl3) 7.33 – 7.28 (2H, m, 3
PhH2), 7.28 – 7.23 (3H, m, 3′-H2, 4
Ph-H), 7.20 – 7.17 (2H, m, 2Ph-H2), 
7.17 – 7.15 (2H, m, 2′-H2), 5.36 (1H, d, J = 8.5 Hz, NH), 4.79 (1H, s, 2-H), 4.21 (1H, tdt, J = 11.5, 
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8.5, 5.5 Hz, 3′′-H), 3.53 – 3.49 (2H, m, 1′′-H2), 1.92 – 1.83 (2H, m, 2′′-H2H′2), 1.78 – 1.73 (4H, m, 
6′′-(H2)2), 1.72 – 1.61 (1H, m, 8′′-H), 1.29 – 1.21 (2H, m, 2′′-H2H′2); δC (151 MHz, CDCl3) 170.7 
(C=O), 139.1 (C-1Ph), 138.1 (C-1′), 133.2 (C-4′), 130.3 (C-2′), 129.0 (C-3Ph), 128.9 (C-3′), 128.8 
(C-2Ph), 127.6 (C-4Ph), 58.5 (C-2), 54.6 (C-1′′), 42.1 (C-3′′), 39.8(3) (C-2′′), 39.8(1) (C-2′′), 29.5 
(C-6′′); m/z (LCMS, ESI+) 355 (M(35Cl)H+), 357 (M(37Cl)H+); Accurate mass: Found MH+, 355.1563: 
C21H24N2O
35Cl requires M, 355.1577. 
N-(1′′-[2′′′-Dimethylaminoethyl]indazol-6′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 118 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 1-(2′-dimethylaminoethyl)-6-aminoindazole 
(41 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(8 mg, 9%) was isolated as a yellow oil. 
νmax (ATR) 3306 (br), 3264 (w), 3070 (w), 2952 (w), 2862 (w), 2818 (w), 2780 (w), 1661 (m), 
1625 (m), 1587 (m), 1546 (m), 1489 (s), 1462 (m), 1359 (m), 1310 (m), 1256 (w), 1167 (m), 
1092 (m) cm−1; δH (600 MHz, CDCl3) 8.23 (1H, br s, 7′′-H), 7.91 (1H, s, 3′′-H), 7.57 (1H, d, J = 8.5 
Hz, 4′′-H), 7.45 (1H, br s, NH), 7.42 – 7.37 (2H, m, 3Ph-H2), 7.36 – 7.31 (5H, m, 3′-H2, 2
Ph-H2, 
4Ph-H), 7.30 – 7.27 (2H, m, 2′-H2), 6.68 (1H, dd, J = 8.5, 1.5 Hz, 5′′-H), 5.08 (1H, s, 2-H), 4.43 (2H, 
t, J = 7.0 Hz, 1′′′-H2), 2.81 (2H, t, J = 7.0 Hz, 2′′′-H2), 2.29 (6H, s, N(CH3)2); δC (151 MHz, CDCl3) 
169.9 (C=O), 140.1 (C-9′′), 138.6 (C-1Ph), 137.5 (C-1′), 136.0 (C-6′′), 133.7 (C-4′), 133.1 (C-3′′), 
130.5 (C-2′), 129.4 (C-3Ph), 129.2 (C-3′), 129.0 (C-2Ph), 128.1 (C-4Ph), 121.7 (C-4′′), 121.2 (C-8′′), 
114.2 (C-5′′), 99.4 (C-7′′), 59.7 (C-2), 58.5 (C-2′′′), 47.2 (C-1′′′), 45.9 (N(CH3)); m/z (LCMS, ESI
+) 
433 (M(35Cl)H+), 435 (M(37Cl)H+); Accurate mass: Found MH+, 433.1769: C25H26N4O
35Cl requires 
M, 433.1795. 
 | 142 | 
Chapter 8: Chemical Experimental Details 
N-(2′′-[2′′′-Dimethylaminoethyl]indazol-6′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 119 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 2-(2′-dimethylaminoethyl)-6-aminoindazole 
(41 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(31 mg, 36%) was isolated as a light brown solid. 
M.p. 76 – 79 °C; νmax (ATR) 3292 (br), 3046 (w), 2950 (w), 2838 (w), 2790 (w), 1672 (m), 1569 
(s), 1488 (s), 1368 (m), 1226 (m), 1148 (w), 1088 (w), 1014 (w) cm−1; δH (600 MHz, CDCl3) 7.94 
(1H, s, 3′′-H), 7.93 (1H, br s, 7′′-H), 7.55 (1H, d, J = 9.0 Hz, 4′′-H), 7.40 – 7.36 (2H, m, 3Ph-H2), 
7.35 – 7.31 (5H, m, 3′-H2, 2
Ph-H2, 4
Ph-H), 7.30 – 7.27 (2H, m, 2′-H2), 7.02 (1H, dd, J = 9.0, 2.0 Hz, 
5′′-H), 5.06 (1H, s, 2-H), 4.46 (2H, t, J = 6.5 Hz, 1′′′-H2), 2.87 (2H, t, J = 6.5 Hz, 2′′′-H2), 2.27 (6H, s, 
N(CH3)2); δC (151 MHz, CDCl3) 169.6 (C=O), 148.9 (C-9′′), 138.9 (C-1
Ph), 137.8 (C-1′), 135.3 (C-6′′), 
133.5 (C-4′), 130.5 (C-2′), 129.3 (C-3Ph), 129.1 (C-3′), 129.0 (C-2Ph), 127.9 (C-4Ph), 123.5 (C-3′′), 
121.0 (C-4′′), 119.5 (C-8′′), 117.1 (C-5′′), 106.7 (C-7′′), 59.6 (C-2), 59.4 (C-2′′′), 52.0 (C-1′′′), 45.8 
(N(CH3)2); m/z (LCMS, ESI
+) 433 (M(35Cl)H+), 435 (M(37Cl)H+); Accurate mass: Found MH+, 
433.1783: C25H26N4O
35Cl requires M, 433.1795. 
 | 143 | 
Chapter 8: Chemical Experimental Details 
N-(2′′-[4′′′-Methylpiperazin-1′′′-yl]pyrimidin-5′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 
120 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 2-[4′-methylpiperazin-1′-yl]-5-aminopyrimidine 
(39 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(30 mg, 36%) was isolated as an off-white solid. 
M.p. 152 – 154 °C; νmax (ATR) 3270 (br), 2942 (w), 2846 (w), 2800 (w), 1655 (m), 1606 (m), 1498 
(br, s), 1447 (m), 1407 (m), 1360 (s), 1300 (m), 1261 (m), 1170 (w), 1096 (w) cm−1; δH (600 MHz, 
CDCl3) 8.37 (2H, s, 4′′-H2), 7.39 – 7.35 (2H, m, 3
Ph-H2), 7.34 – 7.31 (3H, m, 3′-H2, 4
Ph-H), 7.31 – 
7.28 (2H, m, 2Ph-H2), 7.26 – 7.23 (2H, m, 2′-H2), 7.01 (1H, s, NH), 5.01 (1H, s, 2-H), 3.80 (4H, t, 
J = 5.0 Hz, 2′′′-(H2)2), 2.43 (4H, t, J = 5.0 Hz, 3′′′-(H2)2), 2.32 (3H, s, NCH3); δC (151 MHz, CDCl3) 
170.2 (C=O), 159.7 (C-2′′), 151.6 (C-4′′), 138.6 (C-1Ph), 137.5 (C-1′), 133.7 (C-4′), 130.4 (C-2′), 
129.3 (C-3Ph), 129.2 (C-3′), 128.9 (C-2Ph), 128.0 (C-4Ph), 122.3 (C-5′′), 58.8 (C-2), 55.0 (C-3′′′), 46.4 
(NCH3), 44.2 (C-2′′′); m/z (LCMS, ESI
+) 422 (M(35Cl)H+), 424 (M(37Cl)H+); Accurate mass: Found 
MH+, 422.1757: C23H25N5O
35Cl requires M, 422.1748. 
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N-([1′′H-Imidazol-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 121 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (1H-imidazol-2-yl)methylamine•2HCl (34 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (16 mg, 
25%) was isolated as a beige solid. 
M.p. 127 – 130 °C; νmax (ATR) 3232 (br), 3032 (w), 2930 (w), 1656 (s), 1558 (w), 1490 (s), 1420 
(w), 1133 (s), 1091 (s), 1015 (m) cm−1; δH (600 MHz, CDCl3) 9.14 – 9.08 (1H, m, NH), 7.26 – 7.23 
(3H, m, 3Ph-H2, 4
Ph-H), 7.22 – 7.19 (2H, m, 3′-H2), 7.11 – 7.07 (2H, m, 2
Ph-H2), 7.07 – 7.04 (2H, m, 
2′-H2), 6.89 (2H, s, 4′′-(H)2,), 4.83 (1H, s, 2-H), 4.46 (2H, d, J = 6.0 Hz, NHCH2); δC (151 MHz, 
CDCl3) 174.3 (C=O), 145.2 (C-2′′), 138.6 (C-1
Ph), 137.4 (C-1′), 133.4 (C-4′), 130.2 (C-2′), 128.9(1) 
(C-3Ph), 128.8(8) (C-3′), 128.7 (C-2Ph), 127.7 (C-4Ph), 120.4 (C-4′′), 57.2 (C-2), 35.9 (NHCH2); 
m/z (LCMS, ESI+) 326 (M(35Cl)H+), 328 (M(37Cl)H+); Accurate mass: Found MH+, 326.1050: 
C18H17N3O
35Cl requires M, 326.1060. 
N-([Benzothiazol-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 122 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (benzothiazol-2-yl)methylamine•HCl (40 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (18 mg, 
23%) was isolated as a beige solid. 
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M.p. 161 – 163 °C; νmax (ATR) 3294 (br), 3062 (w), 3018 (w), 1654 (s), 1528 (m), 1489 (s), 1412 
(w), 1334 (w), 1218 (w), 1156 (w), 1090 (m), 1015 (m) cm−1; δH (600 MHz, CHCl3) 7.94 (1H, d, 
J = 8.0 Hz, 7′′-H), 7.85 (1H, d, J = 8.0 Hz, 4′′-H), 7.47 (1H, t, J = 8.0 Hz, 5′′-H), 7.39 (1H, t, J = 8.0 
Hz, 6′′-H), 7.37 – 7.30 (2H, m, 3Ph-H2), 7.33 – 7.26 (5H, m, 3′-H2, 2
Ph-H2, 4
Ph-H), 7.28 – 7.22 (2H, 
m, 2′-H2), 6.59 (1H, t, J = 6.0 Hz, NH), 4.98 (1H, s, 2-H), 4.89 – 4.85 (2H, m, NHCH2); 
δC (151 MHz, CDCl3) 171.8 (C=O), 167.9 (C-2′′), 152.8 (C-8′′), 138.7 (C-1
Ph), 137.7 (C-1′), 135.3 
(C-9′′), 133.5 (C-4′), 130.5 (C-2′), 129.2 (C-3Ph), 129.1 (ArC), 129.0 (ArC), 127.8 (C-4Ph), 126.4 
(C-5′′), 125.5 (C-6′′), 123.0 (C-7′′), 121.9 (C-4′′), 58.4 (C-2), 42.3 (NHCH2); m/z (LCMS, ESI
+) 393 
(M(35Cl)H+), 395 (M(37Cl)H+); Accurate mass: Found MH+, 393.0827: C22H18N2OS
35Cl requires M, 
393.0828. 
N-(3′′-[Imidazol-1′′′-yl]prop-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 123 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 3-[imidazol-1′-yl]propylamine (98%, 26 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (30 mg, 
42%) was isolated as a white solid. 
M.p. 116 – 118 °C; νmax (ATR) 3312 (br), 3044 (w), 2952 (w), 1650 (s), 1560 (m), 1489 (s), 1458 
(w), 1352 (w), 1226 (m), 1098 (w) cm−1; δH (700 MHz, CDCl3) 7.58 (1H, s, 2′′′-H), 7.32 (2H, t, 
J = 7.5 Hz, 3Ph-H2), 7.28 (2H, d, J = 8.0 Hz, 3′-H2), 7.26 – 7.23 (3H, m, 2
Ph-H2, 4
Ph-H), 7.20 (2H, d, 
J = 8.0 Hz, 2′-H2), 7.02 (1H, apparent s, 4′′′-H), 6.89 (1H, apparent s, 5′′′-H), 6.31 (1H, t, 
J = 6.5 Hz, NH), 4.86 (1H, s, 2-H), 3.93 (2H, t, J = 7.0 Hz, 3′′-H2), 3.25 (2H, q, J = 6.5 Hz, 1′′-H2), 
1.97 (2H, tt, J = 7.0, 6.5 Hz, 2′′-H2); δC (176 MHz, CDCl3) 172.2 (C=O), 139.1 (C-1
Ph), 137.9 (C-1′), 
137.1 (C-2′′′), 133.3 (C-4′), 130.3 (C-2′), 129.1 (C-3Ph), 129.0 (C-3′), 128.8 (C-2Ph), 128.7 (C-4′′′), 
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119.2 (C-5′′′), 58.2 (C-2), 44.9 (C-3′′), 37.0 (C-1′′), 31.0 (C-2′′); m/z (LCMS, ESI+) 354 (M(35Cl)H+), 
356 (M(37Cl)H+); Accurate mass: Found MH+, 354.1383: C20H21N3O
35Cl requires M, 354.1373. 
N-([N-Methylpyrazol-5′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 124 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (N-methylpyrazol-5-yl)methylamine (97%, 23 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (25 mg, 
37%) was isolated as a white solid. 
M.p. 148 – 150 °C; νmax (ATR) 3274 (br), 3030 (w), 2934 (w), 1648 (s), 1544 (m), 1490 (s), 1400 
(w), 1344 (w), 1280 (w), 1218 (w), 1090 (m), 1015 (m) cm−1; δH (700 MHz, CDCl3) 7.37 (1H, d, 
J = 2.0 Hz, 3′′-H), 7.36 – 7.33 (2H, m, 3Ph-H2), 7.31 – 7.27 (3H, m, 3′-H2, 4
Ph-H), 7.24 – 7.22 (2H, 
m, 2Ph-H2), 7.21 – 7.18 (2H, m, 2′-H2), 6.05 (1H, d, J = 2.0 Hz, 4′′-H), 5.79 (1H, t, J = 5.5 Hz, N-H), 
4.87 (1H, s, 2-H), 4.52 (2H, d, J = 5.5 Hz, NHCH2), 3.77 (3H, s, NCH3); δC (101 MHz, CDCl3) 171.4 
(C=O), 138.6(3) (ArC), 138.5(9) (ArC), 138.4 (C-3′′), 137.6 (C-1′), 133.5 (C-4′), 130.3 (C-2′), 129.1 
(ArC), 129.0 (ArC), 128.7 (C-2Ph), 127.9 (C-4Ph), 105.8 (C-4′′), 58.3 (C-2), 36.6 (NCH3), 34.6 
(NHCH2); m/z (LCMS, ESI
+) 340 (M(35Cl)H+), 342 (M(37Cl)H+); Accurate mass: Found MH+, 
340.1226: C19H19N3O
35Cl requires M, 340.1217. 
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N-Methyl-N-([2′′-methyloxazol-4′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 125 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and N-methyl-(2-methyloxazol-4-yl)methylamine 
(25 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(35 mg, 49%) was isolated as a clear yellow oil. 
νmax (ATR) 3050 (w), 2928 (w), 1643 (s), 1580 (m), 1489 (s), 1397 (m), 1278 (w), 1204 (w), 1089 
(s), 1015 (m) cm−1; δH (600 MHz, CDCl3, mixture of rotamers) 7.42 (0.6H, s, 5′′-H rotamer B), 
7.32 – 7.28 (2H, m, 3Ph-H2), 7.27 – 7.23 (4.2H, m, 3′-H2, 2
Ph-H2 rotamer A, 4
Ph-H, 5′′-H rotamer 
A), 7.21 – 7.18 (2H, m, 2′-H2 rotamer A, 2
Ph-H2 rotamer B), 7.15 – 7.12 (1.2H, m, 2′-H2, rotamer 
B), 5.49 (0.4H, s, 2-H rotamer A), 5.15 (0.6H, s, 2-H rotamer B), 4.45 (1.2H, s, N(CH3)CH2 
rotamer B), 4.36 (0.4H, d, J = 17.0 Hz, N(CH3)CHH′ rotamer A), 4.21 (0.4H, d, J = 17.0 Hz, 
N(CH3)HH′ rotamer A), 3.05 (1.8H, s, N(CH3)CH2 rotamer B), 3.00 (1.2H, s, N(CH3)CHH′ rotamer 
A), 2.46 (1.2H, s, 2′′-CH3 rotamer A), 2.41 (1.8H, s, 2′′-CH3 rotamer B); δC (151 MHz, CDCl3, 
mixture of rotamers) 171.8 (C=O rotamer A), 171.4 (C=O rotamer B), 162.5 (C-2′′ rotamer A), 
161.5 (C-2′′ rotamer B), 139.1 (C-1Ph rotamer A), 138.9 (C-1Ph rotamer B), 138.5 (C-1′ rotamer 
A), 138.2 (C-1′ rotamer B), 137.0 (C-4′′ rotamer A), 136.8 (C-4′′ rotamer B), 136.2 (C-5′′ rotamer 
B), 135.1 (C-5′′ rotamer A), 133.0(4) (C-4′ rotamer B), 133.0(1) (C-4′ rotamer A), 130.7 (C-2′ 
rotamer A), 130.6 (C-2′ rotamer B), 129.0 (ArC), 128.9(1) (ArC), 128.8(8) (ArC), 128.8(6) (ArC), 
128.7(1) (ArC), 128.6(5) (ArC), 127.4(1) (C-4Ph rotamer A), 127.3(8) (C-4Ph rotamer B), 54.3 (C-2 
rotamer B), 53.8 (C-2 rotamer A), 46.1 (N(CH3)CHH′ rotamer A), 44.0 (N(CH3)CH2 rotamer B), 
36.2 (N(CH3)CH2 rotamer B), 34.3 (N(CH3)CHH′ rotamer A), 14.1 (2′′-CH3 rotamer A), 14.0 
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(2′′-CH3 rotamer B); m/z (LCMS, ESI
+) 355 (M(35Cl)H+), 357 (M(37Cl)H+); Accurate mass: Found 
MH+, 355.1220: C20H20N2O2
35Cl requires M, 355.1213. 
N-([Pyridin-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 126 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (pyridin-2-yl)methylamine (22 mg, 0.20 mmol) 
were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (47 mg, 
70%) was isolated as a white solid. 
M.p. 119 – 120 °C; νmax (ATR) 3308 (br), 3056 (w), 2930 (w), 1649 (s), 1600 (w), 1591 (m), 1490 
(s), 1437 (w), 1204 (w), 1091 (m), 1016 (m) cm−1; δH (700 MHz, CDCl3) 8.48 – 8.46 (1H, m, 6′′-H), 
7.64 (1H, td, J = 7.5, 2.0 Hz, 5′′-H), 7.35 – 7.31 (2H, m, 3Ph-H2), 7.30 – 7.26 (5H, m, 3′-H2, 2
Ph-H2, 
4Ph-H), 7.26 – 7.24 (2H, m, 2′-H2), 7.23 – 7.21 (1H, m, 3′′-H), 7.20 – 7.16 (1H, m, 4′′-H), 6.97 – 
6.92 (1H, m, N-H), 4.96 (1H, s, 2-H), 4.59 (2H, d, J = 5.0 Hz, NHCH2); δC (176 MHz, CDCl3) 171.6 
(C=O), 156.1 (C-2′′), 149.1 (C-6′′), 139.2 (C-1Ph), 138.2 (C-1′), 136.9 (C-5′′), 133.2 (C-4′), 130.4 
(C-2′), 129.0 (C-3Ph), 128.9(3) (ArC), 128.9(1) (ArC), 127.6 (C-4Ph), 122.6 (C-4′′), 122.2 (C-3′′), 58.5 
(C-2), 44.8 (NHCH2); m/z (LCMS, ESI
+) 337 (M(35Cl)H+), 339 (M(37Cl)H+); Accurate mass: Found 
MH+, 337.1111: C20H18N2O
35Cl requires M, 337.1108. 
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N-([Azetidin-3′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 127 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (N-boc-azetidin-3-yl)methylamine (37 mg, 
0.20 mmol) were reacted according to general procedure A. Following TFA-mediated 
deprotection and reversed-phase column chromatography (5% → 95% MeCN in H2O with 0.5% 
formic acid), the title compound (10 mg, 16%) was isolated as a yellow solid. 
M.p. 102 – 105 °C; νmax (ATR) 3284 (br), 3066 (w), 2956 (w), 2924 (w), 2866 (w), 1649 (s), 1555 
(m), 1490 (s), 1364 (w), 1226 (w), 1098 (w), 1018 (w) cm−1; δH (700 MHz, CDCl3) 7.35 – 7.30 (2H, 
m, 3Ph-H2), 7.30 – 7.26 (3H, m, 3′-H2, 4
Ph-H), 7.25 – 7.22 (2H, m, 2Ph-H2), 7.22 – 7.19 (2H, m, 
2′-H2), 6.21 – 6.13 (1H, m, NH), 4.88 (1H, s, 2-H), 3.72 – 3.63 (2H, m, 2′′-H2H′2), 3.47 (2H, t, 
J = 6.0 Hz, NHCH2), 3.29 – 3.20 (2H, m, 2′′-H2H′2), 2.86 – 2.78 (1H, m, 3′′-H), 2.04 – 1.87 (1H, m, 
1′′-H); δC (176 MHz, CDCl3) 172.0 (C=O), 139.2 (C-1
Ph), 138.1 (C-1′), 133.3 (C-4′), 130.4 (C-2′), 
129.0 (C-3Ph), 128.9 (C-3′), 128.8 (C-2Ph), 127.6 (C-4Ph), 58.6 (C-2), 50.9 (C-2′′), 43.0 (NHCH2), 
34.5 (C-3′′); m/z (LCMS, ESI+) 315 (M(35Cl)H+), 317 (M(37Cl)H+); Accurate mass: Found MH+, 
315.1257: C18H20N2O
35Cl requires M, 315.1264. 
1-(2′′,6′′-Diazaspiro[3.3]heptan-2′′-yl)-2-(4′-chlorophenyl)-2-phenylethan-1-one 128 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 2-boc-2,6-diazaspiro[3.3]heptane (40 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
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chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (25 mg, 
38%) was isolated as a white crystalline solid. 
M.p. 90 – 92 °C; νmax (ATR) 2942 (w), 2866 (w), 1645 (s), 1490 (m), 1437 (s), 1326 (w), 1290 (w), 
1152 (w), 1092 (w), 1015 (w) cm−1; δH (700 MHz, CDCl3) 7.33 – 7.29 (2H, m, 3
Ph-H2), 7.28 – 7.25 
(5H, m, 3′-H2, 2
Ph-H2, 4
Ph-H), 7.24 – 7.21 (2H, m, 2′-H2), 4.77 (1H, s, 2-H), 4.22 (1H, d, J = 9.0 Hz, 
1′′-(HH′)(H2)), 4.15 (1H, d, J = 9.0 Hz, 1′′-(HH′)(H2)), 4.11 (2H, s, 1′′-(HH′)H2), 3.77 (1H, d, J = 8.5 
Hz, 5′′-(HH′)(HH′)), 3.75 (1H, d, J = 8.5 Hz, 5′′-(HH′)(HH′)), 3.68 (1H, d, J = 8.5 Hz, 5′′-(HH′)(HH′)), 
3.65 (1H, d, J = 8.5 Hz, 5′′-(HH′)(HH′)); δC (176 MHz, CDCl3) 171.0 (C=O), 138.6 (C-1
Ph), 137.6 
(C-1′), 133.2 (C-4′), 130.4 (C-2′), 128.9 (C-3Ph), 128.7(9) (ArC), 128.7(7) (ArC), 127.5 (C-4Ph), 61.5 
(C-1′′), 58.6 (C-1′′), 57.6(4) (AlC), 57.5(5) (AlC), 52.9 (C-2), 37.4 (C-4′′); m/z (LCMS, ESI+) 327 
(M(35Cl)H+), 329 (M(37Cl)H+); Accurate mass: Found MH+, 327.1248: C19H20N2O
35Cl requires M, 
327.1264. 
N-(3′′-[Pyrrolidin-1′′′-yl]prop-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 129 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 3-(pyrrolidin-1′-yl)propylamine (26 mg, 0.20 mmol) 
were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (29 mg, 
41%) was isolated as a yellow oil. 
νmax (ATR) 3278 (br), 3064 (w), 2968 (w), 2930 (w), 2880 (w), 2788 (w), 1654 (s), 1548 (m), 1494 
(s), 1452 (w), 1352 (w), 1222 (w), 1176 (w), 1096 (w), 1015 (w) cm−1; δH (700 MHz, CDCl3) 7.45 – 
7.41 (1H, m, NH), 7.34 – 7.30 (2H, m, ArH), 7.29 – 7.26 (4H, m, ArH), 7.26 – 7.23 (3H, m, ArH), 
4.81 (1H, s, 2-H), 3.42 – 3.38 (2H, m, 1′′-H2), 2.61 (2H, t, J = 6.5 Hz, 3′′-H2), 2.60 – 2.54 (4H, m, 
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2′′′-(H2)2), 1.79 – 1.72 (6H, m, 2′′-H2, 3′′′-(H2)2); δC (176 MHz, CDCl3) 171.8 (C=O), 139.5 (ArC), 
138.4 (ArC), 133.1 (C-4′), 130.4 (ArC), 128.9 (ArC), 128.8(4) (ArC), 128.8(1) (ArC), 127.4 (ArC), 
58.6 (C-2), 54.8 (C-3′′), 54.1 (C-2′′′), 39.3 (C-1′′), 26.6 (C-2′′), 23.5 (C-3′′′); m/z (LCMS, ESI+) 357 
(M(35Cl)H+), 358 (M(37Cl)H+); Accurate mass: Found MH+, 357.1741: C21H26N2O
35Cl requires M, 
357.1734. 
N-(3′′-[Morpholin-4′′′-yl]prop-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 130 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 3-(morpholin-4′-yl)propylamine (29 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (35 mg, 
47%) was isolated as a white solid. 
M.p. 129 – 131 °C; νmax (ATR) 3290 (br), 3054 (w), 2942 (w), 2852 (w), 2808 (w), 1645 (s), 1544 
(m), 1489 (s), 1456 (w), 1356 (w), 1276 (w), 1222 (w), 1117 (s), 1090 (w), 1015 (m) cm−1; 
δH (700 MHz, CDCl3) 7.34 – 7.30 (2H, m, 3
Ph-H2), 7.29 – 7.26 (3H, m, 3′-H2, 4
Ph-H), 7.26 – 7.24 
(2H, m, 2Ph-H2), 7.22 – 7.19 (2H, m, 2′-H2), 6.82 (1H, t, J = 5.0 Hz, NH), 4.80 (1H, s, 2-H), 3.60 – 
3.53 (4H, m, 2′′′-(H2)2), 3.43 – 3.33 (2H, m, 1′′-H2), 2.36 (2H, t, J = 6.5 Hz, 3′′-H2), 2.38 – 2.29 (4H, 
m, 3′′′-(H2)2), 1.65 (2H, p, J = 6.5 Hz, 2′′-H2); δC (176 MHz, CDCl3) 171.3 (C=O), 139.4 (C-1
Ph), 
138.3 (C-1′), 133.2 (C-4′), 130.3 (C-2′), 129.0 (C-3Ph), 128.9 (C-3′), 128.8 (C-2Ph), 127.6 (C-4Ph), 
67.1 (C-2′′′), 58.7 (C-2), 57.6 (C-3′′), 53.8 (C-3′′′), 39.6 (C-1′′), 25.0 (C-2′′); m/z (LCMS, ESI+) 373 
(M(35Cl)H+), 375 (M(37Cl)H+); Accurate mass: Found MH+, 373.1675: C21H26N2O2
35Cl requires M, 
373.1683. 
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N-(2′′-[4′′′-Methylpiperazin-1′′′-yl]eth-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 131 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 2-(4′-methylpiperazin-1′-yl)ethylamine (29 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (29 mg, 
39%) was isolated as a pale yellow oil. 
νmax (ATR) 3308 (br), 2934 (w), 2800 (w), 1651 (s), 1544 (w), 1491 (s), 1456 (w), 1288 (w), 1176 
(w), 1096 (w), 1015 (m) cm−1; δH (700 MHz, CDCl3) 7.36 – 7.32 (2H, m, 3
Ph-H2), 7.31 – 7.26 (3H, 
m, 3′-H2, 4
Ph-H), 7.25 – 7.23 (2H, m, 2Ph-H2), 7.22 – 7.20 (2H, m, 2′-H2), 6.28 – 6.18 (1H, m, NH), 
4.90 (1H, s, 2-H), 3.40 – 3.31 (2H, m, 1′′-H2), 2.55 – 2.11 (8H, m, 2′′′-(H2)2, 3′′′-(H2)2), 2.44 (2H, t, 
J = 6.0 Hz, 2′′-H2), 2.27 (3H, s, NCH3); δC (176 MHz, CDCl3) 171.5 (C=O), 139.4 (C-1
Ph), 138.3 
(C-1′), 133.2 (C-4′), 130.5 (C-2′), 129.0(3) (ArC), 128.9(90) (ArC), 128.9(85) (ArC), 127.6 (C-4Ph), 
58.8 (C-2), 56.0 (C-2′′), 55.1 (C-3′′′), 52.6 (C-2′′′), 46.1 (NCH3), 36.3 (C-1′′); m/z (LCMS, ESI
+) 372 
(M(35Cl)H+), 374 (M(37Cl)H+); Accurate mass: Found MH+, 372.1836: C21H27N3O
35Cl requires M, 
372.1843. 
N-([4′-Chlorophenyl]phenylmethyl)-2-cyclopentylacetamide 132 
 
Procedure: Cyclopentylacetic acid (97%, 0.13 mL, 1 mmol) and 4-chlorobenzhydryl amine HCl 
salt 89 (98%, 285 mg, 1.1 mmol) were reacted according to general procedure A. Following 
SiO2 column chromatography (0% → 50% EtOAc in hexanes), the title compound (260 mg, 79%) 
was isolated as clear needles.  
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Rf 0.36 (10% EtOAc in hexanes); M.p 146 – 148 °C; νmax (ATR) 3274 (br), 3030 (w), 2949 (m), 
2867 (w), 1637 (s), 1533 (m), 1490 (m), 1366 (m), 1217 (m), 1091 (m) cm−1; δH (700 MHz, CDCl3) 
7.33 (2H, t, J = 7.5 Hz, 3Ph-H2), 7.31 – 7.27 (3H, m, 3′-H2, 4
Ph-H), 7.19 (2H, d, J = 7.5 Hz, 2Ph-H2), 
7.16 (2H, d, J = 8.0 Hz, 2′-H2), 6.23 (1H, d, J = 8.0 Hz, NHCH), 5.97 (1H, d, J = 8.0 Hz, NHCH), 2.29 
– 2.23 (3H, m, 2-H2, 1
Cyp-H), 1.86 –  1.80 (2H, m, 2Cyp-H2H′2), 1.66 – 1.59 (2H, m, 3
Cyp-H2H′2), 1.59 
– 1.52 (2H, m, 3Cyp-H2H′2), 1.19 – 1.12 (2H, m, 2
Cyp-H2H′2); δC (176 MHz, CDCl3) 172.0 (C-1), 141.3 
(C-1Ph), 140.3 (C-1′), 133.4 (C-4′), 129.0 (ArC), 128.9 (ArC), 128.8 (ArC), 127.9 (C-4Ph), 127.6 
(C-2Ph), 56.5 (NHCH), 43.2 (C-2), 37.3 (C-1Cyp), 32.7(7) (C-2Cyp), 32.7(6) (C-2Cyp), 25.2 (C-3Cyp); 
m/z (LCMS, ESI+) 328 (M(35Cl)H+), 330 (M(37Cl)H+); Accurate mass: Found MH+, 328.1484: 
C20H23NO
35Cl requires M, 328.1468. 
N-([Tetrahydrofuran-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 133 
A mixture of (2′′R,2R), (2′′R,2S), (2′′S,2R) and (2′′S,2S) diastereomers 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (tetrahydrofuran-2-yl)methylamine (20 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (44 mg, 
66%) was isolated as an off-white solid. 
M.p. 62 – 64 °C; νmax (ATR) 3312 (br), 3086 (w), 3026 (w), 3026 (w), 2964 (w), 2875 (w), 1650 
(s), 1544 (m), 1490 (s), 1448 (w), 1360 (w), 1222 (w), 1086 (m), 1015 (m) cm−1; δH (400 MHz, 
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CDCl3, mixture of diastereomers) 7.36 – 7.19 (9H, m, ArH), 6.05 – 5.98 (1H, m, NH), 4.87 (0.5H, 
s, 2-H), 4.86 (0.5H, s, 2-H), 3.94 (1H, qd, J = 7.0, 3.5 Hz, 2′′-H), 3.74 – 3.64 (2H, m, 5′′-H2), 3.60 
(0.5H, ddd, J = 5.5, 3.5, 2.5 Hz, NHCHH′ isomer A), 3.56 (0.5H, ddd, J = 5.5, 3.5, 2.5 Hz, NHCHH′ 
isomer B), 3.24 (0.5H, ddd, J = 7.0, 5.5, 4.5 Hz, NHCHH′ isomer A), 3.21 (0.5H, ddd, J = 7.0, 5.5, 
4.5 Hz, NHCHH′ isomer B), 1.98 – 1.85 (1H, m, 3′′-HH′), 1.89 – 1.72 (2H, m, 4′′-H2), 1.53 – 1.43 
(1H, m, 3′′-HH′); δC (101 MHz, CDCl3, mixture of diastereomers) 171.6(8) (C=O), 171.6(6) (C=O), 
139.1(2) (ArC), 139.0(8) (ArC), 138.1 (ArC), 138.0 (ArC), 133.2 (C-4′), 130.4 (ArC), 130.3 (ArC), 
129.0 (ArC), 128.9(3) (ArC), 128.8(8) (ArC), 128.8(5) (ArC), 128.8 (ArC), 127.6 (ArC), 77.7 (C-2′′), 
77.6 (C-2′′), 68.3 (C-5′′), 58.6 (C-2), 58.5 (C-2), 43.4(2) (NHCHH′ isomer B), 43.4(1) (NHCHH′ 
isomer A), 28.6(2) (C-3′′), 28.6(0) (C-3′′), 26.0 (C-4′′); m/z (LCMS, ESI+) 330 (M(35Cl)H+), 332 
(M(37Cl)H+); Accurate mass: Found MH+, 330.1261: C19H21NO2
35Cl requires M, 330.1261. 
N-(3′′-[2′′′-Pyrrolidinon-1′′′-yl]prop-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 134 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 3-(2′-pyrrolidinon-1′-yl)propylamine (28 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (38 mg, 
51%) was isolated as a clear colourless oil. 
νmax (ATR) 3282 (br), 3052 (w), 2963 (w), 2934 (w), 2880 (w), 1655 (br, s), 1545 (w), 1490 (m), 
1428 (w), 1291 (w), 1222 (w), 1089 (w) cm−1; δH (400 MHz, CDCl3) 7.33 – 7.21 (9H, m, ArH), 7.08 
– 7.00 (1H, m, NH), 4.82 (1H, s, 2-H), 3.33 (2H, apparent ddd, J = 8.5, 7.0, 1.5 Hz, 5′′′-H2), 3.23 – 
3.16 (4H, m, 1′′-H2, 3′′-H2), 2.34 (2H, t, J = 8.0 Hz, 3′′′-H2), 1.98 (2H, apparent pd, J = 7.5, 2.0 Hz, 
4′′′-H2), 1.64 (2H, p, J = 6.0 Hz, 2′′-H2); δC (101 MHz, CDCl3) 176.1 (C-2′′′), 171.6 (C=O), 139.4 
(C-1Ph), 138.3 (C-1′), 133.0 (C-4′), 130.3 (ArC), 128.8 (ArC), 128.7 (ArC), 127.3 (ArC), 58.3 (C-2), 
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47.5 (C-5′′′), 39.6 (AlC), 36.1 (AlC), 31.0 (C-3′′′), 26.5 (C-2′′), 18.0 (C-4′′′); m/z (LCMS, ESI+) 371 
(M(35Cl)H+), 373 (M(37Cl)H+); Accurate mass: Found MH+, 371.1516: C21H24N2O2
35Cl requires M, 
371.1526. 
N-(1′′,2′′-Diphenylethyl)-2-(pyrrolidin-2′-yl)acetamide 135 
A mixture of (2′S,1′′R) and (2′S,1′′S) diastereomers 
 
Procedure: S-N-Boc-homoproline (S)-62 (46 mg, 0.20 mmol) and 1,2-diphenylethylamine (97%, 
41 mg, 0.20 mmol) were reacted according to general procedure A. Following TFA-mediated 
deprotection and reversed-phase column chromatography (5% → 95% MeCN in H2O with 0.5% 
formic acid), the title compound (32 mg, 52%) was isolated as a yellow oil. 
νmax (ATR) 3270 (br), 3094 (w), 3022 (w), 2918 (w), 1670 (s), 1544 (m), 1496 (w), 1199 (s), 1177 
(s), 1129 (s), 1028 (w) cm−1; δH (700 MHz, CDCl3, mixture of diastereomers) 8.20 (0.5H, d, 
J = 8.0 Hz, 1-NH isomer A), 7.88 (0.5H, d, J = 8.0 Hz, 1-NH isomer B), 7.29 – 7.15 (8H, m, ArH), 
7.13 (1H, d, J = 7.5 Hz, 2Ph-H2 isomer A), 7.09 (1H, d, J = 7.0 Hz, 2
Ph-H2 isomer B), 5.19 (0.5H, q, 
J = 8.0 Hz, 1′′-H isomer A), 5.10 (0.5H, td, J = 8.0, 6.5 Hz, 1′′-H isomer B), 3.61 – 3.53 (1H, m, 
2′-H), 3.10 – 3.03 (1H, m, 5′-HH′), 3.05 (1H, d, J = 8.0 Hz, 2′′-H2 isomer A), 3.02 (0.5H, d, 
J = 6.5 Hz, 2′′-HH′ isomer B), 3.02 (0.5H, d, J = 8.0 Hz, 2′′-HH′ isomer B), 3.00 – 2.95 (1H, m, 
5′-HH′), 2.77 (0.5H, dd, J = 15.5, 7.5 Hz, 2-HH′ isomer B), 2.68 (0.5H, dd, J = 15.0, 7.0 Hz, 2-HH′ 
isomer A), 2.51 (0.5H, dd, J = 15.0, 5.0 Hz, 2-HH′ isomer A), 2.49 (0.5H, dd, J = 15.5, 5.0 Hz, 
2-HH′ isomer B), 1.94 – 1.83 (2H, m, 4′-HH′ isomer A, 4′-HH′ isomer B, 3′-HH′ isomer A, 3′-HH′ 
isomer B), 1.81 – 1.72 (1H, m, 4′-HH′ isomer A, 4′-HH′ isomer B), 1.49 (0.5H, dq, J = 12.5, 9.0 Hz, 
3′-HH′ isomer B), 1.40 (0.5H, dq, J = 13.5, 9.5, 8.5 Hz, 3′-HH′ isomer A); δC (176 MHz, CDCl3, 
mixture of diastereomers) 169.6(1) (C=O isomer A), 169.5(8) (C=O isomer B), 141.9 (ArC), 141.7 
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(ArC), 138.1 (ArC), 137.8 (ArC), 129.5 (C-2Ph isomer A), 129.4 (C-2Ph isomer B), 128.7(0) (ArC), 
128.6(7) (ArC), 128.5 (ArC), 128.4 (ArC), 127.6 (ArC), 127.5 (ArC), 126.8 (ArC), 126.7 (ArC), 
126.5(9) (ArC), 126.5(8) (ArC), 57.5 (C-2′ isomer A), 57.0 (C-2′ isomer B), 55.4 (C-1′′ isomer B), 
55.0 (C-1′′ isomer A), 45.0(0) (C-5′), 44.9(6) (C-5′), 43.0 (C-2′′ isomer B), 42.7 (C-2′′ isomer A), 
36.9 (C-2 isomer B), 36.5 (C-2 isomer A), 29.9 (C-3′ isomer B), 29.4 (C-3′ isomer A), 23.7(3) 
(C-4′), 23.7(0) (C-4′); m/z (LCMS, ESI+) 309 (MH+); Accurate mass: Found MH+, 309.1961: 
C20H25N2O requires M, 309.1967. 
N-([2′′′-Methylphenyl]phenylmethyl)-2-(pyrrolidin-2′-yl)acetamide 136 
A mixture of (2′S,1′′R) and (2′S,1′′S) diastereomers 
 
Procedure: S-N-Boc-homoproline (S)-62 (46 mg, 0.20 mmol) and (2-methylphenyl) 
phenylmethylamine•HCl (95%, 49 mg, 0.20 mmol) were reacted according to general 
procedure A. Following TFA-mediated deprotection and reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (45 mg, 
73%) was isolated as a white solid. 
M.p. 178 – 181 °C; νmax (ATR) 3254 (w), 3060 (w), 3022 (w), 1674 (s), 1632 (s), 1558 (s), 1200 
(s), 1188 (m), 1142 (w) cm−1; δH (700 MHz, CDCl3, mixture of diastereomers) 7.31 – 7.27 (2H, m, 
ArH) 7.26 – 7.22 (2H, m, ArH), 7.21 – 7.10 (5H, m, ArH), 6.30 (0.5H, d, J = 7.5 Hz, 1′′-H), 6.26 
(0.5H, d, J = 7.5 Hz, 1′′-H), 3.80 – 3.74 (1H, m, 2′-H), 3.17 – 3.07 (2H, m, 5′-H2), 2.91 (0.5H, dd, 
J = 16.5, 7.5 Hz, 2-HH′ isomer A), 2.88 (0.5H, dd, J = 16.5, 7.5 Hz, 2-HH′ isomer B), 2.76 (0.5H, 
dd, J = 16.5, 5.0 Hz, 2-HH′ isomer B), 2.73 (0.5H, dd, J = 16.5, 4.5 Hz, 2-HH′ isomer A), 2.27 
(1.5H, s, 2′′′-CH3), 2.22 (1.5H, s, 2′′′-CH3), 2.10 – 2.04 (1H, m, 3′-HH′), 2.00 – 1.91 (1H, m, 
4′-HH′), 1.91 – 1.82 (1H, m, 4′-HH′), 1.71 – 1.61 (1H, m, 3′-HH′); δC (176 MHz, CDCl3, mixture of 
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diastereomers) 169.6(0) (C-1), 169.5(8) (C-1), 140.5 (C-1Ph), 140.3 (C-1Ph), 139.2 (ArC), 139.0 
(ArC), 136.1 (ArC), 136.0 (ArC), 130.9(2) (C-3′′′), 130.9(0) (C-3′′′), 128.9(3) (ArC), 128.8(6) (ArC), 
127.8(4) (ArC), 127.7(9) (ArC), 127.7(5) (ArC), 127.7 (ArC), 127.5 (ArC), 127.0 (ArC), 126.6 (ArC), 
126.5(3) (ArC), 126.4(9) (ArC), 56.9(0) (C-2′), 56.8(5) (C-2′), 54.8 (C-1′′), 54.5 (C-1′′), 45.0(0) 
(C-5′), 44.9(8) (C-5′), 36.4 (C-2 isomer A), 36.2 (C-2 isomer B), 30.0 (C-3′), 29.9 (C-3′), 23.9(2) 
(C-4′), 23.9(1) (C-4′), 19.6 (2′′′-CH3), 19.5 (2′′′-CH3); m/z (LCMS, ESI
+) 309 (MH+); Accurate mass: 
Found MH+, 309.1978: C20H25N2O requires M, 309.1967. 
N-([3′′′-{Methanesulfonyl}phenyl]phenylmethyl)-2-(pyrrolidin-2′-yl)acetamide 137 
A mixture of (2′S,1′′R) and (2′S,1′′S) diastereomers 
 
Procedure: S-N-Boc-homoproline (S)-62 (46 mg, 0.20 mmol) and (3-[methanesulfonyl] 
phenyl)phenyl methylamine (95%, 55 mg, 0.20 mmol) were reacted according to general 
procedure A. Following TFA-mediated deprotection and reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (40 mg, 
53%) was isolated as a yellow oil. 
νmax (ATR) 3300 (br), 3038 (w), 2964 (w), 2866 (w), 1658 (m), 1532 (m), 1418 (w), 1302 (s), 1146 
(s), 1092 (w) cm−1; δH (700 MHz, CDCl3, mixture of diastereomers) 9.14 (0.5H, d, J = 8.0 Hz, 
1-NH isomer B), 9.10 (0.5H, d, J = 8.0 Hz, 1-NH isomer A), 7.92 (0.5H, t, J = 2.0 Hz, 2′′′-H), 7.87 
(0.5H, t, J = 2.0 Hz, 2′′′-H), 7.82 – 7.78 (1H, m, 4′′′-H), 7.54 – 7.51 (1H, m, 6′′′-H), 7.51 – 7.47 (1H, 
m, 5′′′-H), 7.34 – 7.29 (2H, m, 3Ph-H2), 7.28 – 7.25 (1H, m, 4
Ph-H), 7.22 – 7.18 (2H, m, 2Ph-H2), 
6.30 (1H, d, J = 8.0 Hz, 1′′-H), 3.45 (0.5H, ddt, J = 8.0, 7.5, 3.5 Hz, 2′-H isomer A), 3.40 (0.5H, 
ddt, J = 8.5, 7.5, 3.5 Hz, 2′-H isomer B), 3.02 (1.5H, s, SO2CH3), 3.01 (1.5H, s, SO2CH3), 2.92 
(0.5H, ddd, J = 11.0, 7.5, 6.0 Hz, 5′-HH′ isomer B), 2.89 (0.5H, ddd, J = 11.0, 8.0, 6.0 Hz, 5′-HH′ 
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isomer B), 2.87 (0.5H, ddd, J = 11.0, 8.0, 6.5 Hz, 5′-HH′ isomer A), 2.79 (0.5H, ddd, J = 11.0, 7.5, 
6.5 Hz, 5′-HH′ isomer A), 2.47 (0.5H, dd, J = 15.5, 3.5 Hz, 2-HH′ isomer A), 2.46 (0.5H, dd, 
J = 15.5, 3.5 Hz, 2-HH′ isomer B), 2.32 (0.5H, dd, J = 15.5, 8.5 Hz, 2-HH′ isomer B), 2.30 (0.5H, 
dd, J = 15.5, 8.0 Hz, 2-HH′ isomer A), 1.92 – 1.86 (1H, m, 3′-HH′ isomer A, 3′-HH′ isomer B), 1.80 
– 1.73 (0.5H, m, 4′-HH′ isomer B), 1.72 – 1.67 (0.5H, m, 4′-HH′ isomer B), 1.67 – 1.60 (1H, m, 
4′-H2 isomer A), 1.42 – 1.34 (0.5H, m, 3′-HH′ isomer B), 1.38 – 1.30 (0.5H, m, 3′-HH′ isomer A); 
δC (176 MHz, CDCl3, mixture of diastereomers) 171.7 (C-1 isomer A), 171.6 (C-1 isomer B), 
144.5 (C-1′′′), 144.4 (C-1′′′), 141.2 (C-1Ph isomer A), 141.1 (C-1Ph isomer B), 141.0 (C-3′′′), 140.9 
(C-3′′′), 132.9(1) (C-6′′′), 132.8(6) (C-6′′′), 129.7 (C-5′′′), 129.6 (C-5′′′), 129.1 (C-3Ph), 129.0 (C-3Ph), 
128.0 (C-4Ph), 127.9 (C-4Ph), 127.7 (C-2Ph), 127.5 (C-2Ph), 126.2 (C-4′′′), 126.1 (C-4′′′), 125.7 
(C-2′′′), 125.5 (C-2′′′), 56.4 (C-1′′), 55.7(2) (C-2′), 55.6(9) (C-2′), 46.2 (C-5′ isomer B), 46.1 (C-5′ 
isomer A), 44.5(7) (SO2CH3), 44.5(6) (SO2CH3), 40.8 (C-2 isomer A), 40.7 (C-2 isomer B), 31.4 
(C-3′ isomer B), 31.2 (C-3′ isomer A), 25.3(9) (C-4′ isomer A), 25.3(6) (C-4′ isomer B); m/z (LCMS, 
ESI+) 373 (MH+); Accurate mass: Found MH+, 373.1592: C20H25N2O3S requires M, 373.1586. 
N-([Pyrrolidin-2′′-yl]methyl)-2-phenylpropionamide 138 
A mixture of (2′′R,2R), (2′′R,2S), (2′′S,2R) and (2′′S,2S) diastereomers 
 
Procedure: 2-Phenylpropionic acid (97%, 31 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-
pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. Following 
 | 159 | 
Chapter 8: Chemical Experimental Details 
TFA-mediated deprotection and reversed-phase column chromatography (5% → 95% MeCN in 
H2O with 0.5% formic acid), the title compound (13 mg, 28%) was isolated as a yellow oil. 
νmax (ATR) 3282 (br), 3058 (w), 3020 (w), 2964 (w), 2876 (w), 1647 (s), 1542 (br, m), 1456 (w), 
1408 (w), 1360 (w), 1234 (w), 1184 (w), 1118 (w), 1070 (w) cm−1; δH (600 MHz, CDCl3, mixture 
of diastereomers) 7.35 – 7.28 (4H, m, 2Ph-H2, 3
Ph-H2), 7.26 – 7.22 (1H, m, 4
Ph-H), 6.01 – 5.87 
(1H, m, NH), 3.55 (0.5H, q, J = 7.0 Hz, 2-H isomer A), 3.54 (0.5H, q, J = 7.0 Hz, 2-H isomer B), 
3.31 (0.5H, ddd, J = 13.5, 6.5, 4.5 Hz, NHCHH′ isomer A), 3.30 (0.5H, ddd, J = 13.0, 6.5, 4.5 Hz, 
NHCHH′ isomer B), 3.20 (0.5H, qd, J = 7.5, 4.5 Hz, 2′′-H isomer B), 3.15 (0.5H, tdd, J = 7.5, 7.0, 
4.5 Hz, 2′′-H isomer A), 3.05 – 2.97 (1H, m, NHCHH′ isomer A, NHCHH′ isomer B), 2.85 – 2.76 
(1.5H, m, 5′′-H2 isomer A, 5′′-HH′ isomer B), 2.74 (0.5H, dt, J = 10.5, 7.0 Hz, 5′′-HH′ isomer B), 
1.81 – 1.72 (1H, m, 3′′-HH′ isomer A, 3′′-HH′ isomer B), 1.72 – 1.63 (0.5H, m, 4′′-HH′ isomer A), 
1.64 – 1.57 (1.5H, m, 4′′-HH′ isomer A, 4′′-H2 isomer B), 1.51 (3H, d, J = 7.0 Hz, 3-H3), 1.28 (0.5H, 
ddt, J = 13.5, 8.5, 7.0 Hz, 3′′-HH′ isomer A), 1.27 – 1.18 (0.5H, m, 3′′-HH′ isomer B); 
δC (151 MHz, CDCl3, mixture of diastereomers) 174.5 (C=O isomer A), 174.4 (C=O isomer B), 
141.7(7) (C-1Ph isomer B), 141.7(5) (C-1Ph isomer A), 128.9 (C-3Ph), 127.7(0) (C-2Ph), 127.6(9) 
(C-2Ph), 127.3 (C-4Ph), 57.6(7) (C-2′′ isomer A), 57.6(5) (C-2′′ isomer B), 47.3(3) (C-2), 47.3(1) 
(C-2), 46.7 (C-5′′ isomer B), 46.6 (C-5′′ isomer A), 44.0 (NHCHH′ isomer A), 43.9 (NHCHH′ isomer 
B), 29.1 (C-3′′ isomer A), 29.0 (C-3′′ isomer B), 26.0 (C-4′′), 18.7 (C-3), 18.6 (C-3); m/z (LCMS, 
ESI+) 233 (MH+); Accurate mass: Found MH+, 233.1654: C14H21N2O requires M, 233.1654. 
N-([Pyrrolidin-2′-yl]methyl)-2-phenylacetamide293 139 
 
Procedure: 2-Phenylacetic acid (27 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-pyrrolidine 91 
(40 mg, 0.20 mmol) were reacted according to general procedure A. Following TFA-mediated 
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deprotection and reversed-phase column chromatography (5% → 95% MeCN in H2O with 0.5% 
formic acid), the title compound (7 mg, 16%) was isolated as a clear colourless oil. 
νmax (ATR) 3014 (br), 2892 (w), 1674 (s), 1558 (w), 1444 (w), 1364 (s), 1201 (s), 1128 (w) cm
−1; 
δH (600 MHz, CDCl3) 7.82 – 7.77 (1H, m, NH), 7.31 (2H, t, J = 7.5 Hz, 3
Ph-H2), 7.26 – 7.25 (1H, m, 
4Ph-H), 7.23 (2H, d, J = 7.5 Hz, 2Ph-H2), 3.77 – 3.71 (1H, m, 2′-H), 3.56 (1H, apparent dd, J = 15.0, 
7.5 Hz, NHCHH′), 3.53 (2H, s, 2-H2), 3.37 (1H, dt, J = 15.0, 3.5 Hz, NHCHH′), 3.15 (1H, ddd, 
J = 11.5, 8.0, 6.0 Hz, 5′-HH′), 3.07 (1H, dt, J = 11.5, 7.5 Hz, 5′-HH′), 2.09 – 2.00 (1H, m, 3′-HH′), 
1.99 – 1.87 (2H, m, 4′-H2), 1.62 (1H, dq, J = 13.0, 8.5 Hz, 3′-HH′); δC (151 MHz, CDCl3) 173.8 
(C=O), 134.8 (C-1Ph), 129.5 (C-2Ph), 129.0 (C-3Ph), 127.5 (C-4Ph), 60.3 (C-2′), 45.2 (C-5′), 43.2 (C-2), 
41.0 (NHCHH′), 27.8 (C-3′), 24.1 (C-4′); m/z (LCMS, ESI+) 219 (MH+); Accurate mass: Found MH+, 
219.1497: C13H19N2O requires M, 219.1497. 
N-(1′′-Phenylhexyl)-2-(pyrrolidin-2′-yl)acetamide 140 
A mixture of (2′S,1′′R) and (2′S,1′′S) diastereomers 
 
Procedure: S-N-Boc-homoproline (S)-62 (46 mg, 0.20 mmol) and 1-phenylhexylamine (95%, 
37 mg, 0.20 mmol) were reacted according to general procedure A. Following TFA-mediated 
deprotection and reversed-phase column chromatography (5% → 95% MeCN in H2O with 0.5% 
formic acid), the title compound (18 mg, 31%) was isolated as a yellow oil. 
νmax (ATR) 3290 (br), 3076 (w), 2964 (w), 2930 (w), 2858 (w), 1650 (s), 1558 (m), 1456 (w), 1418 
(w), 1199 (s), 1175 (s), 1130 (s) cm−1; δH (700 MHz, CDCl3, mixture of diastereomers) 7.74 (0.5H, 
d, J = 7.5 Hz, 1-NH isomer A), 7.68 (0.5H, d, J = 7.5 Hz, 1-NH isomer B), 7.31 – 7.27 (2H, m, 
3Ph-H2), 7.26 – 7.23 (2H, m, 2
Ph-H2), 7.23 – 7.19 (1H, m, 4
Ph-H), 4.78 (0.5H, q, J = 7.5 Hz, 1′′-H 
 | 161 | 
Chapter 8: Chemical Experimental Details 
isomer B), 4.76 (0.5H, q, J = 7.5 Hz, 1′′-H isomer A), 3.79 – 3.72 (1H, m, 2′-H), 3.21 – 3.15 (1H, 
m, 5′-HH′), 3.13 – 3.07 (1H, m, 5′-HH′), 2.86 (0.5H, dd, J = 16.0, 7.5 Hz, 2-HH′ isomer B), 2.81 
(0.5H, dd, J = 15.5, 7.0 Hz, 2-HH′ isomer A), 2.65 (0.5H, dd, J = 16.0, 5.0 Hz, 2-HH′ isomer B), 
2.62 (0.5H, dd, J = 15.5, 5.0 Hz, 2-HH′ isomer A), 2.11 – 2.04 (1H, m, 3′-HH′ isomer A, 3′-HH′ 
isomer B), 2.02 – 1.94 (1H, m, 4′-HH′), 1.92 – 1.83 (1H, m, 4′-HH′), 1.80 – 1.60 (3H, m, 2′′-H2, 
3′-HH′ isomer A, 3′-HH′ isomer B), 1.32 – 1.13 (6H, m, 3′′-H2, 4′′-H2, 5′′-H2), 0.88 – 0.80 (3H, m, 
6′′-H3); δC (176 MHz, CDCl3, mixture of diastereomers) 169.8 (C=O isomer B), 169.7 (C=O isomer 
A), 142.7 (C-1Ph isomer B), 142.5 (C-1Ph isomer A), 128.7 (C-3Ph), 127.4 (C-4Ph), 127.3 (C-4Ph), 
126.7 (C-2Ph isomer A), 126.5 (C-2Ph isomer B), 57.0(9) (C-2′ isomer A), 57.0(5) (C-2′ isomer B), 
54.4(4) (C-1′′ isomer A), 54.3(6) (C-1′′ isomer B), 45.0 (C-5′ isomer B), 44.9 (C-5′ isomer A), 36.9 
(C-2 isomer B), 36.6(4) (C-2′′ isomer B), 36.6(2) (C-2 isomer A), 36.3 (C-2′′ isomer A), 31.6(4) 
(C-4′′), 31.6(1) (C-4′′), 30.1 (C-3′ isomer B), 29.8 (C-3′ isomer A), 26.0(9) (C-3′′ isomer B), 26.0(6) 
(C-3′′ isomer A), 24.0 (C-4′ isomer A), 23.9 (C-4′ isomer B), 22.6(1) (C-5′′), 22.5(9) (C-5′′), 14.1(3) 
(C-6′′), 14.1(2) (C-6′′); m/z (LCMS, ESI+) 289 (MH+); Accurate mass: Found MH+, 289.2284: 
C18H29N2O requires M, 289.2280. 
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N-([Pyrrolidin-2′′-yl]methyl)-2-(phenyl)-2-cyclopentylacetamide 141 
A mixture of (2′′R,2R), (2′′R,2S), (2′′S,2R) and (2′′S,2S) diastereomers 
 
Procedure: 2-Phenyl-2-cyclopentylacetic acid (41 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-
pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. Following 
TFA-mediated deprotection and reversed-phase column chromatography (5% → 95% MeCN in 
H2O with 0.5% formic acid), the title compound (6 mg, 11%) was isolated as a light yellow oil. 
νmax (ATR) 3296 (br), 2950 (m), 2868 (w), 1645 (s), 1542 (m), 1446 (w), 1374 (w), 1222 (w) cm
−1; 
δH  (600 MHz, CDCl3, mixture of diastereomers) 7.38 – 7.31 (2H, m, 2
Ph-H2), 7.28 (2H, td, J = 7.5, 
2.5 Hz, 3Ph-H2), 7.24 – 7.20 (1H, m, 4
Ph-H), 6.21 – 6.11 (1H, m, NH), 3.37 (0.5H, ddd, J = 13.5, 
6.0, 4.5 Hz, NHCHH′ isomer A), 3.29 (0.5H, ddd, J = 13.0, 6.0, 4.0 Hz, NHCHH′ isomer B), 3.22 
(0.5H, qd, J = 7.5, 4.5 Hz, 2′′-H isomer A), 3.17 (0.5H, ddt, J = 7.5, 7.0, 4.0 Hz, 2′′-H isomer B), 
3.06 (0.5H, ddd, J = 13.0, 7.5, 5.5 Hz, NHCHH′ isomer B), 2.99 (1H, d, J = 11.0 Hz, 2-H), 2.96 
(0.5H, ddd, J = 13.5, 7.5, 5.0 Hz, NHCHH′ isomer A), 2.88 – 2.81 (1.5H, m, 5′′-HH′ isomer A, 
5′′-H2 isomer B), 2.78 (0.5H, dt, J = 10.5, 6.5 Hz, 5′′-HH′ isomer A), 2.67 – 2.56 (1H, m, 1
Cyp-H), 
1.98 – 1.91 (1H, m, 2Cyp-(HH′)(HH′)), 1.82 – 1.73 (1H, m, 3′′-HH′ isomer A, 3′′-HH′ isomer B), 1.73 
– 1.68 (0.5H, m, 4′′-HH′ isomer B), 1.68 – 1.51 (4.5H, m, 3Cyp-(HH′)H2, 3
Cyp-(HH′)H2, 4′′-H2 isomer 
A, 4′′-HH′ isomer B), 1.51 – 1.45 (1H, m, 3Cyp-(HH′)H2), 1.45 – 1.38 (1H, m, 2
Cyp-(HH′)(HH′)), 1.31 
(0.5H, ddt, J = 12.5, 8.5, 7.0 Hz, 3′′-HH′ isomer B), 1.28 – 1.19 (1.5H, m, 2Cyp-(HH′)(HH′), 3′′-HH′ 
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isomer A), 0.98 (1H, dq, J = 12.5, 8.5 Hz, 2Cyp-(HH′)(HH′)); δC (151 MHz, CDCl3, mixture of 
diastereomers) 173.8 (C=O isomer B), 173.7 (C=O isomer A), 140.5(3) (C-1Ph), 140.5(2) (C-1Ph), 
128.6 (C-3Ph), 128.1 (C-2Ph), 127.1 (C-4Ph), 60.2 (C-2), 57.9 (C-2′′ isomer A), 57.7 (C-2′′ isomer B), 
46.6(7) (C-5′′), 46.6(5) (C-5′′), 43.7 (NHCHH′), 43.4 (C-1Cyp), 43.3 (C-1Cyp), 31.8(6) (C-2Cyp), 31.8(5) 
(C-2Cyp), 31.1 (C-2Cyp), 29.0(2) (C-3′′ isomer A), 28.9(9) (C-3′′ isomer B), 26.0(2) (C-4′′ isomer A), 
25.9(9) (C-4′′ isomer B), 25.3(4) (C-3Cyp), 25.3(3) (C-3Cyp), 25.0(4) (C-3Cyp), 25.0(3) (C-3Cyp); 
m/z (LCMS, ESI+) 287 (MH+); Accurate mass: Found MH+, 287.2120: C18H27N2O requires M, 
287.2123. 
N-([Pyrrolidin-2′-yl]methyl)-1-phenyl-cyclohexane-1-carboxamide 142 
 
Procedure: 1-Phenylcyclohexane-1-carboxilic acid (41 mg, 0.20 mmol) and 2-(aminomethyl)-1-
Boc-pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. 
Following TFA-mediated deprotection and reversed-phase column chromatography 
(5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (33 mg, 58%) was isolated 
as an orange oil. 
νmax (ATR) 3340 (br), 2942 (m), 2856 (w), 2782 (w), 1671 (s), 1594 (s), 1524 (s), 1446 (m), 1199 
(s), 1131 (s) cm−1; δH (600 MHz, CDCl3) 7.41 (2H, d, J = 7.5 Hz, 2
Ph-H2), 7.34 – 7.28 (1H, m, NH), 
7.30 (2H, t, J = 7.5 Hz, 3Ph-H2), 7.20 (1H, t, J = 7.5 Hz, 4
Ph-H), 3.69 – 3.61 (2H, m, NHCHH′, 2′-H), 
3.29 – 3.23 (1H, m, NHCHH′), 2.99 (1H, ddd, J = 11.5, 7.5, 4.5 Hz, 5′-HH′), 2.60 (1H, ddd, 
J = 11.5, 9.0, 7.0 Hz, 5′-HH′), 2.40 – 2.29 (2H, m, 2-(HH′)(HH′), 2-(HH′)(HH′)), 2.00 – 1.93 (1H, m, 
2-(HH′)(HH′)), 1.93 – 1.82 (2H, m, 3′-HH′, 2-(HH′)(HH′)), 1.79 – 1.68 (1H, m, 4′-HH′), 1.68 – 1.58 
(2H, m, 4′-HH′, 3-(HH′)H2), 1.58 – 1.47 (4H, m, 3-(HH′)H2, 4-HH′, 3-(HH′)H2), 1.43 (1H, ddd, 
J = 16.5, 13.5, 8.0 Hz, 3′-HH′), 1.38 – 1.30 (1H, m, 4-HH′); δC (151 MHz, CDCl3) 177.5 (C=O), 
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144.1 (C-1Ph) 128.7 (C-3Ph), 126.8 (C-4Ph), 126.3 (C-2Ph), 59.9 (C-2′), 50.6 (C-1), 45.2 (C-5′), 39.9 
(NHCHH′), 34.6 (C-2), 33.8 (C-2), 27.1 (C-3′), 25.8 (C-4), 24.6 (C-4′), 23.3 (C-3); m/z (LCMS, ESI+) 
287 (MH+); Accurate mass: Found MH+, 287.2133: C18H27N2O requires M, 287.2123. 
N-([Tetrahydrofuran-2′′′-yl]phenylmethyl)-2-(pyrrolidin-2′-yl)acetamide 143 
A mixture of (2′S,1′′R,2′′′R), (2′S,1′′R,2′′′S), (2′S,1′′S,2′′′R) and (2′S,1′′S,2′′′S) diastereomers 
 
Procedure: S-N-Boc-homoproline (S)-62 (46 mg, 0.20 mmol) and (tetrahydrofuran-2-yl) 
phenylmethylamine (95%, 37 mg, 0.20 mmol) were reacted according to general procedure A. 
Following TFA-mediated deprotection and reversed-phase column chromatography 
(5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (17 mg, 29%) was isolated 
as a yellow oil. 
νmax (ATR) 3282 (br), 2968 (w), 2876 (w), 1641 (s), 1536 (s), 1070 (m) cm
−1; δH (600 MHz, CDCl3, 
mixture of diastereomers) 8.44 (0.3H, d, J = 8.5 Hz, 1-NH), 8.42 (0.3H, d, J = 8.5 Hz, 1-NH), 8.22 
(0.2H, d, J = 8.5 Hz, 1-NH), 8.18 (0.2H, d, J = 8.5 Hz, 1-NH), 7.37 – 7.27 (4H, m, ArH), 7.25 – 7.20 
(1H, m, ArH), 5.05 (0.2H, dd, J = 8.5, 4.0 Hz, 1′′-H), 5.04 (0.2H, dd, J = 8.5, 4.0 Hz, 1′′-H), 5.00 
(0.3H, dd, J = 8.5, 5.0 Hz, 1′′-H), 4.99 (0.3H, dd, J = 8.5, 5.0 Hz, 1′′-H), 4.22 (0.3H, td, J = 7.0, 
5.0 Hz, 2′′′-H), 4.20 (0.3H, td, J = 7.0, 5.0 Hz, 2′′′-H), 4.16 (0.2H, td, J = 6.5, 4.0 Hz, 2′′′-H), 4.14 
(0.2H, td, J = 6.5, 2.0 Hz, 2′′′-H), 3.91 (0.2H, td, J = 7.0, 3.0 Hz, 5′′′-HH′), 3.90 (0.2H, td, J = 7.0, 
3.0 Hz, 5′′′-HH′), 3.78 (0.2H, td, J = 8.0, 6.0 Hz, 5′′′-HH′), 3.77 (0.2H, td, J = 8.0, 6.0 Hz, 5′′′-HH′), 
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3.73 – 3.66 (1.2H, m, 5′′′-H2), 3.42 – 3.31 (1H, m, 2′-H), 3.00 (0.3H, ddd, J = 11.0, 8.0, 6.0 Hz, 
5′-HH′), 2.99 (0.3H, ddd, J = 10.5, 8.0, 5.5 Hz, 5′-HH′), 2.96 – 2.86 (1.4H, m, 5′-HH′, 5′-H2), 2.46 
(0.2H, dd, J = 15.0, 4.0 Hz, 2-HH′), 2.43 (0.3H, dd, J = 15.5, 4.0 Hz, 2-HH′), 2.42 (0.2H, dd, 
J = 15.0, 4.0 Hz, 2-HH′), 2.39 (0.3H, dd, J = 15.5, 4.0 Hz, 2-HH′), 2.31 (0.2H, dd, J = 15.5, 8.5 Hz, 
2-HH′), 2.28 (0.2H, dd, J = 15.5, 8.5 Hz, 2-HH′), 2.27 (0.3H, dd, J = 15.0, 8.5 Hz, 2-HH′), 2.24 
(0.3H, dd, J = 15.0, 8.0 Hz, 2-HH′), 1.97 – 1.78 (3.4H, m, 4′-H2, 2′′′-H2, 4′′′-H2, 3′′′-H2), 1.77 – 1.63 
(2.4H, m, 4′-H2, 4′′′-H2, 3′′′-H2), 1.63 – 1.56 (0.6H, m, 3′′′-H2), 1.56 – 1.48 (0.6H, m, 4′′′-H2), 1.44 
– 1.26 (1H, m, 3′-H2); δC (151 MHz, CDCl3, mixture of diastereomers) 171.8 (C=O), 171.3 (C=O), 
141.5(3) (C-1Ph), 141.4(6) (C-1Ph), 139.6(0) (C-1Ph), 139.5(5) (C-1Ph), 128.6 (ArC), 128.4 (ArC), 
128.3(1) (ArC), 128.2(6) (ArC), 127.5 (ArC), 127.4 (ArC), 127.3(0) (ArC), 127.2(6) (ArC), 127.2 
(ArC), 127.1 (ArC), 81.8 (C-2′′′), 81.7 (C-2′′′), 81.4(4) (C-2′′′), 81.4(2) (C-2′′′), 69.0 (C-5′′′), 68.9(0) 
(C-5′′′), 68.8(5) (C-5′′′), 68.8 (C-5′′′), 56.3 (C-1′′), 56.2 (C-1′′), 56.0(2) (C-2′), 55.9(5) (C-2′), 55.9 
(C-2′), 55.8 (C-2′), 55.5(4) (C-1′′), 55.4(8) (C-1′′), 46.3(4) (C-5′), 46.3(0) (C-5′), 46.2 (C-5′), 41.6(3) 
(C-2), 41.5(9) (C-2), 41.5 (C-2), 41.3 (C-2), 31.5 (C-3′), 31.4 (C-3′), 31.3 (C-3′), 31.1 (C-3′), 29.2(4) 
(C-3′′′), 29.1(8) (C-3′′′), 28.4(3) (C-3′′′), 28.4(0) (C-3′′′), 26.0(3) (C-4′′′), 25.9(8) (C-4′′′), 25.7(8) 
(C-4′′′), 25.7(5) (C-4′′′), 25.4 (C-4′), 25.3 (C-4′), 25.2(3) (C-4′), 25.1(8) (C-4′); m/z (LCMS, ESI+) 289 
(MH+); Accurate mass: Found MH+, 289.1902: C17H25N2O2 requires M, 289.1916. 
N-([Pyrrolidin-2′′-yl]methyl)-2-(2′,4′-di[trifluoromethyl]phenyl)acetamide 144 
 
Procedure: 2-(2,4-di[trifluoromethyl]phenyl)acetic acid (54 mg, 0.20 mmol) and 2-
(aminomethyl)-1-Boc-pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general 
procedure A. Following TFA-mediated deprotection and reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (35 mg, 
49%) was isolated as an off-white solid. 
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M.p. 90 – 93 °C; νmax (ATR) 3282 (br), 3072 (w), 2964 (w), 2868 (w), 1655 (m), 1564 (w), 1524 
(w), 1346 (s), 1276 (s), 1125 (s), 1056 (m) cm−1; δH (700 MHz, CDCl3) 7.91 (1H, s, 3′-H), 7.79 (1H, 
d, J = 8.0 Hz, 5′-H), 7.68 (1H, d, J = 8.0 Hz, 6′-H), 6.14 (1H, br m, N-H), 3.76 (2H, s, 2-H2), 3.38 
(1H, ddd, J = 13.5, 6.0, 4.5 Hz, NHCHH′), 3.26 (1H, dddd, J = 8.0, 7.5, 7.0, 4.5 Hz, 2′′-H), 3.02 (1H, 
ddd, J = 13.5, 7.5, 5.0 Hz, NHCHH′), 2.90 (1H, ddd, J = 10.5, 7.5, 6.0 Hz, 5′′-HH′), 2.83 (1H, dt, 
J = 10.5, 6.5 Hz, 5′′-HH′), 1.93 (1H, br m, 1′′-H), 1.83 (1H, dtd, J = 13.0, 8.0, 5.5 Hz, 3′′-HH′), 1.77 
– 1.69 (1H, m, 4′′-HH′), 1.72 – 1.63 (1H, m, 4′′-HH′), 1.33 (1H, ddt, J = 13.0, 9.0, 7.0 Hz, 3′′-HH′); 
δC (176 MHz, CDCl3) 168.7 (C=O), 137.9 (C-1′), 133.6 (C-6′), 130.0 (q, J = 33.5 Hz, C-4′), 129.62 
(q, J = 31.0 Hz, C-2′), 128.9 (C-5′), 124.53 (q, J = 274.0 Hz, 2′-CF3), 123.48 (q, J = 272.0 Hz, 
4′-CF3), 123.4 (C-3′), 57.4 (C-2′′), 46.7 (C-5′′), 44.1 (NHCHH′), 40.1 (C-2), 29.2 (C-3′′), 26.1 (C-4′′); 
δF (376 MHz, CDCl3) −60.40 (AlF), −63.30 (AlF); m/z (LCMS, ESI
+) 355 (MH+); Accurate mass: 
Found MH+, 355.1249: C15H17N2OF6 requires M, 355.1245. 
1-(2′-[Dimethylamino]ethyl)-6-(hydroxymethyl)indazole 145 
 
Procedure: To a stirred suspension of LiAlH4 (300 mg, 7.89 mmol) in THF (15 mL) at 0 °C was 
slowly added a solution of ester 149 (650 mg, 2.63 mmol) in THF (3 mL). After 1 h at RT, the 
mixture was re-cooled in an ice bath and quenched according to Fieser’s method (general 
procedure D).273 Subsequent removal of volatiles in vacuo afforded the title compound 
(577 mg, quantitative) as a pale yellow oil. 
Rf 0.12 (40% EtOAc in CHCl3 with 1% NEt3); νmax (ATR) 3348 (br), 2974 (m), 2945 (m), 2864 (m), 
2829 (m), 2786 (m), 1472 (s), 1372 (m), 1316 (m), 1258 (w), 1208 (m), 1191 (m), 1122 (w), 
1044 (s) cm−1; δH (700 MHz, CDCl3) 7.96 (1H, d, J = 1.0 Hz, 3-H), 7.68 (1H, dd, J = 8.0, 1.0 Hz, 
4-H), 7.45 (1H, q, J = 1.0 Hz, 7-H), 7.11 (1H, dd, J = 8.0, 1.0 Hz, 5-H), 4.83 (2H, s, CH2OH), 4.46 
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(2H, t, J = 7.0 Hz, 1′-H2), 2.81 (2H, t, J = 7.0 Hz, 2′-H2), 2.28 (6H, s, N(CH3)2); δC (176 MHz, CDCl3) 
140.0 (C-6, C-9), 133.2 (C-3), 123.6 (C-8), 121.4 (C-4), 120.1 (C-5), 106.8 (C-7), 65.5 (CH2OH), 
58.5 (C-2′), 47.2 (C-1′), 45.8 (N(CH3)2); m/z (LCMS, ESI
+) 220 (MH+); Accurate mass: Found MH+, 
220.1441: C12H18N3O requires M, 220.1450. 
1-(2′-[Dimethylamino]ethyl)-6-([{4′′-chlorophenyl}{phenyl}methoxy]methyl)indazole 146 
 
Procedure: To a cooled solution of benzhydryl alcohol 73 (139 mg, 0.64 mmol) in DCM (1 mL) 
was added NEt3 (116 µL, 0.83 mmol) and methanesulfonyl chloride (59 µL, 0.76 mmol). The 
mixture was stirred at RT until consumption of starting material was observed by TLC. After 
dilution with DCM (10 mL), the mixture was washed with H2O (5 mL), 1 M HCl(aq.) (5 mL) then 
saturated NaHCO3(aq.) (5 mL), before being dried over MgSO4. Removal of volatiles under 
reduced pressure afforded the crude benzhydryl chloride 157 which was used immediately. 
To a 0 °C solution of NaH (60%, 18 mg, 0.45 mmol) in DMF (0.25 mL) was added indazole 145 
(93 mg, 0.42 mmol) in DMF (0.5 mL). After stirring at RT for 2 h, a solution of crude benzhydryl 
chloride 157 in DMF (0.5 mL) was added and the reaction mixture heated to 80 °C for 4.5 h. 
The mixture was re-cooled to 0 °C and quenched by the addition of ice cold H2O (15 mL) prior 
to extraction with EtOAc (6 × 5 mL). The combined organic washings were washed with brine 
(15 mL), concentrated in vacuo then purified on SiO2 column (50% EtOAc in CHCl3 with 1% 
NEt3) to furnish the title compound (25 mg, 14%) as a clear colourless oil. 
Rf 0.28 (40% EtOAc in CHCl3 with 1% NEt3); νmax (ATR) 3063 (w), 3031 (w), 2971 (w), 2861 (w), 
2819 (w), 2768 (w), 1489 (m), 1455 (m), 1366 (s), 1217 (s), 1087 (s), 1014 (m) cm−1; 
δH (600 MHz, CDCl3) 7.98 (1H, s, 3-H), 7.69 (1H, d, J = 8.0 Hz, 4-H), 7.41 (1H, s, 7-H), 7.39 – 7.26 
(9H, m, ArH), 7.13 (1H, d, J = 8.0 Hz, 5-H), 5.45 (1H, s, Ar2CH), 4.68 (2H, s, OCH2), 4.49 (2H, t, 
J = 7.0 Hz, 1′-H2), 2.85 (2H, t, J = 7.0 Hz, 2′-H2), 2.32 (6H, s, N(CH3)2); δC (151 MHz, CDCl3) 141.7 
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(C-1Ph), 140.8 (C-1′′), 139.9 (C-9), 136.9 (C-6), 133.4 (C-4′′), 133.2 (C-3), 128.7(4) (ArC), 128.7(2) 
(ArC), 128.6 (ArC), 128.0 (ArC), 127.2 (ArC), 123.8 (C-8), 121.3 (C-4), 120.8 (C-5), 107.9 (C-7), 
82.1 (Ar2CH), 71.0 (OCH2), 58.5 (C-2′), 47.1 (C-1′), 45.7 (N(CH3)2); m/z (LCMS, ESI
+) 420 
(M(35Cl)H+), 422 (M(37Cl)H+); Accurate mass: Found MH+, 420.1845: C25H27N3O
35Cl requires M, 
420.1843. 
Methyl 1H-indazole-6-carboxylate294 148 
 
Procedure:254 A mixture of 1H-Indazole-6-carboxylic acid 147 (320 mg, 1.97 mmol) and 
concentrated H2SO4 (0.12 mL) in MeOH (5 mL) was heated to 100 °C for 40 min under 
microwave irradiation. The reaction mixture was then poured into cold saturated NaHCO3(aq.) 
solution (20 mL), extracted with EtOAc (3 ×  10 mL) and the combined organic fractions washed 
with brine (20 mL) and dried over MgSO4. Following concentration in vacuo, the title 
compound (309 mg, 89%) was obtained as a yellow solid. 
Rf 0.38 (50% EtOAc in hexanes with 1% NEt3); νmax (ATR) 3017 (w), 2950 (w), 1715 (s), 1435 (w), 
1370 (s), 1292 (w), 1218 (s), 1091 (w) cm−1; δH (700 MHz, CDCl3) 10.62 (1H, br s NH), 8.30 – 8.27 
(1H, m, 7-H), 8.16 (1H, d, J = 1.0 Hz, 3-H), 7.85 (1H, dd, J = 8.5, 1.5 Hz, 5-H), 7.81 (1H, dd, 
J = 8.5, 0.5 Hz, 4-H), 3.97 (3H, s, OCH3); δC (176 MHz, CDCl3) 167.4 (C=O), 139.7 (C-9), 135.2 
(C-3), 128.82 (C-6), 126.0 (C-8), 121.8 (C-5), 120.9 (C-4), 112.3 (C-7), 52.5 (OCH3); m/z (LCMS, 
ESI+) 177 (MH+). 
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Methyl-1-(2′-[dimethylamino]ethyl)indazole-6-carboxylate 149 
 
Procedure:295 Methyl ester 148 (264 mg, 1.50 mmol) was stirred with K2CO3 (622 mg, 
4.50 mmol) and 2-chloro-N,N-dimethylethylamine hydrochloride salt (99%, 327 mg, 
2.25 mmol) in DMF (5 mL) at 80 °C for 14 h. The reaction mixture was then cooled and diluted 
with H2O (60 mL) prior to washing with EtOAc (6 × 10 mL). After combining the organic 
fractions, the volatiles were removed under reduced pressure and the crude mixture 
separated by flash chromatography on silica (10% → 90% EtOAc in hexanes with 1% NEt3). 
Four compounds were isolated, with the title compound (199 mg, 54%) found as a yellow oil. 
Rf 0.32 (80% EtOAc in hexanes with 1% NEt3); νmax (ATR) 2980 (w), 2963 (w), 2855 (w), 2820 (w), 
1710 (s), 1560 (m), 1501 (m), 1440 (m), 1366 (m), 1327 (w), 1290 (m), 1230 (s), 1152 (m) cm−1; 
δH (700 MHz, CDCl3) 8.19 (1H, q, J = 1.0 Hz, 7-H), 8.02 (1H, d, J = 1.0 Hz, 3-H), 7.78 (1H, dd, 
J = 8.5, 1.0 Hz, 5-H), 7.73 (1H, dd, J = 8.5, 1.0 Hz, 4-H), 4.52 (2H, t, J = 7.0 Hz, 1′-H2), 3.95 (3H, s, 
OCH3), 2.83 (2H, t, J = 7.0 Hz, 2′-H2), 2.29 (6H, s, N(CH3)2); δC (176 MHz, CDCl3) 167.4 (C=O), 
139.2 (C-9), 133.2 (C-3), 128.0 (C-6), 126.6 (C-8), 121.1(0) (C-5), 121.0(6) (C-4), 111.6 (C-7), 58.6 
(C-2′), 52.4 (OCH3), 47.5 (C-1′), 45.8 (N(CH3)2); m/z (LCMS, ESI
+) 248 (MH+); Accurate mass: 
Found MH+, 248.1408: C13H18N3O2 requires M, 248.1399. 
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Further elution afforded methyl-2-(2′-[dimethylamino]ethyl)indazole-6-carboxylate 150 
(90 mg, 24%) as a yellow oil. 
 
Rf 0.13 (80% EtOAc in hexanes with 1% NEt3); νmax (ATR) 2972 (w), 2950 (w), 2860 (w), 2823 (w), 
2773 (w), 1713 (s), 1556 (w), 1501 (m), 1436 (m), 1366 (m), 1328 (m), 1295 (m), 1223 (s), 1148 
(m), 1085 (s) cm−1; δH (600 MHz, CDCl3) 8.47 (1H, dt, J = 1.5, 1.0 Hz, 7-H), 8.03 (1H, d, J = 1.0 Hz, 
3-H), 7.67 (1H, dd, J = 9.0, 1.5 Hz, 5-H), 7.65 (1H, dd, J = 9.0, 1.0 Hz, 4-H), 4.52 (2H, t, J = 6.5 Hz, 
1′-H2), 3.92 (3H, s, OCH3), 2.88 (2H, t, J = 6.5 Hz, 2′-H2), 2.27 (6H, s, N(CH3)2); δC (151 MHz, 
CDCl3) 167.7 (C=O), 148.0 (C-9), 127.8 (C-6), 124.0 (C-8), 123.7 (C-3), 121.2(9) (C-5), 121.2(6) 
(C-7), 120.3 (C-4), 59.2 (C-2′), 52.2 (C-1′, OCH3), 45.6 (N(CH3)2); m/z (LCMS, ESI
+) 248 (MH+); 
Accurate mass: Found MH+, 248.1407: C13H18N3O2 requires M, 248.1399. 
The olefin methyl-1-vinylindazole-6-carboxylate 151 (38 mg, 13%) was also isolated from this 
reaction as a pale yellow solid. 
 
Rf 0.74 (80% EtOAc in hexanes with 1% NEt3); M.p. 81 – 83 °C; νmax (ATR) 3072 (w), 2959 (w), 
1710 (s), 1641 (s), 1576 (m), 1472 (m), 1430 (s), 1380 (m), 1342 (s), 1289 (s), 1243 (s), 1214 (s), 
1126 (m), 1104 (m) cm−1; δH (700 MHz, CDCl3) 8.30 (1H, s, 7-H), 8.15 (1H, s, 3-H), 7.86 (1H, d, 
J = 8.5 Hz, 5-H), 7.77 (1H, d, J = 8.5 Hz, 4-H), 7.40 (1H, dd, J = 15.5, 9.0 Hz, 1′-H), 5.79 (1H, d, 
J = 15.5 Hz, 2′-Hcis), 4.98 (1H, d, J = 9.0 Hz, 2′-Htrans), 3.97 (3H, s, OCH3); δC (176 MHz, CDCl3) 
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167.1 (C=O), 138.2 (C-9), 135.6 (C-3), 129.7 (C-1′), 129.1 (C-6), 127.5 (C-8), 122.5 (C-5), 121.3 (C-
4), 111.7 (C-7), 99.8 (C-2′), 52.6 (OCH3); m/z (LCMS, ESI
+) 203 (MH+); Accurate mass: Found 
MH+, 203.0824: C11H11N2O2 requires M, 203.0821. 
The by-product methyl-2-vinylindazole-6-carboxylate 152 (15 mg, 5%) was also obtained via 
SiO2 chromatography as a yellow solid. 
 
Rf 0.61 (80% EtOAc in hexanes with 1% NEt3); M.p. 86 – 88 °C; νmax (ATR) 3124 (w), 3112 (w), 
3001 (w), 2950 (w), 1710 (s), 1646 (m), 1556 (w), 1499 (m), 1434 (m), 1389 (m), 1340 (m), 1300 
(m), 1243 (s), 1220 (s), 1154 (m), 1085 (s) cm−1; δH (700 MHz, CDCl3) 8.52 – 8.48 (1H, m, 7-H), 
8.12 (1H, d, J = 1.0 Hz, 3-H), 7.70 (1H, dd, J = 9.0, 1.0 Hz, 5-H), 7.67 (1H, dd, J = 9.0, 1.0 Hz, 4-H), 
7.32 (1H, dd, J = 15.5, 8.5 Hz, 1′-H), 6.02 (1H, dd, J = 15.5, 1.5 Hz, 2′-Hcis), 5.22 (1H, dd, J = 8.5, 
1.5 Hz, 2′-Htrans), 3.95 (3H, s, OCH3); δC (176 MHz, CDCl3) 167.4 (C=O), 148.8 (C-9), 133.8 (C-1′), 
129.1 (C-6), 124.1 (C-8), 122.3 (C-5), 121.8 (C-7), 121.4 (C-3), 120.5 (C-4), 105.9 (C-2′), 52.38 
(OCH3); m/z (LCMS, ESI
+) 203 (MH+); Accurate mass: Found MH+, 203.0828: C11H11N2O2 requires 
M, 203.0821. 
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2-(2′-[{4′′′-Azidophenyl}phenylmethoxy]ethyl)-1-methylpyrrolidine 162 
A mixture of (2S,1′′R) and (2S,1′′S) diastereomers 
 
Procedure:266 Aryl bromide 164 (263 mg, 1 mmol) was dissolved in a degassed mixture of EtOH 
and H2O (7 : 3, 2 mL). This solution was then added to a mixture of NaN3 (130 mg, 2 mmol), CuI 
(31 mg, 0.16 mmol) and N,N′-dimethylethylenediamine (99%, 27 µL, 0.24 mmol), and the 
reaction mixture was heated in a sealed vial under microwave irradiation (100 °C, 45 min). The 
mixture was then loaded onto a short SiO2 plug and washed with 40% EtOAc in hexanes, to 
provide the crude azide 163 (218 mg, 97%), as a pale yellow oil which was used without further 
purification. 
General procedure B was then used to couple azide 163 (124 mg, 0.55 mmol) and 
homoprolinol (S)-57 (65 mg, 0.50 mmol). Silica flash column chromatography (0% → 5% MeOH 
in CHCl3 with 1% NEt3), furnished the title compound (58 mg, 35%) as a yellow oil. 
Rf 0.24 (10% MeOH in CHCl3 with 1% NEt3); νmax (ATR) 3026 (w), 2942 (w), 2870 (w), 2774 (w), 
2117 (s), 1504 (s), 1453 (m), 1366 (m), 1285 (s), 1217 (m), 1092 (s) cm−1; δH (700 MHz, CDCl3, 
mixture of diastereomers) 7.34 – 7.30 (6H, m, ArH), 7.26 – 7.23 (1H, m, ArH), 7.00 – 6.95 (2H, 
m, ArH), 5.30 (1H, s, 1′′-H), 3.53 – 3.43 (2H, m, 2′-H2), 3.05 (1H, ddd, J = 9.5, 8.0, 2.0 Hz, 5-HH′), 
2.31 (3H, apparent d, J = 2.0 Hz, NCH3 isomer 1, NCH3 isomer 2), 2.18 – 2.05 (3H, m, 1′-HH′, 2-
H, 5-HH′), 1.93 – 1.86 (1H, m, 3-HH′), 1.78 – 1.70 (1H, m, 4-HH′), 1.69 – 1.62 (1H, m, 4-HH′), 
1.57 – 1.50 (1H, m, 1′-HH′), 1.49 – 1.41 (1H, m, 3-HH′); δC (176 MHz, CDCl3, mixture of 
diastereomers) 142.4 (ArC), 142.3 (ArC), 139.7 (ArC), 139.6 (ArC), 139.1(8) (C-4′′′ isomer 1), 
139.1(5) (C-4′′′ isomer 2), 128.6 (ArC), 128.5(3) (ArC), 128.4(8) (ArC), 127.6(8) (ArC), 127.6(5) 
(ArC), 127.0(1) (ArC), 126.9(6) (ArC), 119.1(2) (ArC), 119.1(1) (ArC), 83.3(1) (C-1′′ isomer 1), 
83.3(0) (C-1′′ isomer 2), 67.2(7) (C-2′ isomer 1), 67.2(6) (C-2′ isomer 2), 63.9(2) (C-2 isomer 1), 
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63.9(1) (C-2 isomer 2), 57.3 (C-5), 40.7 (NCH3), 34.2 (C-1′), 31.0(9) (C-3 isomer 1), 31.0(8) (C-3 
isomer 2), 22.1 (C-4); m/z (LCMS, ESI+) 337 (MH+); Accurate mass: Found MH+, 337.2036: 
C20H25N4O requires M, 337.2028. 
4-Bromophenyl(phenyl)methanol296 164 
 
Procedure: 4-Bromobenzaldehyde 165 (2.63 g, 14.23 mmol) was reacted according to general 
procedure C, furnishing the title compound (3.54 g, 95%) as a white solid after 
chromatography on silica (0% → 30% ether in hexanes).  
Rf 0.33 (20% EtOAc in hexanes); M.p. 61 – 62 °C (lit.:
297 62 – 63 °C); νmax (ATR) 3352 (br), 3087 
(w), 3063 (w), 3028 (w), 2877 (w), 1485 (s), 1455 (m), 1366 (m), 1218 (m), 1071 (m), 1010 
(s) cm−1; δH (700 MHz, CDCl3) 7.44 (2H, d, J = 8.0 Hz, 3-H2), 7.35 – 7.31 (4H, m, 2
Ph-H2, 3
Ph-H2), 
7.30 – 7.26 (1H, m, 4Ph-H), 7.26 – 7.22 (2H, m, 2-H2), 5.76 (1H, s, CHOH), 2.40 (1H, s, CHOH); 
δC (176 MHz, CDCl3) 143.5 (C-1
Ph), 142.9 (C-1), 131.7 (C-3), 128.8 (C-3Ph), 128.3 (C-2), 128.0 
(C-4Ph), 126.7 (C-2Ph), 121.5 (C-4), 75.8 (CHOH); m/z (LCMS, ESI+) 245 (M(79Br) − OH−), 247 
(M(81Br) – OH−); Accurate mass: Found M − OH−, 244.9973: C13H10
79Br requires M, 244.9966. 
2-(2′-[{4′′′-Bromophenyl}{phenyl}methoxy]ethyl)-1-methylpyrrolidine 166 
A mixture of (2S,1′′R) and (2S,1′′S) diastereomers 
 
Procedure: General procedure B was used in the reaction of bromide 164 (226 mg, 0.86 mmol) 
and homoprolinol (S)-57 (101 mg, 0.78 mmol). Reversed-phase column chromatography 
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(5% → 100% MeCN in H2O with 0.1% formic acid), furnished the title compound (89 mg, 30%) 
as a clear colourless oil. 
Rf 0.29 (10% MeOH in CHCl3 with 1% NEt3);νmax (ATR) 3033 (w), 3945 (w), 2870 (w), 2775 (w), 
1486 (m), 1453 (m), 1366 (s), 1218 (s), 1092 (s), 1010 (s) cm−1; δH (700 MHz, CDCl3, mixture of 
diastereomers) 7.43 (2H, dd, J = 8.5, 2.5 Hz, 3′′′-H2), 7.35 – 7.28 (4H, m, 2
Ph-H2, 3
Ph-H2), 7.26 – 
7.23 (1H, m, 4Ph-H), 7.21 (2H, dd, J = 8.5, 2.5 Hz, 2′′′-H2), 5.27 (1H, s, 1′′-H), 3.55 – 3.49 (1H, m, 
2′-HH′), 3.49 – 3.44 (1H, m, 2′-HH′), 3.14 (1H, apparent t, J = 9.0 Hz, 5-HH′), 2.36 (3H, app d, 
J = 5.0, NCH3 isomer 1, NCH3 isomer 2), 2.32 – 2.25 (1H, m, 2-H), 2.20 (1H, apparent q, 
J = 9.0 Hz, 5-HH′), 2.14 – 2.07 (1H, m, 1′-HH′), 1.97 – 1.88 (1H, m, 3-HH′), 1.84 – 1.74 (1H, m, 
4-HH′), 1.74 – 1.66 (1H, m, 4-HH′), 1.65 – 1.57 (1H, m, 1′-HH′), 1.55 – 1.46 (1H, m, 3-HH′); 
δC (176 MHz, CDCl3, mixture of diastereomers) 142.0(0) (C-1
Ph isomer 1), 141.9(6) (C-1Ph isomer 
2), 141.7(2) (C-1′′′ isomer 1), 141.7(0) (C-1′′′ isomer 2), 131.6(0) (C-3′′′ isomer 1), 131.5(9) (C-3′′′ 
isomer 2), 128.7(2) (C-2′′′ isomer 1), 128.6(8) (C-2′′′ isomer 2), 128.6 (C-3Ph), 127.8(0) (C-4Ph 
isomer 1), 127.7(7) (C-4Ph isomer 2), 127.0(3) (C-2Ph isomer 1), 126.9(7) (C-2Ph isomer 2), 
121.4(1) (C-4′′′ isomer 1), 121.3(8) (C-4′′′ isomer 2), 83.3(0) (C-1′′ isomer 1), 83.2(7) (C-1′′ 
isomer 2), 67.1(3) (C-2′ isomer 1), 67.0(9) (C-2′ isomer 2), 64.2 (C-2), 57.1 (C-5), 40.5 (NCH3), 
33.8 (C-1′), 31.0 (C-3 isomer 1), 30.9 (C-3 isomer 2), 22.0(4) (C-4 isomer 1), 22.0(3) (C-4 isomer 
2); m/z (LCMS, ESI+) 374 (M(79Br)H+), 376 (M(81Br)H+); Accurate mass: Found MH+, 374.1134: 
C20H25NO
79Br requires M, 374.1120. 
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N-(3′′-[Pyrazol-1′′′-yl]prop-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 167 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 3-[pyrazol-1′-yl]propylamine (25 mg, 0.20 mmol) 
were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (31 mg, 
44%) was isolated as a white solid. 
M.p. 61 – 63 °C; νmax (ATR) 3300 (br), 3072 (w), 3018 (w), 2942 (w), 1646 (s), 1544 (m), 1489 (s), 
1402 (m), 1368 (m), 1275 (m), 1212 (m), 1180 (w), 1092 (m), 1019 (s) cm−1; δH (700 MHz, CDCl3) 
7.43 (1H, dd, J = 2.0, 0.5 Hz, 3′′′-H), 7.34 – 7.31 (3H, m, ArH), 7.30 – 7.26 (3H, m, ArH), 7.25 – 
7.22 (2H, m, ArH), 7.21 – 7.18 (2H, m, ArH), 6.23 – 6.19 (1H, m, 4′′′-H), 6.16 (1H, t, J = 5.5 Hz, 
NH), 4.78 (1H, s, 2-H), 4.13 (2H, t, J = 6.5 Hz, 3′′-H2), 3.32 – 3.22 (2H, m, 1′′-H2), 2.02 (2H, p, 
J = 6.5 Hz, 2′′-H2); δC (176 MHz, CDCl3) 171.7 (C=O), 139.5 (C-3′′′), 139.2 (ArC), 138.1 (ArC), 
133.3 (C-4′), 130.4 (ArC), 129.5 (C-5′′′), 129.0 (ArC), 128.9 (ArC), 128.8 (ArC), 127.6 (ArC), 105.9 
(C-4′′′), 58.6 (C-2), 49.7 (C-3′′), 37.4 (C-1′′), 30.2 (C-2′′); m/z (LCMS, ESI+) 354 (M(35Cl)H+), 356 
(M(37Cl)H+); Accurate mass: Found MH+, 354.1378: C20H21N3O
35Cl requires M, 354.1373. 
N-(2′′-[N-Methyl-1′′′,2′′′,4′′′-triazol-5′′′-yl]eth-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 
168 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 2-[N-methyl-1′,2′,4′-triazol-5′-yl]ethylamine 
(25 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
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column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(22 mg, 31%) was isolated as a clear colourless oil. 
νmax (ATR) 3308 (br), 3040 (w), 2958 (w), 1655 (s), 1524 (w), 1491 (s), 1368 (m), 1222 (m), 1088 
(w), 1015 (w) cm−1; δH (700 MHz, CDCl3) 7.69 (1H, s, 3′′′-H), 7.32 – 7.29 (2H, m, 3
Ph-H2), 7.28 – 
7.25 (3H, m, 3′-H2, 4
Ph-H), 7.19 – 7.17 (2H, m, 2Ph-H2), 7.16 – 7.14 (2H, m, 2′-H2), 6.67 – 6.63 
(1H, m, NH), 4.80 (1H, s, 2-H), 3.75 (3H, s, NCH3), 3.74 (2H, q, J = 6.0 Hz, 1′′-H2), 2.91 (2H, t, 
J = 6.0 Hz, 2′′-H2); δC (176 MHz, CDCl3) 171.9 (C=O), 153.3 (C-5′′′), 150.2 (C-3′′′), 138.9 (C-1
Ph), 
137.8 (C-1′), 133.3 (C-4′), 130.3 (C-2′), 129.0(1) (ArC), 128.9(5) (ArC), 128.8 (C-2Ph), 127.6 (C-4Ph), 
58.6 (C-2), 36.9 (C-1′′), 35.2 (NCH3), 25.5 (C-2′′); m/z (LCMS, ESI
+) 355 (M(35Cl)H+), 357 
(M(37Cl)H+); Accurate mass: Found MH+, 355.1329: C19H20N4O
35Cl requires M, 355.1326. 
N-(2′′-[3′′′,5′′′-Dimethylpyrazol-1′′′-yl]eth-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 169 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 2-[3′,5′-dimethylpyrazol-1′-yl]ethylamine (28 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (36 mg, 
49%) was isolated as a white solid. 
M.p. 100 – 101 °C; νmax (ATR) 3282 (br), 3086 (w), 3060 (w), 2922 (w), 1649 (s), 1551 (s), 1489 
(s), 1453 (m), 1360 (w), 1222 (w), 1090 (m), 1015 (m) cm−1; δH (700 MHz, CDCl3) 7.32 – 7.29 
(2H, m, 3Ph-H2), 7.28 – 7.24 (3H, m, 3′-H2, 4
Ph-H), 7.20 – 7.18 (2H, m, 2Ph-H2), 7.17 – 7.14 (2H, m, 
2′-H2), 6.49 (1H, t, J = 6.0 Hz, NH), 5.75 (1H, s, 4′′′-H), 4.82 (1H, s, 2-H), 4.03 (2H, dd, J = 6.5, 5.0 
Hz, 2′′-H2), 3.69 (2H, ddd, J = 6.5, 6.0, 5.0 Hz, 1′′-H2), 2.12 (3H, s, 5′′′-CH3), 2.11 (3H, s, 3′′′-CH3); 
δC (176 MHz, CDCl3) 171.9 (C=O), 148.1 (C-3′′′), 139.6 (C-5′′′), 138.9 (C-1
Ph), 137.9 (C-1′), 133.3 
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(C-4′), 130.4 (C-2′), 129.0 (ArC), 128.9(4) (ArC), 128.8(8) (ArC), 127.6 (C-4Ph), 105.3 (C-4′′′), 58.7 
(C-2), 46.9 (C-2′′), 39.8 (C-1′′), 13.6 (3′′′-CH3), 11.0 (5′′′-CH3); m/z (LCMS, ESI
+) 368 (M(35Cl)H+), 
370 (M(37Cl)H+); Accurate mass: Found MH+, 368.1525: C21H23N3O
35Cl requires M, 368.1530. 
N-([Imidazo[1,2-a]pyridin-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 170 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (imidazo[1,2-a]pyridin-2-yl)methylamine (29 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (10 mg, 
13%) was isolated as a clear yellow oil. 
νmax (ATR) 3282 (br), 3062 (w), 3020 (w), 1668 (s), 1534 (w), 1490 (s), 1364 (w), 1208 (m), 1136 
(w), 1018 (w) cm−1; δH (600 MHz, CDCl3) 8.10 (1H, d, J = 7.0 Hz, 5′′-H), 7.69 – 7.62 (1H, m, NH), 
7.65 (1H, d, J = 9.0 Hz, 8′′-H), 7.54 (1H, s, 3′′-H), 7.39 – 7.36 (1H, m, 7′′-H), 7.25 – 7.23 (4H, m, 
2Ph-H2, ArH), 7.23 – 7.19 (5H, m, 2′-H2, ArH), 6.96 (1H, t, J = 7.0 Hz, 6′′-H), 4.89 (1H, s, 2-H), 4.60 
(2H, t, J = 5.5 Hz, NHCH2); δC (151 MHz, CDCl3) 172.1 (C=O), 143.3 (C-9′′), 140.4 (C-2′′), 139.1 
(C-1Ph), 138.1 (C-1′), 133.1 (C-4′), 130.4 (ArC), 128.8(4) (ArC), 128.7(7) (ArC), 127.9 (C-7′′), 127.5 
(ArC), 126.4 (C-5′′), 115.9 (C-8′′), 114.4 (C-6′′), 110.9 (C-3′′), 57.9 (C-2), 36.6 (NHCH2); 
m/z (LCMS, ESI+) 376 (M(35Cl)H+), 378 (M(37Cl)H+); Accurate mass: Found MH+, 376.1211: 
C22H19N3O
35Cl requires M, 376.1217. 
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N-([Pyridin-4′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 171 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (pyridin-4-yl)methylamine (22 mg, 0.20 mmol) 
were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (27 mg, 
40%) was isolated as a white solid. 
M.p. 148 – 149 °C; νmax (ATR) 3094 (w), 3022 (w), 2946 (w), 1656 (s), 1371 (m), 1218 (m) cm
−1; 
δH (700 MHz, CDCl3) 8.55 – 8.52 (2H, m, 2′′-H2), 7.37 – 7.34 (2H, m, 3
Ph-H2), 7.32 – 7.29 (3H, m, 
3′-H2, 4
Ph-H2), 7.26 – 7.24 (2H, m, 2
Ph-H2), 7.23 – 7.20 (2H, m, 2′-H2), 7.11 – 7.09 (2H, m, 3′′-H2), 
6.00 – 5.95 (1H, m, NH), 4.94 (1H, s, 2-H), 4.49 (2H, d, J = 6.0 Hz, NHCH2); δC (101 MHz, CDCl3) 
171.9 (C=O), 150.1 (C-2′′), 147.4 (C-4′′), 138.8 (C-1Ph), 137.7 (C-1′), 133.5 (C-4′), 130.3 (C-2′), 
129.2 (C-3Ph), 129.0 (C-3′), 128.8 (C-2Ph), 127.9 (C-4Ph), 122.3 (C-3′′), 58.3 (C-2), 42.7 (NHCH2); 
m/z (LCMS, ESI+) 337 (M(35Cl)H+), 339 (M(37Cl)H+); Accurate mass: Found MH+, 337.1110: 
C20H18N2O
35Cl requires M, 337.1108. 
N-([3′′,5′′-Dimethylisoxazol-4′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 172 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (3,5-dimethylisoxazol-4-yl]methylamine•HCl 
(33 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(10 mg, 14%) was isolated as a white solid. 
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M.p. 169 – 171 °C; νmax (ATR) 3290 (br), 3090 (w), 3044 (w), 2930 (w), 1647 (s), 1548 (m), 1491 
(s), 1454 (m), 1200 (w), 1091 (w), 1015 (w) cm−1; δH (600 MHz, CDCl3) 7.35 – 7.31 (2H, m, 
3Ph-H2), 7.31 – 7.27 (3H, m, 3′-H2, 4
Ph-H), 7.20 (2H, d, J = 7.5 Hz, 2Ph-H2), 7.17 (2H, d, J = 8.5 Hz, 
2′-H2), 5.64 – 5.58 (1H, m, NH), 4.83 (1H, s, 2-H), 4.20 (2H, d, J = 5.5 Hz, NHCH2), 2.33 (3H, s, 
5′′-CH3), 2.11 (3H, s, 3′′-CH3); δC (151 MHz, CDCl3) 171.4 (C=O), 167.3 (C-5′′), 159.4 (C-3′′), 138.8 
(C-1Ph), 137.6 (C-1′), 133.5 (C-4′), 130.3 (C-2′), 129.2 (C-3Ph), 129.1 (C-3′), 128.8 (C-2Ph), 127.9 
(C-4Ph), 110.8 (C-4′′), 58.5 (C-2), 32.5 (NHCH2), 11.2 (5′′-CH3), 10.2 (3′′-CH3); m/z (LCMS, ESI
+) 
355 (M(35Cl)H+), 357 (M(37Cl)H+); Accurate mass: Found MH+, 355.1203: C20H20N2O2
35Cl requires 
M, 355.1213. 
N-(2′′-[Piperazin-1′′′-yl]eth-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 173 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 2-(4′-boc-piperazin-1′-yl)ethylamine (46 mg, 
0.20 mmol) were reacted according to general procedure A. Following TFA-mediated 
deprotection and reversed-phase column chromatography (5% → 95% MeCN in H2O with 0.5% 
formic acid), the title compound (18 mg, 25%) was isolated as a yellow oil. 
νmax (ATR) 3298 (br), 3040 (w), 2942 (w), 2818 (w), 1649 (s), 1556 (m), 1490 (s), 1444 (w), 1320 
(w), 1226 (w), 1139 (w), 1089 (w) cm−1; δH (700 MHz, CDCl3) 7.35 – 7.31 (2H, m, 3
Ph-H2), 7.31 – 
7.27 (3H, m, 3′-H2, 4
Ph-H), 7.25 – 7.22 (2H, m, 2Ph-H2), 7.22 – 7.20 (2H, m, 2′-H2), 6.30 – 6.21 
(1H, m, NH), 4.90 (1H, s, 2-H), 3.39 – 3.30 (2H, m, 1′′-H2), 2.76 – 2.66 (4H, m, 3′′′-(H2)2), 2.40 
(2H, app td, J = 6.0, 2.0 Hz, 2′′-H2), 2.36 – 2.22 (4H, m, 2′′′-(H2)2); δC (176 MHz, CDCl3) 171.5 
(C=O), 139.3 (C-1Ph), 138.3 (C-1′), 133.2 (C-4′), 130.5 (C-2′), 128.9(9) (C-3
Ph), 128.9(6) (ArC), 
128.9 (ArC), 127.6 (C-4Ph), 58.7 (C-2), 56.7 (C-2′′), 54.2 (C-2′′′), 46.2 (C-3′′′), 36.1 (C-1′′); 
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m/z (LCMS, ESI+) 358 (M(35Cl)H+), 360 (M(37Cl)H+); Accurate mass: Found MH+, 358.1681: 
C20H25N3O
35Cl requires M, 358.1686. 
N-([3′′,5′′-Dimethylpyrazol-4′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 174 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and (3,5-dimethylpyrazol-4-yl)methylamine•2HCl 
(40 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(24 mg, 34%) was isolated as a white solid. 
M.p. 177 – 178 °C; νmax (ATR) 3262 (br), 3090 (w), 3032 (w), 2934 (w), 1637 (s), 1540 (m), 1494 
(m), 1208 (m), 1090 (w) cm−1;  δH (700 MHz, CDCl3) 7.34 – 7.31 (2H, m, 3
Ph-H2), 7.30 – 7.27 (3H, 
m, 3′-H2, 4
Ph-H), 7.22 – 7.20 (2H, m, 2Ph-H2), 7.19 – 7.17 (2H, m, 2′-H2), 5.62 – 5.59 (1H, m, NH), 
4.83 (1H, s, 2-H), 4.25 (2H, d, J = 5.2 Hz, NHCH2), 2.18 (6H, s, 3′′-(CH3)2); δC (176 MHz, CDCl3) 
171.3 (C=O), 143.4 (C-3′′), 139.0 (C-1Ph), 137.9 (C-1′), 133.4 (C-4′), 130.3 (C-2′), 129.1 (ArC), 
129.0 (ArC), 128.8 (ArC), 127.8 (ArC), 112.8 (C-4′′), 58.5 (C-2), 33.2 (NHCH2), 10.7 (3′′-(CH3)2); 
m/z (LCMS, ESI+) 354 (M(35Cl)H+), 356 (M(37Cl)H+); Accurate mass: Found MH+, 354.1384: 
C20H21N3O
35Cl requires M, 354.1373. 
 | 181 | 
Chapter 8: Chemical Experimental Details 
N-([1′′-{1′′′,2′′′,4′′′-Triazol-1′′′-yl}phen-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 
175 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 1-([1′′,2′′,4′′-triazol-1′′-yl]phen-2′-yl)methylamine 
(35 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(65 mg, 80%) was isolated as a white solid. 
M.p. 137 – 139 °C; νmax (ATR) 3286 (br), 3098 (w), 3044 (w), 2934 (w), 1662 (s), 1494 (s), 1352 
(w), 1276 (m), 1215 (m) cm−1; δH (700 MHz, CHCl3) 8.30 (1H, s, ArH), 7.90 (1H, s, ArH), 7.66 (1H, 
dd, J = 7.5, 1.5 Hz, 3′′-H), 7.47 (1H, td, J = 7.5, 1.5 Hz, 4′′-H), 7.43 (1H, td, J = 7.5, 1.5 Hz, 5′′-H), 
7.32 – 7.24 (6H, m, ArH), 7.18 – 7.16 (2H, m, 2Ph-H2), 7.14 – 7.12 (2H, m, 2′-H2), 6.94 (1H, t, 
J = 6.5 Hz, NH), 4.87 (1H, s, 2-H), 4.32 (2H, d, J = 6.5 Hz, NHCH2); δC (176 MHz, CDCl3) 171.4 
(C=O), 152.5 (ArC), 143.8 (ArC), 139.1 (ArC), 138.1 (ArC), 135.9 (C-2′′), 133.6 (C-1′′), 133.2 (C-4′), 
132.4 (C-3′′), 130.4 (C-2′), 130.2 (C-4′′), 129.1 (ArC), 128.9(74) (ArC), 128.9(67) (ArC), 128.9 
(ArC), 127.5 (ArC), 124.9 (C-6′′), 58.6 (C-2), 40.5 (NHCH2); m/z (LCMS, ESI
+)  403 (M(35Cl)H+), 405 
(M(37Cl)H+); Accurate mass: Found MH+, 403.1327: C23H20N4O
35Cl requires M, 403.1326. 
N-(3′′-[Thiophene-2′′′-carboxamido]prop-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 176 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 3-(thiophene-2′-carboxamido)propylamine•HCl 
(44 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
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column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(45 mg, 54%) was isolated as a white solid. 
M.p. 164 – 165 °C; νmax (ATR) 3304 (br), 3076 (w), 2938 (w), 1626 (s), 1543 (s), 1490 (s), 1446 
(w), 1353 (w), 1303 (m), 1234 (w), 1090 (m), 1015 (m) cm−1; δH (600 MHz, CHCl3) 7.53 (1H, dd, 
J = 3.5, 1.0 Hz, 3′′′-H), 7.47 – 7.43 (1H, m, 5′′′-H), 7.34 – 7.31 (2H, m, 3Ph-H2), 7.29 – 7.24 (5H, m, 
3′-H2, 2
Ph-H2, 4
Ph-H), 7.23 – 7.21 (2H, m, 2′-H2), 7.13 – 7.07 (1H, m, 3′′-NH), 7.06 – 7.00 (1H, m, 
4′′′-H), 6.38 – 6.30 (1H, m, 1-NH), 4.89 (1H, s, 2-H), 3.40 – 3.33 (4H, m, 1′′-H2, 3′′-H2), 1.70 – 
1.63 (2H, m, 2′′-H2); δC (151 MHz, CDCl3) 172.8 (C-1), 162.5 (2′′′-CO), 139.3 (C-2′′′), 139.0 (C-1
Ph), 
137.9 (C-1′), 133.4 (C-4′), 130.3 (C-2′), 130.2 (C-3Ph), 129.1 (ArC), 129.0 (ArC), 128.8 (C-2Ph), 
128.1 (C-3′′′), 127.8 (C-4′′′), 127.7 (C-4Ph), 58.6 (C-2), 36.5 (C-1′′), 36.1 (C-3′′), 29.9 (C-2′′); 
m/z (LCMS, ESI+) 413 (M(35Cl)H+), 415 (M(37Cl)H+); Accurate mass: Found MH+, 413.1097: 
C22H22N2O2S
35Cl requires M, 413.1091. 
N-[1′-(2′′,2′′-Difluoroethyl)piperidin-4′-yl]-2-(4′-chlorophenyl)-2-phenylacetamide 177 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 1-(2′,2′-difluoroethyl)-4-aminopiperidine (33 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (25 mg, 
32%) was isolated as an off-white solid. 
M.p. 143 – 145 °C; νmax (ATR) 3296 (br), 3058 (w), 2946 (w), 2794 (w), 1639 (s), 1541 (m), 1489 
(s), 1290 (w), 1125 (m), 1089 (m), 1049 (s), 1015 (m) cm−1; δH (400 MHz, CDCl3) 7.36 – 7.26 (5H, 
m, ArH), 7.23 – 7.16 (4H, m, ArH), 5.84 (2H, tt, J = 56.0, 4.0 Hz, 2′′-H), 5.55 – 5.44 (1H, m, NH), 
4.83 (1H, s, 2-H), 3.91 – 3.78 (1H, m, 4′-H), 2.90 – 2.79 (2H, m, 2′-H2H′2), 2.72 (2H, td, J = 15.0, 
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4.0 Hz, 1′′-H2), 2.38 – 2.27 (2H, m, 2′-H2H′2), 1.97 – 1.84 (2H, m, 3′-H2H′2), 1.48 – 1.32 (2H, m, 
3′-H2H′2); δC (101 MHz, CDCl3) 170.9 (C=O), 139.1 (ArC), 138.0 (ArC), 133.3 (ArC), 130.3 (ArC), 
129.1 (ArC), 129.0 (ArC), 128.8 (ArC), 127.7 (ArC), 115.5 (t, J = 241.5 Hz, C-2′′), 59.9 (t, J = 25.0 
Hz, C-1′′), 58.5 (C-2), 53.2 (C-2′), 46.3 (C-4′), 31.9 (C-3′); δF (376 MHz, CDCl3) −118.52 (dt, 
J = 56.0, 15.0 Hz, 2′′-F2); m/z (LCMS, ESI
+) 393 (M(35Cl)H+), 395 (M(37Cl)H+); Accurate mass: 
Found MH+, 393.1546: C21H24N2OF2
35Cl requires M, 393.1545. 
1-(4′′-[Pyrimidin-2′′′-yl]piperazin-1′′-yl)-2-(4′-chlorophenyl)-2-phenylethan-1-one 178 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 4-(pyrimidin-2′-yl)piperazine (33 mg, 0.20 mmol) 
were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (18 mg, 
23%) was isolated as an off-white solid. 
M.p. 150 – 152 °C; νmax (ATR) 3020 (w), 2916 (w), 2856 (w), 1645 (s), 1582 (s), 1548 (s), 1489 
(s), 1428 (s), 1392 (m), 1355 (m), 1307 (w), 1261 (m), 1222 (w), 1089 (w), 1032 (w) cm−1; 
δH (600 MHz, CDCl3) 8.28 (2H, d, J = 4.5 Hz, 4′′′-H2), 7.33 (2H, t, J = 7.5 Hz, 3
Ph-H2), 7.29 – 7.22 
(5H, m, 3′-H2, 2
Ph-H2, 4
Ph-H), 7.19 – 7.15 (2H, m, 2′-H2), 6.51 (1H, t, J = 4.5 Hz, 5′′′-H), 5.21 (1H, s, 
2-H), 3.90 – 3.79 (2H, m, 2′′-(HH′)H2, 3′′-(HH′)(HH′)), 3.78 – 3.73 (1H, m, 3′′-(HH′)(HH′)), 3.70 
(1H, ddd, J = 13.0, 7.5, 3.0 Hz, 2′′-(HH′)H2), 3.64 (1H, dt, J = 13.0, 5.0 Hz, 3′′-(HH′)(HH′)), 3.51 
(2H, t, J = 5.0 Hz, 2′′-(HH′)H2), 3.45 (1H, dt, J = 13.0, 5.0 Hz, 3′′-(HH′)(HH′)); δC (151 MHz, CDCl3) 
170.2 (C=O), 161.6 (C-2′′′), 157.9 (C-4′′′), 138.8 (C-1Ph), 138.1 (C-1′), 133.2 (C-4′), 130.6 (C-2′), 
129.0 (C-3Ph), 128.9 (ArC), 128.8 (ArC), 127.5 (C-4Ph), 110.6 (C-5′′′), 54.5 (C-2), 45.9 (C-2′′), 43.6 
(C-3′′), 42.22 (C-2′′); m/z (LCMS, ESI+) 393 (M(35Cl)H+), 395 (M(37Cl)H+); Accurate mass: Found 
MH+, 393.1470: C22H22N4O
35Cl requires M, 393.1482. 
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1-(4′′-[2′′′-Hydroxyethyl]piperazin-1′′-yl)-2-(4′-chlorophenyl)-2-phenylethan-1-one 179 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 4-(2′-hydroxyethyl)piperazine (27 mg, 0.20 mmol) 
were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (35 mg, 
49%) was isolated as a clear yellow oil. 
νmax (ATR) 3412 (br), 2938 (w), 2868 (w), 2804 (w), 1638 (s), 1490 (m), 1434 (m), 1290 (w), 1223 
(m), 1144 (w), 1087 (m), 1014 (m) cm−1; δH (600 MHz, CDCl3) 7.35 – 7.31 (2H, m, 3
Ph-H2), 7.29 – 
7.26 (3H, m, 3′-H2, 4
Ph-H), 7.22 – 7.20 (2H, m, 2Ph-H2), 7.16 – 7.13 (2H, m, 2′-H2), 5.16 (1H, s, 
2-H), 3.75 (1H, ddd, J = 13.5, 6.5, 3.5 Hz, 2′′-(HH′)H2), 3.67 (1H, ddd, J = 13.5, 6.5, 3.5 Hz, 
2′′-(HH′)H2), 3.59 (2H, t, J = 5.5 Hz, 2′′′-H2), 3.49 – 3.41 (2H, m, 2′′-(HH′)H2), 2.53 – 2.42 (5H, m, 
3′′-H2(HH′), 1′′′-H2, OH), 2.32 – 2.25 (1H, m, 3′′-H2(HH′)), 2.22 – 2.16 (1H, m, 3′′-H2(HH′)); 
δC (151 MHz, CDCl3) 169.9 (C=O), 138.9 (C-1
Ph), 138.2 (C-1′), 133.1 (C-4′), 130.6 (C-2′), 129.0 
(C-3Ph), 128.9 (C-2Ph), 128.8 (C-3′), 127.5 (C-4Ph), 59.3 (C-1′′′), 57.9 (C-2′′′), 54.3 (C-2), 52.9 (C-3′′), 
52.7 (C-3′′), 46.1 (C-2′′), 42.4 (C-2′′); m/z (LCMS, ESI+) 359 (M(35Cl)H+), 361 (M(37Cl)H+); Accurate 
mass: Found MH+, 359.1532: C20H24N2O2
35Cl requires M, 359.1526. 
1-(4′′-[2′′′-Methoxyethyl]piperazin-1′′-yl)-2-(4′-chlorophenyl)-2-phenylethan-1-one 180 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 4-(2′-methoxyethyl)piperazine (29 mg, 0.20 mmol) 
were reacted according to general procedure A. Following reversed-phase column 
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chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (8 mg, 
11%) was isolated as a clear yellow oil. 
νmax (ATR) 2928 (w), 2882 (w), 2808 (w), 1639 (s), 1490 (m), 1432 (m), 1308 (w), 1225 (w), 1113 
(m), 1015 (m) cm−1; δH (600 MHz, CDCl3) 7.32 – 7.29 (2H, m, 3
Ph-H2), 7.27 – 7.22 (3H, m, 3′-H2, 
4Ph-H), 7.21 – 7.18 (2H, m, 2Ph-H2), 7.14 – 7.11 (2H, m, 2′-H2), 5.14 (1H, s, 2-H), 3.75 (1H, ddd, 
J = 13.0, 6.0, 3.5 Hz, 2′′-(HH′)H2), 3.66 (1H, ddd, J = 13.0, 7.0, 3.5 Hz, 2′′-(HH′)H2), 3.49 – 3.39 
(2H, m, 2′′-(HH′)H2), 3.45 (2H, t, J = 5.5 Hz, 2′′′-H2), 3.31 (3H, s, OCH3), 2.50 (2H, t, J = 5.5 Hz, 
1′′′-H2), 2.46 (1H, ddd, J = 11.0, 6.5, 3.5 Hz, 3′′-(HH′)(HH′)), 2.42 (1H, ddd, J = 11.0, 7.0, 3.5 Hz, 
3′′-(HH′)(HH′)), 2.26 (1H, ddd, J = 11.0, 6.5, 3.5 Hz, 3′′-(HH′)(HH′)), 2.16 (1H, ddd, J = 11.0, 6.0, 
4.0 Hz, 3′′-(HH′)(HH′)); δC (151 MHz, CDCl3) 169.8 (C=O), 139.0 (C-1
Ph), 138.3 (C-1′), 133.0 (C-4′), 
130.6 (C-2′), 128.8(8) (ArC), 128.8(7) (ArC), 128.7 (C-3′), 127.4 (C-4Ph), 70.1 (C-2′′′), 59.0 (OCH3), 
57.9 (C-1′′′), 54.2 (C-2), 53.5 (C-3′′), 53.2 (C-3′′), 46.0 (C-2′′), 42.2 (C-2′′); m/z (LCMS, ESI+) 373 
(M(35Cl)H+), 375 (M(37Cl)H+); Accurate mass: Found MH+, 373.1671: C21H26N2O2
35Cl requires M, 
373.1683. 
N-Methyl-N-([1′′-difluoromethylimidazol-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-
phenylacetamide 181 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and N-methyl-(1-difluoromethylimidazol-2-yl) 
methylamine (32 mg, 0.20 mmol) were reacted according to general procedure A. Following 
reversed-phase column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the 
title compound (37 mg, 47%) was isolated as a clear colourless oil. 
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νmax (ATR) 3136 (w), 2942 (w), 1639 (s), 1489 (s), 1460 (m), 1416 (m), 1348 (w), 1273 (s), 1192 
(w), 1160 (m), 1091 (s), 1047 (s) cm−1; δH (600 MHz, CDCl3) 7.77 (1H, t, J = 59.0 Hz, CHF2), 7.34 – 
7.30 (2H, m, 3Ph-H2), 7.29 – 7.26 (4H, m, 3′-H2, 4
Ph-H, 5′′-H), 7.18 – 7.14 (2H, m, 2Ph-H2), 7.12 – 
7.08 (2H, m, 2′-H2), 7.04 (1H, d, J = 1.5 Hz, 4′′-H), 5.17 (1H, s, 2-H), 4.78 (1H, d, J = 15.0 Hz, 
N(CH3)CHH′), 4.72 (1H, d, J = 15.0 Hz, N(CH3)CHH′), 3.05 (3H, s, NCH3CHH′); δC (151 MHz, CDCl3) 
172.2 (C=O), 143.1 (C-2′′), 138.1 (C-1Ph), 137.4 (C-1′), 133.4 (C-4′), 130.4 (C-2′), 129.7 (C-4′′), 
129.1 (C-3Ph), 128.9 (C-3′), 128.7 (C 2Ph), 127.7 (C-4Ph), 116.1 (C-5′′), 108.4 (t, J = 250.0 Hz, CHF2), 
54.3 (C-2), 43.4 (N(CH3)CHH′), 35.3 (NCH3CHH′); δF (376 MHz, CDCl3) −91.65 (dd, J = 231.5, 
59.0 Hz, CHFF′), −92.72 (dd, J = 231.5, 59.0 Hz, CHFF′); m/z (LCMS, ESI+) 390 (M(35Cl)H+), 392 
(M(37Cl)H+); Accurate mass: Found MH+, 390.1181: C20H19N3OF2
35Cl requires M, 390.1185. 
N-Methyl-N-([1′′-methylpyrazol-4′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 182 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and N-methyl-(1-methylpyrazol-4-yl)methylamine 
(32 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(27 mg, 38%) was isolated as a clear colourless oil. 
νmax (ATR) 3050 (w), 2932 (w), 2868 (w), 1639 (s), 1489 (s), 1446 (m), 1394 (s), 1334 (w), 1252 
(w), 1161 (m), 1088 (m), 1015 (m) cm−1; δH (600 MHz, CDCl3, mixture of rotamers) 7.39 (0.7H, s, 
3′′-H rotamer A), 7.33 (0.7H, s, 5′′-H rotamer A), 7.32 – 7.28 (2H, m, 3Ph-H2), 7.28 – 7.22 (3.6H, 
m, 3′-H2, 2
Ph-H2 rotamer B, 4
Ph-H), 7.21 (0.3H, s, 3′′-H rotamer B), 7.22 – 7.17 (1.4H, m, 2Ph-H2 
rotamer A), 7.16 – 7.14 (0.6H, m, 2′-H2 rotamer B), 7.15 – 7.12 (1.4H, m, 2′-H2 rotamer A), 6.90 
(0.3H, s, 5′′-H rotamer B), 5.25 (0.3H, s, 2-H rotamer B), 5.13 (0.7H, s, 2-H rotamer A), 4.45 
(0.7H, d, J = 14.5 Hz, N(CH3)CHH′ rotamer A), 4.41 (0.7H, d, J = 14.5 Hz, N(CH3)CHH′ rotamer A), 
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4.37 (0.6H, s, N(CH3)CH2 rotamer B), 3.85 (2.1H, s, 1′′-CH3 rotamer A), 3.83 (0.9H, s, 1′′-CH3 
rotamer B), 2.98 (0.9H, s, NCH3CH2 rotamer B), 2.92 (2.1H, s, NCH3CHH′ rotamer A); 
δC (151 MHz, CDCl3, mixture of rotamers) 171.2 (C=O), 139.3 (C-3′′ rotamer A), 139.1 (C-1
Ph 
rotamer B), 138.9 (C-1Ph rotamer A), 138.4 (C-1′ rotamer B), 138.2 (C-1′ rotamer A), 138.1 (C-3′′ 
rotamer B), 133.1 (C-4′ rotamer B), 133.0 (C-4′ rotamer A), 130.5(7) (C-2′ rotamer B), 130.5(5) 
(C-2′ rotamer A), 130.0 (C-5′′ rotamer A), 129.0 (ArC), 128.9(1) (ArC), 128.8(8) (ArC), 128.8(5) 
(ArC), 128.7 (ArC), 128.5 (C-5′′ rotamer B), 127.5 (ArC), 127.4 (ArC), 117.4 (C-4′′ rotamer B), 
117.3 (C-4′′ rotamer A), 54.4 (C-2 rotamer A), 54.1 (C-2 rotamer B), 44.8 (N(CH3)CH2 rotamer B), 
42.4 (N(CH3)CHH′ rotamer A), 39.2 (1′′-CH3 rotamer B), 39.0 (1′′-CH3 rotamer A), 35.3 
(N(CH3)CHH′ rotamer A), 34.1 (N(CH3)CH2 rotamer B); m/z (LCMS, ESI
+) 354 (M(35Cl)H+), 356 
(M(37Cl)H+); Accurate mass: Found MH+, 354.1367: C20H21N3O
35Cl requires M, 354.1373. 
N-Methyl-N-([pyridin-3′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 183 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and N-methyl-(pyridin-3-yl)methylamine (24 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (14 mg, 
20%) was isolated as a clear colourless oil. 
νmax (ATR) 3036 (w), 2932 (w), 1642 (s), 1489 (m), 1396 (m), 1270 (w), 1174 (w), 1089 (m), 1015 
(w) cm−1; δH (600 MHz, CDCl3, mixture of rotamers) 8.59 – 8.56 (0.3H, m, 6′′-H rotamer B), 8.54 
– 8.51 (0.7H, m, 6′′-H rotamer A), 8.51 – 8.47 (0.7H, m, 2′′-H rotamer A), 8.44 – 8.42 (0.3H, m, 
2′′-H rotamer B), 7.63 – 7.58 (0.7H, m, 4′′-H rotamer A), 7.38 – 7.34 (0.3H, m, 4′′-H rotamer B), 
7.34 – 7.29 (2H, m, 3Ph-H2), 7.29 – 7.24 (4H, m, 3′-H2, 4
Ph-H, 5′′-H), 7.23 – 7.22 (1.4H, m, 2Ph-H2 
rotamer A), 7.23 – 7.19 (0.6H, m, 2Ph-H2 rotamer B), 7.19 – 7.15 (1.4H, m, 2′-H2 rotamer A), 
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7.14 – 7.10 (0.6H, m, 2′-H2 rotamer B), 5.20 (0.7H, s, 2-H rotamer A), 5.11 (0.3H, s, 2-H rotamer 
B), 4.66 (0.7H, d, J = 15.0 Hz, N(CH3)CHH′ rotamer A), 4.60 (0.7H, d, J = 15.0 Hz, N(CH3)CHH′ 
rotamer A), 4.58 (0.3H, d, J = 17.0 Hz, N(CH3)CHH′ rotamer B), 4.51 (0.3H, d, J = 17.0 Hz, 
N(CH3)CHH′ rotamer B), 3.02 (0.9H, s, N(CH3)CHH′ rotamer B), 2.94 (2.1H, s, N(CH3)CHH′ 
rotamer A); δC (151 MHz, CDCl3, mixture of rotamers) 171.8(4) (C=O rotamer A), 171.8(2) (C=O 
rotamer B), 149.6 (C-2′′ rotamer A), 149.5 (C-6′′ rotamer B), 149.2 (C-6′′ rotamer A), 148.4 (C-2′′ 
rotamer B), 138.7 (C-1Ph rotamer B), 138.6 (C-1Ph rotamer A), 138.0 (C-1′), 136.1 (C-4′′ rotamer 
A), 134.0 (C-4′′ rotamer B), 133.3 (C-4′ rotamer B), 133.2 (C-4′ rotamer A), 132.9 (C-3′′ rotamer 
A), 132.2 (C-3′′ rotamer B), 130.5(0) (C-2′ rotamer A), 130.4(5) (C-2′ rotamer B), 129.1 (ArC), 
129.0 (ArC), 128.8(1) (ArC), 128.7(8) (ArC), 127.7 (ArC), 127.5 (ArC), 123.9 (C-5′′ rotamer B), 
123.8 (C-5′′ rotamer A), 54.4 (C-2 rotamer A), 54.3 (C-2 rotamer B), 51.3 (N(CH3)CHH′ rotamer 
B), 49.4 (N(CH3)CHH′ rotamer A), 35.5 (N(CH3)HH′ rotamer A), 34.8 (N(CH3)HH′ rotamer B); 
m/z (LCMS, ESI+) 351 (M(35Cl)H+), 353 (M(37Cl)H+); Accurate mass: Found MH+, 351.1259: 
C21H20N2O
35Cl requires M, 351.1264. 
N-Methyl-N-([3′′-fluoropyridin-2′′-yl]methyl)-2-(4′-chlorophenyl)-2-phenylacetamide 184 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and N-methyl-(3-fluoropyridin-2-yl)methylamine 
(28 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(32 mg, 43%) was isolated as a clear colourless oil. 
νmax (ATR) 3058 (w), 2928 (w), 1647 (s), 1489 (m), 1443 (s), 1396 (m), 1243 (w), 1159 (w), 1090 
(m), 1015 (w) cm−1; δH (600 MHz, CDCl3, mixture of rotamers) 8.45 (0.5H, dt, J = 5.0, 1.5 Hz, 
6′′-H rotamer A), 8.34 (0.5H, dt, J = 5.0, 1.5 Hz, 6′′-H rotamer B), 7.40 (0.5H, ddd, J = 9.5, 8.5, 
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1.5 Hz, 4′′-H rotamer A), 7.34 (0.5H, ddd, J = 9.5, 8.5, 1.5 Hz, 4′′-H rotamer B), 7.32 – 7.28 (2.5H, 
m, 5′′-H rotamer A, 3Ph-H2), 7.27 – 7.22 (5H, m, 3′-H2, 2
Ph-H2, 4
Ph-H), 7.22 – 7.18 (1.5H, m, 2′-H2 
rotamer B, 5′′-H rotamer B), 7.18 – 7.16 (1H, m, 2′-H2 rotamer A), 5.60 (0.5H, s, 2-H rotamer A), 
5.27 (0.5H, s, 2-H rotamer B), 4.89 (0.5H, dd, J = 15.5, 2.0 Hz, N(CH3)CHH′ rotamer B), 4.79 
(0.5H, dd, J = 15.5, 1.5 Hz, N(CH3)CHH′ rotamer B), 4.70 (0.5H, dd, J = 16.5, 1.5 Hz, N(CH3)CHH′ 
rotamer A), 4.54 (0.5H, dd, J = 16.5, 1.5 Hz, N(CH3)CHH′ rotamer A), 3.08 (1.5H, s, N(CH3)CHH′ 
rotamer B), 3.04 (1.5H, s, N(CH3)CHH′ rotamer A); δC (151 MHz, CDCl3, mixture of rotamers) 
172.6 (C=O rotamer A), 171.8 (C=O rotamer B), 157.9 (d, J = 258.5 Hz, C-3′′ rotamer B), 157.7 
(d, J = 257.5 Hz, C-3′′ rotamer A), 145.7 (d, J = 5.5 Hz, C-6′′ rotamer A), 145.2 (d, J = 14.5 Hz, 
C-2′′ rotamer B), 145.0 (d, J = 5.5 Hz, C-6′′ rotamer B), 144.5 (d, J = 14.5 Hz, C-2′′ rotamer A), 
139.2 (C-1Ph rotamer A), 139.1 (C-1Ph rotamer B), 138.7 (C-1′ rotamer A), 138.4 (C-1′ rotamer B), 
132.9(3) (C-4′ rotamer B), 132.8(6) (C-4′ rotamer A), 130.8 (C-2′ rotamer B), 130.7 (C-2′ rotamer 
A), 129.2 (ArC), 129.0 (ArC), 128.8 (C-3Ph), 128.7 (C-3Ph), 128.6(1) (ArC), 128.5(8) (ArC), 127.3 
(ArC), 124.6 (d, J = 3.5 Hz, C-5′′ rotamer A), 123.8 (d, J = 3.5 Hz, C-5′′ rotamer B), 123.3 (d, 
J = 19.0 Hz, C-4′′ rotamer A), 122.9 (d, J = 18.5 Hz, C-4′′ rotamer B), 54.4 (C-2 rotamer B), 53.8 
(C-2 rotamer A), 49.4 (d, J = 1.5 Hz, N(CH3)CHH′ rotamer A), 48.1 (d, J = 1.0 Hz, N(CH3)CHH′ 
rotamer B), 36.8 (N(CH3)CHH′ rotamer B), 35.2 (N(CH3)CHH′ rotamer A); δF (376 MHz, CDCl3) 
−125.79 (3′′-F); m/z (LCMS, ESI+) 369 (M(35Cl)H+), 371 (M(37Cl)H+); Accurate mass: Found MH+, 
369.1154: C21H19N2OF
35Cl requires M, 369.1170. 
N-Methyl-N-(2′′-[morpholin-4′′′-yl]eth-1′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 185 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and N-methyl-2-(morpholin-4′-yl)ethylamine (30 mg, 
0.20 mmol) were reacted according to general procedure A. Following reversed-phase column 
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chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (9 mg, 
12%) was isolated as a yellow oil. 
νmax (ATR) 2958 (w), 2855 (w), 2812 (w), 1643 (s), 1489 (m), 1456 (w), 1399 (m), 1304 (w), 1260 
(w), 1152 (w), 1116 (s), 1015 (w) cm−1; δH (600 MHz, CDCl3, mixture of rotamers) 7.34 – 7.30 
(2H, m, 3Ph-H2), 7.28 – 7.23 (5H, m, 3′-H2, 2
Ph-H2, 4
Ph-H), 7.19 – 7.15 (2H, m, 2′-H2), 5.28 (0.3H, s, 
2-H rotamer B), 5.18 (0.7H, s, 2-H rotamer A), 3.71 – 3.64 (4H, m, 2′′′-(H2)2), 3.60 (0.7H, dt, 
J = 13.5, 6.5 Hz, 1′′-HH′ rotamer A), 3.53 (0.7H, dt, J = 13.5, 6.5 Hz, 1′′-HH′ rotamer A), 3.43 
(0.3H, ddd, J = 14.5, 7.5, 6.0 Hz, 1′′-HH′ rotamer B), 3.36 (0.3H, ddd, J = 14.5, 7.5, 6.0 Hz, 1′′-HH′ 
rotamer B), 3.01 (0.9H, s, NCH3 rotamer B), 2.99 (2.1H, s, NCH3 rotamer A), 2.51 (1.4H, t, 
J = 6.5 Hz, 2′′-H2 rotamer A), 2.52 – 2.45 (2.8H, m, 3′′′-(H2)2
 rotamer A), 2.45 (0.3H, ddd, 
J = 13.0, 7.5, 6.0 Hz, 2′′-HH′ rotamer B), 2.42 – 2.39 (1.2H, m, 3′′′-(H2)2 rotamer B), 2.37 (0.3H, 
ddd, J = 13.0, 7.5, 6.0 Hz, 2′′-HH′ rotamer B); δC (151 MHz, CDCl3, mixture of rotamers) 171.5 
(C=O rotamer B), 171.4 (C=O rotamer A), 139.2 (C-1Ph rotamer B), 139.0 (C-1Ph rotamer A), 
138.6 (C-1′ rotamer B), 138.4 (C-1′ rotamer A), 133.0(4) (C-4′ rotamer B), 132.9(7) (C-4′ rotamer 
A), 130.7 (C-2′ rotamer A), 130.5 (C-2′ rotamer B), 129.0 (ArC), 128.9 (ArC), 128.8(4) (ArC), 
128.8(0) (ArC), 128.7(0) (ArC), 128.6(6) (ArC), 127.4 (ArC), 127.3 (ArC), 67.2 (C-2′′′ rotamer A), 
67.0 (C-2′′′ rotamer B), 57.3 (C-2′′ rotamer B), 55.8 (C-2′′ rotamer A), 54.5 (C-2 rotamer A), 54.2 
(C-3′′′ rotamer B), 53.8(9) (C-3′′′ rotamer A), 53.8(6) (C-2 rotamer B), 47.6 (C-1′′ rotamer B), 
45.3 (C-1′′ rotamer A), 36.2 (NCH3 rotamer A), 34.6 (NCH3 rotamer B); m/z (LCMS, ESI
+) 373 
(M(35Cl)H+), 375 (M(37Cl)H+); Accurate mass: Found MH+, 373.1673: C21H26N2O2
35Cl requires M, 
373.1683. 
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N-(1′′,3′′-Dihydro-2′′-[2′′′-fluoroethyl]isoindol-5′′-yl)-2-(4′-chlorophenyl)-2-phenylacetamide 
186 
 
Procedure: Acid 90 (50 mg, 0.20 mmol) and 1,3-dihydro-2-[2′-fluoroethyl]-5-aminoisoindole 
(36 mg, 0.20 mmol) were reacted according to general procedure A. Following reversed-phase 
column chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound 
(7 mg, 9%) was isolated as a brown oil. 
νmax (ATR) 3274 (br), 3054 (w), 2946 (w), 2808 (w), 1661 (s), 1602 (w), 1550 (m), 1491 (s), 1442 
(w), 1364 (w), 1210 (w), 1096 (w), 1032 (w) cm−1; δH (700 MHz, CDCl3) 7.48 (1H, d, J = 2.0 Hz, 
4′′-H), 7.38 – 7.35 (2H, m, 3Ph-H2), 7.33 – 7.31 (3H, m, 3′-H2, 4
Ph-H), 7.31 – 7.29 (2H, m, 2Ph-H2), 
7.26 – 7.24 (2H, m, 2′-H2), 7.13 (1H, dd, J = 8.0, 2.0 Hz, 6′′-H), 7.10 (1H, d, J = 8.0 Hz, 7′′-H), 5.01 
(1H, s, 2-H), 4.62 (2H, dt, J = 47.5, 5.0 Hz, 2′′′-H2), 3.97 (4H, s, 3′′-H2, 1′′-H2), 3.04 (2H, dt, 
J = 28.0, 5.0 Hz, 1′′′-H2); δC (176 MHz, CDCl3) 169.7 (C=O), 141.1 (C-5′′), 138.8 (C-1
Ph), 137.7 
(C-1′), 136.5(0) (ArC), 136.4(9) (ArC), 133.6 (C-4′), 130.5 (C-2′), 129.3 (C-3Ph), 129.1 (C-3′), 129.0 
(C-2Ph), 127.9 (C-4Ph), 122.7 (C-7′′), 118.7 (C-6′′), 114.4 (C-4′′), 83.4 (d, J = 167.5 Hz, C-2′′′), 59.7 
(C-3′′), 59.4 (C-2), 59.3 (C-1′′), 55.6 (d, J = 19.5 Hz, C-1′′′); δF (376 MHz, CDCl3) −220.22 – 
−220.69 (m, 2′′′-F); m/z (LCMS, ESI+) 409 (M(35Cl)H+), 411 (M(37Cl)H+); Accurate mass: Found 
MH+, 409.1476: C24H23N2OF
35Cl requires M, 409.1483. 
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N-([Pyrrolidin-2′′-yl]methyl)-1-(4′-fluorophenyl)cyclopropane-1-carboxamide 187 
 
Procedure: 1-(4′-Fluorophenyl)cyclopropane-1-carboxilic acid (36 mg, 0.20 mmol) and 
2-(aminomethyl)-1-Boc-pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general 
procedure A. Following TFA-mediated deprotection and reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (26 mg, 
50%) was isolated as a yellow gum. 
νmax (ATR) 3326 (br), 2958 (w), 2832 (w), 1658 (m), 1511 (s), 1408 (m), 1214 (m) cm
−1; 
δH (700 MHz, CDCl3) 7.37 (2H, dd, J = 8.5, 5.5 Hz, 2′-H2), 7.04 (2H, t, J = 8.5 Hz, 3′-H2), 5.76 – 
5.70 (1H, m, NH), 3.24 (1H, ddd, J = 13.0, 6.0, 4.5 Hz, NHCHH′), 3.16 (1H, qd, J = 7.0, 4.5 Hz, 
2′′-H), 3.00 (1H, ddd, J = 13.0, 7.0, 5.5 Hz, NHCHH′), 2.81 (1H, ddd, J = 10.5, 7.5, 6.0 Hz, 5′′-HH′), 
2.73 (1H, dt, J = 10.5, 6.5 Hz, 5′′-HH′), 1.81 – 1.73 (1H, m, 1′′-H), 1.80 – 1.72 (1H, m, 3′′-HH′), 
1.68 – 1.60 (2H, m, 4′′-H2), 1.61 – 1.56 (2H, m, 2-H2H′2), 1.26 (1H, ddt, J = 13.0, 8.5, 7.0 Hz, 
3′′-HH′), 1.02 – 0.98 (2H, m, 2-H2H′2); δC (176 MHz, CDCl3) 173.9 (C=O), 162.3 (d, J = 247.5 Hz, 
C-4′), 135.9 (d, J = 3.5 Hz, C-1′), 132.8 (d, J = 8.0 Hz, C-2′), 116.0 (d, J = 21.5 Hz, C-3′), 57.4 (C-2′′), 
46.7 (C-5′′), 44.8 (NHCHH′), 29.9 (C-1), 29.1 (C-3′′), 26.0 (C-4′′), 15.8 (C-2), 15.7 (C-2); 
δF (376 MHz, CDCl3) −114.22 – −114.31 (m, 4′-F); m/z (LCMS, ESI
+) 263 (MH+); Accurate mass: 
Found MH+, 263.1566: C15H20N2OF requires M, 263.1560. 
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N-([Pyrrolidin-2′-yl]methyl)-1-methyl-4-phenyl-piperidine-4-carboxamide 188 
 
Procedure: 1-Methyl-4-phenylpiperidine-4-carboxilic acid monohydrate (47 mg, 0.20 mmol) 
and 2-(aminomethyl)-1-Boc-pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to 
general procedure A. Following TFA-mediated deprotection and reversed-phase column 
chromatography (5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (30 mg, 
50%) was isolated as a yellow oil. 
νmax (ATR) 3308 (br), 2946 (m), 2798 (w), 1640 (s), 1532 (s), 1450 (m), 1412 (w), 1290 (m) cm
−1; 
δH (700 MHz, CDCl3) 7.40 – 7.37 (2H, m, 2
Ph-H2), 7.34 (2H, t, J = 7.5 Hz, 3
Ph-H2), 7.27 – 7.22 (1H, 
m, 4Ph-H), 5.95 – 5.88 (1H, m, NH), 3.28 (1H, ddd, J = 13.0, 5.0, 4.5 Hz, NHCHH′), 3.14 (1H, qd, 
J = 7.0, 4.5 Hz, 2′-H), 2.99 (1H, ddd, J = 13.0, 7.0, 5.5 Hz, NHCHH′), 2.79 (1H, dt, J = 10.5, 7.0 Hz, 
5′-HH′), 2.69 (1H, dt, J = 10.5, 6.5 Hz, 5′-HH′), 2.66 – 2.52 (2H, m, 2-H2H′2), 2.47 – 2.43 (2H, m, 
3-H2H′2), 2.43 – 2.35 (2H, m, 2-H2H′2), 2.25 (3H, s, NCH3), 2.14 – 2.06 (2H, m, 3-H2H′2), 1.71 (1H, 
dq, J = 12.5, 7.0 Hz, 3′-HH′), 1.57 (2H, dtd, J = 7.5, 7.0, 6.5 Hz, 4′-H2), 1.17 (1H, dtd, J = 12.5, 7.5, 
7.0 Hz, 3′-HH′); δC (176 MHz, CDCl3) 174.9 (C=O), 143.6 (C-1
Ph) , 128.9 (C-3Ph), 127.0 (C-4Ph), 
126.2 (C-2Ph), 57.4 (C-2′), 53.0 (C-2), 48.7 (C-4), 46.7 (C-5′), 46.4 (NCH3), 43.9 (NHCHH′), 34.2 
(C-3), 28.9 (C-3′), 26.0 (C-4′); m/z (LCMS, ESI+) 302 (MH+); Accurate mass: Found MH+, 
302.2239: C18H28N3O requires M, 302.2232. 
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N-([Pyrrolidin-2′′-yl]methyl)-2-(pyridin-3′-yl)acetamide298 189 
 
Procedure: 2-(Pyridin-3′-yl)acetic acid•HCl (35 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-
pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. Following 
TFA-mediated deprotection and reversed-phase column chromatography (5% → 95% MeCN in 
H2O with 0.5% formic acid), the title compound (13 mg, 30%) was isolated as a yellow oil. 
νmax (ATR) 3262 (br), 3034 (w), 2950 (w), 2870 (w), 1650 (s), 1558 (s), 1524 (s), 1478 (w), 1432 
(s), 1406 (s), 1360 (m), 1192 (w) cm−1; δH (700 MHz, CDCl3) 8.51 – 8.48 (2H, m, 2′-H, 6′-H), 7.65 
(1H, dt, J = 8.0, 2.0 Hz, 4′-H), 7.24 (1H, dd, J = 8.0, 5.0 Hz, 5′-H), 6.63 – 6.54 (1H, m, NH), 3.51 
(2H, s, 2-H2), 3.40 (1H, ddd, J = 13.5, 6.0, 4.0 Hz, NHCHH′), 3.29 – 3.22 (1H, m, 2′′-H), 3.03 (1H, 
ddd, J = 13.5, 8.0, 5.0 Hz, NHCHH′), 3.06 – 2.95 (1H, m, 1′′-H), 2.89 (1H, ddd, J = 10.5, 7.5, 6.0 
Hz, 5′′-HH′), 2.84 (1H, dt, J = 10.5, 7.0 Hz, 5′′-HH′), 1.84 (1H, dtd, J = 13.0, 8.0, 5.5 Hz, 3′′-HH′), 
1.77 – 1.70 (1H, m, 4′′-HH′), 1.70 – 1.62 (1H, m, 4′′-HH′), 1.33 (1H, ddt, J = 13.0, 8.5, 7.0 Hz, 
3′′-HH′); δC (176 MHz, CDCl3) 170.1 (C=O), 150.4 (C-2′), 148.6 (C-6′), 136.9 (C-4′), 131.1 (C-3′), 
123.7 (C-5′), 57.7 (C-2′′), 46.5 (C-5′′), 43.7 (NHCHH′), 40.8 (C-2), 29.2 (C-3′′), 25.9 (C-4′′); 
m/z (LCMS, ESI+) 220 (MH+); Accurate mass: Found MH+, 220.1453: C12H18N3O requires M, 
220.1450. 
N-([Pyrrolidin-2′′-yl]methyl)-2-methyl-2-(pyrazol-1′-yl)propionamide 190 
 
Procedure: 2-Methyl-2-(pyrazol-1′-yl)propionic acid (31 mg, 0.20 mmol) and 2-(aminomethyl)-
1-Boc-pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. 
Following TFA-mediated deprotection and reversed-phase column chromatography 
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(5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (21 mg, 45%) was isolated 
as a yellow oil. 
νmax (ATR) 3326 (br), 2938 (w), 2868 (w), 1655 (s), 1516 (br, s), 1394 (s), 1316 (w), 1250 (w), 
1200 (w), 1156 (w), 1088 (w), 1058 (w) cm−1; δH (700 MHz, CDCl3) 7.63 (1H, d, J = 2.0 Hz, ArH), 
7.60 (1H, d, J = 2.0 Hz, ArH), 6.46 – 6.41 (1H, m, NH), 6.32 (1H, t, J = 2.0 Hz, 4′-H), 3.23 (1H, ddd, 
J = 13.0, 6.0, 4.5 Hz, NHCHH′), 3.15 (1H, qd, J = 7.0, 4.5 Hz, 2′′-H), 3.01 (1H, ddd, J = 13.0, 7.0, 
5.5 Hz, NHCHH′), 2.85 – 2.78 (2H, m, 5′′-H2), 1.85 (3H, s, 2-(CH3)(CH3)), 1.84 (3H, s, 
2-(CH3)(CH3)), 1.74 (1H, dddd, J = 12.5, 8.5, 7.5, 5.5 Hz, 3′′-HH′), 1.70 – 1.58 (2H, m, 4′′-H2), 1.23 
(1H, ddt, J = 12.5, 8.5, 7.0 Hz, 3′′-HH′); δC (176 MHz, CDCl3) 173.4 (C=O), 140.4 (ArC), 128.0 
(ArC), 106.2 (C-4′), 65.2 (C-2), 57.3 (C-2′′), 46.6 (C-5′′), 44.3 (NHCHH′), 29.0 (C-3′′), 26.1 
(2-(CH3)(CH3)), 26.02 (2-(CH3)(CH3)), 25.80 (C-4′′); m/z (LCMS, ESI
+) 237 (MH+); Accurate mass: 
Found MH+, 237.1723: C12H21N4O requires M, 237.1715. 
N-([Pyrrolidin-2′′-yl]methyl)-2-(morpholin-4′-yl)acetamide 191 
 
Procedure: 2-(Morpholin-4′-yl)acetic acid•HCl (36 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-
pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. Following 
TFA-mediated deprotection and reversed-phase column chromatography (5% → 95% MeCN in 
H2O with 0.5% formic acid), the title compound (25 mg, 56%) was isolated as an orange oil. 
νmax (ATR) 3340 (br), 2954 (w), 2864 (w), 2812 (w), 1654 (s), 1523 (s), 1404 (m), 1290 (w), 1114 
(s), 1014 (w) cm−1; δH (700 MHz, CDCl3) 7.47 – 7.39 (1H, m, NH), 3.75 – 3.67 (4H, m, 2′-(H2)2), 
3.40 – 3.33 (1H, m, NHCHH′), 3.29 – 3.23 (1H, m, 2′′-H), 3.13 – 3.07 (1H, m, NHCHH′), 3.02 – 
2.97 (2H, m, 2-H2), 2.93 – 2.87 (2H, m, 5′′-H2), 2.56 – 2.47 (4H, m, 3′-(H2)2), 1.88 – 1.81 (1H, m, 
3′′-HH′), 1.78 – 1.72 (1H, m, 4′′-HH′), 1.71 – 1.64 (1H, m, 4′′-HH′), 1.38 – 1.31 (1H, m, 3′′-HH′); 
δC (176 MHz, CDCl3) 170.07 (C=O), 67.1 (C-2′), 62.2 (C-2), 57.9 (C-2′′), 54.0 (C-3′), 46.8 (C-5′′), 
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43.7 (NHCHH′), 29.3 (C-3′′), 26.0 (C-4′′); m/z (LCMS, ESI+) 228 (MH+); Accurate mass: Found 
MH+, 228.1706: C11H22N3O2 requires M, 228.1712. 
N-([Pyrrolidin-2′-yl]methyl)-2-methylpropionamide299 192 
 
Procedure: 2-Methylpropionic acid (18 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-pyrrolidine 
91 (40 mg, 0.20 mmol) were reacted according to general procedure A. Following TFA-
mediated deprotection and reversed-phase column chromatography (5% → 95% MeCN in H2O 
with 0.5% formic acid), the title compound (20 mg, 59%) was isolated as a yellow oil. 
νmax (ATR) 3300 (br), 3058 (w), 2958 (w), 2928 (w), 2872 (w), 1649 (s), 1542 (br, s), 1460 (w), 
1394 (s), 1244 (w), 1170 (w), 1110 (w) cm−1; δH (600 MHz, CDCl3) 6.08 – 5.98 (1H, m, NH), 3.38 
(1H, ddd, J = 13.0, 6.0, 4.5 Hz, NHCHH′), 3.29 – 3.21 (1H, m, 2′-H), 3.02 (1H, ddd, J = 13.0, 8.0, 
5.0 Hz, NHCHH′), 2.94 – 2.85 (2H, m, 5′-H2), 2.35 (1H, hept, J = 7.0 Hz, 2-H), 1.89 – 1.80 (1H, m, 
3′-HH′), 1.80 – 1.72 (1H, m, 4′-HH′), 1.72 – 1.64 (1H, m, 4′-HH′), 1.41 – 1.31 (1H, m, 3′-HH′), 1.14 
(6H, d, J = 7.0 Hz, 2-(CH3)(CH3)); δC (151 MHz, CDCl3) 177.2 (C=O), 57.9 (C-2′), 46.7 (C-5′), 43.6 
(NHCHH′), 35.8 (C-2), 29.2 (C-3′), 26.1 (C-4′), 19.8(4) (2-(CH3)(CH3)), 19.7(9) (2-(CH3)(CH3)); 
m/z (LCMS, ESI+) 171 (MH+); Accurate mass: Found MH+, 171.1501: C9H19N2O requires M, 
171.1497. 
N-([Pyrrolidin-2′-yl]methyl)1-methylbenzimidazole-2-carboxamide 193 
 
Procedure: 1-Methylbenzimidazole-2-carboxylic acid (35 mg, 0.20 mmol) and 2-(aminomethyl)-
1-Boc-pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. 
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Following TFA-mediated deprotection and reversed-phase column chromatography 
(5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (16 mg, 31%) was isolated 
as an orange oil. 
νmax (ATR) 3326 (br), 2954 (w), 2886 (w), 1665 (s), 1536 (s), 1463 (s), 1395 (m), 1332 (m), 1264 
(m), 1006 (w) cm−1; δH (700 MHz, CDCl3) 8.08 – 8.02 (1H, m, NH), 7.77 (1H, dt, J = 8.0, 1.0 Hz, 
4-H), 7.43 (1H, dt, J = 8.0, 1.0 Hz, 7-H), 7.38 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, 6-H), 7.33 (1H, ddd, 
J = 8.0, 7.0, 1.0 Hz, 5-H), 4.23 (3H, s, NCH3), 3.56 (1H, ddd, J = 13.5, 6.5, 5.0 Hz, NHCHH′), 3.42 – 
3.37 (1H, m, 2′-H), 3.31 (1H, ddd, J = 13.0, 7.5, 5.5 Hz, NHCHH′), 3.01 – 2.92 (2H, m, 5′-H2), 1.93 
(1H, dddd, J = 12.5, 9.0, 7.5, 5.5 Hz, 3′-HH′), 1.88 – 1.79 (1H, m, 4′-HH′), 1.76 – 1.69 (1H, m, 
4′-HH′), 1.48 (1H, ddt, J = 13.0, 9.0, 6.5 Hz, 3′-HH′); δC (176 MHz, CDCl3) 160.1 (C=O), 143.8 
(C-2), 141.2 (C-8), 137.2 (C-9), 124.6 (C-6), 123.5 (C-5), 120.8 (C-4), 110.5 (C-7), 57.9 (C-2′), 46.7 
(C-5′), 44.1 (NHCHH′), 32.2 (NCH3), 29.5 (C-3′), 25.9 (C-4′); m/z (LCMS, ESI
+) 259 (MH+); Accurate 
mass: Found MH+, 259.1565: C14H19N4O requires M, 259.1559. 
N-([Pyrrolidin-2′-yl]methyl)cyclohexanecarboxamide300 194 
 
Procedure: Cyclohexanecarboxylic acid (26 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-
pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. Following 
TFA-mediated deprotection and reversed-phase column chromatography (5% → 95% MeCN in 
H2O with 0.5% formic acid), the title compound (22 mg, 52%) was isolated as a pale yellow 
solid. 
M.p. 107 – 110 °C; νmax (ATR) 3282 (br), 2927 (s), 2860 (m), 1637 (s), 1542 (s), 1456 (m), 1404 
(m), 1256 (w) cm−1; δH (700 MHz, CDCl3) 6.12 – 6.03 (1H, m, NH), 3.40 – 3.34 (1H, m, NHCHH′), 
3.24 (1H, dtd, J = 8.0, 7.0, 4.5 Hz, 2′-H), 3.02 (1H, ddd, J = 13.0, 8.0, 5.0 Hz, NHCHH′), 2.93 – 
2.86 (2H, m, 5′-H2), 2.06 (1H, tt, J = 12.0, 3.5 Hz, 1
Cy-H), 1.88 – 1.79 (3H, m, 2Cy-H2H′2, 3′-HH′), 
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1.79 – 1.71 (3H, m, 3Cy-H2H′2, 4′-HH′), 1.71 – 1.62 (2H, m, 4
Cy-HH′, 4′-HH′), 1.41 (2H, tdd, 
J = 12.5, 12.0, 3.0 Hz, 2Cy-H2H′2), 1.35 (1H, ddt, J = 13.0, 8.5, 7.0 Hz, 3′-HH′), 1.29 – 1.15 (3H, m, 
3Cy-H2H′2, 4
Cy-HH′); δC (176 MHz, CDCl3, mixture of rotamers) 176.4 (C=O), 57.9 (C-2′), 46.7 
(C-5′), 45.7 (C-1Cy), 43.5 (NHCHH′), 29.9(0) (C-2Cy), 29.8(5) (C-2Cy), 29.2 (C-3′), 26.0 (C-4′), 25.9(1) 
(C-4Cy), 25.9(0) (C-3Cy); m/z (LCMS, ESI+) 211 (MH+); Accurate mass: Found MH+, 211.1808: 
C12H23N2O requires M, 211.1810. 
N-([Pyrrolidin-2′-yl]methyl)-2-(benzyloxy)benzamide 195 
 
Procedure: 2-(Benzyloxy)benzoic acid (46 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-
pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. Following 
TFA-mediated deprotection and reversed-phase column chromatography (5% → 95% MeCN in 
H2O with 0.5% formic acid), the title compound (33 mg, 53%) was isolated as an off-white solid. 
M.p. 83 – 85 °C; νmax (ATR) 3396 (br), 3058 (w), 2942 (w), 2864 (w), 1643 (s), 1598 (m), 1534 
(m), 1482 (m), 1450 (m), 1290 (m), 1230 (m), 1166 (w), 1105 (w), 1006 (w) cm−1; δH (600 MHz, 
CDCl3) 8.21 (1H, dd, J = 8.0, 2.0 Hz, 6-H), 8.12 – 8.06 (1H, m, NH), 7.50 – 7.46 (2H, m, 2
Ph-H2), 
7.45 – 7.35 (4H, m, 4-H, 3Ph-H2, 4
Ph-H), 7.09 (1H, td, J = 8.0, 1.0 Hz, 5-H), 7.05 (1H, dd, J = 8.5, 
1.0 Hz, 3-H), 5.17 (2H, s, OCH2), 3.48 (1H, ddd, J = 13.0, 6.0, 4.5 Hz, NHCHH′), 3.19 (1H, ddd, 
J = 13.0, 7.5, 5.0 Hz, NHCHH′), 3.13 (1H, tdd, J = 7.5, 7.0, 4.5 Hz, 2′-H), 2.81 – 2.72 (2H, m, 
5′-H2), 1.75 – 1.65 (2H, m, 4′-HH′, 3′-HH′), 1.64 – 1.56 (1H, m, 4′-HH′), 1.30 – 1.22 (1H, m, 
3′-HH′); δC (151 MHz, CDCl3) 165.6 (C=O), 157.0 (C-2), 135.8 (C-1
Ph), 132.7 (C-4), 132.5 (C-6), 
129.0 (C-3Ph), 128.9 (C-4Ph), 128.5 (C-2Ph), 122.2 (C-1), 121.7 (C-5), 112.6 (C-3), 71.5 (OCH2), 57.8 
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(C-2′), 46.6 (C-5′), 44.8 (NHCH2), 29.3 (C-3′), 25.8 (C-4′); m/z (LCMS, ESI
+) 311 (MH+); Accurate 
mass: Found MH+, 311.1757: C19H23N2O2 requires M, 311.1760. 
N-([Pyrrolidin-2′′-yl]methyl)-3-(1′-methylpyrazol-5′-yl)benzamide 196 
 
Procedure: 3-(1′-Methylpyrazol-5′-yl)benzoic acid (40 mg, 0.20 mmol) and 2-(aminomethyl)-1-
Boc-pyrrolidine 91 (40 mg, 0.20 mmol) were reacted according to general procedure A. 
Following TFA-mediated deprotection and reversed-phase column chromatography 
(5% → 95% MeCN in H2O with 0.5% formic acid), the title compound (34 mg, 60%) was isolated 
as an orange oil. 
νmax (ATR) 3278 (br), 2942 (w), 2876 (w), 1641 (s), 1537 (s), 1476 (w), 1404 (w), 1296 (w), 1188 
(w), 1104 (w) cm−1; δH (700 MHz, CDCl3) 7.88 (1H, td, J = 1.5, 0.5 Hz, 2-H), 7.80 (1H, dt, J = 7.5, 
1.5 Hz, 6-H), 7.52 (1H, dt, J = 7.5, 1.5 Hz, 4-H), 7.52 (1H, d, J = 2.0 Hz, 3′-H), 7.49 (1H, td, J = 7.5, 
0.5 Hz, 5-H), 7.14 – 7.07 (1H, m, NH), 6.34 (1H, d, J = 2.0 Hz, 4′-H), 3.89 (3H, s, NCH3), 3.63 (1H, 
ddd, J = 13.5, 6.0, 4.0 Hz, NHCHH′), 3.43 (1H, dddd, J = 8.0, 7.5, 7.0, 4.0 Hz, 2′′-H), 3.23 (1H, 
ddd, J = 13.5, 8.0, 5.0 Hz, NHCHH′), 2.96 (1H, ddd, J = 11.0, 8.0, 6.0 Hz, 5′′-HH′), 2.92 (1H, dt, 
J = 11.0, 7.0 Hz, 5′′-HH′), 1.94 (1H, dddd, J = 13.0, 9.0, 7.5, 5.5 Hz, 3′′-HH′), 1.86 – 1.79 (1H, m, 
4′′-HH′), 1.77 – 1.70 (1H, m, 4′′-HH′), 1.47 (1H, ddt, J = 13.0, 8.5, 7.0 Hz, 3′′-HH′); δC (176 MHz, 
CDCl3) 167.0 (C=O), 142.8 (C-5′), 138.8 (C-3′), 135.4 (C-1), 131.6 (C-4), 131.4 (C-3), 129.0 (C-5), 
127.7 (C-2), 126.9 (C-6), 106.5 (C-4′), 57.8 (C-2′′), 46.6 (C-5′′), 44.0 (NHCHH′), 37.7 (NCH3), 29.3 
(C-3′′), 26.1 (C-4′′); m/z (LCMS, ESI+) 285 (MH+); Accurate mass: Found MH+, 285.1712: 
C16H21N4O requires M, 285.1715. 
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N-([Pyrrolidin-2-yl]methyl)benzamide301 197 
 
Procedure: Benzoic acid (24 mg, 0.20 mmol) and 2-(aminomethyl)-1-Boc-pyrrolidine 91 (40 mg, 
0.20 mmol) were reacted according to general procedure A. Following TFA-mediated 
deprotection and reversed-phase column chromatography (5% → 95% MeCN in H2O with 0.5% 
formic acid), the title compound (7 mg, 17%) was isolated as a yellow oil. 
νmax (ATR) 3296 (br), 3054 (w), 2928 (w), 2872 (w), 1636 (s), 1538 (s), 1486 (m), 1404 (m), 1356 
(m), 1300 (w) cm−1; δH (700 MHz, CDCl3) 7.82 – 7.79 (2H, m, 2
Ph-H2), 7.50 – 7.45 (1H, m, 4
Ph-H), 
7.44 – 7.39 (2H, m, 3Ph-H2), 7.00 – 6.94 (1H, m, NH), 3.61 (1H, ddd, J = 13.5, 6.0, 4.0 Hz, 
NHCHH′), 3.41 (1H, dddd, J = 8.0, 7.5, 7.0, 4.0 Hz, 2-H), 3.23 (1H, ddd, J = 13.5, 8.0, 5.0 Hz, 
NHCHH′), 2.96 – 2.89 (2H, m, 5-H2), 1.91 (1H, dddd, J = 13.0, 9.0, 7.5, 5.5 Hz, 3-HH′), 1.84 – 1.78 
(1H, m, 4-HH′), 1.75 – 1.68 (1H, m, 4-HH′), 1.46 (1H, ddt, J = 13.0, 8.5, 7.0 Hz, 3-HH′); 
δC (176 MHz, CDCl3) 167.7 (C=O), 134.8 (C-1
Ph), 131.5 (C-4Ph), 128.6 (C-3Ph), 127.1 (C-2Ph), 57.9 
(C-2), 46.6 (C-5), 44.0 (NHCHH′), 29.3 (C-3), 26.1 (C-4); m/z (LCMS, ESI+) 205 (MH+); Accurate 
mass: Found MH+, 205.1347: C12H17N2O requires M, 205.1341. 
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8.4 Additional compounds 
2-(2′-[{4′′′-Chlorophenyl}{phenyl}methoxy]ethyl)-1-(ethoxycarbonyl)pyrrolidine 198 
A mixture of (2R,1′′R), (2R,1′′S), (2S,1′′R) and (2S,1′′S) diastereomers 
 
Procedure:302 Ethyl chloroformate (15 µL, 0.15 mmol) was added dropwise to an ice cold 
solution of amine 77 (43 mg, 0.14 mmol), NEt3 (21 µL, 0.15 mmol) and DCM (0.4 mL). After 
allowing the reaction mixture to warm slowly to RT over 2.5 h, TLC analysis showed 
consumption of amine 77. Ethyl acetate (5 mL) was then added and the solids removed by 
filtration through celite®, followed by washing the filter cake with ethyl acetate (3 × 5 mL). The 
combined organic filtrates were then concentrated in vacuo prior to purification by 
chromatography on SiO2 (15% → 30% EtOAc in hexanes) to afford the title compound (25 mg, 
46%) as a clear colourless oil. 
Rf 0.70 (50% EtOAc in hexanes); νmax (ATR) 2960 (w), 2870 (w), 1689 (s), 1488(w), 1414 (m), 
1379 (w), 1333 (w), 1184 (w), 1088 (s) cm−1; δH (700 MHz, CDCl3,mixture of diastereomers) 
7.33 – 7.20 (9H, m, ArH), 5.33 – 5.28 (1H, m, 1′′-H), 4.15 – 4.05 (2H, m, OCH2CH3), 3.99 – 3.93 
(1H, m, 2-H), 3.52 – 3.27 (4H, m, 2′-H2, 5-H2), 2.21 – 2.04 (1H, m, 1′-HH′), 1.95 – 1.87 (1H, m, 
3-HH′), 1.87 – 1.77 (2H, m, 4-H2), 1.76 – 1.71 (1H, m, 3-HH′), 1.66 – 1.58 (1H, m, 1′-HH′), 1.26 – 
1.18 (3H, m, OCH2CH3); δC (176 MHz, CDCl3, mixture of diastereomers) 155.2 (C=O), 142.1 
(ArC), 141.3 (ArC), 133.2 (ArC), 128.5(8) (ArC), 128.5(6) (ArC), 128.4 (ArC), 127.7 (ArC), 127.0 
(ArC), 83.0 (C-1′′), 66.9 (C-2′), 66.8 (C-2′), 60.9 (OCH2CH3), 60.8 (OCH2CH3), 56.0 (C-2), 55.2 (C-2), 
46.5 (C-5), 46.3 (C-5), 34.9 (C-1′), 34.2 (C-1′), 31.2 (C-3), 30.7 (C-3), 24.0 (C-4), 23.2 (C-4), 14.9 
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(OCH2CH3); m/z (LCMS, ESI
+) 388 (M(35Cl)H+), 390 (M(37Cl)H+); Accurate mass: Found MH+, 
388.1681: C22H27NO3
35Cl requires M, 388.1679. 
2-(1′-Phenylethoxy)-ethyldimethylamine 199  
 
Procedure: To a solution of 2-dimethylaminoethanol 81 (0.50 mL, 5 mmol) in DCM (10 mL) was 
added methanesulfonyl chloride (0.41 mL, 5.25 mmol) and the mixture stirred at RT until TLC 
analysis showed consumption of starting material. The reaction was then diluted with DCM (5 
mL) before the addition of 1-phenylethanol 79 (0.62 mL, 5 mmol) and KOtBu (1.17g, 10.25 
mmol). After stirring for 4 h the reaction was quenched with the addition of H2O (15 mL) and 
the biphasic mixture was extracted with DCM (3 × 10 mL). The combined organic extracts were 
dried over MgSO4 and concentrated in vacuo before purification by SiO2 column (0% → 10% 
MeOH in CHCl3 with 1% NEt3) furnished the title compound (628 mg, 65%) as a clear colourless 
oil. 
Rf 0.23 (10% MeOH and 1% NEt3 in CHCl3); νmax (ATR) 2973 (w), 2929 (w), 2853 (w), 2813 (w), 
2764 (w), 1446 (m), 1276 (w), 1104 (s), 1032 (m) cm−1; δH (700 MHz, CDCl3) 7.33 – 7.29 (4H, m, 
ArH), 7.26 – 7.23 (1H, m, ArH), 4.39 (1H, q, J = 6.5 Hz, 1′-H), 3.39 (2H, t, J = 6.0 Hz, 2-H2), 2.54 –
 2.47 (2H, m, 1-H2), 2.24 (6H, s, N(CH3)2), 1.43 (3H, d, J = 6.5 Hz, 2′-H3); δC (176 MHz, CDCl3) 
143.9 (C-5), 128.5 (ArC), 127.5 (ArC), 126.3 (ArC), 78.6 (C-1′), 66.6 (C-2), 59.1 (C-1), 45.8 
(N(CH3)2), 24.2 (C-2′); m/z (LCMS, ESI
+) 194 (MH+); Accurate mass: Found MH+, 194.1524: 
C12H20NO requires M, 194.1545. 
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Methyl 3-(4′-methylpiperazin-1′-yl)propanoate303 200  
 
Procedure:304 A solution of 1-methylpiperazine (1.12 mL, 10.00 mmol), methyl acrylate 
(1.00 mL, 11.00 mmol) and I2 (838 mg, 3.30 mmol) in DCM (10 mL) was stirred at RT for 18 h. 
The reaction mixture was then washed with saturated aq. sodium thiosulfate (2 × 5 mL), dried 
over MgSO4 and the volatiles removed under reduced pressure. Purification by column 
chromatography (0% → 10% MeOH in CHCl3 with 1% NEt3) gave the title compound (1.20 g, 
64%) as a yellow oil. 
Rf 0.53 (10% MeOH in CHCl3 with 1% NEt3); νmax (ATR) 3360 (br), 2940 (m), 2795 (m), 1733 (s), 
1438 (m), 1282 (m), 1161 (s), 1085 (w), 1010 (s) cm−1; δH (700 MHz, CDCl3) 3.65 (3H, s, OCH3), 
2.68 (2H, t, J = 7.5 Hz, 2-H2), 2.66 – 2.31 (8H, m, 2′-(H2)2, 3′-(H2)2), 2.48 (2H, t, J = 7.5 Hz, 3-H2), 
2.26 (3H, s, NCH3); δC (176 MHz, CDCl3) 173.0 (C=O), 55.1 (C-3′), 53.6 (C-2), 52.9 (C-2′), 51.7 
(OCH3), 46.0 (NCH3), 32.2 (C-3); m/z (LCMS, ESI
+) 187 (MH+). 
3-(4′-Methylpiperazin-1′-yl)propan-1-ol305 201  
 
Procedure:222 To a 0 °C solution of methyl ester 200 (1.00 g, 5.40 mmol) in THF (27 mL) was 
slowly added LiAlH4 (2.4 M solution in THF, 3.40 mL, 8.10 mmol), before being allowed to 
warm to RT. After 3 h the mixture was cooled once more in an ice bath and quenched 
according to Fieser’s method (general procedure D).273 The combined organic filtrates were 
concentrated in vacuo to afford the crude product (715 mg, 84%) as a clear colourless oil which 
was used without any further purification. 
Rf 0.29 (10% MeOH in CHCl3 with 1% NH4OH(aq.)); νmax (ATR) 3324 (br), 2940 (m), 2809 (m), 1649 
(w), 1459 (m), 1283 (m), 1147 (m), 1009 (m) cm−1; δH (700 MHz, CDCl3) 3.75 – 3.73 (2H, m, 
1-H2), 2.84 – 2.12 (8H, m, 2′-(H2)2, 3′-(H2)2), 2.58 – 2.56 (2H, m, 3-H2), 2.23 (3H, s, NCH3), 1.69 – 
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1.65 (2H, m, 2-H2); δC (176 MHz, CDCl3) 64.5 (C-1), 58.7 (C-3), 55.2 (C-3′), 53.3 (C-2′), 46.0 
(NCH3), 27.2 (C-2); m/z (LCMS, ESI
+) 159 (MH+). 
Methyl 3-(imidazol-1′-yl)propanoate306 202 
 
Procedure:304 Imidazole (681 mg, 10.00 mmol) was reacted with methyl acrylate (1.00 mL, 
11.00 mmol) according to the conditions for the synthesis of ester 200, providing the title 
compound (161 mg, 10%) as a pale yellow oil. 
Rf 0.50 (10% MeOH in CHCl3 with 1% NEt3); νmax (ATR) 3306 (br), 3110 (w), 2954 (w), 1728 (s), 
1508 (m), 1438 (m), 1208 (s), 1168 (s), 1080 (m) cm−1; δH (700 MHz, CDCl3) 7.52 (1H, s, 2′-H), 
7.02 (1H, s, 4′-H), 6.92 (1H, s, 5′-H), 4.26 (2H, t, J = 6.5 Hz, 3-H2), 3.67 (3H, s, OCH3), 2.77 (2H, t, 
J = 6.5 Hz, 2-H2); δC (176 MHz, CDCl3) 171.0 (C=O), 137.3 (C-2′), 129.5 (C-4′), 119.0 (C-5′), 52.2 
(OCH3), 42.4 (C-3), 35.9 (C-2); m/z (LCMS, ESI
+) 155 (MH+). 
3-(Morpholin-4′-yl)propan-1-ol307 203 
 
Procedure: A mixture of 3-bromo-1-propanol (1.40 mL, 15.00 mmol), morpholine (3.28 mL, 
37.50 mmol) and potassium iodide (30 mg, 0.18 mmol) in DCM (23 mL) was stirred at RT for 
21 h. 1 M NaOH(aq.) (16 mL) was then added and the biphasic mixture extracted with DCM (3 × 
10 mL), after which the combined organic extracts were dried over MgSO4 and concentrated in 
vacuo. Purification by SiO2 column (0% → 10% MeOH in CHCl3 with 1% NEt3) afforded the title 
compound (928 mg, 43%) as a pale yellow oil. 
Rf 0.63 (10% MeOH in CHCl3 with 1% NEt3); νmax (ATR) 3356 (br), 2942 (m), 2853 (m), 2812 (m), 
1447 (w), 1303 (w), 1269 (w), 1113 (s), 1065 (m) cm−1; δH (700 MHz, CDCl3) 3.78 (2H, t, 
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J = 5.5 Hz, 1-H2), 3.72 – 3.66 (4H, m, 2′-(H2)2), 2.61 (2H, t, J = 6.0 Hz, 3-H2), 2.56 – 2.40 (4H, m, 
3′-(H2)2), 1.74 – 1.70 (2H, m, 2-H2); δC (176 MHz, CDCl3) 67.0 (C-2′), 64.5 (C-1), 59.2 (C-3), 53.9 
(C-3′), 26.9 (C-2); m/z (LCMS, ESI+) 146 (MH+). 
Phenyl(1′-methylimidazol-2′-yl)methanol308 204  
 
Procedure:309 A solution of N-methyl imidazole (0.56 mL, 7.00 mmol), in THF (7 mL) was cooled 
to −78 °C and n-BuLi (1.6 M in hexanes, 4.33 mL, 7.00 mmol) was added dropwise. The mixture 
was stirred for 15 min before being warmed to −20 °C for 1 h. After being cooled once more to 
−78 °C, a solution of benzaldehyde (0.71 mL, 7.00 mmol) in THF (4 mL) was added via cannula 
and the reaction mixture allowed to warm slowly to RT. After TLC analysis showed 
consumption of benzaldehyde, the reaction was quenched by the addition of 3 M HCl(aq.) 
(15 mL) and THF removed under reduced pressure. Ether (20 mL) was added, the mixture was 
separated and the organic phase washed with 3 M HCl(aq.) (3 × 15 mL). The collected aqueous 
washings were then adjusted to pH ≈ 9 and extracted with DCM (3 × 30 mL). The combined 
organic fractions were dried over MgSO4 and concentrated in vacuo to afford the title 
compound (928 mg, 70%) as an off-white solid that was used without further purification. 
Rf 0.57 (10% MeOH in CHCl3 with 1% NH4OH(aq.)); νmax (ATR)
 3076 (br), 2822 (m), 2680 (m), 1492 
(m), 1446 (m), 1406 (w), 1272 (m), 1174 (w), 1134 (w), 1049 (m), 1020 (m) cm−1; δH (700 MHz, 
CDCl3) 7.34 – 7.30 (4H, m, ArH), 7.27 – 7.24 (1H, m, ArH), 6.87 – 6.86 (1H, m, 4′-H), 6.74 – 6.73 
(1H, m, 5′-H), 5.92 (1H, s, 1-H), 3.38 (3H, s, NCH3); δC (151 MHz, CDCl3) 149.3 (C-2′), 141.0 (C-2), 
128.5 (ArC), 127.7 (ArC), 126.4(1) (C-4′), 126.3(8) (C-3), 122.3 (C-5′), 69.2 (C-1), 33.3 (NCH3); 
m/z (LCMS, ESI+) 189 (MH+). 
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4-Methoxyphenyl(phenyl)methanol310 205 
 
Procedure: 4-Methoxybenzaldehyde (99%, 2.13 mL, 20.00 mmol) was reacted according to 
general procedure C, furnishing the title compound (2.57 g, quantitative) as an off-white solid 
after chromatography on silica (0% → 60% ether in hexanes). 
Rf 0.31 (40% ether in hexanes); M.p. 63 – 65 °C (lit.:
311 62 – 65 °C); νmax (ATR) 3552 (br), 3056 
(w), 3029 (w), 3001 (w), 2956 (w), 1511 (s), 1455 (w), 1366 (s), 1230 (s), 1032 (m) cm−1; 
δH (700 MHz, CDCl3) 7.39 – 7.27 (7H, m, ArH), 6.89 – 6.85 (2H, m, 3-H2), 5.82 (1H, s, CHOH), 
3.79 (3H, s, OCH3); δC (176 MHz, CDCl3) 159.2 (C-4), 144.2 (C-1
Ph), 136.3 (C-3), 128.6 (ArC), 
128.1 (ArC), 127.6 (ArC), 126.5 (ArC), 114.0 (C-3), 76.0 (CHOH), 55.4 (OCH3); m/z (LCMS, ESI
+) 
197 (M − OH−). 
4-Bromophenyl(phenyl)(ethoxymethoxy)methane 206 
 
Procedure: To a 0 °C solution of alcohol 164 (1.01 g, 3.85 mmol) in DCM (10 mL) was added 
DIPEA (99%, 1.35 mL, 7.69 mmol) then chloromethylethyl ether (95%, 0.64  mL, 6.55 mmol). 
The mixture was reacted at 40 °C overnight, after which full conversion of starting material 
was observed by TLC analysis. Saturated NH4Cl(aq.) (10 mL) was added and the aqueous layer 
removed and washed with DCM (3 × 10 mL). The combined organic extracts were dried over 
MgSO4, concentrated in vacuo, and the residue purified via silica flash column chromatography 
(0% → 40% ether in hexanes) to provide the title compound (996 mg, 80%) as a clear yellow oil. 
Rf 0.63 (40% ether in hexanes); νmax (ATR) 3017 (w), 2943 (w), 2882 (w), 1486 (m), 1455 (m), 
1366 (s), 1218 (s), 1097 (m), 1008 (s) cm−1; δH (700 MHz, CDCl3) 7.46 – 7.44 (2H, m, 3-H2), 7.33 
(4H, apparent d, J = 4.5 Hz, 2Ph-H2, 3
Ph-H2), 7.29 – 7.26 (1H, m, 4
Ph-H), 7.26 – 7.23 (2H, m, 2-H2), 
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5.71 (1H, s, Ar2CH), 4.73 (2H, apparent d, J = 1.5 Hz, 1
Al-H2), 3.64 (2H, apparent dq, J = 7.0, 1.0 
Hz, 1Al′-H2), 1.18 (3H, t, J = 7.0 Hz, 2
Al′-H3); δC (176 MHz, CDCl3) 141.5 (C-1
Ph), 141.3 (C-1), 131.6 
(C-3), 129.0 (C-2), 128.6 (C-3Ph), 127.8 (C-4Ph), 127.3 (C-2Ph), 121.5 (C-4), 92.9 (C-1Al), 78.4 
(Al2CH), 63.8 (C-1
Al′), 15.2 (C-2Al′); m/z (LCMS, ESI+) 245 (M(79Br) − C3H7O2
−), 247 
(M(81Br) − C3H7O2
−). 
(4S)-N,N,2,2-Tetramethyl-1,3-dioxolane-4-carboxamide312 207 
 
Procedure:312 (−)-Methyl (4S)-2,2-dimethyl-1,3-dioxolane-4-carboxylate (96%, 2.65 g, 
15.90 mmol) was added to a 0 °C solution of dimethylamine (2 M in MeOH, 80 mL). The 
mixture was stirred at RT for 24 h, before the removal of volatiles in vacuo provided a residue 
which was purified on SiO2 column (0% → 50% EtOAc in hexanes). The title compound (2.53 g, 
92%) was isolated as a clear colourless oil. 
No optical rotation measurement was obtained. Rf 0.18 (40% EtOAc in hexanes); νmax (ATR) 
2980 (w), 2934 (w), 2870 (w), 1647 (s), 1498 (w), 1372 (m), 1256 (m), 1213 (m), 1151 (m), 1064 
(s) cm−1; δH (600 MHz, CDCl3) 4.68 (1H, t, J = 6.5 Hz, 4-H), 4.37 (1H, dd, J = 8.5, 6.5 Hz, 5-HH′), 
4.13 (1H, dd, J = 8.5, 6.5 Hz, 5-HH′), 3.11 (3H, s, N(CH3)CH3), 2.96 (3H, s, N(CH3)CH3), 1.42 – 1.39 
(6H, m, 2-(CH3)2); δC (151 MHz, CDCl3) 169.1 (C=O), 110.6 (C-2), 73.6 (C-4), 66.6 (C-5), 37.0 
(N(CH3)CH3), 35.9 (N(CH3)CH3), 26.1 (2-(CH3)(CH3)), 25.9 (2-(CH3)(CH3)); m/z (LCMS, ESI
+) 174 
(MH+), 196 (MNa+). 
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(4S)-2-methyl-3-oxopent-1-ene-4,5-diyl diacetate313 208 
 
Procedure:312,313 Isopropenylmagnesium bromide (0.5 M in THF, 30.30 mL, 15.20 mmol) was 
added to a stirred 0 °C solution of amide 207 (2.50 g, 14.50 mmol) in ether (60 mL). After 
20 min, when TLC analysis revealed consumption of starting material, the solution was cooled 
in an ice bath and 1 M HCl (40 mL) was added. The biphasic mixture was separated and the 
aqueous layer washed with ether (2 × 20 mL) and brine (40 mL). The combined organic extracts 
were dried over MgSO4 and concentrated in vacuo, before purification by SiO2 column (0% → 
20% ether in hexanes) provided 1-((4′S)-2′,2′-dimethyl-1′,3′-dioxolan-4′-yl)-2-methylprop-2-en-
1-one (789 mg, 32%) as a clear colourless oil. 
The prepared dioxolane proved to be unstable, so was carried forward immediately to the next 
step in the sequence. 1-((4′S)-2′,2′-dimethyl-1′,3′-dioxolan-4′-yl)-2-methylprop-2-en-1-one 
(105 mg, 0.62 mmol) was dissolved in 90% MeOH(aq.) (2 mL) and stirred at reflux with DOWEX 
ion exchange resin (50WX2 100-200 mesh, 105 mg) for 1.5 h. The mixture was then filtered 
and concentrated under reduced pressure before being dissolved in DCM (2.5 mL) and cooled 
to 0 °C. Pyridine (0.11 mL, 1.36 mmol), NEt3 (99%, 8 µL, 0.06 mmol) then acetic anhydride 
(0.29 mL, 3.1 mmol) were added and the reaction stirred at RT. After 5 h the volatiles were 
removed in vacuo and the residue separated on silica column (0% → 50% EtOAc in hexanes) to 
furnish the title compound (101 mg, 81%) as a clear colourless oil. 
No optical rotation measurement was obtained. Rf 0.52 (50% EtOAc in hexanes); νmax (ATR) 
2976 (w), 2934 (w), 1737 (s), 1693 (m), 1440 (w), 1371 (m), 1216 (s), 1044 (m) cm−1; 
δH (700 MHz, CDCl3) 6.12 (1H, q, J = 1.0 Hz, 1-Htrans), 5.95 (1H, q, J = 1.5 Hz, 1-Hcis), 5.90 (1H, dd, 
J = 7.0, 3.0 Hz, 4-H), 4.51 (1H, dd, J = 12.0, 3.0 Hz, 5-HH′), 4.26 (1H, dd, J = 12.0, 7.0 Hz, 5-HH′), 
2.16 (3H, s, 2Ac-H3), 2.08 (3H, s, 2
Ac′-H3), 1.91 (3H, dd, J = 1.5, 1.0 Hz, 2-CH3); δC (176 MHz, CDCl3) 
194.8 (C-3), 170.8 (C-1Ac′), 170.3 (C-1Ac), 142.5 (C-2), 126.6 (C-1), 72.8 (C-4), 63.2 (C-5), 20.9 
(C-2Ac′), 20.8 (C-2Ac), 17.9 (4-CH3); m/z (GCMS, EI) 43 (CH3CO
•), 171 (M − CH3CO
•). 
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(2S)-3,4-dioxopentane-1,2-diyl diacetate313 209 
 
Procedure:313 A solution of olefin 208 (155 mg, 0.77 mmol) in MeOH (25 mL) was cooled to 
−78 °C and a mixture of O3 in O2 was bubbled through the stirred solution until a persistent 
blue colour was achieved. The solution was then purged with O2 and dimethylsulfide (0.80 mL, 
10.84 mmol) was added dropwise. The quenched mixture was warmed to RT overnight, after 
which the solution displayed minimal peroxide content. After concentration under reduced 
pressure, the residue was purified by SiO2 flash chromatography (0% → 40% ether in hexanes) 
to furnish the title compound (83 mg, 50%) as a yellow oil. 
No optical rotation measurement was obtained. Rf 0.18 (20% EtOAc in hexanes); νmax (ATR) 
2994 (w), 2924 (w), 1732 (s), 1438 (w), 1373 (m), 1218 (s), 1038 (m) cm−1; δH (700 MHz, CDCl3) 
5.84 (1H, t, J = 4.0 Hz, 2-H), 4.67 (1H, dd, J = 12.5, 4.0 Hz, 1-HH′), 4.34 (1H, dd, J = 12.5, 4.0 Hz, 
1-HH′), 2.38 (3H, s, 5-H3), 2.16 (3H, s, 2
Ac-H3), 2.04 (3H, s, 2
Ac′-H3); δC (176 MHz, CDCl3) 196.0 
(C-4), 190.2 (C-3), 171.1 (C-1Ac′), 170.2 (C-1Ac), 72.8 (C-2), 62.5 (C-1), 23.8 (C-5), 20.7 (C-2Ac′), 
20.5 (C-2Ac); m/z (GCMS, EI) 43 (CH3CO
•), 173 (M − CH3CO
•). 
6-(tert-Butyldimethylsilyloxy)hex-1-ene314 210 
 
Procedure: To a mixture of 5-hexen-1-ol (98%, 304 mg, 2.97 mmol), NEt3 (99%, 0.50 mL, 
3.56 mmol) and 4-dimethylaminopyridine (99%, 74 mg, 0.60 mmol) in DCM (3 mL) was added a 
solution of tert-butyldimethylsilyl chloride (97%, 485 mg, 3.12 mmol) in DCM (2 mL). The 
mixture was stirred for 4 h, after which TLC analysis revealed consumption of the reagent 
alcohol. The reaction was quenched by the addition of H2O (8 mL) and the mixture passed 
through a phase separator. After removal of volatiles, the organic residue was purified via 
silica column chromatography (0% → 20% ether in hexanes) to afford the title compound 
(490 mg, 77%) as a clear colourless oil. 
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Rf 0.79 (20% EtOAc in hexanes); νmax (ATR) 2954 (m), 2928 (m), 2861 (m), 1258 (s), 1032 (br, 
s) cm−1; δH (700 MHz, CDCl3) 5.81 (1H, ddt, J = 17.0, 10.0, 6.5 Hz, 2-H), 5.00 (1H, ddt, J = 17.0, 
2.0, 1.5 Hz, 1-Hcis), 4.94 (1H, ddt, J = 10.0, 2.0, 1.0 Hz, 1-Htrans), 3.61 (2H, t, J = 6.5 Hz, 6-H2), 2.10 
– 2.03 (2H, m, 3-H2), 1.57 – 1.50 (2H, m, 5-H2), 1.47 – 1.39 (2H, m, 4-H2), 0.89 (9H, s, 
OSi(C(CH3)3)(CH3)2), 0.05 (6H, s, OSi(C(CH3)3)(CH3)2); δC (176 MHz, CDCl3) 139.1 (C-2), 114.5 
(C-1), 63.2 (C-6), 33.7 (C-3), 32.5 (C-5), 26.1 (OSi(C(CH3)3)(CH3)2), 25.3 (C-4), 18.5 
(OSi(C(CH3)3)(CH3)2), −5.1 (OSi(C(CH3)3)(CH3)2); m/z (GCMS, EI) 157 (M − C(CH3)3
•), 199 
(M − CH3
•). 
5-(tert-Butyldimethylsilyloxy)pentanal315 211 
 
Procedure:313 A solution of olefin 210 (429 mg, 2.00 mmol) in MeOH (20 mL) was cooled to 
−78 °C and a mixture of O3 in O2 was bubbled through the stirred solution until a persistent 
blue colour was achieved. The solution was then purged with O2 and dimethylsulfide (2.06 mL, 
28.00 mmol) was added dropwise. The quenched mixture was warmed to RT overnight, after 
which the solution displayed minimal peroxide content. After concentration under reduced 
pressure, the residue was purified by SiO2 flash chromatography (0% → 40% EtOAc in hexanes) 
to furnish the title compound (262 mg, 61%) as a clear colourless oil. 
Rf 0.22 (20% ether in hexanes); νmax (ATR) 2954 (w), 2929 (w), 2858 (w), 1729 (s), 1468 (w), 
1410 (w), 1253 (m), 1095 (s) cm−1; δH (600 MHz, CDCl3) 9.78 – 9.76 (1H, m, 1-H), 3.63 (2H, t, 
J = 6.0 Hz, 5-H2), 2.48 – 2.44 (2H, m, 2-H2), 1.74 – 1.67 (2H, m, 3-H2), 1.60 – 1.52 (2H, m, 4-H2), 
0.89 (9H, s, OSi(C(CH3)3)(CH3)2), 0.04 (6H, s, OSi(C(CH3)3)(CH3)2); δC (151 MHz, CDCl3) 202.9 
(C-1), 62.8 (C-5), 43.8 (C-2), 32.3 (C-4), 26.1 (OSi(C(CH3)3)(CH3)2), 18.8 (C-3), 18.5 
(OSi(C(CH3)3)(CH3)2), −5.2 (OSi(C(CH3)3)(CH3)2); m/z (LCMS, ESI
+) 217 (MH+); Accurate mass: 
Found MH+, 217.1635: C11H25O2Si requires M, 217.1624. 
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1-([{Hex-5′-en-1′-yl}oxy]methyl)-4-methoxybenzene316 212 
 
Procedure:316 To a 0 °C solution of NaH (60%, 424 mg, 10.61 mmol) in DMF (8 mL) was added 
5-hexen-1-ol (98%, 1.00 mL, 8.16 mmol) in DMF (20 mL). After stirring in an ice bath for 1 h, 
4-methoxybenzyl chloride (98%, 1.35 mL, 9.79 mmol) was added dropwise and the reaction 
mixture warmed to RT. After 5 h, the mixture was re-cooled to 0 °C and quenched by the 
addition of ice cold H2O (200 mL). The biphasic mixture was extracted with hexanes (6 × 20 mL) 
and the collected organic washings concentrated in vacuo then purified on SiO2 column 
(0% → 20% ether in hexanes) to furnish the title compound (1.47 g, 82%) as a clear colourless 
oil. 
Rf 0.28 (5% ether in hexanes); νmax (ATR) 3000 (w), 2936 (w), 2857 (w), 1613 (w), 1512 (s), 1455 
(w), 1366 (m), 1302 (w), 1245 (s), 1097 (s), 1036 (s) cm−1; δH (700 MHz, CDCl3) 7.29 – 7.24 (2H, 
m, 2-H2), 6.90 – 6.85 (2H, m, 3-H2), 5.80 (1H, ddt, J = 17.0, 10.0, 6.5 Hz, 5′-H), 5.00 (1H, dq, 
J = 17.0, 2.0, 1.5 Hz, 6′-Hcis), 4.94 (1H, ddt, J = 10.0, 2.0, 1.0 Hz, 6′-Htrans), 4.43 (2H, s, OCH2), 3.80 
(3H, s, OCH3), 3.45 (2H, t, J = 6.5 Hz, 1′-H2), 2.06 (2H, tddd, J = 8.0, 6.5, 1.5, 1.0 Hz, 4′-H2), 1.65 – 
1.58 (2H, m, 2′-H2), 1.50 – 1.43 (2H, m, 3′-H2); δC (176 MHz, CDCl3) 159.3 (C-4), 138.9 (C-5′), 
130.9 (C-1), 129.4 (C-2), 114.6 (C-6′), 113.9 (C-3), 72.7 (OCH2), 70.1 (C-1′), 55.4 (OCH3), 33.7 
(C-4′), 29.4 (C-2′), 25.7 (C-3′); m/z (GCMS, EI) 121 (CH2([p-OCH3]C6H4)
•), 220 (M•). 
2-([Hex-5′-en-1′-yl]oxy)tetrahydropyran317 213 
 
Procedure: A mixture of 5-hexen-1-ol (98%, 1.00 mL, 8.16 mmol), 3,4-dihydro-2H-pyran (97%, 
1.14 mL, 12.24 mmol) and pyridinium p-toluenesulfonate (98%, 210 mg, 0.82 mmol) was 
stirred in DCM (30 mL) for 5 h. H2O (20 mL) was added to quench the reaction before the 
mixture was passed through a phase separator. Subsequent removal of volatiles and 
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purification of the organic residue by SiO2 column chromatography (0% → 20% ether in 
hexanes) provided the title compound (1.38 g, 92%) as a colourless clear oil. 
Rf 0.50 (20% ether in hexanes); νmax (ATR) 2939 (m), 2869 (m), 1441 (w), 1353 (w), 1201 (m), 
1119 (m), 1078 (m), 1033 (s) cm−1; δH (700 MHz, CDCl3) 5.81 (1H, ddt, J = 17.0, 10.0, 6.5 Hz, 
5′-H), 5.00 (1H, ddt, J = 17.0, 2.0, 1.5 Hz, 6′-Hcis), 4.94 (1H, ddt, J = 10.0, 2.0, 1.0 Hz, 6′-Htrans), 
4.57 (1H, dd, J = 4.5, 3.0 Hz, 2-H), 3.86 (1H, ddd, J = 11.0, 8.0, 3.0 Hz, 6-HH′), 3.73 (1H, dt, 
J = 9.5, 7.0 Hz, 1′-HH′), 3.52 – 3.46 (1H, m, 6-HH′), 3.38 (1H, dt, J = 9.5, 6.5 Hz, 1′-HH′), 2.08 (2H, 
tddd, J = 7.5, 6.5, 1.5, 1.0 Hz, 4′-H2), 1.86 – 1.79 (1H, m, 4-HH′), 1.74 – 1.68 (1H, m, 3-HH′), 1.65 
– 1.57 (2H, m, 2′-H2), 1.59 – 1.54 (2H, m, 3-HH′, 5-HH′), 1.54 – 1.49 (2H, m, 4-HH′, 5-HH′), 1.49 – 
1.43 (2H, m, 3′-H2); δC (176 MHz, CDCl3) 138.9 (C-5′), 114.6 (C-6′), 99.0 (C-2), 67.5 (C-1′), 62.4 
(C-6), 33.7 (C-4′), 30.9 (C-3), 29.4 (C-2′), 25.7(3) (C-3′), 25.6(5) (C-5), 19.8 (C-4); m/z (LCMS, ESI+) 
391 (M2Na
+). 
2-(3′-Bromopropoxy)tetrahydropyran318 214 
 
Procedure: A mixture of 3-bromopropan-1-ol (97%, 0.23 mL, 2.50 mmol), 3,4-dihydro-2H-pyran 
(97%, 0.35 mL, 3.75 mmol) and pyridinium p-toluenesulfonate (98%, 64 mg, 0.25 mmol) was 
stirred in DCM (10 mL) for 6 h. H2O (8 mL) was added to quench the reaction before the 
mixture was passed through a phase separator. The organic extracts were concentrated in 
vacuo and purified on SiO2 column (0% → 40% ether in hexanes) to afford the title compound 
(558 mg, quantitative) as a colourless clear oil. 
Rf 0.43 (20% ether in hexanes); νmax (ATR) 2941 (m), 2871 (m), 1441 (w), 1353 (m), 1201 (m), 
1134 (m), 1076 (m), 1031 (s) cm−1; δH (600 MHz, CDCl3) 4.60 (1H, t, J = 3.5 Hz, 2-H), 3.90 – 3.84 
(2H, m, 1′-HH′, 6-HH′), 3.57 – 3.49 (4H, m, 1′-HH′, 3′-H2, 6-HH′), 2.13 (2H, p, J = 6.5 Hz, 2′-H2), 
1.87 – 1.76 (1H, m, 4-HH′), 1.76 – 1.67 (1H, m, 3-HH′), 1.64 – 1.47 (4H, m, 3-HH′, 4-HH′, 5-H2); 
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δC (151 MHz, CDCl3) 99.0 (C-2), 65.1 (C-1′), 62.4 (C-6), 33.1 (C-2′), 30.8 (C-3′), 30.8 (C-3), 25.6 
(C-5), 19.7 (C-4); m/z (GCMS, EI) 221 (M(79Br) − H•), 223 (M(81Br) − H•). 
Ethyl 10-(tert-butyldimethylsilyloxy)decanoate 215 
 
Procedure: A mixture of 10-hydroxydecanoic acid (403 mg, 2.14 mmol), concentrated H2SO4 
(50 µL) and EtOH (10 mL) was stirred at reflux for 18 h. The reaction was then cooled, 
concentrated in vacuo and diluted with DCM (20 mL) prior to washing with 3 M NaOH(aq.) 
(3 × 20 mL). The organic fraction was then washed with brine (20 mL), dried over MgSO4 and 
the volatiles removed under reduced pressure to furnish the crude ethyl 10-hydroxydecanoate 
(429 mg, 93%) as a pale yellow oil which was used without further purification. 
To a mixture of ethyl 10-hydroxydecanoate (418 mg, 1.93 mmol), NEt3 (99%, 0.33 mL, 
2.32 mmol) and 4-dimethylaminopyridine (99%, 48 mg, 0.39 mmol) in DCM (2 mL) was added a 
solution of tert-butyldimethylsilyl chloride (97%, 315 mg, 2.03 mmol) in DCM (2 mL). The 
mixture was stirred for 4 h, after which TLC analysis revealed consumption of the reagent 
alcohol. The reaction was quenched by the addition of H2O (5 mL) and the mixture passed 
through a phase separator. After removal of volatiles, the organic residue was purified via 
silica column chromatography (0% → 20% ether in hexanes) to afford the title compound 
(556 mg, 87%) as a clear colourless oil. 
Rf 0.55 (20% ether in hexanes); νmax (ATR) 2971 (w), 2928 (w), 2855 (w), 1737 (s), 1448 (w), 
1366 (s), 1229 (s) cm−1; δH (600 MHz, CDCl3) 4.12 (2H, q, J = 7.0 Hz, OCH2CH3), 3.59 (2H, t, 
J = 6.5 Hz, 10-H2), 2.28 (2H, t, J = 7.5 Hz, 2-H2), 1.61 (2H, p, J = 7.5 Hz, 3-H2), 1.52 – 1.46 (2H, m, 
9-H2), 1.33 – 1.27 (10H, m, 8-H2, 4-H2, AlH), 1.25 (3H, t, J = 7.0 Hz, OCH2CH3), 0.89 (9H, s, 
OSi(C(CH3)3)(CH3)2), 0.04 (6H, s, OSi(C(CH3)3)(CH3)2); δC (151 MHz, CDCl3) 174.1 (C=O), 63.5 
(C-10), 60.3 (OCH2CH3), 34.6 (C-2), 33.0 (C-9), 29.6 (AlC), 29.5 (AlC), 29.4 (AlC), 29.3 (AlC), 26.1 
(OSi(C(CH3)3)(CH3)2), 25.9 (C-8), 25.1 (C-3), 18.5 (OSi(C(CH3)3)(CH3)2), 14.42 (OCH2CH3), −5.1 
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(OSi(C(CH3)3)(CH3)2); m/z (LCMS, ESI
+) 331 (MH+); Accurate mass: Found MH+, 331.2683: 
C18H39O3Si requires M, 331.2668. 
10-(tert-Butyldimethylsilyloxy)decanoic acid319 216 
 
Procedure: Ester 215 (515 mg, 1.56 mmol) and LiOH (74 mg, 3.12 mmol) were stirred in a 
mixture of THF (5 mL) and H2O (5 mL) at 50 °C until TLC analysis displayed full saponification of 
the starting material. The mixture was then cooled in an ice bath and the pH adjusted to 4 
using 1 M HCl, before being washed with EtOAc (3 × 10 mL). The combined organic extracts 
were washed with brine (20 mL), dried over MgSO4 and concentrated in vacuo. SiO2 column 
chromatography (0% → 40% ether in hexanes with 0.5% formic acid) of the crude mixture 
revealed the title compound (218 mg, 46%) as a clear colourless oil. 
Rf 0.58 (20% ether in DCM with 1% formic acid); νmax (ATR) 3017 (w), 2928 (w), 2856 (w), 1728 
(s), 1455 (w), 1366 (s), 1229 (s), 1095 (m) cm−1; δH (700 MHz, CDCl3) 3.59 (2H, t, J = 6.5 Hz, 
10-H2), 2.33 (2H, t, J = 7.5 Hz, 2-H2), 1.62 (2H, p, J = 7.5 Hz, 3-H2), 1.50 (2H, p, J = 6.5 Hz, 9-H2), 
1.36 – 1.24 (10H, m, 8-H2, 4-H2, AlH), 0.89 (9H, s, OSi(C(CH3)3)(CH3)2), 0.04 (6H, s, 
OSi(C(CH3)3)(CH3)2); δC (176 MHz, CDCl3) 180.4 (C=O), 63.5 (C-10), 34.3 (C-2), 33.0 (C-9), 29.6 
(AlC), 29.5 (AlC), 29.3 (AlC), 29.2 (AlC), 26.1 (OSi(C(CH3)3)(CH3)2), 25.9 (AlC), 24.8 (C-3), 18.5 
(OSi(C(CH3)3)(CH3)2), −5.1 (OSi(C(CH3)3)(CH3)2); m/z (LCMS, ESI
−) 301 (M − H+). 
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9.  Biological Experimental Details 
9.1 General experimental details 
MATERIALS: Biological grade materials, solvents, reagents and media components were 
purchased from commercial suppliers and used as provided. Plasmid construction and 
purification were carried out using the In-Fusion® HD cloning kit (Clontech) and plasmid 
miniprep kit (Biomiga) using supplied protocols. ˪-α-Phosphatidylinositol (bovine liver PI; 
predominant species 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1-myo-inositol sodium 
salt) was from Avanti Polar Lipids. NBD-C6-ceramide and BODIPY® FL C5-ceramide complexed to 
BSA were from Invitrogen. AG 4-X4 ion exchange resin was obtained from Bio-Rad. Reactions 
and media were prepared using high purity distilled, deionised water. FBS refers to 
heat-inactivated foetal bovine serum. Solutions of test compounds were made up in DMSO, 
unless otherwise stated. 
 
INSTRUMENTS AND EQUIPMENT: 1.5 mL Protein LoBind tubes (Eppendorf) were used for 
handling microsomal material and metabolic labelling experiments. Media were filter-sterilised 
using a Corning® 1000 mL vacuum filter/storage bottle system with a 0.22 μm pore CA 
membrane. Centrifugation steps were carried out using Beckman Coulter® centrifuges and 
ultracentrifuges. Eppendorf tubes were centrifuged using a Sigma 1-14 microfuge. Disruption 
of yeast cells was performed using an IKA® Vortex Genius 3. Protein content and optical 
density (OD) were determined using a Boeco S-32 spectrophotometer. Eppendorf contents 
were dried using an Eppendorf Vacuum Concentrator 5301 from Brinkmann. Cells were 
counted using a Neubauer haemocytometer. 96-well plates used were Corning® Costar® cell 
culture plates 3596 (clear); Corning® Costar® cell culture plates 3595 (clear); Corning® 
V-bottom 3897 (clear); MultiScreen® Solvinert filter plates (Merck Millipore) and PerkinElmer 
OptiPlate-96 (black). 16-well tissue culture slides were supplied by Lab Tec®. Fluorescence 
quantification was carried out using Synergy H4 and FLx800 microplate readers with Gen5™ 
1.08 data analysis software from Biotek. HPTLC silica plates were from Merck Millipore and 
imaged using a Fuji FLA−3000 plate reader with AIDA image analyser® software (version 3.52). 
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9.2 Solutions, buffers and media compositions 
Buffer Vol./Mass Stock Solution 
STE Buffer (50 mL) 1.25 mL 
12.5 mL 
100 µL 
1 tablet 
36.25 mL 
Tris-HCl (1 M, pH 7.4) 
Sucrose (1 M) 
EDTA (0.5 M) 
Complete® Protease Inhibitor Cocktail 
Water 
Storage Buffer (50 mL) 2.5 mL 
6.25 mL 
0.25 mL 
1 tablet 
41 mL 
Tris-HCl (1 M, pH 7.4) 
80 % w/v Glycerol 
MgCl2 (1 M) 
Complete® Protease Inhibitor Cocktail 
Water 
Tris/EDTA/BSA Buffer 
(50 mL, pH 6.0) 
12.5 mL 
2.5 mL 
750 mg 
35 mL 
Tris-HCl (1 M, pH 7.4) 
EDTA (0.5 M) 
Fatty acid free BSA 
Water 
10 × TE Buffer (1 L) 100 mL 
20 mL 
880 mL 
Tris-HCl (1 M, pH 7.4) 
EDTA (0.5 M, pH 8.0) 
Water 
10 × TE/LiAc (50 mL) 5 mL 
5 mL 
40 mL 
LiAc (1 M) 
10 × TE Buffer 
Water 
10 × PEG/LiAc (50 mL) 5 mL 
5 mL 
40 mL 
LiAc (1 M) 
10× TE Buffer 
50% w/v PEG 3350 
 
Growth Media Vol./Mass Stock Solution 
SD−W−L (1L) 20 g 
± 15 g 
1.93 g 
5 g 
0.64 g 
1000 mL 
Glucose 
Bacto-Agar (for solid media)  
Yeast Nitrogen Base (−Amino acids −(NH4)2SO4) 
(NH4)2SO4 
AA Drop-Out Supplement –W–L 
Water 
SGR–W–L (± 5-FOA) (1L) 40 g 
20 g 
± 15 g 
1.93 g 
5 g 
0.64 g 
± 1 g 
1000 mL 
Galactose 
Raffinose pentahydrate 
Bacto-Agar (for solid media)  
Yeast Nitrogen Base (−Amino acids −(NH4)2SO4) 
(NH4)2SO4 
AA Drop-Out Supplement –W–L 
5-Fluoroorotic acid  
Water 
SGR–W–L−URA (1L) 40 g 
20 g 
Galactose 
Raffinose pentahydrate 
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± 15 g 
1.93 g 
5 g 
0.62 g 
1000 mL 
Bacto-Agar (for solid media)  
Yeast Nitrogen Base (−Amino acids −(NH4)2SO4) 
(NH4)2SO4 
AA Drop-Out Supplement –W–L−URA 
Water 
YPGR (1 L) 10 g 
20 g 
40 g 
20 g 
1000 mL 
Yeast Extract 
Pepton 
Galactose 
Raffinose 
Water 
 
9.3 Standard protocols 
9.3.1 Complementation of ΔAUR1 S. cerevisiae mutant 
The auxotrophic Δaur1 S. cerevisiae strain (α ade− lys− leu− AUR1Δ::TRP1 pRS316–ScAUR1) was 
used for all transformation experiments. Yeast culture (5 mL in YPGR) at OD600 = 0.5 – 0.6 was 
transferred to a 50 mL tube and centrifuged (1,000 × g, RT, 5 min). The supernatant was 
discarded and the cells were re-suspended in sterile H2O (5 mL). The cells were centrifuged 
(1,000 × g, RT, 5 min) and the supernatant was discarded. The cell pellet was the re-suspended 
in freshly prepared, sterile 1 × TE/LiAc buffer (1 mL) to form the competent yeast cells.  
To the competent yeast cells (0.1 mL) was added the required plasmid (0.1 µg, pESC–LEU–IPC 
synthase) and Herring testes carrier DNA (10 µL, previously heated to 95 °C for 10 min). After 
mixing by vortex, freshly prepared sterile PEG/LiAc solution (0.6 mL) was added and the 
solution mixed by vortex prior to incubation at 30 °C for 30 min with shaking. DMSO (70 µL) 
was subsequently added and mixed by gentle inversion. The cells were subjected to a heat 
shock for 15 min at 42 °C and then chilled on ice for 2 min. Following centrifugation 
(14,000 rpm, RT, 5 s), the supernatant was removed and the cell pellet re-suspended in 1× TE 
buffer (0.5 mL) before being plated onto agar plates of permissive (SGR−W−L) and non-
permissive media (SD−W−L). Counterselection was achieved through growth on agar plates of 
SGR–W–L+5-FOA medium.261 
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9.3.2 ΔAUR1 S. cerevisiae mutant culture 
9.3.2.1 Agar plates 
Stocks of the complemented yeast were stored at −80 °C in 80% glycerol and cultures were 
maintained in SGR−W−L agar medium. Plates were incubated at 30 °C and fully grown plate 
cultures were kept at 4 °C until use. Yeast colonies from these plates were used to inoculate 
liquid SGR−W−L medium. 
9.3.2.2 Culture scale-up 
Cultures were propagated in liquid SGR−W−L medium. Liquid culture (5 mL) was incubated at 
30 °C until OD600 ≥ 0.8. Fresh medium (500 mL) was added and the culture incubated at 30 °C 
until OD600 ≥ 0.8. The culture was then diluted with fresh medium (5 L) and incubated at 30 °C 
until OD600 = 0.5 – 0.6. 
9.3.3 Preparation of microsomal membrane fraction 
9.3.3.1 Preparation of cell extract 
Crude membranes from the mutant S. cerevisiae were prepared as described by Fischl et al.320 
Cells were harvested by centrifugation (4,000 × g, 4 °C, 10 min) and washed with non-sterile 
cold PBS buffer (3 × 20 mL). The cell pellet was weighed and re-suspended in STE buffer 
(1.5 mL per 1 g wet cell mass (WCM)). The yeast cells were disrupted using pre-chilled, acid 
washed glass beads (212–300 μm, 1.5 g per 1 g WCM), using a vortex mixer. Disruption 
involved 20 cycles of 1 min vortex mixing followed by 1 min resting on ice. Glass beads, 
unbroken cells and cell-wall debris were pelleted by centrifugation (1,500 × g, 4 °C, 15 min) 
and the cell extract (supernatant) removed and stored. The pellet was re-suspended in STE 
buffer (0.5 mL per 1 g WCM) and subjected to 10 further disruption cycles. Following 
centrifugation (1,500 × g, 4 °C, 15 min), the supernatant was removed and the cell extracts 
combined. 
9.3.3.2 Preparation of crude microsomal membrane fraction 
The microsomal membrane fraction, containing IPC synthase, was isolated from the cell 
extract by differential centrifugation. An initial centrifugation of the cell extract (27000 × g, 
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4 °C, 30 min) pelleted large organelles and cell debris. The supernatant was removed and 
re-centrifuged (150,000 × g, 4 °C, 90 min) to obtain a pellet enriched with microsomal 
membranes. The pellet was suspended in a minimal amount of storage buffer (generally 50 – 
200 µL) and the protein content was determined according to Bradford’s protocol.321 The 
concentration was adjusted to 20 mg.mL−1 and 100 µL aliquots were stored in LoBind 
Eppendorf tubes at −80 °C. 
9.3.3.3 Preparation of washed microsomal membranes 
The following protocol was carried out under non-sterile conditions. The crude microsomal 
membranes were adjusted to a concentration of 10 mg.mL−1 using STE buffer and a 5% w/v 
CHAPS stock solution was diluted to 2.5% with STE buffer. Equal volumes of the membranes 
and 2.5% CHAPS solution were mixed and kept on ice for 1 h. The mixture was centrifuged 
(150,000 × g, 4 °C, 90 min) and the pellet re-suspended in storage buffer. The protein content 
was determined according to Bradford and the membranes were stored in LoBind Eppendorf 
tubes at −80 °C.321 
9.3.3.4 Determination of protein activity in units (U)209 
Microsome samples were normalized with respect to active enzyme content. Enzymatic 
activity was measured in enzyme units (U), where 1 U of enzyme is defined as that which 
converts 1 pmol of substrate per minute under the conditions described (i.e. 
1 U = 1 pmol(product).min−1).  
 A stock solution of NBD-C6-ceramide 34 at a concentration of 100 μM was used to 
create a standard curve ranging from 0.2 pmol to 80 pmol. The volumes were adjusted to 
200 μL with 1 M potassium formate in MeOH and the fluorescence measured (Ex460/Em540). 
Samples of the washed microsomal membranes were incubated with NBD-C6-ceramide 34 and 
PI under assay conditions (see Section 8.4.2) and the product fluorescence measured. 
Correlation with the standard curve allowed the activity of the microsome preparation to be 
calculated in U.μL−1. The membranes were adjusted to 1.5 U.μL−1 with storage buffer and 
stored in LoBind Eppendorf tubes at −80 °C. 
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9.3.4 Leishmania culture 
Leishmania major (MHOM/IL/81/Friedlin; FV1 strain (WT and spt2−) and 
MHOM/SA/85/JISH118) promastigotes were maintained at 26 °C in Schneider’s insect medium 
(pH 7), supplemented with 15% heat-inactivated foetal bovine serum.  
9.4 Assay protocols 
9.4.1 HPTLC NBD-C6-ceramide fluorescence assay
322 
10 mM PI in CHCl3 (1 µL) was dried into a LoBind Eppendorf tube using a vacuum concentrator 
(Eppendorf Concentrator 5301). To the dried PI, Tris/EDTA/BSA buffer (20 µL) was added and 
the solution mixed by vortex. The volume was adjusted to 48 µL with distilled H2O, followed by 
the addition of test compound (0.5 µL) and 100 µM NBD-C6-ceramide 34 in DMSO (1 µL). The 
reaction was started by addition of microsomal membranes (1.5 U.µL−1, 0.5 µL), and the 
mixture incubated at 30 °C for 25 min. After quenching with CHCl3 : MeOH : H2O (10 : 10 : 3, 
150 µL), the mixture was centrifuged (14,400 × g, RT, 5 min). 50 μL of the organic layer was 
loaded onto a HTPLC plate, and the lipid components separated using the solvent system 
CHCl3 : MeOH : 0.25% KCl(aq.) (55 : 45 : 10). The Rf values for the substrate NBD-C6-ceramide 34 
and the product NBD-C6-IPC 35 were 0.96 and 0.57 respectively. Product quantification was 
carried out using a fluorescence plate reader (Ex473/Em520). 
9.4.2 96-well plate NBD-C6-ceramide fluorescence assay
322 
In a V-bottom 96-well plate, CHAPS-washed membranes (0.6 U) were used in a reaction mix 
containing 100 µM PI, 5 µM NBD-C6-ceramide 34, 50 mM PO4
− and 600 µM CHAPS. Per well, 
10 mM PI in CHCl3 (0.4 µL) was dried using a vacuum concentrator. To the dried PI was added 
200 µM NBD-C6-ceramide 34 in DMSO (1 µL), H2O (1.1 µL), 3 mM CHAPS(aq.) (8 µL) and 71.4 mM 
phosphate buffer (28 µL). Test compounds in DMSO (0.4 µL) were added, and mixed 
thoroughly. The reaction was initiated by the addition of microsomal material (1.5 U.μL−1, 
0.4 µL) diluted with storage buffer (1.1 µL). The reaction was conducted with shaking at 30 °C 
for 25 min, prior to quenching by the addition of 200 µL of MeOH. 
Separation of the reaction product, NBD-C6-IPC 35, from the substrate 
NBD-C6-ceramide 34 was achieved via anion exchange chromatography. 20% w/v AG4-X4 resin 
in EtOH (200 µL) was dispensed into 96-well filter plates and the plate centrifuged (2,450 × g, 
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RT, 30 s). Formic acid (50 µL) was added to each well and, after 5 min, excess acid was 
removed by centrifugation (2,450 × g, RT, 30 s). The protonated resin was then washed with 
H2O (100 µL) and centrifuged (2,450 × g, RT, 30 s). The quenched reaction mixture (200 µL) was 
loaded onto the prepared resin and centrifuged (2,450 × g, RT, 30 s). Excess material was 
removed by washing with MeOH (5 × 200 µL) and subsequent centrifugation (2,450 × g, RT, 
30 s). The product IPC 35 was eluted into a black plate by washing with 1 M potassium formate 
in MeOH (4 × 50 µL) followed by centrifugation (2,450 × g, RT, 30 s). Assays were carried out in 
triplicate, with quantification carried out using a fluorescence plate reader (Ex460/Em540). IC50 
values were calculated using sigmoidal regression analysis (GraphPad Prism). 
9.4.3 Metabolic labelling assay 
Cultured L. major spt2− mutant promastigotes were centrifuged (1,500 × g, RT, 10 min) and the 
pellet washed three times with Schneider’s insect medium (pH 7, no FBS). The pellet was 
subsequently re-suspended in Schneider’s insect medium (pH 7, no FBS) to a parasite 
concentration of 1 × 107 mL−1 and dispensed into Eppendorf tubes (250 μL). Following 
incubation at 26 °C for 1 h, the test compounds were added (1 μL) and the tubes incubated at 
26 °C for 18 h. The reaction was initiated by the addition of 0.5 mM BODIPY FL C5-ceramide 
complexed to BSA (1.25 μL). Following further incubation at 26 °C for 1 h, the tubes were 
centrifuged (12,500 × g, RT, 5 min) and the pellets washed twice with PBS (250 μL). The pellets 
were re-suspended in CHCl3 : MeOH : H2O (10 : 10 : 3, 200 μL), followed by sonication in a 
water bath for 15 min. Water (25 μL) was added before centrifugation (14,400 × g, RT, 10 s) of 
the cell lysate. 50 μL of the organic layer was loaded onto a HTPLC plate, and lipid components 
separated using the solvent system CHCl3 : MeOH : 0.25% KCl(aq.) (55 : 45 : 10). The Rf values for 
the substrate BODIPY FL C5-ceramide and the product BODIPY FL C5-IPC were 0.89 and 0.47 
respectively. Product quantification was carried out using a fluorescence plate reader 
(Ex473/Em520). IC50 values were calculated using sigmoidal regression analysis (GraphPad 
Prism). 
9.4.4 L. major promastigote assay214 
L. major promastigotes (100 µL at 4 × 105 mL−1) were incubated in sterile 96-well plates with 
compounds in triplicate (amphotericin B was used as a positive control, and untreated 
parasites with DMSO as a negative control) at 26 °C for 24 h. AlamarBlue® (10 µL) was then 
added and the plate incubated at 26 °C for 4 h prior to measurement using a 
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fluorescence plate reader (Ex540/Em600). ED50 values were calculated using sigmoidal 
regression analysis (GraphPad Prism). 
9.4.5 L. major intramacrophage amastigote assay323 
Primary peritoneal mouse (CD1) macrophages were diluted in RPMI 1640 medium 
(supplemented with 200 mM ˪-glutamine, 16.5 mM NaHCO3 and 10% FBS) to a concentration 
of 4 × 105 mL−1. An aliquot of 100 µL of culture was added to 16-well tissue culture slides and 
incubated for 24 h at 37 °C and 5% CO2. Then, 100 µL of L. major (JISH118) promastigotes (in 
supplemented RPMI 1640 medium) were added at a ratio of seven promastigotes to one 
macrophage and the cells were incubated at 34 °C and 5% CO2. After 24 h, extracellular 
parasites were removed and the infected cells were gently washed with cold medium (lacking 
FBS). Serial dilutions of the test compounds in medium (100 µL) were added and the slides 
were incubated at 34 °C and 5% CO2 for 5 days (including replacement with fresh drug-
containing medium after 72 h). Amphotericin B and miltefosine were used as controls. Parasite 
growth was microscopically assessed after methanol fixation and staining with a 10% Giemsa 
solution. The level of infection was evaluated by counting the percentage of infected 
macrophages per well. Assays were performed in quadruplicate, with results expressed as the 
percentage reduction of infected cells (compared with untreated control wells). ED50 values 
were calculated using sigmoidal regression analysis (GraphPad Prism). 
9.4.6 Macrophage cytotoxicity assay324 
Primary peritoneal mouse (CD1) macrophages in RPMI 1640 medium (supplemented with 
200 mM ˪-glutamine, 16.5 mM NaHCO3 and 10% FBS) (2 × 10
6 mL−1, 200 µL.well−1) were seeded 
in sterile 96-well plates and incubated for 24 h at 37 °C and 5% CO2. Following removal of 
media, serial dilutions of the test compounds in fresh medium (200 µL) were added and the 
plate was incubated for 24 h at 37 °C and 5% CO2. Aliquots of AlamarBlue® (20 µL) were then 
added and the plate was incubated at 37 °C and 5% CO2 for 4 h. Cell-viability measurement 
was carried out using a fluorescence plate reader (Ex540/Em600). Podophyllotoxin was used as 
a reference compound. ED50 values were calculated using sigmoidal regression analysis 
(GraphPad Prism). 
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Appendix A: Clemastine Analogue Screening Data 
No Structure 
LmjIPCS 
inhibition % 
at 20 µM ± 
SD 
LmjIPCS 
IC50 (µM) 
(95% CI) 
L. major 
promastigote 
ED50 (µM) 
(95% CI) 
41 
 
82.6 ± 9.3 
2.87 (2.25 – 
3.66) 
0.47 (0.37 – 
0.59) 
77 
 
78.1 ± 12.5 
6.26 (5.60 – 
7.00) 
4.10 (3.35 – 
5.01) 
78B 
 
78.1 ± 9.7 
4.13 (3.72 – 
4.59) 
0.78 (0.63 – 
0.96) 
78A 
 
81.2 ± 10.6 
4.45 (4.01 – 
4.94) 
1.69 (1.23 – 
2.32) 
162 
 
– 
3.66 (3.24 – 
4.14) 
2.85 (2.28 – 
3.56) 
166 
 
– 
3.21 (2.38 – 
4.33) 
1.36 (1.08 – 
1.71) 
146 
 
– 
4.72 (3.90 – 
5.72) 
>5 
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83B 
 
71.0 ± 9.7 
8.49 (7.67 – 
9.39) 
>33 
83A 
 
60.6 ± 9.2 
14.52 (12.39 
– 17.02) 
>33 
98 
 
82.7 ± 1.3 
6.95 (6.15 – 
7.85) 
>33 
99 
 
81.2 ± 1.3 
6.90 (6.10 – 
7.80) 
>33 
110 
 
4.7 ± 2.5 – – 
111 
 
8.6 ± 2.1 – – 
117 
 
89.2 ± 2.6 
5.40 (3.99 – 
7.30) 
– 
118 
 
90.2 ± 2.4 
2.41 (1.84 – 
3.16) 
>10 
119 
 
90.2 ± 1.7 
4.37 (3.56 – 
5.36) 
– 
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120 
 
89.6 ± 2.2 
6.11 (4.83 – 
7.72) 
– 
121 
 
53.4 ± 8.5 
23.89 (20.84 
– 27.39) 
– 
122 
 
79.4 ± 9.0 
36.21 (30.06 
– 43.61) 
– 
123 
 
28.3 ± 5.3 – – 
124 
 
2.5 ± 7.8 – – 
125 
 
0.6 ± 1.8 – – 
126 
 
2.7 ± 1.7 – – 
127 
 
86.0 ± 2.7 
13.09 (11.43 
– 15.00) 
– 
128 
 
77.9 ± 5.1 
11.38 (9.03 
– 14.34) 
– 
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129 
 
76.1 ± 8.5 
20.49 (18.30 
– 22.94) 
– 
130 
 
35.8 ± 3.9 – – 
131 
 
16.3 ± 3.8 – – 
132 
 
−5.4 ± 2.3 – – 
133 
 
2.9 ± 1.4 – – 
134 
 
−0.3 ± 0.8 – – 
135 
 
44.4 ± 4.9 
24.86 (22.22 
– 27.82) 
– 
136 
 
89.4 ± 4.1 
18.94 (16.83 
– 21.32) 
– 
137 
 
11.3 ± 7.4 – – 
138 
 
−1.1 ± 2.5 – – 
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139 
 
1.7 ± 3.4 – – 
140 
 
81.9 ± 2.8 
12.67 (11.12 
– 14.44) 
– 
141 
 
46.4 ± 5.8 
28.31 (25.50 
– 31.34) 
– 
142 
 
24.7 ± 7.5 – – 
143 
 
7.3 ± 1.9 – – 
144 
 
57.2 ± 10.9 
16.51 (12.80 
– 21.29) 
– 
167 
 
7.5 ± 7.3 – – 
168 
 
2.4 ±1.7 – – 
169 
 
7.3 ± 6.5 – – 
170 
 
24.4 ± 3.3 – – 
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171 
 
0.5 ± 2.1 – – 
172 
 
12.0 ± 3.1 – – 
173 
 
27.5 ± 8.3 – – 
174 
 
4.3 ± 1.8 – – 
175 
 
4.3 ± 3.1 – – 
176 
 
9.0 ± 2.1 – – 
177 
 
3.5 ± 3.1 – – 
178 
 
−1.7 ± 5.3 – – 
179 
 
16.0 ± 0.6 – – 
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180 
 
9.3 ± 1.8 – – 
181 
 
8.5 ± 1.2 – – 
182 
 
−3.2 ± 1.7 – – 
183 
 
8.0 ± 1.2 – – 
184 
 
5.1 ± 1.5 – – 
185 
 
5.5 ± 3.2 – – 
186 
 
59.8 ± 29.9 
17.07 (13.48 
– 21.62) 
– 
187 
 
0.4 ± 5.3 – – 
188 
 
26.5 ± 12.1 – – 
189 
 
−1.8 ± 6.4 – – 
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190 
 
−1.5 ± 4.2 – – 
191 
 
−1.1 ± 8.2 – – 
192 
 
−4.9 ± 3.6 – – 
193 
 
0.9 ± 5.3 – – 
194 
 
−1.3 ± 3.7 – – 
195 
 
40.6 ± 15.7 – – 
196 
 
−2.1 ± 2.7 – – 
197 
 
−0.7 ± 2.4 – – 
– Value not determined 
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Note: Residual ethyl acetate peaks at δH = 4.12, 2.04 and 1.26 ppm; δC = 171.3, 60.5, 21.2 and 14.3 ppm 
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Note: Residual ethyl acetate peaks at δH = 4.12, 2.04 and 1.26 ppm; δC = 171.3, 60.5, 21.2 and 14.3 ppm 
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Note: Residual ethyl acetate peaks at δH = 4.12, 2.04 and 1.26 ppm; δC = 171.3, 60.5, 21.2 and 14.3 ppm 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
4
2 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
4
3 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
4
4 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
4
5 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
4
6 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
4
7 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
4
8 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
4
9 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
0 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
1 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
2 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
3 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
4 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
5 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
6 | 
 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
7 | 
 
  
A
p
p
en
d
ix B
: N
M
R
 Sp
ectra
 
| 2
5
8 | 
 
Note: Residual acetone peaks at δH = 2.17 ppm; δC = 207.0 and 31.0 ppm 
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Note: Residual ether peaks at δH = 3.48 and 1.21 ppm; residual acetone peak at δH = 2.17 ppm 
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Note: Residual ether peaks observable at δH = 1.21 ppm; δC = 66.0 and 15.4 ppm 
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